FORM 2 The Patents Act, 1970 (39 of 1970) & The Patent Rules, 2003 COMPLETE SPECIFICATION (See section 10 and rule 13) THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS Abbott Laboratories, a company incorporated in USA having its Registered Office at Dept. 377 Bldg APA-1, 200 Abbott Park Road, Abbott Park, IL 60064-6008 (US). The following specification particularly describes the invention and the manner in which it is to be performed WO 2005/010009 PCT/ US 2004/0 24 003 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS Technical Field The present invention relates to compounds which are useful for inhibiting protein tyrosine kinases, methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds. Background of the Invention Protein tyrosine kinases (PTKs) are enzymes winch catalyse the phosphorylation of specific tyrosine residues in cellular proteins. This post-translational modification of these substrate proteins, often enzymes themselves, acts as a molecular switch regulating cell proliferation, activation, or differentiation. Aberrant or excessive PTK activity has been observed in many disease states including benign and malignant proliferate disorders as well as diseases resulting from inappropriate activation of the immune system (e.g., autoimmune disorders), allograft rejection, and graft vs. host disease. Endothelial-cell specific receptor PTKs such as KDR and Tie-2 mediate the angiogenic process, and are thus involved in supporting the progression of cancers and other diseases involving inappropriate vascularization (e.g., diabetic retinopathy, choroidal neovascularization due to age-related macular degeneration, psoriasis, arthritis, retinopathy of prematurity, and infantile hemangiomas). The non-receptor tyrosine kinases represent a collection of cellular enzymes which lack extracellular and transmembrane sequences. At present, over twenty-four individual non-receptor tyrosine kinases, comprising eleven subfamilies (Src, Frk, Btk, Csk, Abl, Zap 70, Fes/Fps, Fak, Jak, Ack and LIMK) have been identified. At present, the Src subfamily of non-receptor tyrosine kinases is comprised of the largest number of PTKs and includes Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. The Src subfamily of enzymes has been linked to oncogenesis and immune responses. The identification of effective small compounds which specifically inhibit signal transduction and cellular proliferation by modulating the activity of tyrosine kinases to WO 2005/010009 PCT/US2004/024003 exudates, and macromolecular extravasation and matrix deposition as well as associated disorders would be beneficial. Summary of the Invention In its principle embodiment, the present invention provides a compound of formula (I) or a therapeutically acceptable salt thereof, wherein X is selected from the group consisting of O and S; Z is selected from the group consisting of C and N; R1 is selected from the group consisting of hydrogen, alkenyl, alkoxy alkynyl, alkoxy carbonyl, alkoxycarbonylalkenyl, alkoxycarbonylalkyl, alkoxycarbonylalkynyl, alkyl, alkynyl, aryl, arylalkenyl, arylalkyl, aryl alkynyl,-aryloxyalky I, aryloxyalkynyl, arylsulfanylalkyl, arylsulfanylalkynyl, arylsulfonyloxyalkenyl, carboxy, carboxyalkenyl, carboxyalkyl, carboxyalkynyl, cyano, cyanoalkenyl, cyanoalkyl, cyanoalkynyl, cycloalkyl, cycloalkylalkoxyalkynyl, cycloalkylalkenyl, cycloalkylafkynyl, formylalkcenyl, formylalkyl, halo, haloalkyl, heteroaryl, heteroarylalkenyl, hetero aryl alkyl, heteroarylalkynyl, heteroary lea rbonyl, heteroarylcarbonylalkenyl, heteroarylcarbonylalkyl, heterocyclyl, heterocyclylalkenyl, heterocyclylalkyl, heterocyclylalkylcarbonyl, heterocyclylalkynyl, heterocyclylcarbonyl, heterocyclylcarbonylalkenyl, hetero eye lylcarbonylalkyl, heterocyclyloxyallcenyl, hydroxyalkenyl, hydroxyalkyl, hydroxyalkynyl, NRaRb, (NRaRb)alkenyl, (NRaRb)alkyl, (NRaRb)alkynyl, (NRaRb)carbonyl, (NRaRb)carbonylalkenyl, (NRaRb)carbonylalkyl, (NRaRb)carbonylalkynyl, nitro, nitroalkenyl, nitroalkyl, and nitroalkynyl; R2 is absent or selected from the group consisting of hydrogen and alkyl; R3 is selected from the group consisting of halo, aryl, heteroaryl, and heterocyclyl, wherein the aryl, the heteroaryl, and the heterocyclyl are optionally substituted with one, two, or three substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, heteroaryl, heterocyclyl, hydroxy, hydroxyalkyl, LR4, and NRaRb; provided that at least two of the three substituents are other than LR4; L is selected from the group consisting of O, (CH2)mC(0)NR5, NR5C(0)(GH2)m, NR5S02, S02NR5, (CH2)mN(R5)C(O)N(R6)(CH2)m, and (CH,)mN(R5)C(S)N(R6)(CH2)n,wherein WO 2005/010009 PCT/US2004/024003 m.and n are independently 0 or-1, and wherein, each group is drawn with its riglit end attached to R4; R4 is selected from the group consisting of aryl, arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R5 and R6 are independently selected from the group consisting of hydrogen and alkyl; Ra and Rb are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, allcoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylsulfanylalkyl, alkylsulfonyl, aryl, arylalkoxycarbonyl, arylalkoxycarbonylalkyl, arylalkyl, arylcarbonyl, arylsulfonyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, formylalkyl, heteroaryl, heteroarylalkyl, heteroarylcarbonyl, heteroarylsulfonyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkylcarbonyl, hetero cyclylcarbonyl, heterocyclylsulfonyl, hydroxy alkoxy alkyl, hydroxyalkyl, (NRcRd)alkyl, (NRcRd)alkylcarbonyl, (NRcRd)carbonyl, and (NRcRd)carbonylalkyl, wherein the aryl, the aryl part of the arylalkoxycarbonyl, the arylalkoxycarbouylalkyl, the arylalkyl, the arylcarbonyl, and the arylsulfonyl, the cycloalkyl., the cycloalkyl part of the eyeloalleylalkyl, the heteroaryl, the heteroaryl part of the hetero arylalkyl, and the heteroarylcarbonyl, the heterocyclyl, and the heterocyclyl part of the heterocyclylalkyl and the hetero cyclylcarbonyl can be further optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, allcoxycarbonyl., alkyl, alkylcarbonyl, aryl, arylalkyl, halo, haloalkoxy, haloalkyl, hydroxy, nitro, NRcRd, (NRcRd)alkyl, (NRcRd)alkylcarbonyl, (NRcRd)carbonyl, (NRcRd)carbonylalkyl, oxo, and spiroheterocyclyl, wherein the aryl and the aryl part of the arylalkyl can be substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkoxy, alkyl, cyano, halo, haloalkoxy, haloalkyl, nitro, and oxo; Rc and Rd are independently selected from the group consisting of hydrogen, alkoxy, alkyl, aryl, carboxyalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, hydroxyalkoxyalkyl, hydroxyalkyl, and (NRcRd)alkyl, wherein the aryl, the heteroaryl, and the heterocyclyl can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkyl, halo, haloalkoxy, haloalkyl, hydroxy, and nitro; and Rc and Rf are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R2 is hydrogen and R1, R3, Z, and X are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R3 is selected from the group consisting of halo, heteroaryl, and heterocyclyl; and R1, R2, Z, and X are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R3 is aryl and R1, R3, Z, and X are as defined in formula (I). WO 2005/010009 PCT/US2004/024003 In another embodiment, the present invention provides compounds of formula (I) wherein R3 is aryl wherein the aryl is unsubstantiated or substituted with one or two substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl; hydroxyalkyl, and NRaRb; and Ra, Rb, R1, R2, Z, and X are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (1) wherein R3 is aryl wherein the aryl is substituted with LR4 and optionally with one or two additional substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NRaRb; and Ra, Rb, R1R2, R4 L, Z, and X are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R3 is aryl wherein the aryl is substituted with LRd and optionally with one or two additional substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NRaRb; L is O; and and Ra, Rb, R1, R:, R4, Z, and X are as defined in formula (I). In another embodiment the present invention provides compounds of formula (I) wherein R3 is aryl wherein the aryl is substituted with LR4 and optionally with one or two additional substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo haloalkoxy, haloalkyl, hydroxyalkyl, and NRaRb; L is O; R1 is selected from the group consisting of heterocyclylalkenyl, heterocyclylcarbonylalkenyl, (NRaRb)alkenyl, and (NRaRb)carbonylalkenyl; and Ra, Rb, R2, R4 Z, and X are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R3 is aryl wherein the aryl is substituted with LR4 and optionally with one or two additional substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NRaRb; L is O; R1 is selected from the group consisting of hydrogen, alkoxycarbonylalkenyl, carboxyalkenyl, heteroaryl, and hydroxyalkenyl; and Ra, Rb, R2, R4, Z, and X are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R3 is aryl wherein the aryl is substituted with LR4 and optionally with one or two additional substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NRaRb; L is selected from the group consisting of NR5C(0)(CH3)m and NR5S02; and m, Ra, Rb R1, R2, R4, R5, Z, and X are as defined in formula (I). In another more preferred embodiment the present invention provides the compound of formula (I) wherein R3 is aryl, wherein the aryl is substituted with LR4 and optionally with one or two additional substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NRaRb; L is WO 2005/010009 PCT/US2004/024003 selected from the group consisting of NR5 C(O)(CH2)m and NR5 SO2 R1 is (NRaRb) alkenyl;. and m, Ra, Rb, R2, R4 R5, Z, and X are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R3 is aryl wherein the aryl is substituted with LR4 and optionally with one or two additional substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NRaRb; L is selected from the group consisting of NR5C(0)(CH,)m and NRaS02; R1 is selected from the group consisting of heterocyclylalkenyl, heterocyclylalley 1, and (NRaRb)carbonylalkenyl; and m, Ra, Rb, R2, R4, R3, Z, and X are as defined in formula (I). In another embodiment the present invention provides compounds of formula (I) wherein R3 is aryl wherein the aryl is substituted with LR4 and optionally with one or two additional substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NRaRb; L is selected from the group consisting of NR5C(0)(CH2)m and NR5S02; R1 is selected from the group consisting of hydrogen, alkoxycarbonylalkenyl, carboxyalkenyl, formylalkenyl, and heteroaryl; and m, Ra, Rb, R2, R4, R5, Z, and X are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R3 is aryl wherein the aryl is substituted with LR4 and optionally with one or two additional substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NRaRb; L is selected from the group consisting of NR5C(0)(CH2)m and NR5S02; R1 is selected from the group consisting of alkoxyallcynyl, aryla1kynyl,-carboxyalkynyl, cycloalkylalkynyl, halo, heteroarylalkynyl, heterocyclylatkyl, heterocyclylalkynyl, hydroxyalkynyl, and (NRaRb)alkynyl; and m, Ra, Rb, R2, R4, R5, Z, and X are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R3 is aryl wherein the aryl is substituted with LR4 and optionally with one or two additional substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NRaRb; L is (CH2)mN(R5)C(0)N(R6)(CH2)n; and m, n, Ra, Rb, R1 R25 R4, R5, R6, Z, and X are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R3 is aryl wherein the aryl is substituted with LR4 and optionally with one or two additional substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NRaRb; L is (CH2)mN(R5)C(0)N(R6)(CH2)n; Rl is selected from the group consisting of alkynyl, arylalkynyl, aryloxyalkynyl, arylsulfanylalkynyl, cyanoalkynyl, heteroarylalkynyl, hydroxyalkynyl, and (NRaRb)alkynyl; and m, n, Ra, Rb, R3, R1 R5, R6, Z, and X are as defined in formula (I). WO 2005/010009 PCT/US2004/024003 In another embodiment, the present invention provides compounds of formula (I) wherein R3 is aryl wherein the aryl is substituted with LR4 and optionally with one or two additional substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NRaRb; L is (CH2)mN(R5)C(0)N(R6)(CH2)n; Rl is selected from the group consisting of alkoxycarbonylalkenyl, carboxyalkenyl, heteroarylcarbonylalkenyl, heterocyclylcarbonylalkenyl, and (NRaRb)carbonylalkenyl; and m, n, Ra, Rb, R2, R4, R5, R6, and X are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R3 is aryl wherein the aryl is substituted with LR4 and optionally with one or two additional substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NRaRb; L is (CH2)mN(R5)C(0)N(R6)(CH2)n; R' is selected from the group consisting of aryl and heteroaryl; and m, n, Ra, Rb, R2, R4, R5, R6, Z, and X are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R3 is aryl wherein the aryl is substituted with LR4 and optionally with one or two additional substituents independently selected from the group consisting of allcoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NR.aRb; L is (CH2)mN(R5)C(0)N(R6)(CH2)n; R' is selected from the group consisting of allcoxycarbonylalkyl, carboxyalkyl, heterocyclylalkyl, hydroxyalkyl, (NRaRb)alkyl, and (NRaRb) arbonylalkyl; and m, n, Ra, Rb, R2, R4, R5, R6, Z, and X are as defined in formula ft In another embodiment, the present invention provides compounds of formula (I) wherein R3 is aryl wherein the aryl is substituted with LR4 and optionally with one or two additional substituents independently selected from the group consisting of allcoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NRaRb; L is (CH2)mN(Rs)C(0)N(R6)(CH2)Q; R1 is selected from the group consisting of hydrogen, halo, nitro, and NRaRb; and m, n, Ra, Rb, R2, R4, R5, R6, Z, and X are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of alkynyl, arylalkynyl, aryloxyallcynyl, arylsulfanylalkynyl, cyanoalkynyl, cycloalkylalkoxy alkynyl, heteroarylalkynyl, hydroxyalkynyl, and (NRaRb)alkynyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4 and optionally with one or two additional substituents independently selected from the group consisting of alkoxy, alkyl, aryl, cyano, halo, haloalkoxy, haloalkyl, hydroxyalkyl, and NRaRb; R4 is aryl; L is (CH2)mN(Rs)C(0)N(R6)(CH2)Q X is S, Z is C; and m, n, Ra, Rb, R5, and R6 are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R! is selected from the group consisting of alkynyl, arylalkynyl, aryloxyallcynyl, arylsulfanylalkynyl, cyanoalkynyl, cycloalkylalkoxyalkynyl, heteroarylalkynyl, WO 2005/010009 PCT/US2004/024003 hydroxyalkynyl, and (NRaRb) alkynyl; R2 is hydrogen; R3 is aryl wherein: the aryl is phenyl substituted with LR4; R4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkylcarbonyl, cyano, halogen, and haloalkyl wherein the preferred groups are chloro, fluoro, methyl, and tnfluoromethyl; L is (CH2)m N(R5)C(0)N(R6)(CPI2)n; RS and R6 are hydrogen; m is 0; n is 0; 34 is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, and heterocyclylcarbonyl wherein the heterocyclyl is pyridinyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is (NRaRb)alkynyl; R2 is hydrogen; R3 is aryl where the aryl is phenyl substituted with LR4; R4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkylcarbonyl, cyano, halogen, and haloalkyl wherein the preferred groups are chloro, fluoro, methyl, and tnfluoromethyl; L is (CH2)mN(R5)C(0)N(R6)(CH2)ri; Rs and R6 are hydrogen; m is 0; n is 0;} is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen alkyl, alkylcarbonyl, alkylsulfonyl, and heterocyclylcarbonyl wherein the heterocyclyl is pyridinyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is (NRaRb) alkynyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; R4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkylcarbonyl, cyano halogen, and haloalkyl wherein preferred groups are chloro, fluoro, methyl, and tnfluoromethyl; L is (CH2)mN(R5)C(0)N(R6)(CH2)n; Rs and RG are hydrogen; rn is 0; n is 0; ] is S; Z is C; Ra is selected from the group consisting of hydrogen and alkyl; and Rb is heteroarylcarbonyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is (NRaRb)alkynyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; K4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkylcarbonyl, cyano halogen, and haloalkyl wherein preferred groups are chloro, fluoro, methyl, and tnfluoromethyl; L is (CH2)mN(R5)C(0)N(R6)(CH2)n; R5 and R6 are hydrogen; m is 0; n is 0;: is S; Z is C; Ra is selected from the group consisting of hydrogen and alkyl; and Rb is heteroarylcarbonyl wherein the heteroaryl is pyridinyl. In another embodiment, the present invention provides compounds of formula (I) wherein Rl is selected from the group consisting of alkynyl, arylalkynyl, aryloxyalkynyl, arylsulfanylalkynyl, cyanoalkynyl, cycloalkylalkoxyalkynyl, heteroarylalkynyl, hydroxyalkynyl, and (NRaRb)alkynyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4 and optionally substituted with 1 alkoxy group; R4 is heteroaryl; L is -7- WO 2005/010009 PCT/US2004/024003 N(R5)C(0) (CH2)m Rl wherein the nitrogen is attached to R3 and the carbonyl is attached to p.4; E is hydrogen; m is 0; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylsulfonyl, and heteroarylcarbonyl, wherein the heteroaryl is pyridinyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of alkynyl, arylalkynyl, aryloxyalkynyl, arylsulfanylallcynyl, cyanoalkynyl, cycloalkylalkoxyalkynyl, heteroarylalkynyl, hydroxyalkynyl, and (NRaRb)alkynyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR" and optionally substituted with 1 alkoxy group; R4 is heteroaryl wherein the heteroaryl is selected from the group consisting of indolyl and thienyl wherein the heteroaryl is optionally substituted with 1 alkyl group wherein the preferred heteoaryl is 1-methyl-lH-indol-2-yl; L is N(Rs)C(0)(CH,)m wherein the nitrogen is attached to R3 and the carbonyl is attached to R"; R5 is hydrogen; m is 0; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylsulfonyl, and heteroarylcarbonyl, wherein the heteroaryl is pyridinyl. In another embodiment, the present invention provides compounds of formula (I) wherein R! is selected from the group consisting of alkenyl, arylalkenyl, heterocyclylalkenyl, hydroxyalkenyl, (NRaRb)carbonylalkenyl, and (NRaRb)alkenyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR'; R4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkylcarbonyl, cyano, halogen, and haloalkyl wherein the preferred groups are chloro, fluoro, methyl, and trifluoromethyl; R5 and R° are hydrogen; L is (CH3)mN(R5)C(0)N(R6)(CH2)n; m is 0; n is 0; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with NH3. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is heterocyclylalkenyl wherein the heterocycle is selected from the group consisting of piperazinyl and piperidinyl wherein the heterocycle is optionally substituted with 1 substiruent selected from the group consisting of carboxy, hydroxy, hydroxyalkyl, oxo, NRaRb, and (NRaRb)alkyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; R4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkylcarbonyl, cyano, halogen, and haloalkyl wherein the preferred groups are chloro, fluoro, methyl, and trifluoromethyl; Rs and R6 are hydrogen; L is (CH2)mN(R5)C(0)N(R6)(CH2)n; m is 0; n is 0; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with NH2. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is (NRaRb)carbonylalkenyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl WO 2005/010009 PCT/US2004/024U03 substituted with LR4; ,R4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkylcarbonyl, cyano, halogen, and haloalkyl wherein the preferred groups are chloro, fluoro, methyl, and trifiuoromethyl; R5 and R6 are hydrogen; L is (CH2)mN(R5)C(0)N(R6)(CH2)n; m is 0; n is 0; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with NH2 In another embodiment, the present invention provides compounds of formula (I) wherein R' is (NRaRb)alkenyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; R4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkylcarbonyl, cyano, halogen, and haloalkyl wherein the preferred groups are chloro, fluoro, methyl, and trifiuoromethyl; R5 and R6 are hydrogen; L is (CH2)in N(R5)C(0)N(R6)(CH2)n; m is 0; n is 0; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with NH2 In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of alkenyl, arylalkenyl, heterocyclylalkenyl, hydroxyalkenyl, (NRaRb)carbonylalkenyl, and (NRaRb)alkenyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4 and optionally substituted with 1 alkoxy group; R4 is heteroaryl; L is N(R3)C(0)(CH2)m wherein the nitrogen is attached to R3 and the carbonyl is attached to R4; R5 is hydrogen; m is 0; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with NH2. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is heterocyclylalkenyl wherein the heterocycle is selected from the group consisting of piperazinyl and piperidinyl wherein the heterocycle is optionally substituted with 1 substituent selected from the group consisting of carboxy, hydroxy, hydroxyalkyl, oxo, NRaRb and (NRaRb)alkyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4 and optionally substituted with 1 alkoxy group; R4 is heteroaryl wherein the heteroaryl is selected from the group consisting of indolyl and thienyl wherein the heteroaryl is optionally substituted with 1 alkyl group wherein the preferred heteoaryl is 1- methyl-lH-indol-2-yl; L is N(Rs)C(0)(CH2)m wherein the nitrogen is attached to R3 and the carbonyl is attached to R4; R5 is hydrogen; m is 0; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with NH2. In another embodiment, the present invention provides compounds of formula (I) wherein Rl is (NRaRb)alkenyl; R3 is aryl wherein the aryl is phenyl substituted with LR4 and optionally substituted with 1 alkoxy group; R4 is heteroaryl wherein the heteroaryl is selected from the group consisting of indolyl and thienyl wherein the heteroaryl is optionally -9- WO 2005/010009 PCT/US2004/024003 substituted with alkyl group wherein 'the preferred heteoaryl is l-methyl-lH-indol-2-yl; L is N(Rs)C(0)(CH2)m wherein the nitrogen is attached to R3 and the carbonyl is attached to R4; R; is hydrogen; m is 0; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with NH,. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is heteroaryl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; R4 is aryl; L is (CH2)mN(R5)C(0)N(R6)(CH2)n; R5 and R6 are hydrogen; m is 0; n is 0; Z is C; and X is S. In another embodiment, the present invention provides compounds of formula (I), wherein R' is heteroaryl wherein the heteroaryl is selected from the group consisting of benzothiazolyl, benzothienyl, benzoxazolyl, fury], indolyl, pyrazolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, and thienyl wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkyl, formyl, halogen, and haloalkyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; R4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkylcarbonyl, cyano, halogen, and haloalkyl wherein the preferred groups are chloro, fluoro, methyl, and tnfluoromethyl; L is (CH3)mN(Rs)C(0)N(R6)(CH2)n; R5 and R6 are hydrogen; m is 0; n is 0; Z is C; and X is S. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is heteroaryl wherein the heteroaryl is selected from the group consisting of indolyl, pyridinyl, and pyrimidinyl, wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkyl, halogen, and haloalkyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; R4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkylcarbonyl, cyano, halogen, and haloalkyl wherein the preferred groups are chloro, fluoro, methyl, and tnfluoromethyl; L is (CH2)mN(R5)C(0)N(R6)(CH2)n; R5 and R° are hydrogen; m is 0; n is 0; Z is C; and X is S. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is heteroaryl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR"; R4 is heteroaryl; L is N(R5)C(0)(CH2)m wherein the nitrogen is attached to R3 and the carbonyl is attached to R4; R5 is hydrogen; m is 0; Z is C; and X is S. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzothiazolyl, benzothienyl, benzoxazolyl, furyl, indolyl, pyrazolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, and thienyl wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkyl, formyl, halogen, and haloalkyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; R4 is -10- WO 2005/010009 PCT/US2004/024003 heteroaryl wherein the heteroaryl-is .selected from the group consisting of indolyl and thienyl wherein the heteroaryl is optionally substituted with 1 alkyl group wherein the preferred heteoaryl is 1 -methyl-lH-indol-2-yl; L is N(R5)C(0)(CH2)m wherein the nitrogen is attached to R3 and the carbonyl is attached to R4; Rs is hydrogen; m is 0; Z is C; and X is S. In another embodiment, the present invention provides compounds of formula (I) wherein R' is heteroaryl wherein the heteroaryl is selected from the group consisting of indolyl, pyridinyl, and pyrimidinyl, wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkyl, halogen, and haloalkyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; R4 is heteroaryl wherein the heteroaryl is selected from the group consisting of indolyl and thienyl wherein the heteroaryl is optionally substituted with 1 alkyl group wherein the preferred heteoaryl is l-methyl-lH-indol-2-yl; L is N(R5)C(0)(CH2)m wherein the nitrogen is attached to R3 and the carbonyl is attached to R4; Rs is hydrogen; m is 0; Z is C; and X is S. In another embodiment, the present invention provides compounds of formula (I) wherein R" is hydrogen; R3 is heteroaryl; Z is C; X is S; and R1 is as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of alkenyl, arylalkenyl, heterocyclylalkenyl, hydroxyalkenyl, (NRaRb)carbonylalkenyl, and (NRaRb)alkenyl; R2 is hydrogen; R3 is heteroaryl; Z is C; X is S; and Ra and Rb are as defined in formula (I): In another embodiment, the present invention provides compounds of formula (I) wherein R1 is heterocyclylalkenyl wherein the heterocycle is selected from the group consisting of piperazinyl and piperidrnyl wherein the heterocycle is optionally substituted with 1 substituent selected from the group consisting of carboxy, hydroxy, hydroxy alkyl, oxo, NRaRb, and (NRaRb)alkyl; R2 is hydrogen; R3 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzisoxazolyl, benzofuranyl, benzothiazolyl, benzothienyl, benzoxadiazolyl, benzoxazolyl, indolyl, isoquinolinyl, and quinolinyl wherein the heteroaryl is optionally-substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxy carbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, and nitro; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, and cycloatkyl wherein the cycloalkyl is cyclohexyl optionally substituted with NH2. In another embodiment, the present invention provides compounds of formula (I) wherein Rl is heterocyclylalkenyl wherein the heterocycle is selected from the group consisting of piperazinyl and piperidinyl wherein the heterocycle is optionally substituted with 1 substituent selected from the group consisting of carboxy, hydroxy, hydroxyalkyl, oxo, NRaRb, and (NRaRb)alkyl; R2 is hydrogen; R3 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzofuranyl, benzothienyl, and indolyl wherein the WO 2005/010009 PCT/US2004/024003 heteroaryl is optionally substituted with 1 or 2 substituents selected- from the 'group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, and nitro; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with NH2. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is (NRaRb) carbonylalkenyl; R2 is hydrogen; R3 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzisoxazolyl, benzofuranyl, benzothiazolyl, benzothienyl, benzoxadiazolyl, benzoxazolyl, indolyl, isoquinolinyl, and quinolinyl wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, and nitro; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with NH3. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is (NRaRb)carbonylalkenyl; R2 is hydrogen; R3 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzofuranyl, benzothienyl, and indolyl, wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, and nitro; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with NH2. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is (NRaRb)alkenyl; R2 is hydrogen; R3 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzisoxazolyl, benzofuranyl, benzothiazolyl, benzothienyl, benzoxadiazolyl, benzoxazolyl, indolyl, isoquinolinyl, and quinolinyl wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, and nitro; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with NH2. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is (NRaRb)alkenyl; R2 is hydrogen; R3 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzofuranyl, benzothienyl, and indolyl, wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting -12- WO 2005/010009 PCT/US2004/024003 of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, and nitro; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with NH2. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of alkynyl, arylalkynyl, aryloxyalkynyl, arylsulfanylalkynyl, cyanoalkynyl, heteroarylalkynyl, hydroxyalkynyl, and (NRaRb)alkynyl; R2 is hydrogen; R3 is heteroaryl; X is S; Z is C; and Ra and Rb are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R1 is (NRaRb) alkynyl; R2 is hydrogen; R3 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzisoxazolyl, benzofuranyl, benzothiazolyl, benzothienyl, benzoxadiazolyl, benzoxazolyl, indolyl, isoquinolinyl, and quinoliny! wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, and nitro; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, and heterocyclylcarbonyl wherein the heterocyclyl is pyridinyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is (NRaRb) alleynyl; R2 is hydrogen; R3 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzofuranyl, benzothienyl, and indolyl, wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, and nitro; X is S; Z is C; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, and heterocyclylcarbonyl wherein the heterocyclyl is pyridinyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is heteroaryl; R2 is hydrogen; R3 is heteroaryl; X is S; Z is C; and Ra and Rb are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R1 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzothiazolyl, benzothienyl, benzoxazolyl, furyl, indolyl, pyrazolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, and thienyl wherein die heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkyl, formyl, halogen, and haloalkyl; R2 is hydrogen; R3 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzisoxazolyl, benzofuranyl, benzothiazolyl, benzothienyl, benzoxadiazolyl, benzoxazolyl, indolyl, isoquinolinyl, and quinolinyl wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of -13- WO 2005/010009 PCT/US2004/024003 alkenyl, alkoxy; alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, and nitro; Z is C; and X is S. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is heteroaryl wherein the heteroaryl is selected from the group consisting of indolyl, pyridinyl, and pyrimidinyl wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkyl, formyl, halogen, and haloalkyl; R2 is hydrogen; R3 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzofiiranyl, benzothienyl, and indolyl wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, and nitro; Z is C; and X is S. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is heteroaryl; R2 is hydrogen; R3 is heterocyclyl; X is S; Z is C; and Ra and Rb are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R1 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzothiazolyl, benzothienyl, benzoxazolyl, friryl, indolyl, pyrazolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, and thienyl wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkyl, formyl, halogen, and haloalkyl; R2 is hydrogen; R3 is heterocyclyl wherein the heterocyclyl is selected from the group consisting of dihydroindolyl and dihydroisoindolyl wherein the heterocyclyl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, carbbxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, and hydroxyalkyl; Z is C; and X is S. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is heteroaryl wherein the heteroaryl is selected from the group consisting of indolyl, pyridinyl, and pyrimidinyl wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkyl, formyl, halogen, and haloalkyl; R2 is hydrogen; R3 is heterocyclyl wherein the heterocyclyl is selected from the group consisting of dihydroindolyl and dihydroisoindolyl wherein the heterocyclyl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, and hydroxyalkyl; Z is C; and X is S. In another embodiment, the present invention provides compounds of formula (X) wherein R1 is selected from the group consisting of alkynyl, arylalkynyl, aryloxyalkynyl, arylsulfanylalkynyl, cyanoalkynyl, heteroaryl alkynyl, hydroxyalkynyl, and (NRaRb)alkynyl; R2 is hydrogen; R3 is heterocyclyl; Z is C; X is S; and Ra and Rb are as defined in formula (I). -14- WO 2005/010009 PCT/US2004/024003 In another embodiment, .the, present invention provides compounds of formula (I) wherein R1 is (NRaRb)alkynyl; R2 is hydrogen; R3. is heterocyclyl wherein the heterocyclyl is selected from the group consisting of dihydroindolyl and dihydroisoindolyl wherein the heterocyclyl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, and hydroxy alky I; Z is C; X is S; and Ra and Rb are independently selected from the group consisting of hydrogen, alley 1, alkylcarbonyl, alkylsulfonyl, and heterocyclylcarbonyl wherein .the heterocyclyl is pyridinyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of alkenyl, arylalkenyl, heterocyclyl alkenyl, hydroxyalkenyl, (NRaRb)carbonylalkenyl, and (NRaRb) alkenyl; R2 is hydrogen; R3 is heterocyclyl; Z is C; X is S; and Ra and Rb are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R1 is heterocyclylalkenyl wherein the heterocycle is selected from the group consisting of piperazinyl and piperidinyl wherein the heterocycle is optionally substituted with 1 substttuent selected from the group consisting of carboxy, hydroxy, hydroxyalkyl, oxo, NRaRb, and (NRaRb)'alkyl; R2 is hydrogen; R3 is heterocyclyl wherein the heterocyclyl is selected from the group consisting of dihydroindolyl and dihydroisoindolyl wherein the heterocyclyl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, and hydroxyalkyl; Z is C; X is S; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with NH2. In another embodiment, the present invention provides compounds of formula (I) wherein Rl is (NRaRb)carbonylalkenyl; R2 is hydrogen; R3 is heterocyclyl wherein the heterocyclyl is selected from the group consisting of dihydroindolyl and dihydroisoindolyl wherein the heterocyclyl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, and hydroxyalkyl; Z is C; X is S; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with NH2. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is (NRaRb)alkenyl; R2 is hydrogen; R3 is heterocyclyl wherein the heterocyclyl is selected from the group consisting of dihydroindolyl and dihydroisoindolyl wherein the heterocyclyl is optionally substituted with 1 or 2 substituents selected from the group -15- WO 2005/010009 PCT/US2004/024003 consisting of alkenyl; alkoxy, alkoxyalkyl alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, and hydroxyalkyl; Z is C; X is S; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with NH2. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is aryl; and Z, X, R2, and R3 are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R1 is aryl wherein the aryl is phenyl optionally substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkylsulfonyl, carboxy, cyano, halo, haloallcoxy, haloalkyl, hydroxy, methylenedioxy, 4-methylpiperazin-l-yl, phenoxy, (3-piperidm-l-ylpropanoyl)amino, pyrrolidin-1-ylmethyl, -NRaRb, (NRaRb)alkyl, and (NR3Rb)carbonyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; R4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents selected from the group consisting of alkyl, alkylcarbonyl, cyano, halogen, and haloalkyl wherein the preferred groups are chloro, fluoro, methyl, and trifluoromethyl; L is (CH2)mN(Rs)C(0)N(R6)(CH2)n; R5 and R6 are hydrogen; m is 0; n is 0; Z is C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, and (NR3Rb) alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is aryl wherein the aryl is phenyl optionally substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkylsulfonyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, methylenedioxy, 4-methylpiperazin-l-yl, phenoxy, (3-piperidin-l-ylpropanoyl)ammo, pyrrolidin-1-ylmethyl, -NRaRb(NRaRb)alkyl, and (NRaRb)carbonyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with NH2; Z is C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, and (NRcRd)alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein Rl is aryl wherein the aryl is phenyl optionally substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkylsulfonyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, methylenedioxy, 4-methylpiperazin-l-yl, phenoxy, (3-piperidin-l-ylpropanoyl)amino, pyrrolidin-l-ylmethyl, -NRaRb, (NRaRb)alkyl, and (NRaRb)carbonyl; R2 is hydrogen; R3 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzofuranyl, benzothienyl, and indolyl wherein the heteroaryl is optionally substituted with 1 or 2 -16- WO 2005/010009 PCT/US2004/024003 substituents selected from the group. consisting of alkenyl, alkoxy, alkaxyalkyl,,. alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, and nitro; Z is C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, and (NRcRd)alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is aryl wherein the aryl is phenyl optionally substituted with 1,2, or 3 substituents selected from the group consisting of alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkylsulfonyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, methylenedioxy, 4-methylpiperazin-l-yl, phenoxy, (3-piperidin-l-ylpropanoyl)amino, pyrrolidine-ylmethyl, -NRaRb, (NRaRb) alkyl, and (NRaRb)carbonyl; R2 is hydrogen; R3 is heterocyclyl wherein the heterocyclyl is selected from the group consisting of dihydroindolyl and dihydroisoindolyl wherein the heterocyclyl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, and hydroxyalkyl; Z is C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen,-alkyl, alkylcarbonyl, alkylsulfonyl, and (NRcRd)alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, and (NRaRb)carbonyl; and Z, X, Ra, Rb, R2, and R3 are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, and (NRaRb)carbonyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; R4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkylcarbonyl, cyano, halogen, and haloalkyl wherein the preferred groups are chloro, fluoro, methyl, and trifluoromethyl; L is (CH2)mN(R5)C(0)N(R6)(CH2)n; R5 and R6 are hydrogen; m is 0; n is 0; Z is C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, heteroarylalkyl, and (NR alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, and (NRaRb)carbonyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with NH2; Z is C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen, -17- WO 2005/010009 PCT/US2004/024003 alkyl, alkylcarbonyl, alkylsulfonyl, heteroarylalkyl, and (NRcRd)alkylcarbonyl and .Rc and Rl are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, and (NRaRb)carbonyl; R2 is hydrogen; R3 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzofriranyl., benzothienyl, and indolyl wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfonyl, alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, and nitro; Z is C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, heteroarylalkyl, and (NRcRd)alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, and (NRaRb)carbonyl; R2 is hydrogen; R3 is heterocyclyl wherein the heterocyclyl is selected from the group consistmg of dihydroindolyl and dihydroisoindolyl wherein the heterocyclyl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, and hydroxyalkyl; Z is C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, heteroarylalkyl, and (NRcRd)alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of heterocyclyl, heterocyclylalkynyl, heterocyclylcarbonyl, and heterocyclyl alkyl; and X, R2, and R3 are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of heterocyclyl, heterocyclylalkynyl, heterocyclylcarbonyl, and heterocyclylalkyl, wherein the heterocyclyl is selected from the group consisting of morpholinyl, piperazinyl, and piperidinyl, wherein the heterocyclyl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, oxo, phenyl, pyrinudinyl, pyridinyl, and (NR )alkyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; R4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkylcarbonyl, cyano, halogen, and haloalkyl wherein the preferred groups are chloro, fluoro, methyl, and trifluoromethyl; L is (CH2)mN(R5)C(0)N(R6)(CH2)n; R5 and R6 are hydrogen; m is 0; n is 0; Z is C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, 18 WO 2005/010009 PCT/US2004/024003 alkylsulfonyl, and (NRcRd)alkylcarbonyl; and Rc and R4 are independently, selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of heterocyciyl, heterocyclylalkynyl, heterocyclylcarbonyl, and heterocyclylalkyl, wherein the heterocyciyl is selected from the group consisting of morpholinyl, piperazmyl, and pipendinyl, wherein the heterocyciyl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, oxo, phenyl, pyrimidinyl, pyridinyl, and (NRaRb)alkyl; R2 is hydrogen; R: is aryl wherein the aryl is phenyl substituted with NH2; Z is C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, and (NRcRd)alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein Rl is selected from the group consisting of heterocyciyl, heterocyclylalkynyl, heterocyclylcarbonyl, and heterocyclylalkyl, wherein the heterocyciyl is selected from the group consisting of morpholinyl, piperazinyl, and pipendinyl, wherein the .heterocyciyl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, oxo, phenyl, pyrimidinyl, pyridinyl,. and (NRaRb)alkyl; R2 is hydrogen; R3 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzofuranyl, benzothienyl, and indolyl wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, and nitro; Z is C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, and (NRaRd ) alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (1) wherein R1 is selected from the group consisting of heterocyciyl, heterocyclylalkynyl, heterocyclylcarbonyl, and heterocyclylalkyl, wherein the heterocyciyl is selected from the group consisting of morpholinyl, piperazinyl, and pipendinyl, wherein the heterocyciyl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, oxo, phenyl, pyrimidinyl, pyridinyl, and (NRaRb)alkyl; R2 is hydrogen; R3 is heterocyciyl wherein the heterocyciyl is selected from the group consisting of dihydroindolyl and dihydroisoindolyl wherein the heterocyciyl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alleylcarbonyl, alkylsulfanyl, alkynyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, and hydroxyalkyl; Z is C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, -19- WO 2005/010009 PCT/US2004/024003 alkylsulfonyl, and (NRcRd)alkylcarbonyl; and Rc and Rd are independently selected from the' group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, and carbonyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR"; R4 is heteroaryl wherein the heteroaryl is selected from the group consisting of indolyl and thienyl wherein the heteroaryl is optionally substituted with 1 alkyl group wherein the preferred aieteoaryl is l-methyl-lH-indol-2-yl; L is (CH2)mN(R5)C(0)N(R')(CH2)ri; R5 and R6 are hydrogen; m is 0; n is G, Z-rs C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, heteroarylalkyl, and (NRcRd)alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzothiazolyl, benzotluenyl, benzoxazolyl, furyl, indolyl, pyrazolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, and thienyl wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkyl, formyl, halogen, and haloalkyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; R4 is heteroaryl wherein the heteroaryl is selected from the group consisting of indolyl and thienyl wherein the heteroaryl is optionally substituted with 1 alkyl group wherein the preferred heteoaryl is l-methyl-lH-indol-2-yl; L is (CH2)in N(R5)C(0)N(R6)(CH2)n; R5 and R6 are hydrogen; m is 0; n is 0; Z is C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, heteroarylalkyl, and (NRcRd) alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, and (NRaRb)carbonyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; R4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkylcarbonyl, cyano, halogen, and haloalkyl wherein the preferred groups are chloro, fluoro, methyl, and trifluoromethyl; L is (CH2)mN(R5)C(0)N(R6)(CH2)n; R5 and R6 are hydrogen; m is 0; n is 0; Z is C; X is O; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, heteroarylalkyl, and (NRaRb) alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is aryl wherein the aryl is phenyl optionally substituted with 1, 2, or 3. substituents selected from the group consisting of alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, -20- WO 2005/010009 PCT/US2004/024003 alkylsulfanyl, alkylsulfonyl, carboxy cyano halo haloalkoxy, haloalkyl, hydroxy, methylenedioxy, 4-methylpiperazin-l-yl, phenoxy, (3-piperidin-l-ylpropanoyl)amino, pyrrohdin-1-ylmethyl, -NRaRb, (NRaRb)alkyl, and (NRaRb)carbonyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; R4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents selected from the group consisting of alkyl, alkylcarbonyl, cyano, halogen, and haloalkyl wherein the preferred groups are chioro, fluoro, methyl, and trifluoromethyl; L is (CH2)mN(R5)C(0)N(R6)(CH2)11; Rs and R6 are hydrogen; rn is 0; n is 0; Z is C; X is O; Rn and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alley Isulfonyl, and (NRcRd)alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is heteroaryl wherein the heteroaryl is selected from the group consisting of benzothiazolyl, benzothienyl, benzoxazolyl, furyl, indolyl, pyrazolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, and thienyl wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkyl, formyl, halogen, and haloalkyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; R4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkylcarbonyl, cyano, halogen, and haloalkyl wherein the preferred groups are chioro, fluoro, methyl, and trifluoromethyl; L is (CH2)niN(R5)C(0)N(R6)(CH2)u; R5 and R6 are hydrogen; m is 0; n is 0; Z is C; and X is O. In another embodiment, the present invention provides compounds of formula (I) wherein R! is selected from the group consisting of alkynyl, arylalkynyl, aryloxy alkynyl, arylsulfanylalkynyl, cyanoalkynyl, cycloalleylalkoxyalkynyl, heteroarylalkynyl, hydroxyalkynyl, and (NRaRb)alkynyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with LR4; R4 is aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkylcarbonyl, cyano, halogen, and haloalkyl wherein the preferred groups are chioro, fluoro, methyl, and trifluoromethyl; L is (CH2)mN(R5)C(0)N(Rc)(CH2)u; R5 and R6 are hydrogen; m is 0; n is 0; Z is C; X is O; and Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, and heterocyclylcarbonyl wherein the heterocyclyl is pyridinyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of heterocyclyl, heterocyclylalkynyl, heterocyclylcarbonyl, and heterocyclylalkyl, wherein the heterocyclyl is selected from the group consisting of morphohnyl, piperazinyl, and piperidinyl, wherein the heterocyclyl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, oxo, phenyl, pyrimidinyl, pyridinyl, and (NRaRb)alkyl; Rz is hydrogen; R3 is heterocyclyl wherein the heterocyclyl is selected from the group -21- WO 2005/010009 PCT/US2004/024003 consisting of dihydroindolyl anddihydroisoindolyl wherein. the heterocyclyl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkynyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, and hydroxyalkyl; Z is C; X is O; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, and (NRcRd)alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with alkoxy and LR4; R" is heteroaryl wherein the heteroaryl is indolyl optionally substituted with an alkyl group wherein the preferred alkyl group is methyl; L is NR5C(0)(CH2)n]; R5 and R6 are hydrogen; m is 0; Z is C; X is S; and R1 is as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R1 is aryl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with alkoxy and LR4; R4 is heteroaryl wherein the heteroaryl is indolyl optionally substituted with an alkyl group wherein the preferred alkyl group is methyl; L is NR5C(0)(CH,)m; R5 and K6 are hydrogen; m is 0; Z is C; and X is S. In another embodiment, the present invention provides compounds of formula (I) wherein R' is aryl wherein the aryl is phenyl optionally substituted with 1, 2, or 3 substituentsselected from the group consisting of alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl,alkylsulfanyl, alkylsulfonyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, methylenedioxy, 4-methylpiperazin-l-yl, phenoxy, (3-piperidin-l-ylpropanoyl)amino, pyrrolidin-1-ylmethyl, -NRaRb, (NRaRb)alkyl, and (NRaRb)carbonyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with alkoxy and LR4; R4 is heteroaryl wherein the heteroaryl is indolyl optionally substituted with an alkyl group wherein the preferred alkyl group is methyl; L is NR5C(0)(CH2)m; RS and R6 are hydrogen; m is 0; Z is C; X- is S; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, and (NR alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, cyano, (NRaRb)alkenyl, and (NRaRb)carbonyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with alkoxy and LR4; R4 is heteroaryl wherein the heteroaryl is indolyl. optionally substituted with an alkyl group wherein the preferred alkyl group is methyl; L is NR5C(0)(CH2)m; R5 and R6 are hydrogen; m is 0; Z is C; X is S; and Ra and Rb are as defined in formula (I). In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, -22- WO 2005/010009 PCT/US2004/024003 cyano, (NRaRb)alkenyl, and (NRaRb)carbonyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with alkoxy and LR4; R4 is heteroaryl wherein the heteroaryl is indolyl optionally substituted with an alkyl group wherein the preferred alkyl group is methyl; L is NRsC(0)(CH2)m; R5 and RG are hydrogen; m is 0; Z is C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl alkkylsulfonyl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, and (NRcRd)alkylcarbonyl; and Rc and RJ are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein Rl is selected from the group consisting of heterocyclyl, heterocyclylalkenyl, heterocyclylalkynyl, heterocyclylcarbonyl, and heterocyclylalkyl; Rz is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with alkoxy and LR4; R4 is heteroaryl wherein the heteroaryl is indolyl optionally substituted with an alkyl group wherein the preferred alkyl group is methyl; L is NR5C(0)(CH2)in; R5 and R6 are hydrogen; m is 0; Z is C; and X is S. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of heterocyclyl, heterocyclylalkenyl, heterocyclylalkynyl, heterocyclylcarbonyl, and heterocyclylalkyl, wherein the heterocyclyl is selected from the group consisting of morpholinyl, piperazinyl, and piperidinyl, wherein the heterocyclyl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, oxo, phenyl, pyrimidinyl, pyridinyl, and (NRaRb)a!kyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with alkoxy and LR4; R4 is heteroaryl wherein the heteroaryl is indolyl optionally substituted with an alkyl group wherein the preferred alkyl group is methyl; L is NR5C(0)(CH2)m; R5 and Rc are hydrogen; m is 0; Z is C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, and (NRcRd)alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment, the present invention provides compounds of formula (I) wherein R1 is selected from the group consisting of heteroaryl, heteroarylalkyl, and heteroarylcarbonyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with allcoxy and LR"; R4 is heteroaryl wherein the heteroaryl is indolyl optionally substituted with an alkyl group wherein the preferred alkyl group is methyl; L is NRsC(0)(CH2)m; R5 and R6 are hydrogen; m is 0; Z is C; and X is S. In another embodiment, the present invention provides compounds of formula (I) wherein R' is heteroaryl wherein the heteroaryl is selected from the group consisting of benzothiazolyl, benzothienyl, benzoxazolyl, furyl, indolyl, pyrazolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, and thienyl wherein the heteroaryl is optionally substituted with 1 or 2 substituents selected from the group consisting of alkoxy, alkyl, formyl, halogen, haloalkyl, NRaRb, and (NRaRb)carbonyl; R2 is hydrogen; R3 is aryl wherein the aryl is phenyl substituted with alkoxy and LR4; R4 is heteroaryl wherein the heteroaryl is indolyl optionally -23- WO 2005/010009 PCT/US2004/024003 substituted with an alkyl group wherein the preferred alkyl group is methyl; L is NR5C(0)(CH3)m; R5 and R6 are hydrogen; m is 0; Z is C; X is S; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, and (NRaRb)alkylcarbonyl; and Rc and Rd are independently selected from the group consisting of hydrogen and alkyl. In another embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a therapeutically acceptable salt thereof, in combination with a therapeutically acceptable carrier. In another embodiment the present invention provides a method for inhibiting one or more protein kinases in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula . (I), or a therapeutically acceptable salt thereof. Preferably the protein kinases are selected from the group consisting of KDR, Ckit, CSF-1R, PDGFRp, PDGFRct, F1M, Flt-3, Flt-4, Tie-2, Lck, Src, Fyn, Lyn, Blk, Hck, Fgr, Cot, and Yes. More preferably the protein kinases are selected from the group consisting of KDR and Lck. In another embodiment the present invention provides a method for treating a condition in a patient comprising administering a therapeutically effective amount of a compound of formula (1), or a therapeutically acceptable sab thereof, to the patient, wherein the condition is selected from the group consisting of an ocular condition, a cardiovascular condition, a cancer, Oow-Fukase (POEMS) syndrome, a diabetic condition, sickle cell anemia, chronic inflammation, systemic lupus, g10merulonephritis, synovitis, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, osteoarthritis/multiple sclerosis, graft rejection, lyme disease, sepsis, von Hippel Lindau disease, pemphigoid, psoriasis, Paget's disease, polycystic kidney disease, fibrosis, sarcoidosis, cirrhosis, thyroditis, hyperviscosity syndrome, Osier-Web er-Rendu disease, chronic occlusive pulmonary disease, asthma or edema following burns, trauma, radiation, stroke, hypoxia, ischemia, overian hyperstimulation syndrome, preecampsia, menometrorrhagia, endometriosis, or infection by Herpes simplex, Herpes Zoster, human immunodeficiency virus, parapoxyvirus, protozoa, and toxoplasmosis. More preferably the condition is a cancer. Detailed Description of the Invention All publications, issued patents, and patent applications cited herein are hereby incorporated by reference. As used in the present specification the following terms have the meanings indicated: As used herein, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. -24- WO 2005/010009 PCT/US2004/024003 The term "alkenyl," as used herein, refers to astraight ortonched chain group of two to ten carbon atoms containing at least one carbon-carbon double bond. Preferred allcenyl groups of the present invention contain two to three carbon atoms. The term "alkoxy," as used herein, refers to an alkyl group attached to the parent molecular moiety through an oxygen atom. The term " alkoxy alkyl," as used herein, refers to an alkyl group substituted with at least one alkoxy group. The term "alkoxycarbonyl," as used herein, refers to an alkoxy group attached to the parent molecular moiety through a carbonyl group. The term "alkoxycarbonylalkenyl," as used herein, refers to an allcenyl group substituted with at least one alkoxycarbonyl group. The term "alkoxycarbonylalkyl," as used herein, refers to an alkyl group substituted with at least one alkoxycarbonyl group. The term "alkoxycarbonylallcynyl," as used herein, refers to an alkynyl group substituted with at least one alkoxycarbonyl group. The term "alkyl," as used herein, refers to a group derived from a straight or branched chain saturated hydrocarbon containing from one to ten carbon atoms. Preferred alkyl groups of the present invention contain one to four carbon atoms. The term "alkylcarbonyl," as used herein, refers to an alkyl group attached to the parent molecular moiety through a carbonyl group. The term "alleylsulfanyl," as used herein, refers to an alkyl group attached to the parent molecular moiety through a sulfur atom. The term "alkylsulfanylalkyl," as used herein, refers to an alkyl group substituted with at least one alkylsulfanyl group. The term "alkylsulfonyl," as used herein, refers to an alkyl group attached to the parent molecular moiety through a sulfonyl group. The term "alkynyl," as used herein, refers to a straight or branched chain hydrocarbon of two to ten carbon atoms containing at least one carbon-carbon triple bond. Preferred alkynyl groups of the present invention contain between two and six carbon atoms. The term "aryl," as used herein, refers to a phenyl group, or a bicyclic or tricyclic fused ring system wherein one or more of the fused rings is a phenyl group. Bicyclic fused ring systems are exemplified by a phenyl group fused to a monocyclic cycloalkenyl group, as defined herein, a monocyclic cycloalkyl group, as defined herein, or another phenyl group. Tricyclic fused ring systems are exemplified by a bicyclic fused ring system fused to a monocyclic cycloalkenyl group, as defined herein, a monocyclic cycloalkyl group, as defined herein, or another phenyl group. Representative examples of aryl groups include, but are not limited to, anthracenyl, azulenyl, fluorenyl, indanyl, indenyl, naphthyl, phenyl, and tetrahydronaphthyl. The aryl groups of the present invention can be optionally substitute -25- WO 20(15/010009 PCT/US2004/024003 with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkylsulfonyl, alkynyl, a second aryl group, arylalkenyl, arylalkoxy, arylalkyl, aryloxy, carboxy, carboxyalkenyl, carboxyalkyl, cyano, formyl, formylalkenyl, halo, haloalkoxy, haloalkyl, heteroaryl, heteroaryl alkyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, hydroxy, hydroxyalkyl, methylenedioxy, nitro, NRaRb, (NRaRb)alkyl, (NRaRb)carbonyl, and oxo; wherein the second aryl group, the aryl part of the arylalkenyl, the arylalkoxy, the arylalkyl, and the aryloxy, the heteroaryl, the heteroaryl part of the heteroarylalkyl, the heterocyclyl, and the heterocyclyl part of the heterocyclylalkyl can be further optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkyl, halo, haloalkoxy, haloalkyl, hydroxy, nitro, and heterocyclyl wherein the heterocyclyl can be further optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkyl, halo, haloalkoxy, haloalkyl, hydroxy, and nitro. The term "arylalkenyl," as used herein, refers to an alkenyl group substituted with at least one aryl group. The term "arylalkoxy," as used herein, refers to an arylalkyl group attached to the parent molecular moiety through an oxygen atom. The term "arylalkoxycarbonyl," as used herein, refers to an arylalkoxy group to the parent molecular moiety through a carbonyl group. The term "arylalkoxycarbonylalkyl," as used herein, refers to an alkyl group substituted with at least one arylalkoxycarbonyl group. The term "arylalkyl," as used herein, refers to an alkyl group substituted with at least one aryl group. The term "arylalkynyl," as used herein, refers to an alkynyl group substituted with at least one aryl group. The term "arylcarbonyl," as used herein, refers to an aryl group attached to the parent molecular moiety through a carbonyl group. The term "aryloxy," as used herein, refers to an aryl group attached to the parent molecular moiety through an oxygen atom. The term "aryloxyalkyl," as used herein, refers to an alkyl group substituted with at least one aryloxy group. The term "aryloxyalkynyl," as used herein, refers to an alkynyl group substituted with at least one aryloxy group. The term "arylsulfanyl," as used herein, refers to an aryl group attached to the parent molecular moiety through a sulfur atom. The term "arylsulfanylalkyl," as used herein, refers to an alkyl group substituted with at least one arylsulfanyl group. -26- WO 2005/0.10009 PCT/US2004/024003 The term "arylsu'lfanylalkynyl," as used herein, refers to an alkynyl group substituted with at least one arylsulfanyl group. The term "arylsulfonyl," as used herein, refers to an aryl group attached to the parent molecular moiety through a sulfonyl group. The term "arylsulfonyloxy," as used herein, refers to an arylsulfonyl group attached to the parent molecular moiety through an oxygen atom. The term "arylsulfonyloxy alkenyl," as used herein, refers to an alkenyl group substituted with at least one arylsulfonyloxy group. The term "carbonyl," as used herein, refers to -C(O)-. The term "carboxy," as used herein, refers to -C02H. The term "carboxyalkenyl," as used herein, refers to an alkenyl group substituted with at least one carboxy group. The term "carboxyalkyl," as used herein, refers to an alkyl group substituted with at least one carboxy group. The term "carboxyalkenyl," as used herein, refers to an alkenyl group substituted with at least one carboxy group. The term " carboxy alkynyl," as used herein, refers to an alkynyl group substituted with at least one carboxy group. The term "cyano," as used herein, refers to -CN. The term "cyanoalkynyl," as used herein, refers to an alkynyl group substituted with at least one cyano group. The term "cycloalkenyl," as used herein, refers to a non-aromatic cyclic or bicyclic ring system having three to ten carbon atoms and one to three rings, wherein each five-membered ring has one double bond, each six-membered ring has one or two double bonds, each seven- and eight-membered ring has one to three double bonds, and each nine-to ten-membered ring has one to four double bonds. Representative examples of cycloalkenyl groups include, but are not limited to, cyclohexenyl, octahydronaphthalenyl, and norbornylenyl. The term "cycloalkyl," as used herein, refers to a saturated monocyclic, bicyclic, or tricyclic hydrocarbon ring system having three to twelve carbon atoms. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, bicyclo[3.1.1]heptyl, and adamantyl. The cycloalkyl groups of the present invention can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkoxy, alkyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, nitro, NRaRd and spiroheterocyclyl. A preferred cycloalkyl group of the present invention is cyclohexyl. The term "cycloalkylalkoxy," as used herein, refers to an alkoxy group substituted with at least one cycloalkyl group. -27- WO 2005/010009 PCT/US2004/024003 The term "cycloalkylalkoxyalkynyl,” as used herein, refers to an alkynyl group substituted with at least one cycloalkylalkoxy group. The term "cycloalkylalkenyl," as used herein, refers to an alkenyl group substituted with at least one cycloalkyl group. The term "cycloalkylalkyl," as used herein, refers to an alkyl group substituted with at least one cycloalkyl group. The term "formyl," as used herein, refers to –C (O)- The term "formylalkenyl," as used herein, refers to an alkenyl group substituted with at least one formyl group. The term "formylalkyl," as used herein, refers to an alkyl group substituted with at least one formyl group. The terms "halo" and "halogen," as used herein, refer to F, CI, Br, or I. The term "haloalkoxy," as used herein, refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom. The term "haloalkyl," as used herein, refers to an alkyl group substituted by one, two, three, or four halogen atoms. A preferred haloalkyl group of the present invention is trfiluoromethyl. The term "heteroalkylene," as used herein, refers to a divalent group of two to eight atoms derived from a saturated straight or branched chain containing one or two heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein the remaining atoms are carbon. The heteroalkylene groups of the present invention are attached to the parent molecular moiety through the carbon atoms or the heteroatoms in the chain. The term "heteroaryl," as used herein, refers to an aromatic five- or six-membered ring where at least one atom is selected from the group consisting of N, O, and S, and the remaining atoms are carbon. The five-membered rings have two double bonds, and the six-membered rings have three double bonds. The heteroaryl groups are connected to the parent molecular moiety through a substitutable carbon or nitrogen atom in the ring. The term "heteroaryl" also includes bicyclic systems where a heteroaryl ring is fused to a phenyl group, a monocyclic cycloalkenyl group, as defined herein, a monocyclic cycloalkyl group, as defined herein, a monocyclic heterocyclyl group, as defined herein, or an additional monocyclic heteroaryl group; and tricyclic systems where a bicyclic system is fused to a phenyl group, a monocyclic cycloalkenyl group, as defined herein, a monocyclic cycloalkyl group, as defined herein, a heterocyclyl group, as defined herein, or an additional monocyclic heteroaryl group. Representative examples of heteroaryl groups include, but are not limited to, benzimidazolyl, benzoxadiazolyl, benzoxazolyl, benzofuranyl, benzisoxazolyl, benzothiazolyl, benzothienyl, cinnolinyl, dibenzofuranyl, furanyl, imidazolyl, indazolyl, indolyl, isoxazolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxadiazolyl, oxadiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, quinolinyl, 28 WO 2005/010009 PCT/US 2OO4/O24003 thiazolyl, mienopyridinyl, thienyl, triazolyl, thiadiazolyl, and triazinyl. Preferred heteroaryl groups of the present invention are benzofuranyl, benzoxazolyl, furyl, imidazolyl, indolyl, isoquinolinyl, isoxazolyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl, and thienyl. The heteroaryl groups of the present invention can be optionally substituted with one, two, three, folio five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alleylsulfanyl, alkynyl, aryl, arylalkenyl, aiylalkoxy, arylalkyl, cyano, formyl, halo, haloalkoxy, haloalkyl, a second heteroaiyl group, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, hydroxy, hydroxyalkyl, nitro, NRaRb, (NRaRb)alkyl, (NRaRb)carbonyl, and oxo; wherein the aryl, the aryl part of the alkenyl, the arylalkoxy, and the arylalkyl, the second heteroaryl group, the heteroaryl part of the hetero arylalkyl, the heterocyclyl, and the heterocyclyl part of the heterocyclylalkyl can be further optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkyl, halo, haloalkoxy, haloalkyl, hydroxy, and nitro. The term "heteroarylalkenyl," as used herein, refers to an alkenyl group substituted with at least one heteroaiyl group. The term "heteroarylalkyl," as used herein, refers to an alkyl group substituted with at least one heteroaryl group. The term "heteroarylalkynyl," as used herein, refers to an alkynyl group substituted with at least one heteroaryl group. The term "heteroarylcarbonyl," as used herein, refers to a heteroaryl group attached to the parent molecular moiety through a carbonyl group. The term "heteroarylcarbonylalkenyl," as used herein, refers to an alkenyl group substituted with at least one hetero arylcarbonyl group. The term "heteroarylcarbonylalkyl as used herein, refers to an alkyl group substituted with at least one hetero arylcarbonyl group. The term "hetero arylsulfonyl," as used herein, refers to a heteroaryl group attached to the parent molecular moiety through a carbonyl group. The term "heterocyclyl," as used herein, refers to a non-aromatic four-, five-, six-, seven-, or eight-membered monocyclic or bicyclic ring where at least one atom is selected from the group consisting of oxygen, nitrogen, and sulfur. The four- and five-membered rings have zero or one double bonds and the six- and seven-membered rings have zero, one, or two double bonds. The heterocyclyl groups of the invention are connected to the parent molecular group through a substitutable carbon or nitrogen atom in the ring. The term "heterocyclyl" also includes systems where a heterocyclyl ring is fused to a phenyl group, a monocyclic cycloalkenyl group, as defined herein, a monocyclic cycloalkyl group, as defined herein, or an additional monocyclic heterocyclyl group; and tricyclic systems where a bicyclic system is fused to a phenyl group, a monocyclic cycloalkenyl group, as defined -29- WO 2005/010009 PCT/US2004/024003 herein, a monocyclic cycloalkyl group, as defined herein,' or an additional monocyclic, heterocyclyl group. Representative examples of heterocyclyl groups include, but are not limited to, azetidinyl, benzodioxolyl, benzothiazolyl, diazepanyl, dihydroindolyl, dihydroisomdolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl, moipholinyl, piperazinyl, pyrrolidinyl, tetrahydropyndinyl, piperidinyl, and thiomorpholinyl. Preferred heterocyclyl groups of the present invention are benzodioxolyl, diazepinyl, imidazolidinyl, moipholinyl, piperazinyl, piperidinyl, pyrrolidinyl, and tetrahydropyranyl. The heterocyclyl groups of the present invention can be optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfanyl, alkylsulfonyl, alkynyl, aryl, arylalkenyl, arylallcoxy, arylalkyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, halo, haloalkoxy, haloalkyl, heteroaryl, heteroarylalkyl, heteroarylcarbonyl, a second heterocyclyl group, heterocyclylalkyl, hydroxy, hydroxyalkyl, nitro, lSTRaRb, (NRaRb)alkyl, (NRaRb)alkylcarbonyl, (NRaRb)carbonyl, (NRaRb)carbonylalkyl, (NRaRb)sulfonyl, oxo, and spiroheterocyclyl; wherein the aryl group, the aryl part of the arylalkenyl, the arylalkoxy, and the arylalkyl, the heteroaryl, the heteroaryl part of the heteroarylalkyl and the heteroarylcarbonyl, the second heterocyclyl group, and the heterocyclyl part of the heterocyclylalkyl can be further optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkyl, halo, haloalkoxy, haloalkyl, hydroxy, and nitro. The term "heterocyclylalkenyl," as used herein, refers to an alkenyl group substituted with at least one heterocyclyl group. The term "heterocyclylalkyl," as used herein, refers to an alkyl group substituted with at least one heterocyclyl group. The term "heterocyclylalkylcarbonyl," as used herein, refers to a heterocyclylalkyl group attached to the parent molecular moiety through a carbonyl group. The term "heterocyclylalkynyl," as used herein, refers to an alkynyl group substituted with at least one heterocyclyl group. The term "heterocyclylcarbonyl," as used herein, refers to a heterocyclyl group attached to the parent molecular moiety through a carbonyl group. The term "heterocyclylcarbonylalkenyl," as used herein, refers to an alkenyl group substituted with at least one heterocyclylcarbonyl group. The term "heterocyclylcarbonylalkyl," as used herein, refers to an alkyl group substituted with at least one heterocyclylcarbonyl group. The term "hydroxy," as used herein, refers to -OH. The term "hydroxyalkenyl," as used herein, refers to an alkenyl group substituted with at least one hydroxy group. -30- WO 2005/01000!) PCT/US2004/024003 The term " hydroxyalkoxy," as used herein, refers to a hydroxyalkyl group attached to the parent molecular moiety through an oxygen atom. The term "hydroxyalkoxyalkyl," as used herein, refers to an alkyl group substituted with at least one hydroxyalkoxy group. The term "hydroxyalkyl," as used herein, refers to an alkyl group substituted with at least one hydroxy group. The term "hydroxy alkynyl," as used herein, refers to an alkynyl group substituted with at least one hydroxy group. The term "methylenedioxy" as used herein, means a -OCH20- group wherein the oxygen atoms of the methylenedioxy are attached to the parent molecular moiety through two adjacent carbon atoms. The term "nitre," as used herein, refers to -N02. The term "nitroalkenyl," as used herein, refers to an alkenyl group substituted with at least one nitro group. The term "nitroalkyl," as used herein, refers to an alkyl group substituted with at least one nitro group. The term "nitroalkynyl," as used herein, refers to an alkynyl group substituted with at least one nitro group. The term "NR"Rb," as used herein, refers to two groups, Ra and Rb, which are attached to the parent molecular moiety through a nitrogen atom. R° and Rb are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylsulfanylalkyl, alleylsulfonyl, aryl, arylalkoxycarbonyl, arylalkoxycarbonylalkyl, arylalkyl, arylcarbonyl, arylsulfonyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, formylalkyl, heteroaryl, heteroarylalkyl, heteroarylcarbonyl, heteroarylsulfonyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkylcarbonyl, heterocyclylcarbonyl, heterocycly lsulfonyl, hydroxyalkoxy alkyl, hydroxyalkyl, (NRcRd)alkyl, (NRcRd)alkylcarbonyl, (NRcRd)carbonyl, and (NRcRd)carbonylalkyl, wherein the aryl, the aryl part of the arylalkoxycarbonyl, the arylalkoxycarbonylalkyl, the arylalkyl, the arylcarbonyl, and the arylsulfonyl, the cycloalkyl, the cycloalkyl part of the cycloalkylalkyl, the heteroaryl, the heteroaryl part of the heteroarylalkyl, and the heteroarylcarbonyl, the heterocyclyl, and the heterocyclyl part of the heterocyclylalkyl and the heterocyclylcarbonyl can be further optionally substituted with one, two, three, four, or five substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, aryl, arylalkyl, halo, haloalkoxy, haloalkyl, hydroxy, nitro, NR9.47 (s, 1H);MS (ESI(+)) m/e 447.0 (M+H)+. Example 4 N-[4-(4-aminothieno[3,2-c]pvridin-3-vl)-2-fluorophenvl]-N'-[2-fluoro-5- (trifluoromethyl)phenyl]urea The desired product was prepared by substituting l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene for l-isocyanato-3-methylbenzene in Example 1. 1HNMR(300 MHz, DMSO-dg) δ 5.43 (s, 2H), 7.26 (dd, J-9.0, 2.2 Hz, IH), 7.28 (d, J=5.4 Hz, IH), 7.41 (dd, J=12.0, 1.9 Hz, IH), 7.40-7.45 (m, IH), 7.51 (s, IH), 7.53 (dd, J=11.2, 8.5 Hz, IH), 7.85 (d, J=5.8 Hz, IH), 8.32 (t, J-S.5 Hz, IH), S.66 (dd, J=7.3, 2.2 Hz, IH), 9.33 (d, J=2.4 Hz, IH), 9.45 (d, J=2.7 Hz, IH); MS (ESI(+)) m/e 465.0 (M+H)+. Example 5 N-[4-(4-aminothieno[3,2-c]pyridin-3-yl)-2-fluorophenvl]-N'-[3--brornophenyl)urea The desired product was prepared by substituting l-bromo-3-isocyanatobenzene for 1-isocyanato-3-rnethylbenzene in Example 1. JH NMR (300 MHz, DMSO-d6) δ 5.44 (s, 2H), 7.19 (dt, J=7.1, 1.9 Hz, IH), 7.24-7.33 (m, 4H), 7.39 (dd, J=11.9, 2.0 Hz, IH), 7.50 (s, IH), 7.84 (d, J=5.S Hz, IH), 7.89-7.91 (m, IH), 8.27 (t, J=S.5 Hz, IH), 8.77 (d, J-2.7 Hz, IH), 20 9.31 (s, IH); MS (ESI(+)) m/e 457.0, 458.S (M+H)+. Example 6 N-[4-(4-animotrueno[3,2-c]pyridin-3-yl)-3-fluorophenyl]-N,-(3-rnethylphenyl)urea Example 6A 3-(4-arnino-2-fluorophenyl)thieno[-3,2-c]pyridin-4-amine The desired product was prepared by substituting 4-bromo-3-fluoroaniline for 4-bromo-2-fluoroaniline in Example 1C. MS (ESI(+)) m/e 260.0 (M+H)+. Example 6B N-[4-(4-amrnothieno[3,2-c]pyridin-3-yl)-3-fluorophenyl]-N'-(3-methylphenvl)urea The desired product was prepared by substituting Example 6A for Example 1C in Example ID. !H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 5.34 (s, 2H), 6.82 (d, J=7.1 Hz, IH), 7.18 (t, J=7.6 Hz, IH), 7.24-7.28 (m, 3H), 7.32 (s, IH), 7.37 (t, J=8.5 Hz, IH), 7.53 (s, 35 IH), 7.65 (dd, J=12.2,2.0 Hz, IH), 7.83 (d, J=5.4 Hz, IH), 8.73 (s, IH), 9.06 (s, IH); MS (ESI(+)) m/e 393.0 (M+H)+. Example 7 -56- WO 2005/010009 PCT/US2004/024003 N-[4-(4-amrnothieno[3,2-c]pyridin-3-yl)-3-fluorophenyl]-N'-(3-methylphenvl)urea The desired product was prepared by substituting Example 6A and l-isocyanato-3-(trifluoromethyl)benzene for Example IC and l-isocyanato-3-methylbenzene, respectively, in Example ID. 1H NMR (300 MHz, DMSO-d6) & 5.34 (s, 2H), 7.28 (d, J=5.8 Hz, IH), 7.30-7.42 (rn, 3H), 7.51-7.57 (m, 2H), 7.61-7.6S (m, 2H), 7.S3 (d, J=5JSJ3z, IH), 8.02 (s, IH), 9.21 (s, IH), 9.22 (s, IH); MS (ESI(+)) m/e 447.0 (M+H)+. Example 8 N-[4-(4-aminothieno[3,2-c]pyridin-3-yl)-3-fiuorophenyl]-N'-(3-cblorophenYl)urea The desired product was prepared by substituting Example 6A and l-chloro-3- isocyanatobenzene for Example IC and l-isocyanato-3-methylbenzene, respectively, in Example ID. 1H NMR (300 MHz, DMSO-d6) δ 5.34 (s, 2H), 7.05 (ddd, JM6.2, 2.4,2.2 Hz, IH), 7.27 (d, J=5.4 Hz, IH), 7.28-7.32 (m, 3H), 7.39 (t, J=8.3 Hz, 1H),7.54 (s, IH), 7.64 (dd, J=12.5, 2.0 Hz, IH), 7.72-7.73 (m, IH), 7.S3 (d, J=5.4 Hz, IH), 9.04 (s, IH), 9.17 (s, IH); 15 MS (ESI(+)) m/e 413.0, 414.9 (M+H)+. Example 9 N-[4-(4-aminothieno[3,2-c]pyridm-3-yl)-3-chlorophenYl]-N'-(3-methylphenyl)urea Example 9A 3-(4-amino-2-chlorophenyl)thieno[3,2-c]pyridin-4-amine The desired product was prepared by substituting 4-bromo-3-chloroaniline for 4-bromo-2-fluoroaniline in Example IC. MS (ESI(+)) m/e 275.9, 278.1 (M+H)+. Example 9B N-[4-(4-arrunothieno[3,2-c]pyridin-3-yl)-3-chlorophenyl]-N'-(3-methylphenyl)urea The desired product was prepared by substituting Example 9A for Example IC in Example ID. 1HNMR (300 MHz, DMSO-d6) 8 2.29 (s, 3H), 5.22 (s, 2H), 6.82 (d, J=7.1 Hz, IH), 7.18 (t, J=7.S Hz, IH), 7.24-7.26 (m, IH), 7.26 (d, J-5.4 Hz, IH), 7.33 (s, IH), 7.41 (app. s, 2H), 7.4S (s, IH), 7.82 (d, J=5.8 Hz, IH), 7.91 (s, IH), 8.75 (s, IH), 9.04 (s, IH); MS (ESI(+)) m/e 409.0, 411.1 (M+H)+. Example 10 3-(4-pheuoxyphenyl)-7-(4-pyridmyl)tbieno[3,2-c]pyridin-4-arnine Example 10A 3-(4-phenoxypheny0thieno[3,2-c]pyridin-4-amine A mixture of Example IB (1.5g, 6.5 mmol), 4-phenoxyphenylboronic acid (1.53g, 7.1 -57- WO 2005/010009 PCT/US2004/024003 mmol) and Na2CO3 (l.Slg, '17.1'mmol) in toluene (26 mL), ethanol (5 mL), and water (10 mL) was purged with nitrogen for 45 minutes, then treated with Pd(PPh3)4 (0.3S2g, 0.33 mmol) and heated to 90 °C overnight. The reaction was cooled to room temperature and partitioned between water and ethyl acetate. The'aqueous phase was extracted with ethyl acetate twice and the combined organic extracts were washed with brine, dried (Na SO,,), filtered, and concentrated. The residue was purified by flash column chromatography on silica gel with 40% ethyl acetate/hexanes to provide 1.69g (82% yield) of the desired product. MS (ESI(+)) m/e 318.9 (M+H)+. Example 10B 7-iodo-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amine A solution of Example 10A (1.69$, 5.3 mmol) in DMF (20 mL) was treated with NTS (1.26g, 5.6 mmol), stirred at room temperature for 3 hours, poured into water, and filtered. The filter cake was purified by flash column chromatography on silica gel with 15% ethyl acetate/hexanes to provide 1.64g (70% yield) of the desired product. MS (ESI(+)) m/e 444.8 (M+H)+. Example IPC 3-(4'phenoxyphenyl)-7-(4-pyridinyl)thieno[3,2-c]pyridin-4-amine The desired product was prepared by substituting Example 10B, 4-pyridylboronic acid, and PdCl2(dppf) for Example IB, 4-phenoxyphenylboronic acid, and Pd(PPh3)4 respectively, in Example 10A. 1H NMR (300 MHz, DMSO-d6) δ 5.74 (s, 2H), 7.12-7.16 (m, 4H), 7.21 (t, J=7.5 Hz, 1H), 7.45 (dd, J=8.7, 7.3 Hz, 2H), 7.50 (d, J=8.5 Hz, 2H), 7.5S (s, 1H), 7.72 (d, J=6.1 Hz, 2H), 8.09 (s, 1H), 8.68 (d, J=6.1 Hz, 2H); MS (ESI(+)) m/e 396.0 (M+H)+. Example 11 4-((2E)-3-[4-aminQ-3-(4-Tjhenoxyphenyl)thieno[3,2-c]pyridin-7-yl]-2-propenoyl}-2- piperazinone Example 11A tert-butyl (2E)-3-[4-amino-3-('4-phenoxvphenvl')thieno[3,2-c]pvridin-7-vl]acrvlate A mixture of Example 10B (0.417g, 0.94 mmol), tert-butyl acrylate (0.26 mL, 1.74 mol) and triethylamine (0.7 mL, 5 mmol) in DMF (3 mL) was degassed with nitrogen for 45 minutes, treated with PdCl2(o-tol3P)2 (0.032g, 0.046 mmol), and heated to 80 °C overnight. The resulting mixture was cooled to room temperature, then partitioned between water and ethyl acetate. The organic extract was washed with brine, dried (Na2SO4,), filtered, and concentrated. The residue was purified by flash column chromatography on silica gel with -58- WO 2005/010009 PCT/US2004/024003 30% ethyl acetate/hexanes to provide 0.25g (61% yield) of the desired product. MS (ESI(+)) m/e445(M+H)+. Example 11B (2E)-3-[4-amino-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]acrylicacid A solution of Example 11A (0.25g, 0.57 mmol) in TEA (5 mL) was stirred at room temperature for 14 hours then concentrated under a stream of nitrogen to provide the desired product. MS (ESI(+)) m/e 3S8.9 (M+H)+. Example 11C 4-{(2E)-3-[4-amino-3-(4-phenoxyphenyl')thieno[-3,2-c]pyridin-7-yl]-2-propenoyl]-2- piperazinone A mixture of Example 1 IB (0.09g, 0.23 mmol), 2-piperazinone (0.069g, 0.69 mmol), HOBT (0.095g, 0.7 mmol), N-methylmorpholine (0.22 mL, 0.92 mmol), and EDCI (0.136g, 0.71 minol) in DMF (1 mL) was stuxed at room temperature overnight, treated with water (20 mL), and filtered. The filter cake was dried to provide 11 Omg of the desired product. 1H NMR (30t>MHz, DMSO-d6) 5 3.20-3.36 (br m, 2H), 3.71-3.91 (br m, 2H), 4.03-4.35 (m, 2H), 5.94 (brs,2H), 6.92-7.15 (brm, IH), 7.11-7.16 (m, 4H)', 7.21 (t, J-7.3 Hz, 1H),7.42-7.52 (m, 4H), 7.63 (s, IH), 7.71 (d, J-14.9 Hz, IH), 8.13 (br s, IH), 8.33 (s, IH); MS (ESI(-)) 20 m/e 469.3 (M-H)-. Example 12. tert-butyl (2E)-3-(4-amino-3-phenylthieno[3,2-c]pyridin-7-yl)acrylate Example 12A 7-iodo-3-phenylthieno[3,2-c]pyridin-4-amme The desired product was prepared by substituting phenylboronic acid for 4-phenoxyphenylboronic acid in Example 10A and 10B. Example 12B tert-butyl (2E)-3-(4-arnino-3-phenylthieno[3,2-c]pyridin-7-yl)acrylate The desired product was prepared by substituting Example 12A for Example 10B in Example 11 A. 1H NMR (300 MHz, DMSO-d6) 5 1.51 (m, 9H), 5,95 (br s, IH), 6.33 (d, H5.9 Hz, IH), 7.53 (m, 5H), 7.64 (s, IH), 7.72 (d, J=16.3 Hz, IH), 8.24 (s, IH); MS 35 (ESI(+))m/e353(M+H)+. Example 13 (2E)-3-(,4-amino-3-phenylthieno[3,2-c]pyridin-7-yl)acrylicacid -59- WO 2005/010009 PCT/US2004/024003 The desired product was prepared as the trifluoroacetate salt: by. substituting Examgi 12B for Example 11A in Example 1 IB. 1H NMR. (300 MHz, DMSO-dJ 5 6.52 (d, J-16.3 Hz, IH), 6.6-6.S (br s, 2H), 7.55 (m, 5H), 7.76 (d, J=16.3 Hz, IH), 7.86 (s, IH), 8.34 (s, IH) MS (ESI(+)) m/e 297 (M+H)+. Example 14 (2E)-3-(4-amino-3-phenylthieno[3,2-c]pvridin-7-vl)-N-methylacrvlamide A mixture of Example 13 (O.lg, 0.34 mmol), methylamine hydrochloride (0.115g, 1.69 mmol), HOBT (0.137g, 1.01 mmol), N-memylmorpholine ( 0.25 mL, 2.36 mmol), and EDCI (0.199g, 1.01 mmol) in DMF (5 mL) was stirred at room temperature for 2 hours, diluted with water (20 mL), and extracted with ethyl acetate (2 x 20 mL). The combined extracts were washed with brine, dried (MgS04), filtered, aud concentrated to provide 89 mg of the desired product. 1H NMR (300 MHz, DMSO-d δ 2.73 (d, J=4.8 Hz, 3H), 5.75,5.85 (br s, 2H), 6.58 (d, J=15.9 Hz, IH), 7.53 (m, 5H), 7.58 (d, J=15.9 Hz, IH), 7.67 (s, IH), 8.14 (ra, 2H); MS (ESI(+)) m/e 310 (M+H)+. Example 15 3-(4-amino-3-phenylthieno[3,2-c]pyridin-7-yl)-N-methylpropanamide A mixture of Example 14 (30mg, O.lmmol) and 10% Pd on carbon (30 mg) in 1:1 methanol/DMF (4 mL) was stirred under an atmosphere of hydrogen overnight. The suspension was filtered through diatomaceous earth (Celite®). The pad was washed with methanol and the filtrate was concentrated to half its original volume. The residue was diluted with diethyl ether and filtered. The filter cake was dried to provide 26 mg of the desired product. 1H NMR (300 MHz, DMSO-d,) 8 2.47 (m, 2H), 2.58 (d, J=4.6 Hz, 2H), 2.91 (t, J=7.9 Hz, 2H), 5.21 (s, IH), 7.50 (m, 6H), 7.66 (s, IH), 7.S1 (m, J=4.3 Hz, IH); MS (ESI(+))m/e312(M+H)+. Example 16 4-[(2E)-3-(4-anu'no-3-phenyltliLeno[3,2-c]pyridin-7-yl)-2-propenoyl]-2-piperazinone The desired product was prepared by substituting Example 13 for Example 1 IB in Example 1 IC. 1H NMR (300 MHz, DMSO-dJ 5 3.82 (br m, 2H), 4.20 (br m, 2H), 5.86 (br s 2H), 7.03 (br m, IH), 7.53 (m, 5H), 7.64 (s, IH), 7.71 (d, J=14.9 Hz, IH), 8.14 (s, IH), 8.33 (s, IH); MS (ESI(+)) m/e 379 (M+H)+. Example 17 tert-butyl (2E)-3- [3-[4-(acetylamino)phenyl]-4-aminotlueno[3,2-c]pvridin-7-yl) acrylate Example 17A -60- WO 2O05/0J0009 PCT7US200-I/024003 3-(4-aminophenvnthieno [3-,2-c]pyridin -4- amine The desired product was prepared by substituting 4-(4,4,5,54etramethyl-l,3,2-dioxaborolan-2-yl)aniline for 4-phenoxyphenylboronic acid in Example 10A. MS (ESI(+)) m/e 242 (M+H)+; 1H NMR (300 MHz, DMSO-d6) δ 5.35 (s, 2H), 5.48 (s, 2H), 6.66 (d, J=8.14 5 Hz, 2H), 7.08 (d, J=8.14 Hz, 2H), 7.20 (d, J=5.42 Hz, 1H), 7.27 (s, 1H), 7.78 (d, J=5.76 Hz, 1H). Example 17B N-[4-(4-aminothieno[3,2-c]pyridm-3-yl)phenyl]acetamide A -30 °C solution of Example 17A (O.lg, 0.41 mmol) and N-methylmorpho line (0.03 mL, 0.41 mmol) in THF (5 mL) was treated dropwise with acetyl chloride (0.03 mL, 0.41 mmol), stirred for 1 hour, warmed to 0 °C over 1 hour, quenched with water, and extracted twice with ethyl acetate. The combined extracts were washed with brine, dried (MgS04), filtered, and concentrated to provide 111 mg of the desired product. Rf= 0.24 (5% methanol/dichloromethane). Example 17C N-[4-(4-amino-7-iodothieno[3,2-c]pyridin-3-yl)phenyl]acetamide The desired product was prepared by substituting Example 17B for Example 10A in Example 10B. Example 17D tert-buty-(2E)-3-(3-[4-(acetylamino)phenyl -aminotlueno[3,2-c]pyridin-7-yUacrylate The desired product was prepared by substituting Example 17C for Example 10B in Example 11A. 1H NMR (300 MHz, DMSO-d6) 5 1.51 (m, 9H), 2.09 (m, 3H), 5.98 (s, 2H), 6.31 (d, J-15.9 Hz, 1H), 7.41 (d, J=8.5 Hz, 2H), 7.59 (s, 1H), 7.72 (m, 3H), 8.23 (s, 1H), 10.14 (s, 1H); MS (ESI(+)) m/e 410 (M+H)+. Example 18 (2E)-3-{3-[4-(acetylamino)phenyl]-4-aminothieno[3,2-c]pvridin-7-yl}acrylic acid The desired product was prepared as the trifluoroacetate salt by substituting Example 17D for Example 11A in Example UB. 1HNMR (300 MHz, DMSO-dfi) δ 2.10 (m, 3H), 6.51 (d, J=16.3 Hz, 1H), 6.74 (br s, 2H), 7.44 (d, J=8.5 Hz, 2H), 7.76 (dd, JM16.6, 7.8 Hz, 4H), 8.33 (s, 1H), 10.18 (s, 1H); MS (ESI(+)) m/e 354 (M+H)+. Example 19 (2E)-3-{3-[4-( acetylamino)phenyl]-4-arninothieno[3,2-c]pyridiri-7-yl}-N-methylacrvlarnide The desired product was prepared by substituting Example 18 for Example 13 in -61- WO 2005/010009 PCT/US2004/024003 Example 14. 1HNMR (300 MHz, DMSO-d6) δ 2.09 (m, 3H), 2.73 (m,3H), 5;82'(s; 2H) 6.57 (d, J=15.9 Hz, 1H), 7.41 (d, >8.5 Hz, 2H), 7.59 (m, 2H), 7.73 (d, J=8.5 Hz, 2H), 8.14 (m, 2H), 10.14 (s, 1H); MS (ESI{+)) m/e 367 (M+H)+ Example 20 N-(4-{4-amino-7-[(lE)-3-oxo-3-(3-oxo-l-piperazinyl)-l-propenynthieno[3,2-c]pyridin-3- yl) phenyl) acetamide The desired product was prepared by substituting Example 18 for Example 1 IB in Example 11C. 1HNMR (300MHz,DMSO-d6) δ 2.09 (rn, 3H), 3.81 (brm, 2H), 4.19 (brm, 2H), 5.S9 (br s, 2H), 7.02 (br m, 1H), 7.41 (d, J=8.5 Hz, 2H), 7.59 (s, 1H), T-.72 (m, 3H)3 8.14 (br s, 1H), 8.32 (s, 1H), 10.14 (s, 1H); MS (ESI(+)) m/e 436 (M+H)+. Example 21 (2E)-3-[4-animo-3-(4-ch]orophenyl)thieno[3,2-c]pyridin-7-vl]-N-methvlacrvlamide Example 21A 3-bromo-7-iodothieno[3,2-c]pyridin-4-amine The desired product was prepared by substituting Example IB for Example 10A in Example 10B. Example 21B (2E)-3-(4-amino-3-bromothiepo[3,2-c]pvridin-7-yl)-N-methylacrylamide The desired product was prepared by substituting Example 21A for Example 10B and methylamine for piperazin-2-one in Examples 11A-C. MS (ESI(+)) m/e 311.6,313.6 (M+H)+. Example 21C (2E)-3-[4-mumo-3-(4-chlorophenyl)thieno[3,2-c]pyTidin-7-yl] N-methylacrvlamide A mixture of Example 21B (150mg, 0.48 mmol), 4-chlorophenylboronic acid (75mg, 0.48 mmol), PdCl2(PPh3)2 (3mg) and CsXOj (188 mg) in DME/water/ethanol (70:30:20 mixture, 2 mL) was heated in a sealed vial to 160 °C for 7.5 minutes with stirring in a Smith Synthesizer microwave oven (at 300W). The reaction was partinioned between water and dichloromethane and die organic layer was concentrated. The residue collected was purified by preparative HPLC on a Waters Symmetry C8 column (25mm x 100mm, 7u.ni particle size) using a gradient of 10% to 100% acetonitrile:5 mM aqueous ammonium acetate over 8 minutes (10 minute run time) at a flow rate of 40mL/min to provide 59 mg (36% yield) of the . desired product. !H NMR (300 MHz, DMSO-d6) δ 2.73 (d, J=4.7Hz, 3H), 5.81 (s, 2H), 6.58 (d, J=15.9 Hz, 1H), 7.51 (d, J=8.5 Hz, 2H), 7.58 (d, J=15.9 Hz, 1H), 7.60 (d, J=S.5 Hz, 2H), -62- WO 2005/010009 PCT/US2004/024003 7 .'70 (s,lH), 8.13 (S 1H),8.I6 (q, J=4.7Hz, IH), MS (ESI(-)) m/e 341.8 (M-H) Examples 22-35 were prepared by substituting the appropriate boronic acid (X) for 4-chloro-phenylboronic acid in Example 21C. Example 22 (2E)-3-[4-amino-3-[4-(trifluoromethoxy)phenyl]thieno[3,2-c]pvridin-7-yl}-N- methylacrylamide X = 4-trifluoromethoxyphenylboronic acid. 1H NMR (300 MHz, DMSO-d6) δ 2.73 (d, J=4.7 Hz, 3H), 5.83 (s, 2H), 6.59 (d, J=15.9 Hz, IH), 7.52 (dd, J=8.8,1.0 Hz, 2H), 7.58 (d, J=15.9 Hz, IH), 7.63 (d, J=S.S Hz, 2H), 7.75 (s, IH), 8.14 (s, IH), 8.16 (q, J-4.7 Hz, IH); MS (ESI(+)) m/e 393.9 (M+H)+. Example 23 (2E)-3-[4-amino-3-(l,3-benzodioxol--5-yl)triieno[3,2-c]pyridin-7-yl]-N- methylacrylamide X = l,3-benzodioxol-5-ylboronic acid. 1HNMR (300 MHz, DMSO-dfi) δ 2.73 (d, J=4.7 Hz, 3H), 5.89 (s, 2H), 6.12 (s, 2H), 6.56 (d, J=15.6 Hz, IH), 6.93 (dd, J=7.8,1.7 Hz, IH), 7.05 (d, J=1.7 Hz, IH), 7.06 (d, J=7.8 Hz, IH), 7.57 (d,*J=15.6 Hz, IH), 7.61 (s, IH), 8.11 (s, lH),8.14(q, J-4.7Hz, IH); MS (ESI(+)) m/e 353.9 (M+H)+. Example 24 (2E)-3-[4-aminQ-3-(4-methylphenvnthieno[3,2-c]pyridm-7-yl]-N-methylacrylamide X - 4-methylphenylboronic acid. lH NMR (400 MHz, DMSO-d6) 8 2.49 (s, 3H), 2.S2 (d, J=4.6 Hz, 3H), 5.88 (s, 2H), 6.66 (d, J=16.0 Hz, IH), 7.44 (m, 4H), 7.66 (d, J-16.0 25 Hz, IH), 7.69 (s, IH), S.20 (s, IH), 8.22 (q, J=4.6 Hz, IH); MS (ESI(+)) m/e 324.0 (M+H)+ Example 25 (2E)-3-[4-amino-3-(4-fluorophenyl)thienoC3,2-c]pyridin-7-yl]-N-methylacrylamide X - 4-fluorophenylboronic acid. 1H NMR (400 MHz, DMSO-d6) δ 2.73 (d, J=4.6 Hz, 30 3H)f 5.78 (s, 2H), 6.58 (d, J-16.0 Hz, IH), 7.37 (t, J-S.S Hz, 2H), 7.54 (dd, J=8.8, 5.5 Hz, 2H), 7.58 (d, J=16.0 Hz, IH), 7.67 (s, IH), 8.13 (s, IH), 8.14 (q, J=4.6 Hz, IH); MS (ESI(+)) m/e 327.9 (M+H)+. Example 26 (2E)-3-[4-ainmo-3-(4-methoxyphenyl)trueno[3,2-c]pyridin-7-yl]-N-methylacrylamide X = 4-methoxyphenylboronic acid. 1H NMR (400 MHz, DMSO-d6) δ 2.50 (d, J=4.6 Hz, 3H), 3.60 (s, 3H), 5.58 (s, 2H), 6.34 (d, J=16.0Hz, IH), 6.86 (d, J=8.8 Hz, 2H), 7.17 (d, >S.S Hz, 2H), 7.34 (d, J=16.0 Hz, IH), 7.35 (s, IH), 7.87 (s, IH), 7.90 (q, J=4.6 Hz, IH); -63- WO 2005/010009 PCT/US2004/024003 MS (ESI(+)) m/e 339.9 (M+H)+. Example 27 (2E)-3-{4-aminoO-[4-(trifluoiomethyl)phenyl]pheno[3,2-c]pvridin--7-yl}-N- methylacrylamide X = 4-(trifluoromethyl)phenylboronic acid. 1H NMR (400 MHz, DMSO-d6) δ 2.50 (d, J=4.6 Hz, 3H), 5.56 (s, 2H), 6.35 (d, J=16.0 Hz, IH), 7.35 (d, J=16.0 Hz, IH), 7.49 (d, J-8.0 Hz, 2H), 7.54 (s, IH), 7.65 (d, J=S.0 Hz, 2H), 7.91 (q, J-4.6 Hz, IH), 7.92 (s, IH); MS (ESI(+)) m/e 37,7.9 (M+H)+. Example 28 (2E)-3-{4-aim"no-3-[4-n3enzyloxy)phenyl]thieno[3,2-c]pyridin-7-yl)-N-methylacrylainide X = 4-(benzyloxy)phenylboronic acid. 1H NMR (400 MHz, DMSO-d6) δ 2.50 (d, J=4.6 Hz, 3H), 4.95 (s, 2H), 5.59 (s, 2H), 6.34 (d, J-16.0 Hz, IH), 6.94 (d, J=8.6 Hz, 2H), 15 7.12 (t, J=7,2 Hz, IH), 7.16-7.20 (m, 4H), 7.26 (d, J=7.0 Hz, 2H), 7.34 (d, J=16.0 Hz, IH), 7.36 (s, IH), 7.87 (s, IH), 7.90 (q, J=4.6 Hz, IH); MS (ESI(+)) m/e 416.0 (M+H)+. Example 29 (2E)-3-[4-amino-3-(lH-indoI-5-yl)thieiio[3,2-c] pyridin -7-yl]-K-methvlacrylamide X = lH-indol-5-ylboronic acid. lH NMR (400 MHz, DMSO-d6) 8 2.80 (d, J=4.7 Hz, 3H), 5.86 (s, 2H), 6.5S (m, IH), 6.65 (d, J-15.7Hz, IH), 7.21 (dd, J-S.3,1.8 Hz, IH), 7.53 (app t, J=2.5 Hz, IH), 7.61 (d, J=8.3 Hz, IH), 7.64 (s, IH), 7.65 (d, J=15.7 Hz, IH), 7.70 (d, J=1.S Hz, IH), 8.16 (s, IH), S.20 (q, J=4.7 Hz, IH), 11.39 (s, IH); MS (ESI(+)) m/e 348.9 (M+H)+. Example 30 (2E)-3-[4-amino-3-(3-aminophenyl)thieno[3,2-c] pyridin -7-yl]-N-methylacrylamide X = 3-aminophenylboronic acid. lH NMR (300 MHz, DMSO-d6) δ 2.73 (d, J=4.4 Hz, 3H), 5.37 (s, 2H), 5.98 (s, 2H), 6.52-6.56 (m, IH), 6.56 (d, J=15.9 Hz, IH), 6.60 (t, J=2.0 Hz, 30 IH), 6M (ddd, J=8.1, 2.0, 0.7 Hz, IH), 7.16 (t, J=7.6 Hz, IH), 7.57 (d, 3=15.9 Hz, IH), 7.57 (s, IH), 8.09 (s, IH), S.14 (q, J=4.4 Hz, IH); MS (ESI(+)) m/e 325.0 (M+H)+. Example 31 (2E)-3-[4-amino-3-(4-brQmophenyl)thienQ[3,2-c]pyridin-7-yl]-N-methylacrylamide X - 4-bromophenylboronic acid. 1H NMR (300 MHz, -DMSO-dg) δ 2.73 (d, J=4.7 Hz, 3H), 5.82 (s, 2H), 6.58 (d, J=15.9 Hz, IH), 7.45 (d, J=8.5 Hz, 2H), 7.58 (d, J=15.9 Hz, IH), 7.71 (s, IH), 7.73 (d, J-8.5 Hz, 2H), S.13 (s, IH), 8.15 (q, J=4.7 Hz, IH); MS (ESI(+)) m/e 387.8, 389.8 (M+H)+. -64- WO 2005/010009 PCT/US200-I/024003 Example 32 (2E)-3-[4-amino-3-(l,1-biphenyl-4-yl)trueno[3,2-c]pyridin-7-yl]-N-methylacrylamide X = l,l'-biphenyl-4-ylboromc acid. 1H NMR (300 MHz, DMSO-d6) δ 2.74 (d, J=4.7 Hz, 3H), 5.88 (s, 2H), 6.59 (d, J=15.9 Hz, IH), 7.41 (t, J=7.3 Hz, IH), 7.47-7.62 (m, 2H), 7.59 (d, J=15.6 Hz, IH), 7.59 (d, J=8.5 Hz, 2H), 7.72 (s, IH), 7.73-7.87 (m, 4H), 8.14 (s, 1HJ 8.16 (q, J=4.7 Hz, IH); MS (ESI(+)) m/e 3S6.0 (M+H)+. Example 33 (2E)-3-[4-ammoO-(4-cyanophenyl)thieno[3,2-c]pyridin-7-yl]-N-methylacrylamide X = 4-cyanophenylboronic acid. 1H NMR (300 MHz, DMSO-d6) δ 2.73 (d, J=4.4 Hz, 3H), 5.86 (s, 2H), 6.58 (d, J=15.9 Hz, IH), 7.59 (d, J-15.9 Hz, IH), 7.69 (d, J=8.5 Hz, 2H), 7.80 (s, IH), 7.99 (d, J-8.5 Hz, 2H), 8.15 (q, J=4.4 Hz, IH), 8.16 (s, IH); MS (ESI(+)) m/e 335.0 (M+H)+. Example 34 (2E)-3-[4-aniiao-3-(3-methylpheayl)thieno[3,2-c]pvridin-7-yl]-N-methylacrylarmde X= 3-methylphenylboronic acid. lH NMR (300 MHz-, DMSO-d6) δ 2.39 (s, 3H), 2.73 (d, 1=4.7 Hz, 3H), 5.80 (s, 2H), 6.58 (d, J=15.9 Hz, IH), 7.26-7.35 (m, 3H), 7.43 (t, 20 J=7.5 Hz, IH), 7.58 (d, J=15.9 Hz, IH), 7.64 (s, IH), 8.12 (s, IH), S.15 (q, J=4.7 Hz, IH); MS (ESI(+)) m/e 324.0 (M+H)+. Example 35 (2E)-3-[4-ammo-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]-N-inethylacrylamide X = 4-phenoxyphenylboronic acid. 1H NMR (400 MHz, DMSO-d6) δ 2.73 (d, J=4.6 Hz, 3H), 5.97 (s, 2H), 6.60 (d, J=15.7 Hz, IH), 7.12-7.15 (m, 4H), 7.21 (t, J=7.4 Hz, IH), 7.45 (dd, JMS.3, 7.4 Hz, 2H), 7.50 (d, J-S.6 Hz, 2H), 7.5S (d, J=45.7 Hz, IH), 7.69 (s, IH), 8.14 (s, IH), 8.16 (q, J=4.6 Hz, IH); MS (ESI(+)) m/e 402.0 (M+H)+. Example 36 (2E)-3-[4-ammo-3-(3-phenoxy-l-propynyl)thieno[3,2-c]pvridin-7-yl]-N-methylacrylamide A mixture of Example 21A (150mg, 0.48 mmol), (2-propynyloxy)benzene (0.13 mL, 0.96 mmol), PdCl2(PPh3)2 (17mg, 0.024 mmol), PPh3 (15mg, 0.057 mmol), Cul (3 mg), and Et3N (1 mL, 7.2 mmol) in DME/water/ethanol (70:30:20 mixture, 2 mL) was heated in a 35 sealed vial tol25 °C for 25 minutes with stirring in a Smith Synthesizer microwave oven (at 300W). The reaction mixture was concentrated and the residue was purified by HPLC using the conditions described in Example 21C to provide 47 mg (27% yield) of the desired product. 1HNMR (400 MHz, DMSO-d6) δ 2.71 (d, J=4.6 Hz, 3H), 5.18 (s, 2H), 6.50 (d, -65- WO 2005/010009 PCT/US200-I/0240' J=16.0 Hz, IH), 6.91 (s, 2H), 7.00 ft J=7;4 Hz; 1H),7.0S:(dd, J=8.8;0:9 Hz,'2H), 7.35 (dd, J=8.8, 7.4 Hz, 2H), 7.52 (d, H6.0 Hz, IH), 8.10-8.13 (m, 2H), S.14 (s, IH); MS (ESI(+)) m/e 364.0 (M+H)+. Examples 37-65 were prepared by substituting Example 17A and the appropriate isocyanide (X) for Example 1C and l-isocyanato-3-methylbenzene, respectively, in Example ID. The crude product was purified either by trituration from dichloromethane by flash column chromatography on silica gel. Example 37 N-[4-(4-aminothieno[3,2-c]pyridin-3-yl)phenyl]-N'-(3-methylphenyl)urea X = l-isocyanato-3-methylbenzene. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 5.44 (s, 2H), 6.S1 (d, J=7.12 Hz, IH), 7!l7 (t, J=7.80 Hz, IH), 7.26 (d, J=5.76 Hz, 2H), 7.34 (d, W1.53 Hz, 2H), 7.40 (d, J-l 1.87 Hz, 2H), 7.60 (d, J-8.4S Hz, 2H), 7.83 (d, J=5.43 Hz, IH), S.67 (s, IH), 8.86 (s, IH); MS (ESI(+)) m/e 375 (M+H)+. Example 38 l-[4-R4-Armno-thieno[3,2-c]pvridin-3-yl)-phenyl]-3-(3-chloro-phenyl)-urea X = l-isocyanato-3-cMorobenzene. 1H NMR (300 MHz, DMSO-d6) δ 5.42 (s, 2H), 7.03-7.13 (m, IH), 7.26 (d, >5.76 Hz, IH), 7.31-7.33 (m, 2H), 7.3S (d, J=8.48 Hz, 2H), 7.42 (s, IH), 7.60 (d, J=8.48 Hz, 2H), 7.73 (d, J=1.70 Hz, IH), 7.83 (d, J-5.76 Hz, IH), S.95 (s, IH), 8.96 (s, IH); MS (ESI(+)) m/e 395 (M+H)+. Example 39 N-[4-(4-ammothieno[3,2-c]pyridin-3-yl)phenyl]-N'-[2-fluoro-5-trifluoromethyl)phenyl]urea X = l-isocyanato-2-fluoro-5-(trifluoromethyl)benzene. 1H NMR (300 MHz, DMSO-S.4S Hz, 2H), 7.41 (s, IH), 7.5S (d, J=8.48 Hz, 2H), 7.S2 (d, J=5.76 Hz, IH), S.62 (s, IH), S.SO (s, IH); MS (ESI(+)) m/e 405 (M+H)+ Example 44 N-[4-(4-aimuotl'iieno[3,2-c]pyridin--3-yl)phenyl]-N'-(3-mtrophenyl)urea X = Hsocyanato-3-nitrobenzene. lH NMR (300 MHz, DMSOdc) δ 5.42 (s, 2H), 7.26 (d, J=5.76 Hz, IH), 7.40 (d, J=S.4S Hz, 2H), 7.43 (s, IH), 7.63 (d, J-8.4S Hz, 3H), 7.74-7.76 (m, IH), 7.83 (d, J=5.42 Hz, 2H), S.5S (t, J=2.20 Hz, IH), 9.05 (s, IH), 9.30 (s, IH); MS (ESI(+)) m/e 406 (M+H)+. Example 45 N-[4-(4-aminotbieno[3,2-c]pyridin-3-yl)plienyl]-N-(3-cliloro-4-methoxyphenyl)urea X = l-isocyanato-3-chloro-4-methoxybenzene. 1H NMR (300 MHz, DMSO-d6) 6 3.82 (s, 3H), 5.42 (s, 2H), 7.10 (d, J=9.16 Hz, IH), 7.25 (d, J=5.43 Hz, IH), 7.29 (dd, J=8,82, 2.71 Hz, IH), 7.37 (d, J=8.48 Hz, 2H), 7.42 (s, IH), 7.59 (d, J=8.82 Hz, 2H), 7.68 (d, J-2.37 Hz, IH), 7.82 (d, J=5.76 Hz, IH), 8.71 (s, IH), S.S7 (s, IH); MS (ESI(+)) m/e 425 (M+H)+- Example 46 N-[4-(4-aminothieno[3,2-c]pyridin-3-yl)phenyl]-N'-(3,4-dimethylphenyl)urea X = l-isocyanato-3,4-dimethylbenzene. lH NMR (300 MHz, DMSO-d6) δ 2.24 (s, 6H), 5.42 (s, 2H), 6.63 (s, IH), 7.09 (s, 2H), 7.25 (d, J=5.43 Hz, IH), 7.36 (d, J=S.48 Hz, -67- WO 2005/010009 PCT/US2004/024003 2H), 7.42 (s, IH), 7.59 (d, J=S.48 Hz, 2H), 7.82 (d, J=5.43 Hz, IH), 8.57 (s, IH), 8.83 (s IH); MS (ESI(+)) m/e 389 (M+H)+. Example 47 N-[4-(4-aminothieno[3,2-c]pvridin-3-yl)phenyl]-N'-[2-(trifluoromethyl)phenyl]urea X = l-isocyanato-2-(trifluoromethyl)benzene. 1H NMR (300 MHz', DMSO-d6) δ 5.41 (s, 2H), 7.26 (d, J=5.76 Hz, IH), 7.30 (t, J=7.63 Hz, IH), 7.39 (d, J=8.81 Hz, 2H), 7.43 (s, IH), 7.61 (d, J=8.81 Hz, 2H), 7.69 (t, J=7.S0 Hz, 2H), 7.83 (d, J=5.42 Hz, IH), 7.96 (d, J=8.4S Hz, IH), 8.15 (s, IH), 9.56 (s, IH); MS (ESI(+)) m/e 429 (M+H)+. Example 48 N-[4-R4-aminothieno[3,2-c]pyridin-3-yl)phenyl]-N’(2-fluoro-5-methylpherivl)urea X = l-isocyanato-2-fluoro-5-methylbenzene. 1H NMR (300 MHz, DMSO-d6) δ 2.28 (s, 3H), 5.41 (s, 2H), 6.79-6.84 (m, IH), 7.12 (dd, J-11.36, 8.31 Hz, IH), 7.26 (d, J=5.43 Hz, IH), 7.38 (d, J-8.4S Hz, 2H), 7.43 (s, IH), 7.60 (d, J=8.48 Hz, 2H), 7.83 (d, J-5.43 Hz, IH), 8.00 (dd, J-7.97, 2.20 Hz, IH), 8.54 (d, 3=2.11 Hz, IH), 9.25 (s, IH); MS (ESI(+)) m/e 393 (M+H)+. Example 49 N-[4-(4-aminothieno}-3,2-c]pyridin-3-vl)phenyl]-N'-(3-fluorophenyl)urea X = l-isocyanato-3-fluorobenzene. 1H NMR (300 MHz, DMSO-d6) δ 5.42 (s, 2H), 6.77-6.83 (m, IH), 7.15 (dd, J=7.46,2.03 Hz, IH), 7.26 (d, J-5.76 Hz, IH), 7.3S (d, J-8.81 Hz, 2H), 7.42 (s, IH), 7.4S-7.54 (m, 2H), 7.60-7.62 (m, 2H), 7.83 (d, J=5.42 Hz, IH), 8.94 (s, IH), 8.9S (s, IH); MS (ESI(+)) m/e 379 (M+H)+. Example 50 N-[4-(4-aminothieno[3,2-c]pyridin-3-yl)phenyn-N'-(3-phenoxyphenyl)urea X = l-isocyanato-3-phenoxybenzene. 1H NMR (300 MHz, DMSO-d6) δ 5.41 (s, 2H), 6.61-6.65 (m, IH), 7.03-7.05 (m, 2H), 7.15-7.20 (m, 2H)S 7.24-7.30 (m, 3H), 7.34 (s, IH), 7.38-7.44 (d, J=3.39 Hz, 2H), 7.42 (m, 2H), 7.56 (d, J=8.S1 Hz, 2H), 7.82 (d, J=5.42 Hz, IH), 8.84 (s, IH), 8.87 (s, IH); MS (ESI(+)) m/e 453 (M+H)+. Example 51 N-[4-(4-ammomieno[3,2-c]pyridin-3-yl)phenyn-N'-('3-cyanophenyl)urea X = l-isocyanato-3-cyanobenzene. 1H NMR (300 MHz, DMSO-d6) δ 5.42 (s, 2H), 7.26 (d, J=5.43 Hz, IH), 7.39 (d, J=8.48 Hz, 2H), 7.43 (s, IH), 7.50 (d, J=7.80 Hz, 2H), 7.61 (d, J=S.4S Hz, 2H), 7.69-7.72 (m, IH), 7.83 (d, J=543 Hz, IH), 8.00 (s, IH), 9.05 (s, IH), 9.10 (s, IH); MS (ESI(+)) m/e 386 (M+H)+. -68- WO 2005/010009 PCT/US2004/024003 Example 52 N-[4-(4-aminothieno[3,2-c]pvridin-3-vl)phenvl]-N'-(2-fluorophenvl)urea X = l-isocyanato-2-fluorobenzene. 1H NMR (300 MHz, DMSO-d6) δ 5.42 (s, 2H), 7.04-7.06 (m, IH), 7.15 (d, J=7.12 Hz, IH), 7.26-7,28 (m, 2H), 7.39 (d, JM8.81 Hz, 2H), 7.43 (s, IH), 7.60-7.62 (m, 2H), 7.83 (d, J-5.42 Hz, IH), 8.17-8.20 (m, IH), 8.62 (d, J=2.37 Hz, IH), 9.27 (s, IH); MS (ESI(+)) m/e 379 (M+H) Example 53 N-[4-(4-aminothieno[3,2-c]pvridin-3-yl)phenyn-N'-(3-chloro-4-methylphenyl)urea X = l-isocyanato-3-chloro-4-methylbenzene. lH NMR (300 MHz, DMSO-d6) δ 2.27 (s, 3H), 5.42 (s, 2H), 7.25 (t, J=5.93 Hz, 3H), 7.37 (d, J=8.48 Hz, 2H), 7.42 (s, IH), 7.59 (d, J-8.S1 Hz, 2H), 7.71 (d, J=2.03 Hz, IH), 7.82 (d, J=5.76 Hz, IH), 8.84 (s, IH), 8.91 (s, IH) MS (ESI(+)) m/e 409 (M+H) Example 54 N-[4-(4-aminothieno[3,2-c]pyridin-3-yl)phenyn-N'-(4-ediylphenyl)urea X= l-isocyanato-4-ethylbenzene. lHNMR.(300MHz,DMSO-d6) 5 1.19 (t, J=7.46 Hz, 3H), 2.58 (q, J=7.46 Hz, 2H), 5.42 (s, 2H), 6.84 (d, J=7.46 Hz, IH), 7.19 (t, J=7.63 Hz, 20 IH), 7.25 (d, J=5.76 Hz, 2H), 7.34 (s, IH), 7.37 (d, J=8.4S Hz, 2H), 7.42 (s, IH), 7.60 (d, J-S.48 Hz, 2H), 7.82 (d, J=5.76 Hz, IH), 8.67 (s, IH), 8.84 (s, IH); MS (ESI(+)) m/e 389 (M+H)+. Example 55 N-[4-(4-aminothieno[3,2-c]pyridin-3-yl)phenyl]-N'-(4-fluorophenyl)urea X = l-isocyanato-4-fluorobenzene. lH NMR (300 MHz, DMSO-d6) δ 5.42 (s, 2H), 7.14 (t, J-8.99 Hz, 2H), 7.26 (d, J=5.76 Hz, lH),-7.37 (d, J=S.4S Hz, 2H), 7.42 (s, IH), 7.49 (dd, J-9.16, 4.75 Hz, 2H), 7.59 (d, J=8.48 Hz, 2H), 7.82 (d, J=5.76 Hz, IH), 8.77 (s, IH), 8.86 (s, IH); MS (ESI(+)) m/e 379 (M+H)+. Example 56 N-[4-(4-aminothieno [3,2-c]pyridin-3-yl)phenyn-N-phenylurea X = isocyanatobenzene 1H NMR (300 MHz, DMSO-d6) δ 5.42 (s, 2H), 6.98 (t, J=7.46 Hz, IH), 7.26 (d, J=5.76 Hz, IH), 7.31 (d, J=7.80 Hz, 2H), 7.37 (d, J=8.48 Hz, 2H), 7.42 (s, IH), 7.48 (d, J-7.80 Hz, 2H), 7.60 (d, J=8.48 Hz, 2H), 7.82 (d, J=5.43 Hz, IH), 8.73 (s, IH), 8.86 (s, IH); MS (ESI(+)) m/e 361 (M+H)+- Example 57 -69- WO 2005/010009 PCT/US2004/024003 N-[4-(4-aminothieno[3,2-c]pvridin-3,yl:)pheny]-N'-(3-bromophenyl)urea X = l-isocyanato-3-bromobenzene. 1H NMR (300 MHz, DMSO-d6) δ 5.42 (s, 2H), 7.18-7.28 (m, 4H), 7.27 (s, IH), 7.38-7.40 (m, 2H), 7.43 (s, IH), 7.60 (d, J=8.81 Hz, 2H), 7.82 (d, J=5.76 Hz, IH), 8.95 (s, 2H); MS (ESI(+)) m/e 440 (M+H)+. Example 58 N-(3-acetvlphenvl)-N'-[4-(4-aminothieno[3,2-c]pvridin-3-vl)phenvl]urea X = l-isocyanato-3-acetylbenzene. 1H NMR (300 MHz, DMSO-d6) δ 2.58 (s, 3H), 5.42 (s, 2H), 7.26 (d, J=5.76 Hz, IH), 7.39 (d, J=8.4S Hz, 2H), 7.43 (s, IH), 7.47 (d, J=7.80 10 Hz, IH), 7.59-7.63 (m, 3H), 7.70 (dd, J=7.12, 2.37 Hz, IH), 7.83 (d, J=5.76 Hz, IH), 8.10 (d, J=2.03 Hz, IH), 8.92 (s, IH), 8.99 (s, IH); MS (ESI(+)) m/e 403 (M+H)+. Example 59 methyl 3-[({R4-(4-aminothieno[3,2-c]pvridin-3-yl)pbenyl]amino]carbonynamigo]benzoate X = methyl 3-isocyanatobenzoate. lH NMR (300 MHz, DMSO-d6) 5 3.87 (s, 3H), 5.42 (s, 2H), 7.26 (d, J-5.76 Hz, IH), 7.39 (d, J=8.82 Hz, 2H), 7.45-7.49 (m, 2H), 7.59 (d, J=8.S2 Hz, 2H), 7.65-7.67 (m, 2H), 7.83 (d, J=5.43 Hz, IH), 8.23 (t, J-1.87 Hz, IH), 8.91 (s, IH), 9.02 (s, IH); MS (ESI(+)) m/e 419 (M+H)+. Example 60 N-[4-(4-aminothieno[3,2-c]pyridin-3-yl)phenyl]-N'-2,3-dihydro-lH-inden-5-ylurea X = 5-isocyanatoindane. "H NMR (300 MHz, DMSO-d6) 5 1.96-2.05 (m,2H),2.77-2.86 (m, 4H), 5.42 (s, 2H), 7.13 (s, IH), 7.15 (d, J=1.70 Hz, IH), 7.25 (d, J=5.42 Hz, IH), 7.36 (d, J=8.81 Hz, 2H), 7.39 (s, IH), 7.41 (s, IH), 7.59 (d, J-S.S2 Hz, 2H), 7.S2 (d, J-5.76 Hz, IH), 8.59 (s, IH), 8.81 (s, IH); MS (ESI(+)) m/e 401 (M+H)+. Example 61 N-[4-R4-aminothieno[3,2-c]pyridin-3-yl)phenyl]-N'-[4-('trifluoromethyl")pheriyl]urea X = l-isocyanato-4-(trifluoromethyl)benzene. lHNMR (300 MHz, DMSO-d6) δ 5.42 (s, 2H), 7.26 (d, J=5.76 Hz, IH), 7.39 (d, J=S.4S Hz, 2H), 7.43 (s, IH), 7.62 (d, J=S.48 Hz, 2H), 7.67 (d, J=4.75 Hz, 4H), 7.83 (d, J-5.43 Hz, IH), 9.01 (s, IH), 9.18 (s, IH); MS (ESI(+)) m/e 429 (M+H)+. Example 62 N-[4-(4-aminothieno[3,2-c]pyridin-3-yl)phenyl]-N'-(3-fluoro-4-methylphenyl)urea X = l-isocyanato-3-fluoro-4-methylbenzene. !H NMR (300 MHz, DMSO-d6) δ 2.17 (d, J=1.36 Hz, 3H), 5.42 (s, 2H), 7.05 (dd, J=8.31, 2.20 Hz, IH), 7.18 (t, J=8.48 Hz, IH), 7.26 (d, J=5.42 Hz, IH), 7.37 (d, J=8.48 Hz, 2H), 7.42 (s, IH), 7.47 (d, J=2.03 Hz, IH), 7.59 (d, -70- WO 2005/010009 PCT/US2004/024003 J=8.48 Hz, 2H), 7.82 (d, J=5.76 Hz/1H), 8J85 (s, 1H), 8.89 (s, 1H); MS (ESI(+)) m/e 393 (M+H)+. Example 63 - N-[4-(4-aminothieno[3,2-c]pyridin-3-yl)phenyl]-N'-(4-bromo-3-methylphenyl)urea X'=l-isocyanato-4-bromo-3-methylbenzene. 1HNMR(300MHz,DMSO-d6) δ 2.33 (s, 3H), 5.42 (s, 2H), 7.26 (d, J=5.76 Hz, 1H), 7.29 (d, J=2.37 Hz, 1H), 737 (d, J=8.S2 Hz, 2H), 7.42 (s, 1H), 7.45-7.51 (m, 2H), 7.59 (d, J=8.S2 Hz, 2H), 7.82 (d, J=5.76 Hz, 1H), 8.81 (s, 1H), 8.90 (s, 1H); MS (ESI(+)) m/e 454 (M+H)+. Example 64 N-[4-(4-aminothieno[3,2-c]pyridin-3-yl)pheriyl]-N'-[4-chloro-3-(trifluoromethyl)pbenyl]urea X = l-isocyanato-4-chloro-3-(trifluoromethyl)benzene. 1H NMR (300 MHz, DMSO-d6) δ 5.42 (s, 2H), 7.26 (d, J=5.43 Hz, 1H), 7.39 (d, J=8.48 Hz, 2H), 7.43 (s, 1H), 7.60 (s, 1H), 7.64 (d, J=4.07 Hz, 2H), 7.66 (d, J-2.37 Hz, 1H), 7.83 (d, J=5.43 Hz, 1H), 8.13 (d, J=2.03 Hz, 1H), 9.05 (s, 1H), 9.24 (s, 1H); MS (ESI(+)) m/e 463 (M+H)+. Example 65 N-[4-(4-arm'nothieno[3,2-c]pyridin-3-yl,)phenyl]-N'-(3-chloro-4-fluorophenyl')urea X = l-isocyanato-3-chloro-4-fluorobenzene. 1H NMR (300 MHz, DMSO-d6) δ 5.42 (s, 2H), 7.26 (d, J=5.76 Hz, 1H), 7.357.39 (m, 3H), 7.41 (d, J=8.81 Hz, 2H), 7.60 (d, J=8.48 Hz, 2H), 7.82 (d, J=5.42 Hz, 2H), 8.95 (s, 1H), S.97 (s, 1H); MS (ESI(+)) m/e 413 (M+H)+. Example 66 N-[4-(4-amino-2-methyl-7-mtrothieno[3,2-c]pyridin-3--yl)phenyl]-N'-(3-methylphenyl)urea Example 66 A 3-bromo-2-methylthieno[3,2-c]pyridin-4(5H)-one The desired product was prepared by substituting 3-(4-bromo-5-methyl-2- thienyl)acrylic acid for (2E)-3-(4-bromo-2-thienyl)acrylic acid in Example 1A. MS (ESI(+)) m/e 245 (M+H)+. Example 66B 3-bromo-2-methyl-7-nitrothieno[3,2-c]pyridin-4(5H)-one A solution of nitric acid (1.68 mL, 70%, 26. 8 mmol) in sulfuric acid (5 mL) was added dropwise to a 0 °C solution of Example 66A (3.27g, 13.4 mmol) in sulfuric acic (15 mL). The resulting mixture was stirred at 0 °C for 1 hour, wanned to room temperature overnight, and poured into ice water. The resulting precipitate was collected by filtration, -71- WO 2005/010009 PCT/US2004/024003 washed with water, ariddried in a vacuum oven to provide'2:47g 64 % yield) of the desirsi product. MS (ESI(+)) m/e 290 (M+H)+. Example 66C 3-bromo-2-methvl-7-nitrothieno[-3,2-c]pyridin-4-amine The desired product was prepared by substituting Example 66B for Example 1A in Example IB. MS (ESI(+)) m/e 289 (M+H)+. Example 66D N-(3-methylphenyl)-N'-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl]urea A 0 °C mixture of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)aniline (5.03g, 23 mmol) and l-isocyanato-3-methylbenzene (2.95 mL, 23 mmol) in THE (90 mL) was stirred at room temperature for 1 hour, concentrated, suspended in acetonitrile, and filtered. The filter cake was dried to provide 8.09g of the desired product. Example 66E N-[4-(4-amino-2-memyl-7-mtrotrueno[3,2-c]pyridm-3-yl)phenyl]-N'-(3-methylphenyl)urea The desired product was prepared by substituting Example 66C and Example 66D for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 2.31 (s, 3H), 4.91 (br s, 2H), 6.S1 (d, J=7.46 Hz, IH), 7.17 (t, J=7.63 Hz, IH), 7.26-7.27 (m, IH), 7.30-7.33 (m, 3H), 7.66 (d, J=8.48 Hz, 2H), 8.68 (s, IH), 8.91 (s, IH), 8.93 (s, IH); MS (ESI(+)) m/e 434 (M+H)+. Example 67 N-[4-(4-ammo-2-methylthieno[3,2-c]pyridin-3-yl)phenyl]-N'-(3-methylphenyl)m-ea Example 67A 3-bromo-2-memylthieno[3,2-c]pyridin-4-amine The desired product was prepared by substituting Example 66A for Example 1A in Example IB. MS (ESI(+)) m/e 244 (M+H)+. Example 67B N-[4-(4-ammo-2-methylthieno[3,2-c]pyridin-3-yl)phenyl]-N'-(,3-methylphenyl)urea The desired product was prepared by substituting Example 67A and Example 66D for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1H NMR (300 MHz, DMSO-d6) δ 2.26 (s, 3H), 2.29 (s, 3H), 5.18 (s, 2H), 6.81 (d, J-7.46 Hz, IH), 7.17-7.25 (m, 2H), 7.30 (m, 4H), 7.62 (d, J=8.82 Hz, 2H), 7.75 (d, J=5.43 Hz, IH), 8.66 (s, IH), 8.86 (s, IH); MS (ESI(+)) m/e 389 (M+H)+. -72- WO 2005/010009 PCT/US2004/024003 Example 68 N-[4-(4-arrimo-2-methylthieno[3,2-c]pvridin-3-yl)phenyl]-N'-(3-chlorophenyl)urea The desired product was prepared by substituting Example 67 A and 4-({[(3-5 chlorophenyl)amino]carbonyl}amino)phenylbororiic acid (prepared by substituting 1- isocyanato-3-chlorobenzene for l-isocyanato-3-methylbenzene in Example 66D) for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1H NMR (300 MHz, DMSO-dG) δ 2.26 (s, 3H), 5.17 (s, 2H), 7.04-7.11 (m, 1H), 7.16 (d, J=5.43 Hz, 1H), 7.29 (d, J=S.48 Hz, 2H), 7.32 (d, J=3.39 Hz, 2H), 7.63 (d, J=8.82 Hz, 2H), 7.73 (s, 1H), 7.75 (d, 10 J=5.43 Hz, 1H), S.96 (s, 1H), 8.97 (s, 1H); MS (ESI(+)) m/e 409 (M+H)+. Example 69 N-[4-(4-amino-2-rnethyltlueno[3,2-c]pyridin-3-yl)phenyl]-5,7-dimethyl-l,3-benzoxazol-2- amine Example 69A 5,7-dimethyl-N-[4-(4,4,5,5-tetramethyl-13,2-dioxaborolan-2-yl')phenyl]-l,3-benzoxazol-2- amine A mixture of l-bromo-4-isothiocyanatobenzene (63.92g, 0.298 mol) and THE (1200 mL) was treated with 2-amino-4,6-dimethylphenol (41 .Sg, 0.304 mol), stirred at room temperature for 3 hours, treated with EDCI (68.46g, 0.358 mol), warmed to 40 °C for 16 hours, cooled to room temperature, and filtered. The filtrate was concentrated at 50 °C to a final volume of about 300 mL, treated with acetonitrile (800 mL), concentrated to a volume of about 200 mL, treated with acetonitrile (S00 mL), and again concentrated to a volume of about 200 mL. The mixture was treated with acetonitrile (800 mL), cooled to room temperature, and filtered. The filter calve was washed with acetonitrile (100 mL) and dried to constant weight in a vacuum oven at 45 °C over 24 hours to provide 85.8g (85%) of 5,7-dimethyl-l,3-benzoxazol-2-amine. A mixture of 5,7-dimethyl-lJ3-benzoxazol-2-amine (76.4g, 0.230 mol), 4,4,4,,4,5,5,5,,5,-octamethyl-2,2'-bi-l,3,2-dioxaborolane (73.9g, 0.292 mol), potassium acetate (71.5g, 0.730 mol), and DMF (760 mL) was cycled three times through vacuum degassing and nitrogen purging, treated with Pd(dppf)Cl2-CH2Cl2 (19.9g, 0.024 mol), sealed, cycled three times through vacuum degassing and N2 purging, heated to 80 °C for 5 hours, and distilled on high vacuum (0.2 mm Hg) at 40 °C to 80 °C to remove DMF. The residue was treated with CH2C12 (1300 mL), stirred for 10 minutes, and filtered. The filter cake was washed with CH2C12 (300 mL) and the filtrate was concentrated to a volume of about 800 mL. The solution was treated with Si02 (509 g), stirred for 10 minutes, poured onto a bed of Si02 (790 g) in a 4L coarse glass fritted funnel. The Si02 was washed with 16L of 15% ethyl acetate and the solution was concentarated at 50 °C. The concentrate was treated with heptane (800 mL), concentrated, treated with heptane (900 mL), stirred at 50 °C for 30 minutes, cooled to room temperature over 2 hours, and filtered. The filter cake was -73- WO 2005/010009 PCT/US2004/024003 washed with 100 mL heptane and dried to constant weight in a vacuum oven at 45 °C ovbr % hours to provide 6S.3g (77%) of the desired product. The final product was determined to be 98.2% potency (vs. analytical standard) by HPLC. R, = 6.5 min. HPLC conditions: Zorbax SB-C8 Rapid Resolution (4.6 mm x 75 mm, 3.5 iim); flow 1.5 mL/min; 5:95 to 95:5 acetonitrile:water (0.1% H3PO4) over 7 minutes. Example 69B N-[4-(4-amino-2-methylthieno[3,2-c] pvridin-3-yl)phcnvn-5,7, imethvl-l,3-benzoxazol-2- amine The desired product was prepared by substituting Example 67A and Example 69A for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1H NMR (300 MHz, DMSO-d6) δ 2.27 (s, 3H), 2.34 (s, 3H), 2.41 (s, 3H), 5.19 (s, 2H), 6.80 (s, 1H), 7.11 (s, 1H), 7.17 (d, J=5.42 Hz, 1H), 7.37 (d, J=8.48 Hz, 2H), 7.76 (d, J=5.76 Hz, 1H), 7.92 (d, J=8.4S Hz, 2H), 10.S6 (s, 1H); MS (ESI(+)) m/e 401 (M+H)+. Example 70 N-[4-(4-aminotlu no[3,2-c]pyridin-3-yl)phenyl]-5,7-dimethyl-l,3-benzoxazol-2-amine The desired product was prepared by substituting Example 69A for 4-phenoxyphenylboronic acid in Example 10A. 1H NMR (300 MHz, DMSO-dg) δ 2.34 (s, 3H), 2.40 (s, 3H), 5.41 (s, 2H), 6.79 (s, 1H), 7.11 (s, 1H), 7.26 (d, J-5.76 Hz, 1H), 7.-[4-7.50 (m, 2H), 7.48 (s, 1H), 7.S3 (d, J=5.76 Hz, 1H), 7.89 (d, J=8.48 Hz, 2H), 10.84 (s, 1H); MS (ESI(+)) m/e 387 (M+H)+. Example 71 N-[4-(4,7-diamino-2-methylthieno[3,2-c]pyridui-3-yl)phenyl]-N’-[3-methylphenvl)urea A suspension of Example 66E (0.44& 1.01 mmol), NH4C1 (0.054g, 1.01 mmol), and iron powder (0.45g, S.l mmol)in ethanol (16 mL) and water (4 mL) was heated at 80 °C for 3 hours, cooled to room temperature, and filtered through diatomaceous earth (Celitef). The pad was washed with ethyl acetate and ethanol and the filtrate was extracted three times with ethyl acetate. The combined extracts were washed with brine, dried (NajSOJ, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel with 5% methanol/dichloromethane to provide 0.15 g of the desired product. 1H NMR (300 MHz, DMSO-dJ δ 2.27 (s, 3H), 2.29 (s, 3H), 4.48 (s, 2H), 4.59 (s, 2H), 6.80 (d, J=7.46 Hz, 1H), 7.17 (t, J=7.80 Hz, 1H), 7.25-7.29 (m, 3H), 7.30 (s, 1H), 7.31 (s, 1H), 7.60 (d, J=8.81 Hz, 2H), 8.67 (s, 1H), 8.86 (s, 1H); MS (ESI(+)) m/e 404 (M+H)+. Example 72 N-{4-amino-2-methyl-3-[4-({[(3-methylphenyl)aminolcarbonyl}amino)phenyl]thieno[3,2- clpyridin-7-yl) nicotinamide WO 2005/010009 PCT/US2004/024003 Example 72 A tert-butyl 3-bromo-2-methyl-7-introthieno[3,2-c]pyridin-4-vlcarbarnate A 0 °C mixture of Example 66C (0.506g„1.76 mmol) andNaH (1 llmg, 95% dispersion, 4.4 mmol) was stirred for 20 minutes, treated with a solution of di-tert-butyl dicarbonate (461mg, 2.1 mmol) inDMF (15 mL), stirred for an additional 2 hours at 0 °C, quenched with saturated aqueous NH4C1, and extracted three times with ethyl acetate. The combined extracts were washed with water and brine, dried (NazS04), filtered, and concentrated to provide 0.605g of the desired product. MS (ESI(+)) m/e 389 (M+H)+. Example 72B tert-butyl 7-amino-3-bromo-2-methylthieno[3,2-c]pyridin-4-ylcarbamate The desired product was prepared by substituting Example 72A for Example 66E in Example 71. MS (ESI(+)) m/e 359 (M+H)+. Example 72C tert-butyl 3-bromo-2-methyl-7-[(3-pyridinylcarbonyl)ammolthieno[3,2-c]pyridin-4- ylcarbamate The desired product was prepared by substituting Example 72B and nicotinoyl chloride for Example 17A and acetyl chloride, respectively, in Example 17B. MS (ESI(-))m/e 462 (M-H).+ Example 72D N-{4-amino-2-methyl-3-[4-({[(3-methylphenyl)aminolcarbonyl)amino)phenyl]thieno[3,2- c] lpyridin-7-yl} nicotinamide The desired product was prepared by substituting Example 72C and Example 66D for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1HNMR (300 MHz, DMSO-d6) δ 2.27 (s, 3H), 2.29 (s, 3H), 5.24 (s, 2H), 6.81 (d, J=7.46 Hz, 1H), 7.17 (t, J=7.80 Hz, 1H), 7.27 (d, J=11.53 Hz, 2H), 7.32 (s, 2H), 7.59 (d, J=5.09 Hz, 1H), 7.64 (d, J=8.48 Hz, 2H), 7.76 (s, 1H), 8.35 (d, J-7.80 Hz, 1H), 8.69 (s, 1H), 8.79 (d, J=5.76 Hz, 1H), 8.90 (s, 1H), 9.17 (s, 1H), 10.47 (s, Hi); MS (ESI(+)) m/e 509 (M+H)+. Example 73 N-{4-arnino-2-methyl-3-[4-({[(3-methylphenyl)amino]carbonyl)amino)phenyl]thieno[3,2- c]pyridin-7-yl)-2-fluoro-5-(trifluoromethyl)benzamide The desired product was prepared by substituting 2-fluoro-5-trifluromethylbenzoyl chloride for nicotinoyl chloride hi Examples 72C-D. lH NMR (300 MHz, DMSO-d6) δ 2.29 (s, 6I-I), 5.36 (s, 2H), 6.81 (d, J-7.12 Hz, 1H), 7.17 (t, J=7.S0 Hz, 1H), 7.27 (d, J=12.88 Hz, 2H), 7.32 (s, 2H), 7.64 (d, J-8.81 Hz, 3H), 7.83 (s, 1H), 8.04 (d, J=5.76 Hz, 1H), 8.09 (s, -75- WO 2005/010009 PCT/US2004/024003 IH), S.69 (s, IH), 8.91 (s, IH), 10.46 (s, IH); MS (ESI(+)) m/e 594 (M+H)+. Example 74 N- (4-amino-2-methyl-3-f 4-( {[ (3-methylphenyljairnnolcarbonyl) amino)phepyl]thieno[3,2- c]pyridin-7-yl)-3-(dimethylamino)benzamide The desired product was prepared by substituting 3-dimethylaminobenzoyl chloride for nicotinoyl chloride in Examples 72C-D. 1H NMR (300 MHz, DMSO-d6) δ 2.26 (s, 3H), 2.29 (s, 3H), 2.98 (s, 6H), 5.20 (s, 2H), 6.81 (d, J=7.46 Hz, IH), 6.95 (d, J=7.46 Hz, IH), 7.1' ft J=7.63 Hz, IH), 7.27 (d, J-10.85 Hz, 2H), 7.31 (s, 5H), 7.64 (d, JM8.48 Hz, 2H), 7.71 (s, IH), S.67 (s, IH), 8.87 (s, IH), 10.14 (s, IH); MS (ESI(+)) m/e 551 (M+H)+. Example 75 N-{4-amino-2-methyl-3-[4-({[(3-methylphenyl)amino]carbonyl)amino)phenyl]thieno[3,2- clpyridin-7-yl) pentanamide The desired product was prepared by substituting pentanoyl chloride for nicotinoyl chloride in Examples 72C-D. 1H NMR (300 MHz, DMSO-d,) 5 0.94 (t, J=7.29 Hz, 3H), 1.33-1.45 (m, 2H), 1.57-1.67 (m, 2H), 2.25 (s, 3H), 2.29 (s, 3H), 2.33 (t, >7.29 Hz, 2H), 5.1 (s, 2H), 6.81 (d, J=7.12 Hz, IH), 7.17 ft J=7.63 Hz, IH), 7.25 (d, J=3.05 Hz, 2H), 7.30 (d, J=8.S2 Hz, 2H), 7.62 (d, J=4.07 Hz, 2H), 7.64 (s, IH), 8.67 (s, IH), 8.87 (s, IH), 9.64 (s, IH): MS (ESI(+)) m/e 488 (M+H)+. Example 76 N-[4-(4-amino-7-bromotlueno[-3,2-c]pyridin-3-yl)phenyl]-N'-(3-methylphenyl)urea Example 76A tert-butyl 4-(4-aminothieno[3,2-c]pyridin-3-yl)phenylcarbamate The desired product was prepared by substituting Example 17A for Example 66C in Example 72A. MS (ESI(-)) m/e 340 (M-H) Example 76B tert-butyl 4-(4-amino-7-bromothieno[3,2-c]pyridin-3-yl)phenylcarbamate A solution of bromine (0.4 mL, 4.6 mmol) in dichloromethane (5 mL) was added dropwise to a -5 °C solution of Example 76A (1.57g, 4.6 mmol) in dichloromethane (30 mL). The mixture was stirred at-5 °C to 0 °C for 15 minutes and quenched with 1:1 saturated NaHC03 and saturated NaHS03 (10 mL). The organic phase was separated, washed with water andbrine, dried (NaoSOJ, filtered, and concentrated to provide 1.85g of the desired product. MS (ESI(+)) m/e 421 (M+H)+. -76- WO 2005/010009 PCT/US2004/024003 Example 76C 3-(4-aminophenyl)-7-bromothieno[3,2-c]pyridin-4-amine A solution of Example 76B (0.5g, 1.1 mmol) in TFA (4 mL) and dichloromethane (5 mT.) was stirred at 0 °C for 5 minutes, warmed to room temperature for 2 hours, then - 5 concentrated. The residue was dissolved in dichloromethane, washed with brine, dried (NajSOJ, filtered, and concentrated to provide 0.332g of the desired product. MS (ESI(+-)) m/e321(M+H)+. Example 76P N-[4-(4-amino-7-broniothieno[3,2-c]pyridin-3-yl)phenyl]-N'-(3-methvlphenvl)urea The desired product was prepared by substituting Example 76C for Example IC in Example ID. 1HNMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 5.62 (s, 2H), 6.S1 (d, J=7.46 Hz, IH), 7.17 (t, J=7.63 Hz, IH), 7.25-7.27 (m, IH), 7.31 (s, IH), 7.38 (d, J=8.4S Hz, 2H), 7.56 (s, IH), 7.60 (d, J-S.48 Hz, 2H), 7.94 (s, IH), 8.66 (s, Hi), S.87 (s, IH); MS (ESI(+)) 15 m/e 454 (M+H)+. Example 77 tert-butyl (2E)-3-{4-amino-3-[4-(([(3-methylphenyl)aminolcarbonyl|amino)phenyl]thieno[3,2--clpyridin-7-yl}acrylate Example 77A tert-butyl 4-(4-amino-7-iodothieno[-3,2-c]pyridin-3-yl)phenylcarbamate The desired product was prepared by substituting Example 76A for Example 10A in Example 10B. MS (ESI(+)) m/e 468 (M+H)+. Example 77B 3-(4-aminophenyl')-7-iodothieno[3,2-c]pyridin-4-amine The desired product was.prepared by substituting Example 77A for Example 76B in Example 76C. MS (ESI(+)) m/e 368 (M+H)+. Example 77C tert-butyl (2E)-3-(4-amino-3-[4-({[ (3-methvlphenyl)amino1carbonyl}amino)phenyl]thieno[3,2-c]pyridin-7-yl)acrylate The desired product was prepared by substituting Example 77B for Example 10B in Example 11A then substituting the product for Example IC in Example ID. 1H NMR (300 MHz, DMSO-d6) 5 1.51 (s, 9H), 2.29 (s, 3H), 6.03.(s, 2H), 6.32 (d, J=15.94 Hz, IH), 6.81 (d, J=7.46 Hz, IH), 7.17 (t, J=7.80 Hz, IH), 7.26-7.27 (m, IH), 7.32 (s, IH), 7.40 (d, J=8.48 Hz, 2H), 7.60 (d, J=3.73 Hz, 2H), 7.63 (s, IH), 7.72 (d, J=15.94Hz, IH), 8,23 (s, IH), 8.67 (s, -77- WO 2005/010009 PCT/US2004/024003 IH), 8.87 (s, IH); MS (ESI(+)) m/e 501 (M+H)+. Example 78 (2E)-3-[4-amino-3-[4-({[(3-methvlphenvl)amino]carbonvl}airuno)phenyl]thieno[3,2- c]pyridin-7-yl}acrylic acid The desired product was prepared by substituting Example 77C for Example 11A in Example 1 IB. 1HNMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 5.09 (s, 2H), 6.59 (d, J=16.2S Hz, IH), 6.81 (d, J=7.80 Hz, IH), 7.10 (s, IH), 7.17 (t, J=7.63 Hz, IH), 7.25-7.29 (m, IH), 7.32 (s, IH), 7.44 (d, J=8.48 Hz, 2H), 7.66 (d, J-S.82 Hz, 2H), 7.76 (d, J=16.28 Hz, IH), 7.90 (s, IH), 8.37 (s, IH), 8.80 (s, IH), 9.06 (s, IH); MS (ESI(+)) m/e 445 (M+H)+. Examples 79-103 were prepared by substituting the appropriate amine (X), Example 7S, and TBTU for 2-piperazinone, Example 1 IB, and HOBT, respectively, in Example 11C. Example 79 (2E)-3-{4-amino-3-[4-({[(3-methylphenyl)amino1cai"bonvl|amino)phenyl]thieno[3,2-c]pyridm-7-yl}-N,N-dimethylacrylamide X = dimethylamine hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 2.97 (s, 3H), 3.19 (s, 3H), 5.90 (s, 2H), 6.81 (d, J=7.46 Hz, IH), 7.02 (d, J=15.60 Hz, IH), 7.17 (t, J=7.80 Hz, IH), 7.26-7.28 (m, IH), 7.32 (s, IH), 7.39 (d, J=S.4S Hz, 2H), 7.60-7.62 (m, 2H), 7.65-7.6S (m, IH), 7.95 (s, IH), 8.25 (s, IH), S.66 (s, IH), 8.87 (s, IH); MS (ESI(+)) m/e 472 (M+H)+. Example 80 N-(4-{4-amino-7-[(lE)-3-oxo-3-(3-oxo-l-piperazinyl)-l-propenyl]thieno[3,2-c]pyridin-3- yl}phenyl")-N'-(3-methylphenyl)urea X =2-piperazinone. The product was prepared as the trifluoroacetate salt by purifylng the crude product as described in Example 82. ]H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 3.81 (d, J=36.96 Hz, 4H), 4.21 (d, J-65.77 Hz, 2H), 6.81 (d, J=7.46 Hz, IH), 6.88 (s, 30 2H), 7.17-7.20 (m, IH), 7.26-7.28 (m, 2H), 7.32 (s, IH), 7.44 (d, J=8.48 Hz, 2H), 7.64 (s, 2H), 7.68-7.70 (ra, IH), 7.85 (s, IH), 8.16 (s, IH), 8.41 (s, IH), 8.76 (s, IH), 9.01 (s, .IH); MS (ESI(+)) m/e 527 (M+H)+. Example 81 (2E)-3-[4-amino-3-[4-(|f(3-mefcylphenyl)amino1carbonyUamino')phenyl]thieno[3,2- c1pyridm-7-yl}-N-(2-pyridmvlmethyl)acrylamide X = l-(2-pyridinyl)methanamme. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 4.52 (d, J-6.10 Hz, 2H), 5.91 (s, 2H), 6.73 (d, J=15.94 Hz, IH), 6.81 (d, J-7.12 Hz, IH), 7.17 -78- WO 2005/010009 PCT/US2004/024003 (t, J=7.S0 Hz, 1H), 7.24-7.36 (m, 4H), 7.40 (d, J=8.4S Hz, 2H), 7.61 (d, J=3.73 Hz, 2H);-7.65-7.67 (m, 2H), 7.78-7.81 (m, Hi), 8.14 (s, 1H), 8.53 (d, J=4.75 Hz, 1H), 8.66 (s, 1H), 8.83 (t, J=5.93 Hz, 1H), 8.87 (s, 1H); MS (ESI(+)) m/e 535 (M+H)+. Example 82 3-[((2E)-3-(4-aTrimo-3-[4-({[(3-methvlphenyl)aminolcarbonvl)amino)phenvl]thieno[3,2-c]pyridin-7-yl]-2-propenoyl)3minol-2-thiophenecarboxamide X= 3-amino-2-thiophenecarboxamide. The product was prepared as the trifluoroacetate salt by preparative HPLC purification on a Waters Symmetry C8 column (25mm x 100mm, 7um particle size) using a gradient of 10% to 100% acetonitrile/0.1% aqueous TFA over 8 minutes (10 minute run time) at a flow rate .of 40mL/min. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 3.87 (s, 2H), 6.81 (d, J=7.46 Hz, 1H), 6.88-6.96 (m, 2H), 7.17 (t, J=7.S0 Hz, 1H), 7.26-7.29 (m, 1H), 7.32 (s, 1H), 7.45 (d, J=8.S2 Hz, 2H), 7.66 (d, J=S.48 Hz, 3H), 7.77 (dd, J=10.51, 5.09 Hz, 2H), 7.S6 (s, 1H), 8.07 (d, J-5.43 Hz, 1H), 8.42 (s, 1H), 8.77 (s, 1H), 9.02 (s, 1H), 11.49 (s, 1H); MS (ESI(+)) m/e 569 (M+H)+. Example 83 (2E)-3-(4-amino-3-[4-({[(3-methylphenyl')amino]carbonyl}amino)phenyl]thieno[3,2- c]pyridin-7-yl)-N-[2-(4-morpholinyl)ethyl]acrylamide X = 2-(4-moroholinyl)ethanamine. lH NMR (300 MHz, DMSO-dJ δ 2.29 (s, 3H), 2.43 (t, J=6.10 Hz, 4H), 3.32-3.37 (m, 5H), 3.59-3.61 (m, 4H), 5.87 (s, 2H), 6.62 (d, J=15.94 Hz, 1H), 6.81 (d, J=7.12 Hz, 1H), 7.17 (t, J=7.S0 Hz, 1H), 7.26-7.28 (m, 1H), 7.32 (s, 1H), 7.40 (d, J=8.82 Hz, 2H), 7.55-7.63 (m, 3H), 8.12 (s, 1H), 8.18 (t, J=5.59 Hz, 1H), S.67 (s, 1H), 8.87 (s, 1H); MS (ESI(+)) m/e 557 (M+H)+. Example 84 (2E)-3-{4-airimo-3-[4-({[(3-methylphenyl)amio] carbonyl}amino)phenyl]thieno[3,2-c]pyridin- 7-yl}-N-[3-(l-pyrroUdinyl)propyl]acrylamide X= 3-(l-pyrrolidinyl)-l-propanamine. 1H NMR (300 MHz, DMSO-d6) 5 1.67-1.70 30 (m, 5H), 2.29 (s, 3H), 3.28-3.37 (m, 9H), 5.86 (s, 2H), 6.59 (d, J=15.94Hz, 1H), 6.81 (d, J=7.12 Hz, 1H), 7.17 (t, J=7.63 Hz, 1H), 7.26-7.28 (m, 1H), 7.32 (s, 1H), 7.40 (d, J=S.48 Hz, 2H), 7.55-7.63 (m, 4H), 8.11 (s, 1H), 8.23 (t, J=5.43 Hz, 1H), 8.67 (s, 1H), S.S8 (s, 1H); MS (ESI(+)) m/e 555 (M>H)+. Example 85 (2E)-3-{4-apTjmo-3-[4-({[(3-methylphenyl)aminolcarbonyl|armino)phenvl]thieno[3,2-c]pyridin-7-yl)-N-[(l-ethyl-2-pyrrolidinyl)methyl]acrylamide X= (l-ethyl-2-pyrrohdinyl)methylamine. 1H NMR (300 MHz, DMSO-d6) 8 1.06 (t -79- WO 2005/010009 PCT/US2004/02400. J-7.29 Hz, 3H), 1.53-1.S7(m, 4H), 2.07-2.27 (m, 2H), 2.29 (s, 3H), 2.84-2.87 (m, 2H), 3 3.08 (m, 2H)3 3.39-3.47 (m, IH), 5.87 (s, 2H), 6.66 (d, J=15.94 Hz, IH), 6.81 (d, J=7.46 Hz, IH), 7.17 (t, J-7.63 Hz, IH), 7.26-7.28 (m, IH), 7.32 (s, IH), 7.40 (d, J=S.4S Hz, 2H), 7.55-7.63 (m, 4H), 8.10 (d, J=7.46 Hz, 2H), 8.67 (s, IH), 8.8S (s, IH); MS (ESI(+)) m/e 555 (M+H)+. Example 86 (2E)-3-{4-amino-3-[4-({[(3-methylphenvl)amino]carbonyl}amino)phenyl]thieno[3,2- c]pyridin-7-yl}-N-[2-(diethy]amino)etliyl]acrylamide X= N,N-diethyl-l,2-ethanediamine. 1HNMR (300 MHz, DMSO-d6) 5 0.97 (t, J=7.12 Hz, 6H), 2.29 (s, 3H), 2.51-2.55 (m, 4H), 3.27-3.29 (m, 4H), 5.87 (s, 2H), 6.61 (d, J=15.94 Hz, IH), 6.81 (d, J=7.12 Hz, IH), 7.17 (t, J=7.63 Hz, IH), 7.26-7.28 (m, IH), 7.32 (s, IH), 7.40 (d, J=S,48 Hz,2H), 7.55-7.63 (m, 4H), S.ll (s, IH), 8.14-8.17 (ra, IH), 8.67 (s, IH), 8.87 (s, IH); MS (ESI(+)) m/e 543 (M+H)+. Example 87 (2E)-3-{4-amino-3-[4-({[(3-methylphenyl)amino1carbonyl}amino)phenyl]thieno[3,2- c]pyridin-7-yl)-N-(2-hydroxyethyl)a'crylamide X= 2-aminoethanol. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 3.29-3.37 (m, 2H), 3.49 (q, J=5.88 Hz, 2H), 4.75 (t, J=5.43 Hz, IH), 5.87 (s, 2H), 6.64 (d, J=15.94 Hz, IH), 6.80 (d, J=7.46 Hz, IH), 7.16 (t, J=7.S0Hz, IH), 7.28 (d, J=S.14Hz, IH), 7.31 (s, IH), 7.39 (d, J=8.48 Iiz, 2H),,7.61-7.64 (m, 4H), S.ll (s, IH), 8.28 (t, J=5.76 Hz, IH), 9.09 (s, IH), 9.35 (s, IH); MS (ESI(+)) m/e 488 (M+H)+. Example 88 (2E)-3-[4-ammQ-3-[4-(([(3-methylphenyl)ammo1carbonyl]amino)phenyl]tbieno[3,2-c]pyridin-7-yl}-N-(3-pyridinylmethyl)acrylamide X= l-(3-pyridinyl)methanamine. !H NMR (300 MHz, DMSO-dJ δ 2.29 (s, 3H), 4.45 (d, J-5.76 Hz, 2H), 5.90 (s, 2H), 6.65 (d, J=15.94 Hz, IH), 6.81 (d, J-7.46 Hz, IH), 7.17 (t, 30 J=7.S0 Hz, IH), 7.26-7.28 (m, IH), 7.32 (s, IH), 7.39-7.41 (m, 2H), 7.63-7.67 (m, 5H), 7.73 (d, J=7.S0 Hz, IH), 8.13 (s, IH), 8.48 (dd, J=4.75,1.70 Hz, IH), 8.56 (d, J=2.03 Hz, IH), 8.66 (s, IH), 8.78 (t, J-5.76 Hz, IH), 8.87 (s, IH); MS (ESI(+)) m/e 535 (M+H)+. Example 89 (2E)-3-{4-aimino-3-[4-({[(3-methy3phenyl)ammo1carbonyl|amino)phenyl]thieno[3,2- clpvridin-7-yl}-N-(2,3-dihydroxypropyl)aorylamide X= 3-amioo-l,2-propanediol. lH NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 3.12-3.37 (m, 4H), 3.58-3.60 (m, IH), 4.59 (t, J-5.76 Hz, IH), 4.83 (d, J-4.75 Hz, IH), 5.87 (s, -80- WO 2005/010009 PCT/US2004/024003 2H), 6.69 (d, J-15.94 Hz, IH), 6.81 (d, J=7.12 Hz, IH), 7.17 (t, J=7.80 Hz. IH), 7.26-7.28 (m, IH), 7.32 (s, IH). 7.40 (d, J=8.48 Hz, 2H), 7.56-7.63 (m, 4H), 8.12 (s, IH), 8.26 (t, J=5.76 Hz, IH), 8.67 (s, IH), 8.87 (s, IH); MS (ESI(-)) m/e 516 (M-H)". Example 90 (2E)-3-{4-amino-3-[4-({[(3-methylphenyl)aminolcarbonyl)airiino')plienvl]amieno[332-c]pyridin-7-yl}-N-(4-pyridmylmethyl)acrylamide X= l-(4-pyridinyl)methanamine. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 4.46 (d, J=5.76 Hz, 2H), 5.92 (s, 2H), 6.69 (d, J-15.94 Hz, IH), 6.S1 (d, J=7.46 Hz, IH), 7.17 (t, >7.80 Hz, IH), 7.26,7.28 (m, IH), 7.31 (d, J=5.76 Hz, 3H), 7.40 (d, J=S.S2 Hz, 2H), 7.64-7.68 (m, 4H), 8.15 (s, IH), 8.52 (d, J=1.70 Hz, IH), 8.53 (d, J=1.70 Hz, IH), 8.67 (s, IH), S.83 (t, J=6.10 Hz, IH), 8.87 (s, IH); MS (ESI(+)) m/e 535 (M+H)+. Example 91 N-(4-{4-amino-7-[(lE')-3-oxo-3-(l-piperazinyl)-l-propenyl]thieno[3,2-c]pyridin-3- yl}plienyl')-N'-(3-methylplienyl')urea X= piperazine. 1HNMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 3.63-3.90 (m, 8H), 6.66 (s, 2H), 6.S1 (d, J=6.78 Hz, IH), 7.22-7.28 (m, 2H), 7.33 (s, IH), 7.42 (d, J=7.12 Hz, 2H), 7.65 (d, J=6.10 Hz, 2H), 7.75 (d, J-21.36 Hz, 2H), 8.38 (s, IH), 8.86 (s, 3H), 9.10 (s, IH); MS (ESI(+)) m/e 513 (M+H)+ Example 92 (2E)-3- (4-ammo-3-[4-( {[(3-methylphenyl)ammo1carbonyl} aminQ)phenyl]thieno[3,2- c1pyridm-7-yl]-N-[3-(2-oxo-l-pyrrolidinyl')propyl]acrylamide X= l-(3-ammopropyl)-2-pyrrolidinone. 1H NMR (300 MHz, DMSO-d6) 6 1.67-1.72 (m, 2H), 1.93-1.98 (m, 2H), 2.22 (t, >7.91 Hz, 2H), 2.29 (s, 3H), 3.15-3.38 (m, 6H), 5.87 (s, 2H), 6.59 (d, J=15.94 Hz, IH), 6.81 (d, J=7.12 Hz, IH), 7.17 (t, J-7.63 Hz, IH), 7.26-7.28 (m, IH), 7.32 (s, IH), 7.40 (d, J=8.48 Hz, 2H), 7.56-7.63 (m. 4H). S.12 (s, IH), 8.21 (t, J=5.60 Hz, IH), 8.66 (s, IH), 8.87 (s, IH); MS (ESI(+)) m/e 569 (M+H)+. Example 93 (2E)-3-{4-amino-3-[4-({[(3-methylphenyl)amino]carbonvl)amino)phenyl]thieno[3,2- c]pyridin-7-yl} -N-phenylacrylamide X- aniline. 1H NMR (300 MHz. DMSO-d6) δ 2.29 (s, 3H), 5.97 (s. 2H), 6.79-8.84 35 (m, 2H), 7.07 (t, J=7.29 Hz. IH), 7.17 (t, J=7.80 Hz, IH). 7.25-7.27 (m. IH). 7.35-7.37 (m, 3H), 7.41 (d, J 8.4S Hz, 2H), 7.63 (d, J=8.48 Hz, 2H), 7.68 (s, IH), 7.74-7.75 (m, 2H), 7.78 (s, IH), 8.19 (s, IH), 8.79 (s, IH), 9.02 (s. IH), 10.28 (s, IH); MS (ESI(-)) m/e 518 (M-H)'. -81- WO 2005/010009 PCT/US2004/024003 Example 94 (2E)-3-(4-ammo-3-[4-({[(3-methylphenyl) amino]carbonvl)amino)phenyl]thieno[3,2- c]pyridm-7-yl}-N-3-pyridinylacrylamide X= 3-pyridinamine. 1H NMR (300 M&z, DMSO-dfi) δ 2.29 (s, 3H), 6.02 (s, 2H), 6.79 (d, J-5.09 Hz, 2H), 6.S3 (d, J=3.39 Hz, IH), 7.17 (t, J=7.S0Hz, IH), 7.26-7.27 (m, IH), 7.32 (s, IH), 7.40-7.43 (m, 2H), 7.62-7.65 (m, 2H), 7.69 (s, IH), 7.80 (d, J=15.93 Hz, IH), 8.18-8.20 (m, IH), 8.21 (s, IH), 8.28 (dd, J=4.75,1.36 Hz, IH), 8.68 (s, IH), 8.87 (d, J=2.03 Hz, IH), S.89 (s, IH), 10.49 (s, IH); MS (ESI(-)) m/e 519 (M-H)+ Example 95 N-[(2E)-3-(4-aminQ-3-[4-({[(3-metbylphenyl)aminolcarbonyOamino)phenyl]thieiio[3,2- c]pyridin-7-yl}-2-propenoyl)filycinamide X=glycinamide. 1H NMR (300 MHz, DMSO-d6) S 2.29 (s, 3H), 3.80 (d, J==5.76 Hz, 2H), 5.S9 (s, 2H), 6.70 (d, J=15.94 Hz, IH), 6.81 (d, J=7.12 Hz, IH), 7.03 (s, IH), 7.17 (t, 15 J=7.63 Hz, IH), 7.26-7.27 (m, IH), 7.32 (s. IH), 7.40 (d, J=8.48 Hz, 3H), 7.59 (d, J=8.S2 Hz, 2H), 7.63 (s, 2H), 8.13 (s, IH), 8.43 (t, J=5.76 Hz, IH), 8.67 (s, IH), S.87 (s, IH); MS (ESI(+))m/e501(M+H)+ Example 96 (2E)-3-{4-amino-3-[4-({[(3-methylphenyl)ammo1carboQyl}amirio)phenyl]thieno[3,2- clpyridin-7-yl}-N-[3-dH-imidazol-l-yl)propyl]acrylamide X=3-(lH-imidazol-l-yl)-l-propanamine. 1H NMR (300 MHz, DMSO-d6) 5 1.89-1.99 (m, 2H), 2.29 (s, 3H), 3.18 (dd, J=12.55, 6.78 Hz, 2H), 4.05 (t, J-6.95 Hz, 2H), 5.90 (s, 2H), 6.59 (d, J=15.94 Hz, IH), 6.SI (d, J=7.46 Hz, IH), 7.00 (s, IH), 7.17 (t, J-7.S0 Hz, IH), 7.26 (d, J=8.48 Hz, 2H), 7.31 (d, J=7.46 Hz, 2H), 7.40 (d, J=8.48 Hz, 2H), 7.59 (d, J=8.82 Hz, 2H), 7.63 (s, IH), 7.84 (s, IH), 8.13 (s, IH), 8.30 (t, J=5.59 Hz, IH), 8.67 (s, IH), S.SS (s, IH); MS (ESI(+)) m/e 552 (M+H)+. Example 97 tert-butyl N-(qE)-3-(4-amino-3-[4-({(3- methylphenyl)amino]carbonyl)amino)phenyl]thieno[3,2-c]pyridin--7-yl)-2-propenoyl)-β alaninate X=tert-butyl P-alaninate. 1H NMR (300 MHz, DMSO-d6) 5 1.42 (s, 9H). 2.29 (s, 3H), 2.45 (t, J-6.7S Hz, 2H), 3.36-3.42 (m, 2H), 5.89 (s, 2H), 6.59 (d, J-15.94 Hz, IH), 6.81 (d, 15 J=7.12 Hz. IH). 7.17 (t, J=7.S0 Hz, IH), 7.26-7.28 (m, IH), 7.32 (s, IH), 7.40 (d, J=8.48 Hz, 2H), 7.56-7.63 (m, 4H), 8.12 (s, IH), 8.30 (t, J=5.59 Hz, IH), 8.68 (s, IH), 8.88 (s, IH); MS (ESI(+))m/e572(M+H)+. -82- Example 98 N-(4-{4-amino-7-[(lE)-3-(4-morpholinvl)3-oxo--l--propenvl]thieno[3,2-c]pvridin-3- yl)phenyl)-N'-(3-methylphenyl)urea X= morpholine. 1H NMR (3.00 MHz, DMSO-dc) δ 2.29 (s, 3H), 3.64 (s, 8H), 5.93 (s, 2H), 6.81 (d, J=7.46 Hz, IH), 7.05 (d, M5.26 Hz, IH), 7.17 (t, J=7.80 Hz, IH), 7.23-7.27 (m, IH), 7.32 (s, IH), 7.39 (d, J=8.48 Hz, 2H), 7.58 (s, IH), 7.62 (d, J=S.4S Hz, 2H), 7.70 (d, J=15.60 Hz, IH), 8.29 (s, IH), 8.67 (s, IH), S.S8 (s, IH); MS (ESI(+)) m/e 514 (M+H)+ Example 99 (2E)-3-(4-amino-3-[4-({[(3-methylphenyl)aminolcaibonyUamino)phenyl]thieno[3,2- clpyridin-7-yl)-N-methylacrylamide X=methylamine hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 2.73 (s, 3H), 5.S7 (s, 2H), 6.58 (d, J=15.94Hz, IH), 6.S1 (d, J=7.12 Hz, IH), 7.17 (t, J=7.63 Hz, IH), 7.26-7.2S (m, IH), 7.32 (s, IH), 7.39 (d, J=8.4S Hz, 2H), 7.62-7.65 (m, 4H), S.ll (s, IH), 8.16 (d, J=4.75 Hz, IH), 8.77 (s, IH), 8.99 (s, IH); MS (ESI(+)) m/e 458 (M+H)+ Example 100 (2E)-3-{4-amitio-3-[4-({[(3-methylphenyl)ammolcarbonyUamino)phenyl]thienor3;2- c]pyridin-7-yl} acrylamide X= ammonia. 1H NMR (300 MHz, DMSO-dfi) δ 2.29 (s, 3H), 5.88 (s, 2H), 6.58 (d, J=16.27 Hz, IH), 6.81 (d, J-7.12 Hz, IH), 7.05 (s, IH), 7.17 (t, J-7.46 Hz, IH), 7.25-7.27 (m, IH), 7.32 (s, IH), 7.40 (d, JM8.14 Hz, 2H), 7.60-7.62 (m, 5H), S.ll (s, IH), 8.67 (s, IH), 8.87 (s, IH); MS (ESI(+)) m/e 444 (M+H)+. Example 101 N-(4-(4-amino-7-[(lE)-3-(5-amino-lH-pYrazol-l-yl)-3-oxo-l-propenyl]thieno[3,2-c]pyridin- 3-yl]phenyl)-N'-(3-methylphenyl')urea X = lH-pyrazol-5-amine. lH NMR (300 MHz, DMSO-d6) 6 1.73-1.75 (m, IH), 2.29 (s, 3H), 3.02-3.07 (m, IH), 3.58 (s, 2H), 6.02 (d, J-2.71 Hz, IH), 6.81 (d, J=7.46 Hz, IH), 30 7.17 (t, J=7.63 Hz, IH), 7.27-7.29 (m, IH), 7.33 (s, IH), 7.45 (d, J=8.4S Hz, 2H), 7.66 (d, J=8.82 Hz, 2H), 7.80 (d, J=16.2S Hz, IH), 7.88 (s, IH), 8.02 (d, J=16.27 Hz, IH), 8.19 (d, J=3.05 Hz, IH), 8.42 (s, IH), 8.76 (s, IH), 9.01 (s, IH); MS (ESI(+)) m/e 510 (M+H)+. ' Example 102 tert-butyl N-((2E)-3-{4-amino-3-[4-(([(3- methylphenyl)aminolcarbonyl)amino)phenyl]thieno[3,2-c]pyridln-7-vl}-2- propenoyl)glycinate X= tert-butyl glycinate. 1H NMR (300 MHz, DMSO-dG) 5 1.44 (s, 9H), 2.29 (s, 3H), -83- WO 2005/010009 PCT/US2004/024003 3.SS (d, J=6.10 Hz, 2H), 5.91 (s, 2H), 6.66 (d, J=16:28 Hz, 1H), 6.81 (d; J=7.12 Hz;--lH),- J=7.80 Hz, IH), 7.26-7.28 (m, 1H), 7.32 (s, IH), 7.40 (d, J-8.48 Hz, 2H), 7.60 (d, J=3.73 Hz, 2H), 7.64-7.66 (m, 2H), 8.14 (s, IH), S.59 (t, J=5.93 Hz, IH), S.77 (s, IH), 8.99 (s, IH); MS (ESI(+)) m/e 55S (M+H)+. Example 103 N-((2E)-3-(4-amino-3-[4-({[(3-mediylphenyl)ainmo]carbonyl)ammo)phenyl]thieno[3,2-- C]oyridm-7-yl}-2-propenoyl)-β -alanine The desired product was prepared by substituting Example 97 for Example 11A in Example 1 IB. lH NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 2.4S (d, J=10.S5 Hz, 2H), 3.41 (q, J=6.44 Hz, 2H), 6.75 (s, IH), 6.S2-6.87 (m, 4H), 7.17 (t, J=7.80 Hz, IH), 7.26-7.29 (m, IH), 7.33 (s, IH), 7.44 (d, J=S.S1 Hz, 2H), 7.58-7.64 (m, 2H), 7.67 (s, IH), 7.90 (s, IH), 8.23 (s, IH), 8.46 (t, J=5.59 Hz, IH), 8.81 (s, IH), 9.06 (s, IH); MS (ESI(+)) m/e 516 (M+H)+. Example 104 N-((2E)-3-{4-ammo-3-[4-({[(3-memylphenyl)amino1carbonyl}amiDo)phenynthiexio[3<2- c]pyridin-7-yl}-2-propenoyl)glycme The desired product was prepared as the trifluoroacetate salt by substituting Example 102 for Example 11A in Example 11B. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 3.94 (d, J=5.76 Hz, 2H), 4.95 (s, 2H), 6.S1 (d, J=7.46 Hz, IH), 6.90 (d, J-16.2S Hz, IH), 7.16 (dd, J=16.2S, S.4S Hz, 2H), 7.27-7.29 (m, IH), 7.33 (s, IH), 7.45 (d, J=8.4S Hz, 2H), 7.62-7.69 (m, 3H), 7.96 (d, J=5.43 Hz, IH), 8.29 (s, IH), 8.75 (t, J=5.76 Hz, IH), 8.92 (s, IH), 9.18 (s, IH); M:S (ESI{+)) m/e 502 (M+H)+. Example 105 tert-buty!3-[4--amino-3-[4-({[(3-methylphenyl)amino]carbonyl}arnino)phenyl]thieno[3,2- c]pyridin-7-yl)propanoate The desired product was prepared by substituting Example 77 for Example 14 in Example . 1H NMR (300 MHz, DMSO-dJ 6 1.3S (s, 9H), 2.29 (s, 3H), 2.63 (t, J-7.29 Hz, 2H), 2.93 (t, J-7.46 Hz, 2H), 5.31 (s, 2H), 6.80 (d, J=7.46 Hz, IH), 7.17 (t, J=7.S0 Hz, IH), 7.25-7.27 (m, IH), 7.31 (s, IH), 7.34-7.37 (m, 2H), 7.44 (s, IH), 7.59 (d, J=S.81 Hz, 2H), 7.68 (s, IH), S.67 (s, IH), 8.87 (s, IH); MS (ESI(+)) m/e 503 (M+H)+. Example 106 3-[4-animo-3-[4-(([(3-mefoylphenyl)armno] carbonyl)amino)phenyl]thieno[3,2-c]pyridm-7- yl}propanoic acid The desired product was prepared as the trifluoroacetate salt by substituting Example 105 for 11A in Example 1 IB. lH NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 2.74 (t, J=7.29 -84- WO 2005/010009 PCT/US2004/024003 Hz, 2H), 3.02 (t, J=7.46 Hz, 2H), 3.85 (s, 1H), 6.81 (d, J=7.46 Hz, 1H), 6.96 (s, 2H), 7.17 (t, J=7.63 Hz, 1H), 7.26-7.27 (m, 1H), 7.32 (s, 1H), 7.44 (d, J=8.48 Hz, 2H), 7.66 (d, J=8.48 Hz, 2H), 7.76 (s,1H), 7.89 (s, 1H), S.S2 (s, 1H), 9.08 (s, 1H); MS (ESI(+)) m/e 447 (M+H)+. Example 107 3-{4-ammo-3-[4-({[(3-memylphenyl)ammo]carbony ]amino)phenyl]thieno[3,2-c]pyridm-7- yl}-N"[2-(4-morpholinyl]ethyl]propanamide The desired product was prepared by substituting 2-(4-morpholinyl)ethanamine, Example 106, and TBTU for 2-piperazinone, Example 1 IB, and HOBT, respectively, in Example 11C. 1HNMR (300 MHz, DMSO-d6) & 2.31-2.36 (m, 9H), 2.92 (m3 2H), 3.16 (q, J=6.67 Hz, 2H), 3.26-3.37 (m, 2H), 3.54-3.56 (m, 4H), 5.27 (s, 2H), 6.80 (d, J=7.46 Hz, 1H), 7.17 (t, J=7.63 Hz, 1H), 7.25-7.27 (m, 1H), 7.31 (s, 1H), 7.35 (d, J=8.4S Hz, 2H), 7.44 (s, 1H), 7.59 (d, J=S.4S Hz, 2H), 7.66 (s, 1H), 7.S0 (t, J=5.59 Hz, 1H), 8.65 (s, 1H), 8.84 (s, 1H); MS (ESI(+)) m/e 559 (M+H)+. Example 108 3-{4-ammo-3-[4-({[(3-metliylphenyl)amino1carbonyl)amino)phenyl]thieno[3,2-c]pyridm-7- yl}-N-methylpropanamide The desired product was prepared by substituting methylamine, Example 106, and TBTU for 2-piperazinone, Example 1 IB, and HOBT, respectively, in Example 1 IC. lH NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 2.57 (d, J=4.41 Hz, 3H), 2.89-2.94 (m, 4H), 5.28 (s, 2H), 6.80 (d, J=7.46 Hz, 1H), 7.17 (t, J-7.63 Hz, 1H), 7.25-7.27 (m, 1H), 7.31 (s, 1H), 7.36 (d, J=S.48 Hz, 2H), 7.44 (s, 1H), 7.59 (d, J=8.48 Hz, 2H), 7.65 (s, 1H), 7.80 (d, J=4.41 Hz, 1H), 8.65 (s, 1H), 8.84 (s, 1H); MS (ESI(+)) m/e 460 (M+H)+. 25 Example 109 3-{4-amino-3-[4-({[(3-methylphenvl)amino]carbonvl]ammo)phenyl]trueno[3,2-c]pyridin-7- yppropanamide The desired product was prepared by substituting Example 100 for Example 14 in Example 15. 1HNMR (500 MHz, DMSO-d6) δ 2.29 (s, 3H), 2.50 (s, 2H), 2.92 (s, 2H), 5.26 (s, 2H), 6.79 (s, 2H), 7.21 (d, J-44.61 Hz, 2H), 7.34 (d, J-17.78 Hz, 4H), 7.43 (s, 1H), 7.60 (s, 2H), 7.68 (s, 1H), 8.76 (s, 1H), 8.96 (s, 1H); MS (ESI(+)) m/e 446 (M+H)+. Example 110 ethyl (2E)-3-{4-aimno-3-[4-({[(3-methylphenvl)amino1carbonyl)amino)phenyl]thieno[3,2- c]pyridin-7-yl]acrylate The desired product was prepared by substituting Example 76B and ethyl acrylate for Example 10B and tert-butyl acrylate, respectively, in Example UA, then substituting the -85- WO 2005/010009 PCT/US2004/024003 product for Example 76B in Examples 76C-D. 1H NMR (300 MHz, DMSO-dJ 8 1.29 (t, ., J=7.12 Hz, 3H), 2.29 (s, 3H), 4.22 (q, J=7.23 Hz, 2H), 6.05 (s, 2H), 6.39 (d, J=16.27 Hz, IH 6.81 (d, J=7.12 Hz, IH), 7.17 (t, J=7.63 Hz, IH), 7.23-7.27 (m, IH), 7.32 (s, IH), 7.39 (d, J=8.S2 Hz, 2I-I), 7.61 (s, 2H), 7.63 (s, IH), 7.81 (d, M5.60 Hz, IH), 8.27 (s, IH), 8.67 (s, IH), S.S8 (s, IH); MS (ESI(+)) m/e 473 (M+H)+. Example 111 ethyl 3-{4-aimno-3-['4-('{[('3-niethvlphenyl)amino1carbonvl)amino)phenyl]thieno[3,2- c]pyridin-7-yl}propanoate The desired product was prepared by substituting Example 110 for Example 14 in Example 15. 1H NMR (300 MHz, DMSO-d6) 5 1.17 (t, J=7.12 Hz, 3H), 2.29 (s, 3H), 2.72 (t, J-7.46 Hz, 2H), 2.97 (t, J=7.29 Hz, 2H), 4.07 (q, J=7.12 Hz, 2H), 5.31 (s, 2H), 6.80 (d, J-7.12 Hz, IH), 7.16 (t, J=7.63 Hz, IH), 7.25 (d, J=8.14 Hz, IH), 7.31 (s, IH), 7.36 (d, J-8.4S Hz, 2H), 7.44 (s, IH), 7.59 (d, J-8.4S Hz, 2H), 7.69 (s, IH), 8.69 (s, IH), 8.88 (s, IH) 15 MS (ESI(+)) m/e 475 (M+H)+. Example 112 (2E)-3-[4-animo-3-(4-aminophenyl)thieno[3,2-c]pyridm-7-vl]-N-methylacrylamide Example 112A (2E)-3-[4-amino-3-(4-aminophenyl)tbienol'3,2-c]pyridin-7-yl]acrylicacid The desired product was prepared by substituting Example 77A for Example 10B in Examples 11A-B. 1H NMR (300 MHz, DMSO-d6) δ 5.-[4-5.48 (br s, 2H), 6.55 (d, J-16.27 Hz, IH), 6.7S (d, J-S.48 Hz, 2H), 7.03 (s, 3H), 7.20 (d, J=S.4S Hz, 2H), 7.72-7.77 (m, 2H), 8.33 (s, IH); MS (ESI(+)) m/e 312 (M+H)+. Example 112B (2E)-3-[4-amino-3-(4 -aminophenyl)thieno[3,2-c]pyridin-7-yl]-N-methylacrylamide The desired product was prepared by substituting methylamine, Example 112A, and TBTU for 2-piperazinone, Example 1 IB, and HOBT, respectively, in Example 11C. 1H NMR (300 MHz, DMSO-d δ 2.72 (s, 3H), 5.39 (s, 2H), 5.92 (s, 2H), 6.55 (d, J=15.94 Hz, IH), 6.6$ (d, J=8.48 Hz, 2H), 7.10 (d, J=S.4S Hz, 2H), 7.47 (s, IH), 7.56 (d, J=15.94 Hz, IH), 8.08 (s, IH), S.14 (q, J=4.1S Hz, IH); MS (ESI(+)) m/e 325 (M+H)+ Example 113 N-(4-(4-ammo-7-[("lE)-3-(memylammo)-3-oxo-l-propenynthieno[3,2c]1pyridin-3- yl)phenvl)-3-metlivlbenzamide The desired product was prepared by substituting 3-methylbenzoyl chloride and -86- WO 2005/010009 PCT/US2004/024003 Example 112 for acetyl chloride and Example 17A, respectively, in Example 17B: lH NMR (300 MHz, DMSOd6) δ 2.42 (s, 3H), 2.74 (d, J=4.41 Hz, 3H), 5.86 (s, 2H), 6.5$ (d, J=15.60 Hz, IH), 7.44 (d, J=5.43 Hz, 2H), 7.48 (d, J-3.4S Hz, 2H), 7.59 (d, J-15.94 Hz, IH), 7.66 (s, IH), 7.80 (s, 2H), 7.95 (d, J-S.14 Hz, 2H), 8.13 (s, IH), 8.16 (d, J=4.75 Hz, IH), 10.41 (s, IH); MS (ESI(+))m/e 443 (M+Hf. Example 114 (2E)-3-[4-amino-3-(4-{[(3-methylphenyl)sulfonyl]amino)phenyl)thieno[3,2-c]pyridin-7-yl]- N-methylacrylamide A solution of 3-methylbenzenesulfonyl chloride (70mg, 0.37 mmol) in DMF (1 mL) was added dropwise to a -30 °C solution of Example 112 (0.117g, 0.36 mmol) andN- methylmorpholine (0.057 mL, 0.54 mmol) in DMF (3 mL). The resulting mixture was stirred at -30 °C for 30 minutes, warmed to room temperature over 1.5 hours, and partitioned between water and ethyl acetate. The aqueous phase was extracted with ethyl acetate two times. The combined organics were dried (NajSOJ, filtered, concentrated and the residue was purified by flash column chromatography on silica gel with 5% methanol/dichloromethane to provide 55 mg (32% yield) of the desired product. lH NMR (300 MHz, DMSO'-dJ δ 2.37 (s, 3H), 2.72 (d, J=4.75 Hz, 3H), 5.73 (s, 2H), 6.56 (d, J-15.94 Hz, IH), 7.22 (d, J=S.S2 Hz, 2H), 7.36 (d, J=S.48 Hz, 2H), 7.46 (d, J=5.43 Hz, 2H), 7.58 (s, 2H), 7.64 (s, 2H), S. 10 (s, IH), 8.14 (d, J-5.09 Hz, IH), 10.50 (s, IH); MS (ESI(+)) m/e 479 (M+H)+ Example 115 N-(4-[4-amino-7-[(lE)-3-(methylamino)-3-oxo-l-propenyl]thieno[3,2-c]pyridin-3- yl}phenyl)benzamide The desired product was prepared by substituting benzoyl chloride and Example 112 for acetyl chloride and Example 17A, respectively, in Example 17B. 1H NMR (300 MHz, DMSO-d5) δ 2.74 (d, J=4.75 Hz, 3H), 5.87 (s, 2H), 6.58 (d, J=15.93 Hz, IH), 7.48-7.50 (m, 2H), 7.56 (s, IH), 7.60-7.62 (m, 3H), 7.66 (s, IH), 7.95 (s, IH), 7.99-S.O (m, 3H), 8.13 (s, IH), 8.16 (d, J-4.75 Hz, IH), 10.46 (s, IH); MS (ESI(+)) m/e 429 (M+H)+. Example 116 (2E)-3-(4-amino-3-phenylthieno[3,2-c]pyridin-7-yl')-N,N-dimethylacrylamide The desired product was prepared by substituting dimethylamhie for methylamine hydrochloride in Example 14. !H NMR (300 MHz, DMSO-d,) 8 2.97 (s, 3H), 3.19 (s, 3H), 5.83 (s, 2H), 7.03 (d, J=15.60 Hz, IH), 7.52-7.57 (m,-5H), 7.64-7.6S (m, 2H), 8.26 (s, 1H> MS (ESI(+)) m/e 324 (M+H)+. -87- WO 2005/010009 PCT/US2004/02-1003 Example 117 (2E)-3-[4-amino-3-(4-amino)phenyl)thieno[3,2-c]pyridin-7-yl]-N-[4- (dimethylamino)butyl ]acrylamide The desired product was prepared by substituting N,N-dimethyl-l,4-butanediamine, Example 112A, and TBTU for 2-piperazinone, Example 1 IB, and HOBT, respectively, in Example 11C. 1HNMR (300 MHz, DMSO-d6) 5 1.10 (s, 6H), 2.S3 (s, 4H), 3.40 (s, 4H), 5.40 (s, 2H),- 5.94 (s, 2H), 6.57 (d, J-15.94 Hz, 1H), 6.68 (d, J=8.4S Hz, 2H), 7.10 (d, J=8.4S Hz, 2H), 7.48 (s, 1H), 7.59 (d, J-15.94 Hz, 1H), 8.09 (s, 1H), 8.34 (s, 1H); MS (ESI(+)) m/e 410 (M+H)+. 10 Example 118 (2E)-3-[4-amino-3-(4-ammophenyl)thieno[3,2-c]pyridin-7-yl]-N-(3- pyridinylmethyl)acrylamide The desired product was prepared by substituting l-(3-pyridinyl)methanamine, Example 112A, and TBTU for 2-piperazinone, Example 1 IB, and HOBT, respectively, in Example 11C. 1H NMR (300 MHz, DMSO-d6) 5 3.33 (s, 2H), 4.46 (d, J-5.76 Hz, 2H), 6.30 (s, 2H), 6.68 (d, J=5.42 Hz, 1H), 6.72 (d, J=2.03 Hz, 2H), 7.13 (d, J=8.48 Hz, 2H), 7 41 , J=7.46, 4.41 Hz, 1H), 7.59 (s, 1H), 7.63 (d, J=15.93 Hz, lH),7.77-7.80 (m, 1H), 8.14 (s, 1H), 8.50(dd,J=4.75,1.70 Hz, 1H), 8.57 (d, J=1.36Hz, 1H), 8.84 (t, J=5.76 Hz, 1H);MS (ESI(+)) m/e 402 (M+H)+. Example 119 3-[4-aminophenyl)-7-[(lE)-3-oxo-3-(l"piperazinyl)-l-propenyl]thieno[3,2-c]pyridm-4-amine The desired product was prepared as the bis-trifluoroacetate salt by substituting tert-butyl 1-piperazinecarboxylate and Example 112A for piperazin-2-one and Example 1 IB, respectively, in Example 11C, then by removing the protecting group following the procedure of Example 11B. 1HNMR (300 MHz, DMSO-dJ 6 3.85 (s, 8H), 4.24 (s, 2H), 6.76 (d, J=8.48 Hz, 2H), 6.9S(s, 1H), 7.18 (d, J=8.48 Hz, 2H), 7.26 (d, J=15.60 Hz, 1H), 7.66 (d, J=15.60 Hz, 1H), 7.74 (s, 1H), 8.38 (s, 1H), 8.92 (s, 2H); MS (ESI(+)) m/e 380 (M+H)+. Example 120 3-[4-amino-3-(4-aminophenyl)thieno['3,2-c]pyridin-7-yl]propanoicacid The desired product was prepared by substituting Example 112A for Example 14 in Example 15. lH NMR (300 MHz, DMSO-d6) δ 2.72 (d, J-6.78 Hz, 4H), 2.89-2.99 (m, 2H), 35 6.71 (d, J=7.S0 Hz, 2H), 6.97 (s, 2H), 7.15 (d, J=7.80 Hz, 2H), 7.73 (d, J-6.10 Hz, 2H), 12.36 (s, 1H); MS (ESI(+)) m/e 314 (M+H)+. Example 12. -88- WO 2005/010009 PCT/US2004/0240U3 3-(4-ammophenyl)-7-(4-pVridinyl)trueno[3,2-c]pyridn-4-amine Example 121A tert-butyl 4-['4-amino-7-(4-pyridinyl)thieno[3,2-c]pyridin-3-yl]phenylcarbarnate A mixture of Example 77A (1.559g, 3.34 mmol), 4-pyridylboronic acid (0.431 g, 3.51 mmol) and Na2CO3 (0.37g, 3.51 mmol) in THF/methanol/water (12 mL:2.4 mL:4 mL) was degassed by bubbling nitrogen through the solution for 15 minutes, then treated with Pd(dppf)CU (136mg, 0.17 mmol). The reaction vessel was sealed and heated to 90 °C for 17 hours. The reaction was cooled to room temperature and partitioned between water and ethyl acetate. The aqueous phase was extracted twice with ethyl acetate. The combined extracts were dried (Na SCX,), filtered, concentrated, and the residue was purified by flash column chromatography on silica gel with 3% methanol/dichloromethane to provide 0.65g (46%) of the desired product. MS (ESI(+)) m/e 419 (M+H)+. Example 121B 3-(4-aminophenyl)-7-(4-pyridinyl)thieno[3,2-c]pyridin-4-amine A solution of Example 121A (0.1 lg, 0.263 mmol) in TFA (3 mL) and dichloromethane (1 mL) was stirred at room temperature fpr 30 minutes and concentrated under a stream of nitrogen. The residue was triturated from ethyl acetate/hexanes to provide 108 mg of the desired product. 1H NMR (300 MHz, DMSO-d6) δ 5.66 (s, 2H), 6.78 (d, J=8.14 Hz, 2H), 6.97 (s, 2H), 7.20 (d, J=8.4S Hz, 2H), 7.75 (s, IH), 7.91 (d, J=6.44 Hz, 2H), 8.19 (s, IH), 8.83 (d, J=6.44 Hz, 2H); MS (ESI(+)) m/e 319 (M+H)+ Example 122 N-{4-[4-amino-7-(4-pyridinyl)thieno[3,2-c]pyridin-3-yl]phenyl)-N'-[2-fluoro-5- (trifluoromethvl) phenyl] urea A -20 °C solution of Example 121B (0.18g, 0.57 mmol) inDMF (3 mL) andTHF (3 mL) was treated dropwise with l-fluoro-2-isocyanato-4-(trifluorometliyl)benzene (0.085 ml 0.57 mmol) and warmed to room temperature over 1.5 hours. The resulting mixture was diluted with water and extracted twice with ethyl acetate. The combined extracts were driec (Na2SOJ, filtered, concentrated and the residue was purified by flash column chromatography on silica gel with 3-5% methanol/dichloromethane to provide 138 mg of tb desired product. 1H NMR (300 MHz, DMSO-d6) δ 5.74 (s, 2H), 7.44 (d, J=S.48 Hz, 3H), 7.51 (d, J-10.85 Hz, IH), 7.55 (s, IH), 7.64 (d, J-8.82 Hz, 2H), 7.71-7.72 (m, IH), 7.74 (d, J=1.70 Hz, IH), S.10 (s, IH), 8.64 (dd, J=7.29,2.20 Hz, IH), 8.67-8.69 (m, IH), 8.70 (d, JN1.70 Hz, IH), 8.98 (d, J=2.71 Hz, IH), 9.40 (s, IH); MS (ESI(+)) m/e 524 (M+H)+. Example 123 -89- WO 2005/010009 PCT/US2004/024003 N-{4-[4-amino-7-(4-pyridinvl)thieno [3,2-c]pyridin-3-yl]phenyl)-N'-[2-fluoro-5- methylphenyl)urea The desired product was prepared by substituting l-fluoro-2-isocyanato-4-methylbenzene for l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in Example 122. ]H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 5.74 (s, 2H), 6.80-6.85 (m, IH), 7.12 (dd, J=11.36, 8.31 Hz, IH), 7.42 (d, J=S.82 Hz, 2H), 7.54 (s, IH), 7.62 (d, J-S.48 Hz, 2H), 7.73-7.75 (m, 2H), 8.00 (dd, J=7.S0, 2.03 Hz, IH), S.09 (s, IH), S.56 (d, J=2.71 Hz, IH), S.65-S.6E (m, Hi), 8.69 (d, J=1.70Hz, IH), 9.28 (s, IH); MS (ESI(+)) m/e 470 (M+H)+ Example 124 3-(4-aminophenyl)-7-[3-pyridinyl)thieno[3,2-c]pyridin-4-amine The desired product was prepared by substituting 3-pyridylboronic acid for 4-pyridylboronic acid in Examples 121A-B. 1H NMR (300 MHz, DMSO-d6) δ 5.39 (s, 2H), 5.69 (s, 2H), 6.69 (d, J=8.48 Hz, 2H), 7.11 (d, J=8.14 Hz, 2H), 7.36 (s, IH), 7.54 (dd, J=7.S0, 4.75 Hz, IH), 7.92 (s, IH), 8.08 (d, J=7.S0 Hz, IH), 8.61 (d, J=4.07 Hz, IH), 8.86 (s, IH); MS (ESI(+)) m/e 319 (M+H)+ Example 125 N-{4-[4-ammo-7-(3-pyridinyl)thieno[3,2-c]pyridin-3-yl]phenyl}-N1-(3-methylphenyl)urea The desired product was prepared by substituting l-isocyanato-3-methylbenzene and Example 124 for l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene and Example 121B, respectively, in Example 122. lH NMR (300 MHz, DMSO-d,) δ 2.29 (s, 3H), 5.64 (s, 2H), 6.81 (d, J=7.46 Hz, IH), 7.17 (t, J-7.S0 Hz, IH), 7.26-7.27 (m, IH), 7.32 (s, IH), 7.41 (d, J=S.S2 Hz, 2H), 7.51 (s, IH), 7.56 (dd, J=8.14, 4.75 Hz, IH), 7.62 (d, J-8.S2 Hz, 2H), 7.96 25 (s, IH), 8.10-8.13 (m, 1H), 8.62 (dd, J=4.75, 1.70 Hz, IH), 8.67 (s, IH), 8.87 (s, IH), S.88 (s, IH); MS (ESI(+)) m/e 452 (M+H)+. Example 126 3-(4-animophenyl)-7-(3-thienyl)tmino[3,2-c]pyridin-4-amine The desired product was prepared by substituting Example 77B and 3-thienylboronic acid for Example 77A and 4-pyridylboronic acid, respectively, in Example 121 A. 1H NMR (300 MHz, DMSO-d6) δ 5.37 (s, 2H), 5.59 (s, 2H), 6.68 (d, >8.4S Hz, 2H), 7.11 (d, J-S.4S Hz, 2H), 7.36 (s, IH), 7.55 (dd, J=5.09,1.36 Hz, IH), 7.72-7.73 (m, IH), 7.78-7.79 (m, IH), 8.05 (s, .IH); MS (ESI(+)) m/e 324 (M+H)+. Example 127 N-{4-[4-amino-7-(3-thienyl)thieno[3,2-c]pyridm-3-yl]phenyl}-N'-(3-methylphenyl)urea The desired product was prepared by substituting for l-isocyanato-3-methylbenzene -90- WO 2005/010009 PCT/US2004/024003 and Example 126 for l-fluoro-2-isocyanato-4-(trifluoromethyl)berizene and Example 121B, respectively, in Example 122. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 5.53 (s, 2H), 6.81 (d, J=7.46 Hz, IH), 7.17 (t, J=7.80 Hz, 1H), 7.26-7.28 (m, IH), 7.32 (s, IH), 7.40 (d, J-8.S1 Hz, 2H), 7.51 (s, IH), 7.57 (dd, J=5.09,1,36 Hz, IH), 7.61 (d, J=8.S1 Hz, 2H), 7.73 (dd, J-4.92, 2.8S Hz, IH), 7.80-7.83 (m, IH), 8.09 (s, IH), 8.66 (s, IH), 8.86 (s, IH); MS (ESI(-))m/e455(M-H)+ Example 128 N-{4-[4-amino-7-(6-methoxy-3-pyridinyl)thieiio[3,2-c]pyridin-3-yl]phenyn-N'-[2-fluoro-5- (tri fluoromethyl) phenyl]urea Example 128 A 3-(4-aminQphenyl)-7-(6-methoxy-3-pyridinyl')thieno[3,2-c]pyridin-4-amine The desired product was prepared by substituting Example 77B and 6-methoxy-3- pyridinylboronic acid for Example 77A and 4-pyridylboronic acid, respectively, in Example 121A. MS (ESI(+)) m/e 349 (M+H)+. Example 128B N-{4-[4-amino-7-(6-methoxy-3-pyridinyl)thieno[3,2-c]pyridin-3-yl]phenyl]-N1-[2-fluoro-5- (trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 128A for Example 121B in Example 122. 1H NMR (300 MHz, DMSO-d6) 5 3.93 (s, 3H), 5.55 (s, 2H), 6.99 (d, J=8.4S Hz, IH), 7.39-7.45 (m, 3H), 7.49-7.55 (m, 2H), 7.64 (d, J=S.48 Hz, 2H), 7.89 (s, IH), 8.00 (dd, J=8.65, 2.54 Hz, IH), 8.45 (d, J-2.37 Hz, IH), S.64 (dd, J=7.46,2.03 Hz, IH), 8.98 (d, J2.71 Hz, IH), 9.39 (s, IH); MS (ESI(+)) m/e 554 (M+H)+. Example 129 N-(4-[4-arnino-7-(6-methoxy-3-pyridinYl)thieno[3,2-c]pyridm-3-yl]phenyl)"N'-(2-fluoro-5- methylphenyl)urea The desired product was prepared by substituting for l-fluoro-2-isocyanato-4- methylbenzene and Example 128A for. l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene and Example 121B, respectively, in Example 122. lH NMR (300 MHz, DMSO-dfi) δ 2.29 (s, 3H), 3.93 (s, 3H), 5.55 (s, 2H), 6.82-6.84 (m, IH), 6.97-7.00 (m, IH), 7.12 (dd, J=11.53, 8.48 Hz, IH), 7.41 (d, J=S.4S Hz, 2H), 7.50 (s, IH), 7.62 (d, J=8.48 Hz, 2H), 7.88 (s, IH), 8.00-35 8.03 (m,2H), 8.44 (d, J=2.37Hz, IH), 8.56 (d, J«2,37Hz, IH), 9.27 (s, 1H);MS (ESI(+)) m/e500(M+H)+. Example 130 -91- WO 2005/010009 PCT/US2004/02400; N-{4-[4-ammo-7-(6-methoxy-3-pyriduivl)mieno[3,2-c]pvridm-3-yl:|phenyl}--N'-[3- (trifluoromethyl)phenyl]urea The desired product was prepared by substituting for l-isocyanato-3-(trifluoromethyl)benzene and Example 12SA for 1-fluoro-2-isocyanato-4- (trifluoromethyl)benzene and Example 121B, respectively, in Example 122. 1H NMR (300 MHz, DMSO-d6) 6 3.93 (s, 3H), 5.56 (s, 2H), 6.99 (dj=8.48 Hz, 1H), 7.33 (d, J=7.46 Hz, 1H), 7.42 (d, J=8.4S Hz, 2H), 7.50 (s, 1H), 7.55 (d, J=7.46 Hz, 1H), 7.60 (s, 1H), 7.64 (d, J=8.4S Hz, 2H), 7.89 (s, 1H), 8.00 (dd, J=8.48,2.71 Hz, 1H), 8.04 (s, 1H), 8.44 (d, J=2.37 Hz, 1H), 9.02 (s, 1H), 9.13 (s, 1H); MS (ESI(+)) m/e 534 (M+H)+ 10 Example 131 N-(4-[4-amino-7-(4-cyanophenyl)thieno[3,2-c]pyridin-3-yl]phenyl}-N'-[2-fluoro-5- (trifluorom ethyl) phenyl ] urea Example 131A 4-[4-Amino-3-(4-arriino-phenyl)-thieno[3,2-c]pyridin-7-yn-berizonitrile The desired product was prepared by substituting Example 77B and 4-cyanophenylboronic acid for Example 77A and 4-pyridylbofonic acid, respectively, in Example 121 A. MS (ESI(+)) m/e 343 (M+H)+ Example 13 IB N-{4-[4-amino-7-(4-cyanophenyl)thieno[3,2'C]pyridin-3-yl]phenyl}-N'-["2-fluoro-5- (trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 131A for Example 121B in Example 122. 1H NMR (300 MHz, DMSO-dfi) δ 5.71 (s, 2H), 7.40-7.45 (m, 3H), 7.51 (d, J=10.S5 Hz, 1H), 7.54 (s, 1H), 7.64 (d, >8.81 Hz, 2H), 7.90 (d, J=8.81 Hz, 2H), 7.96-S.00 (m, 2H), S.02 (s, 1H), 8.64 (dd, J=7.46,2.37 Hz, 1H), 8.98 (d, J=3.05 Hz, 1H), 9.39 (s, 1H); MS (ESI(+)) m/e 548 (M+H)*. Example 132 N-(4-[4-arm'no-7-(4-cyanophenyl)amino[3,2-c]pyridrn-3-yl]phenyl}-N'-(2-fltioro-5- methylphenyl)urea The desired product was prepared by substituting for l-fluoro-2-isocyanato-4-methylbenzene and Example 131A for l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene and Example 121B, respectively, in Example 122. 1H NMR (300 MHz, DMSO-dg) 8 3.31 (s, 3H), 5.71 (s, 2H), 6.79-6.84 (m, 1H), 7.12 (dd, J=l 1.36, 8.31 Hz, 1H), 7.42 (d, J=8.48 Hz, 2H), 7.53 (s, IH), 7.62 (d, J=8.48 Hz, 2H), 7.90 (d, J=8.48 Hz, 2H), 7.97-8.03 (m, 4H), 8.56 (d, J=2.37 Hz, 1H), 9.28 (s, 1H); MS (ESI(+)) m/e 494 (M+H)+. -92- WO 2005/010009 PCT/US2004/024003 Example 133 N-{4-[4-amino-7-(2-methoxy-5-pyrimidinyl)thieno[3,2-c]pyridin-3-yl]pheiivli-N'-[2-fluoro- 5-(trifluoromethyr)phenyriurea Example 133A 3-(4-aminopheriyl)-7-(2-memoxy-5-pyrimidinyl)thieno[3,2-c]pyridm-4-amine The desired product was prepared by substituting 2-methoxy-5-pyrimidinylboromc acid for 4-pyridylboronic acid in Examples 121A-B. MS (ESI(+)) m/e 350 (M+H)+. Example 133B N-{4-[4-amino-7-2-methoxy-5-pyrimidinyl)thieno[3,2-c]pyridin-3-yl]phenyl)-N'-[2-fluoro- 5-(trifluoromethyl')phenyl'lurea The desired product was prepared by substituting Example 131A for Example 121B in Example 122. !H NMR (300 MHz, DMSO-d6) 5 4.00 (s, 3H), 5.64 (s, 2H)3 7.43 (d, J=8.48 Hz, 3H), 7.49-7.55 (m, 2H), 7.64 (d, J=8.48 Hz, 2H), 7.95 (s, IH), 8.63-8.66 (m, IH), 8.90 (s, 2H), 8.98 (d, J=2.37 Hz, IH), 9.39 (s, IH); MS (ESI(+)) m/e 555 (M+H)+. Example 134 N-[4-R4-amino-7-(2-methoxy-5-pyrimidinyl)thieno[3,2-c]pyridin-3-yl]pheriyl}-N'-[3- (trifluoromethyl)phenyl]urea The desired product was prepared by substituting l-isocyanato-3-(trifluoromethyl)benzene and Example 131A for l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene and Example 121B, respectively, in Example 122. 1HNMR (300 25 MHz, DMSO-d6) 6 4.00 (s, 3H), 5.65 (s, 2H), 7.33 (d, J-7.80 Hz, IH), 7.42 (d, J=S.4S Hz, 2H), 7.51-7.56 (m, 2H), 7.61 (d, J=8.4S Hz, 2H), 7.65 (s, IH), 7.94 (s, IH), 8.04 (s, IH), 8.90 (s, 2H), 9.03 (s, IH), 9.13 (s, IH); MS (ESI(+)) m/e 537 (M+H)+. Example 135 N-{4-[4-amino-7-(2,6-dimethyl-3-pyridinyl)tmino[3,2-c]pyridin--3-yl]phenyl]-N'-[2-fluoro- 5-(trifluoromethyl)phenyl]urea Example 135A 3-(4-ammophenyQ-7-(2,6-dimethvl-3-pyridiy-3-pyridiyl)thioeno[3,2-c]pyridin-4-amine The desired product was prepared by substituting 2,6-dimethyl-3-pyridinylboronic acid for 4-pyridylboronic acid in Examples 121A-B. MS (ESI(+)) m/e 347 (M+H)+. Example 135B -93- WO 2005/010009 PCT/US2004/024003 N-{4-[4-amino-7-(2,6-dimethyl-3-pyridinyl)tmino[3,2-c]pyridin--3-yl]phenyl]-N'-[2-fluoro- 5-(trifluoromethyl)phenyl"livrea The desired product was prepared by substituting Example 135A for Example 12 IB in Example 122. 1H NMR (300 MHz, DMSO-dJ δ 2.31 (s, 3H), 2.32 (s, 3H), 5.54 (s, 2H), 6.68 (d, J-S.4S Hz, IH), 7.12 (d, J=S.4S Hz, IH), 7.17-7.21 (m, 2H), 7.40-7.49 (m, 3H), 7.57-7.67 (m, 2H), 7.72 (s, IH), 8.64 (dd, J=7.46,2.03 Hz, IH), 8.98 (d, 3=2.71 Hz, IH), 9.38 (s, IH); MS (ESI(+)) m/e 552 (M+H)+. Example 136 N-{4-[4-amino-7-(5-pvrimidinyl')thieno[3,3-c]pyridin-3-yl]phenyl}-N'-('3-metliylphenyl)urea Example 136A 3-(4-aminophenyl)-7-(5"pyrimidinyl)thieno[3,2-c]pyridin-4-amine The desired product was prepared by substituting 5-pyrimidinylboronic acid for 4-pyridylboronic acid in Examples 121A-B. MS (ESI(+)) m/e 320 (M+H)+. Example 136B N-(4-[4-amino-7-(5-pyrimidinyl)thieno[3,2-c]pyridin-3-yl]phenyl)-N'-(3-methylphenyl)urea The desired product was prepared by substituting l-isocyanato-3-methylbenzene and Example 136A for l-fluoro-2-isocyanato-4-(triiluoromethyl)benzene and Example 121B, respectively, in Example 122. 1H NMR (300 MHz, DMSO-d6) 8 2.29 (s, 3H), 5.75 (d, J-2.71 Hz, 2H), 6.81 (d, J-7.46 Hz, IH), 7.17 (t, J=7.80Hz, IH), 7.26-7.28 (m, IH), 7.32 (s, IH), 7.40 (d, J=8.48 Hz, 2H), 7.54 (s, IH), 7.62 (d, J=8.4S Hz, 2H), S.04 (s, IH), 8.67 (s, IH), 8.88 (s, IH), 9.14 (s, 2H), 9.23 (s, IH); MS (ESI(+)) m/e 453 (M+H)+. Example 137 N-(4-[4-ammo-7-(5-pyrimidinyl)thieno[3,2-c]pyridin-3-yl]phenyl}-N'--[2-fluoro-5-- (trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 136A for Example 121B in Example 122. 1H NMR (300 MHz, DMSO-d6) δ 5.74 (s, 2H), 7.44 (d, >8.48 Hz, 3H), 7.49-7.56 (m, 2H), 7.65 (d, J=8.48 Hz, 2H), 8.05 (s, IH), 8.65 (d, J-7.12 Hz, IH), S.9S (d, J=2.37 Hz, IH), 9.14 (s, 2H), 9.24 (s, IH), 9.40 (s, IH); MS (ESI(+)) m/e 525 (M+H)+. Example 138 3-(4-aminQphenyl)-7-[4-(benzyloxy)phenyl]thieno[3,2-c]pvridin amine The desired product was prepared by substituting Example 77B and 4-benzyloxyphenylboronic acid for Example 77A and 4-pyridylboronic acid, respectively, in Example 121A. 1H NMR (300 MHz, DMSO-dfi) δ 5.18 (s, 2H), 5.37 (s, 2H), 5.53 (s, 2H), -94- WO 2005/010009 PCT/US2004/024003 6.6S (d; J=8.14 Hz,-2H); 7.10'(d, J-8.14Hz,2H)i 7.15 (d, J=8.S2 Hz, 2H), 7.32 (s, 1H), 7.48-7.51 (m, 3H), 7.53-7.55 (m, 2H), 7.57 (d, J-S.S2 Hz, 2H), 7.81 (s, 1H); MS (ESI(+)) m/e 424 (M+H)+. Example 139 4-[4-amino-3-(4-aminophenyl)thieno[3,2-c]pyridin-7-yl]phenol A suspension of Example 138 (132 rag) in 48% HBr (2 mL) and acetic acid (4 mL) was heated to 80 °C for 3 hours. The resulting homogeneous solution was concentrated and the residue was triturated from ethanol/diethyl ether to provide 130 mg of the desired product the diliydrobromide salt. lH NMR (300 MHz, DMSO-d6) 5 3.67 (s, 2H), 6.95-6.98 (m, 6H), 7.34 (d, J-8.4S Hz, 2H), 7.51 (d, J-S.S2 Hz, 2H), 7.85 (d, J=S.S2 Hz, 2H), 9.83 (s, 1H); MS (ESI(+))m/e334(M+H)+. Example 140 N-{4-[4-amino-7-(4-hydroxyphenyl)thieno[3,2-c]pyridin-3-yl]pheqyl]-N'-(3- methylphenyl")urea The desired product was prepared as the hydrobroraide salt by substituting Example 138 for Example IC in Example ID, then substituting the product for Example 138 in Example 139. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 6.82 (d, J=7.12 Hz, 1H), 6.90 (s, 21-1), 6.96-6.99 (m, 2H), 7.18 (t, J=7.80 Hz, 1H), 7.27 (d, J-8.4S Hz, 1H), 7.32 (s, 1H), 7.46 (d, J-8.48 Hz, 2H), 7.52-7.55 (m, 2H), 7.67 (d, J=S.48 Hz, 2H), 7.89 (d, J=4.07 Hz, 2H), 8.75 (s, 1H), 9.02 (s, 1H), 9.SS (s, 1H); MS (ESI(+)) m/e 467 (M+H)+. Example 141 3-[4-amino-3-[4-({l(3-methylphenyl)aminolcarbonyl}ammo)plienyl]thieno[3,2-c]pyridin-7- yl}-N-methylbenzamide The desired product was prepared as the trifluoroacetate salt by substituting 3-[(methylamino)carbonyl]phenylboronic acid for 4-pyridylboronic acid in Examples 121A-B, then substituting the product and l-isocyanato-3-methylbenzene for Example 121B and 1-30 fluoro-2-isocyanato-4-(trifluoromethyl)benzene, respectively, in Example 122. The product was purified by HPLC as described in Example 82. 1H NMR (300 MHz, DMSO-d6) δ 2.09 (s, 3H), 2.29 (s, 3H), 6.82 (d, J=7.46 Hz, 1H), 6.96 (s, 2H), 7.18 (t, J-7.80 Hz, 1H), 7.27-7.2 (m, 1H), 7.34-7.36 (m, 2H), 7.47 (d, J=S.82 Hz, 2H), 7.53-7.55 (m, 1H), 7.61-7.63 (m, 1H), 7.67 (d, J-8.48 Hz, 2H), 7.88 (s,-lH), 7.95 (s, 1H), 8.12 (s, 1H), 8.83 (s, 1H), 9.09 (s, 1H), 10.19 (s, 1H); MS (ESI(+)) m/e 508 (M+H)+. Example 142 N-[4-(4-armno-7-phenylfliieno[3,2-c]pyridin--3-yl')phenyl]-N'-(3-methylphenyl)urea -95- WO 2005/010009 PCT/US2004/02400J The desired product was prepared by substituting phenylboronic acid for 4-pyridylboronic acid in Examples 121A-B, then substituting the product and l-isocyanato-3-methylbenzene for Example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene, respectively, in Example 122. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 5.54 (s, 2H), 6.81 (d, J=7.46 Hz, IH), 7.17 (t, J=7.63 Hz, IH), 7.26-7.28 (m, IH), 7.32 (s, IH), 7.40 (d, J-8.14 Hz, 2H), 7.48-7.55 (m, 4H), 7.61 (d, J=S.4S Hz, 2H), 7.67 (d, J=7.12 Hz, 2H), 7.91 (s, IH), 8.67 (s, IH), 8.86 (s, IH); MS (ESI(+)) m/e 451 (M+H)+. Example 143 N-{4-[4-amino-7-('4-pvridmyl)thieno[3,2-c]pvridin-3-vl]phenyl}-N-(3-methylphenyl)urea The desired product was prepared by substituting l-isocyanato-3-methylbenzene for l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in Example 122. 1H NMR (300 MHz, DMSO-dfi) δ 2.29 (s, 3H), 5.74 (s, 2H), 6.81 (d, J=7.46 Hz, IH), 7.17 (t, J=7.80 Hz, IH), 7.26-7.27 (m, IH), 7.32 (s, IH), 7.40 (d, J=8.S1 Hz, 2H), 7.53 (s, IH), 7.62 (d, JNS.4S Hz, 2H), 7.72-7.73 (m, IH), 7.73 (d, J=1.70 Hz, IH), 8.09 (s, IH), 8.67 (t, J-2.20 Hz, 2H), 8.69 (d, J=1.36 Hz, IH), 8.87 (s, IH); MS (ESI(+)) m/e 452 (M+H)+- Example 144 N-{4-[4-amino-7-(4-hylroxv-l-butynyl)thieno[3,2-c]pyridin-3-yl]phenyl}-N'-(3- methylphenyl)urea Example 144A N-[4-('4-ammo-7-iodothieno[3,2-c]pyridin-3--yl')phenyl]-N,-(3-methylphenyl)urea The desired product was prepared by substituting Example 77B for Example 1C in Example ID. MS (ESI(+)) m/e 501 (M+H)+. Example 144B N-{4-[4-ardno-7-(4-hydroxy-l-butynyl)trueno[3,2-c]pyridin-3-yl]phenyl)-N'-(-3- methylphenyl)urea A suspension of Example 144A (0.227g, 0.45 mmol) in piperidine (3 mL) was degassed by bubbling nitrogen through the suspension for 5 minutes, treated with 3-butyn-l-ol (0.069 mL, 0.91 mmol), Pd(PPh3)4 (26mg, 0.023 mmol), and Cul (5mg, 0.023 mmol), then heated to 80 °C in a sealed tube for 30 minutes. The resulting homogeneous solution was cooled to room temperature and concentrated under a stream of nitrogen. The residue was purified by flash column chromatography on silica gel with 5% methanol/dichloromethane to provide 164 mg (81%) of the desired product. 1HNMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 2.65 (t, J=6.7S Hz, 2H), 3.63 (q, J=6:73 Hz, 2H), 4.92 (t, J=5.59 Hz, IH), 5.70 (s, 2H), 6.81 (d,'J=7.46 Hz, IH), 7.17 (t, J=7.S0 Hz, IH), 7.25-7.28 (m, IH), 7.32 (s, IH), 7.37 (d, -96- WO' 2005/010009 PCT/US2004/024003 J=8.48 Hz, 2H), 7.49 (s, IH), 7.60 (d, J=8.48 Hz, 2H), 7:93 (s, TH), 8.65 (s, 1H);8.85 (s; IH); MS (ESI(+)) m/e 443 (M+H)+. Examples 145-156 were prepared by substituting the appropriate alkyne (X) for 3- butyn-1-ol in Example 144B. Example 145 N-{4-[4-ammo-7-(3-phenoxv-l-propynvl)thieno[3,2-c]pvridm-3-vl]phenvl}-N'-(3- methylphenyl)urea X = (2-propynyloxy)benzene. 1HNMR(300 MHz, DMSO-d6) 5 2!29 (s, 3H), 5.14 (s, 2H), 5.S5 (s, 2H), 6.S0 (d, J-7.46 Hz, IH), 6.99 (t, >7.29 Hz, IH), 7.09 (d, J=7.46 Hz, 2H), 7.16 (t, J=7.80 Hz, IH), 7.25-7.27 (m, IH), 7.31-7.38 (m, 5H), 7.51 (s, IH), 7.60 (d, J=8.48 Hz, 2H), 8.00 (s, IH), 8.65 (s, IH), 8.85 (s, IH); MS (ESI(+)) m/e 505 (M+H)+. Example 146 N-{4-[4-ammo-7-(4-pyridmylethynyl)thieno[3,2-c]pyridin-3-yl]phenyl)-N'-(3- methylphenyl)urea X-= 4-ethynylpyridine. !H HMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 6.00 (s, 2H)3 6.S1 (d, J=6.7S Hz, IH), 7.17 (t, J=7.80 Hz, IH), 7.24-7.27 (m, IH), 7.32 (s, IH), 7.40 (d, 20 J=S.4S Hz, 2H), 7.53 (d, J=5.09 Hz, 2H), 7.59 (d, J-6.10 Hz, 2H), 7.63 (s, IH), 8.18 (s, IH), 8.66 (s, 3H), 8.87 (s, IH); MS (ESI(+)) m/e 476 (M+H)+. Example 147 N-[4-(4-amino-7-{3-[benzyl(methyl)aminoX-l-propynyl)thieno[3,2-c]pyridin-3-yl)phenyl]- N'-(3-methylphenyl)urea X = N-benzyl-Nrmethyl-N-2-propynylamine. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 2.34 (s, 3H), 3.61 (s, 2H), 3.66 (s, 2H), 5.78 (s, 2H), 6.81 (d, J=7.46 Hz, IH), 7.17 (t, J-7.63 Hz, IH), 7.32-7.40 (m, 9H), 7.53 (s, IH), 7.61 (d, J=8.81 Hz, 2H), 8.01 (s, IH), 8.66 (s, IH), 8.86 (s, IH); MS (ESI(+)) m/e 532 (M+H)+. Example 148 N-{4-[4-amino-7-(3-hydroxy-l-propynyl)thieno[3,2-c]pyridin-3-yl]phenyl)-N'-(3- methylphenyQurea X= 2-propyn-l-ol. The product was prepared as the trifluoroacetate salt by HPLC purification using the conditions described in Example 82. 1H XSfMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 4.41 (s, 2H), 6.54 (s, 2H), 6.81 (d, J=7.12 Hz, IH), 7.17 (t, J=7.80 Hz, IH), 7.26 (t, J-4.41 Hz, 2H), 7.32 (s, IH), 7.41 (d, J=S.48 Hz, 2H), 7.63 (d, J--S.81 Hz, 2H), 7.71 (s, IH), 8.06 (s, IH), 8.78 (s, IH), 9.01 (s, IH); MS (ESI(+)) m/e 429 (M+H)+. -97- WO 2005/010009 PCT/US2004/024003 Example 149 N-(4-[4-amino-7-(3-pyridinylethvnyl)thieno[3,2-clpvridino-vl1phenyl)-N'-(3- methylphenyl)urea X = 3-ethynylpyridine. The product was prepared as the bis(trifluoroacetate) salt HPLC purification using the conditions described in Example 82. lH NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 6.61 (s, 2H), 6.81 (d, J=7.46 Hz, 1H), 7.17 ft J=7.63 Hz, 1H), 7.26-7.28 (in, 1H), 7.32 (s, 1H), 7.43 (d, J-8.S1 Hz, 2H), 7.50-7.55 (m, 1H), 7.62-7.66(m, 2H), 7.75 (s, 1H), 8.04 (ddd, J=S.31, 1.86,1.70 Hz, 1H), 8.24 (s, 1H), 8.64 (d, J-4.07 Hz, 1H), 8.76 (s, 1H), 8.82 (s, 1H), 8.99 (s, 1H); MS (ESI(+)) m/e 476 (M+H)+. Example 150 N-(4-{4-amino-7-[3-(phenylsulfanyl)-l-propynyl]thieno{'3,2-c1pyridui-3-yl}phenyl')-N'-(3- methylphenyl)urea X = (2-propynylsulfanyl)benzene. The product was prepared as the trifluoroacetate salt by HPLC purification using the conditions described in Example 82. 1H NMR (400 MHz, DMSO-d6) δ 2.29 (s, 3H), 4.24 (s, 2H), 6.80 (d, J=7.36 Hz, 2H), 7.17.(t, J=7.67 Hz, 1H), 7.27 (d, J=4.60 Hz, 2H), 7.34 (s, 1H), 7.38-7.41 (m, 5H),'7.53 (d, J=7.36 Hz, 2H), 7.65 (d, J=8.59 Hz, 2H), 7.73 (s, 1H), 8.01 (s, 1H), 8.94 (s, 1H), 9.1 S (s, 1H); MS (ESI(+)) m/e 521 (M+H)+. Example 151 N-{4-[4-amino-7-(4-cvano-l-butynyl)thieno[3,2-c]pyridin-3-yl]phenyl}-N'-(3- methylphenyl)urea X = 4-pentynenitrile. The product was prepared as the trifluoroacetate salt by HPLC purification using the conditions described in Example 82. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 2.85-2.95 (m, 4H), 6.66 (s, 2H), 6.81 (d, J=7.46 Hz, 1H), 7.17 ft J=7.63 Hz, . 1H), 7.26-7.27 (m, 1H), 7.32 (s, 1H), 7.41 (d, J=S.4S Hz, 2H), 7.64 (d, J=8.48 Hz, 2H), 7.76 (s, 1H), 8.06 (s, 1H), 8.76 (s, 1H), 8.99 (s, 1H); MS (ESI(+)) m/e 452 (M+H)+. Example 152 N-[4-{4-amino-7-(l-pentynyl)thieno[3,2-c]pyridin-3-yl]phenyl)"N,-(3-methylphenyl)urea X= 1-pentyne. The product was prepared as the trifluoroacetate salt by HPLC purification using the conditions described in Example 82. 1H NMR (300 MHz, DMSO-d6) 5 1.07 ft J=7.29 Hz, 3H), 1.63 (m, 2H), 2.29 (s, 3H), 2.52-2.56 (m, 2H), 6.75 (s, 2H), 6.81 (d, J=7.46 Hz, 1H), 7.17 ft J-7.63 Hz, 1H), 7.26-7.28 (m, 1H), 7.32 (s, 1H), 7.42 (d, J=8.48 Hz, 2H), 7.64 (d, J=8.48 Hz, 2H), 7.77 (s, 1H), 8.04 (s, 1H), 8.7S (s, 1H), 9.02 (s, 1H); MS (ESI(+))m/e441(M+H)+. -98- WO 2005/010009 CT/US2004/024003 Example 153 N-(4-{4-aTruuo-7-[3-(diethylamino)4-propynyl]thieno[3,2-c]pYridm-3-yl}phenyl)-N'-(3- methylphenyl)urea X = N,N-diethyl-N-2-propynylamine. lH NMR (300 MHz, DMSO-d6) 5 1.06 (t, J=7.12 Hz, 6H), 2.29 (s, 3H), 2.59 (q, J=7.12 Hz, 4H), 3.70 (s, 2H), 5.75 (s, 2H), 6.S0 (d, J=7.46 Hz, IH), 7.17 (t, J=7.63 Hz, IH), 7.25-7.28 (m, IH), 7.32 (s, IH), 7.37 (d, J=8.48 Hz, 2H), 7.50 (s, IH), 7.60 (d, J=8.4S Hz, 2H), 7.96 (s, IH), 8.66 (s, IH), 8.87 (s, IH); MS (ESI(+)) m/e 4S4 (M+H)+. Example 154 N-{4-['4-amino-7-('4-phenyl-l-butynyl)tlneno[3,2-c]pyridin[3-yl]phenyl)-N'-(3- methylphenyl)urea X = 3-butynylbenzene. The product was prepared as the trifluoro acetate salt by HPLC purification using the conditions described in Example 82. 1H NMR (300 MHz, DMSO-d5) δ 2.29 (s, 3H), 2.83-2.96 (m, 4H), 6.67 (s, 2H), 6.81 (d, J=7.46 Hz, IH), 7.17 (t, J=7.80 Hz, IH), 7.25-7.28 (m, 2H), 7.34-7.38 (m, 5H), 7.40 (d, J=S.81 Hz, 2H), 7.64 (d, J=8.81 Hz, 2H), 7.75 (s, IH), 7.98 (s, IH), 8.78 (s, IH), 9.02 (s, IH); MS (ESI(-)) m/e 501 (M-H)+ 20 Example 155 N-(4-[4-amino-7-[3-(methylarnino)-l-propynyl]theno[3,2-c]pyridin-3-yl)phenyl)-N'-(3- niethylphenyl)urea X = N-methyl-N-2-propynylamine. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 2.41 (s, 3H), 3.39 (s, IH), 3.60 (s, 2H), 5.74 (s, 2H), 6.81 (d, J=7.46 Hz, IH), 7.17 (t, J=7.80 Hz, IH), 7.24-7.27 (m, IH), 7.32 (s, 1H), 7.38 (d, J=8.82 Hz, 2H), 7.50 (s, IH), 7.60 (d, J=8.82 Hz, 2H), 7.95 (s, IH), S.69 (s, IH), 8.89 (s, IH); MS (ESI(+)) m/e 442 (M+H)+. Example 156 .- N-[4-(4-amino-7-[3-[(aminocarbonyl)aminol-l-propvnvl}thieno[3,2-c]pyridm-3-yl')phenyl]- N'-(3-methylphenyr)urea X = N-2-propynylurea. The product was prepared as the bis(trifluoroacetate) salt by HPLC purification using the conditions described in Example 82. lH NMR (300 MHz, DMSO-dfi) δ 2.29 (s, 3H), 4.14 (d, J=4.75 Hz, 2H), 5.67 (s, 2H), 6.45 (t, J=5.59 Hz, IH), 6.71 (s, 2H), 6.81 (d, J=7.12 Hz, IH), 7.17 (t, J=7.80 Hz, IH), 7.24-7.27 (m, IH), 7.32 (s, IH), 7.42 (d; J=8.48 Hz, 2H), 7.64 (d, J-8.4S Hz, 2H), 7.77 (s, 1H), 8.06 (s, IH), 8.78 (s, IH), 9.02 (s, IH); MS (ESI(+)) m/e 471 (M+H)+ -99- WO 2005/010009 PCT/US2004/024003 Example 157 N-{4-[4-amino-7-(4-hydiDxvbutyl )thieno[3,2-c]pyridm-3-vl1phenyl}-N,-(3- methylphenyl)urea The desired product was prepared by substituting Example 144B for Example 14 in Example 15. 1HNMR(300MHz,DMSO-d6) 8 1.48-1.57 (m,2H), 1.69-1.74 (m, 2H), 2.29 (s, 3H), 2.71 (t, J=7.29 Hz, 2H), 3.43-3.46 (m, 2H), 4.39 (t, J=5.09 Hz, IH), 5.39 (s, 2H), 6.81 (d, J-7.12 Hz, IH), 7.17 (t, J=7.63 Hz, IH), 7.25-7.2S (m, IH), 7.31 (s, IH), 7.37 (d, J=8.4S Hz, 2H), 7.46 (s, IH), 7.59 (d, J=S.4S Hz, 2H), 7.68 (s, IH), 8.66 (s, IH), 8.85 (s, IH); MS (ESI(+)) m/e 447 (M+H)+. Example 158 3-(4-aminophenyD-7-(4-isoquinolmyl)thieno[3,2-c]pyridin-4-amine .. The desired product was prepared by substituting 4-isoquinolinylboronic acid for 4-pyridylboronic acid in Examples 121A-B. lH NMR (300 MHz, DMSO-d6) δ 5.40 (s, 2H), 5.75 (s, 2H), 6.70 (d, J-8.48 Hz, 2H), 7.14 (d, J=8.48 Hz, 2H), 7.39 (s, IH), 7.65-7.70 (m, IH), 7.81 (ddd, J=S.39, 6.87,1.70 Hz, IH), 8.09-8.11 (m, 3H), 8.63 (d, J-2.37 Hz, IH), 9.21 (d, J=2.03 Hz, IH). MS (ESI(+)) m/e 369 (M+H)+. Example 159 3-(4-aminophenyl)-7-(2,6-difluoro-3"pyridinyl)thieno[3,2-c]pyridin-4-amine The desired product was prepared by substituting 2,6-difluoro-3-pyridinylborouic acid for 4-pyridylboronic acid in Examples 121A-B. 1H NMR (300 MHz, DMSO-d6) δ 5.39 (s, 2H), 5.75 (s, 2H), 6.67-6.70 (m, 2H), 7.11 (d, J=8.48 Hz, 2H), 7.33-7.37 (m, 2H), 7.S5 (s, IH), 8.34-8.42 (m, IH). MS (ESI(+)) m/e 355 (M+H)+. Example 160 3-(lH-indol-6-yl)thieno[3,2-c]pyridin-4-amine The desired product was prepared by substituting lH-indol-6-ylboronic acid for 4-phenoxyphenylboronic acid in Example 10A. 1H NMR (300 MHz, DMSO-d6) δ 5.41 (s, 2H), 6.52 (s, IH), 7.05 (dd, J=S.14,1.70 Hz, IH), 7.26 (d, J=5.76 Hz, IH), 7.45 (m, 3H), 7.67 (d, J=S.14Hz, IH), 7.82 (d, J-5.43 Hz, lH),T1.29(s, 1H);MS (ESI(+)) m/e 266 (M+H)+. Example 161 N-{4-[4-amino-7-(2,6-difluoro-3-pyridinyl) thieno[3,2-c]pyridin-3-yl]phenvl]-N'-(2-fluoro-5-methylphenvl)urea The desired product was prepared by substituting Example 159 and l-fluoro-2-isocyanato-4-methylbenzene for Example 121 and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene, respectively, in Example 122. lH NMR (300 MHz, DMSO-d6) δ -100- WO 2005/010009 PCT/US2004/024003 2.28 (s, 3H)',:5.71(s, 2H), 6.83 (dd, J-4.58,2:20Hz, 4H), 7.09 7.16 (m, IH), 7.36 (dd, J=8.14, 2.37 Hz, IH), 7.42 (d? JN8.4S Hz, 2H), 7.51 (s, IH), 7.62 (d, J=8.4S Hz, 2H), 7.90 (s, IH), 8.00 (dd, J=7.97,1.87 Hz, IH), 8.36-8.44 (m, IH), 8.56 (d, J=2.37 Hz, IH), 9.27 (s, IH). MS (ESI(+)) m/e 506 (M+fr)+. Example 162 N-{4-[4-ammo-7-(2,6-difluoro-3-pyridmyl)thieno[3,2-c]pyridin-3-vl1phenyl}-N,-(3- methylphenyr)urea The desired product was prepared by substituting Example 159 and l-isocyanato-3- methylbenzene for Example 121 and l-fluoro-2-isocyanato-4-(trfluoromethy)benzene, respectively, in Example 122. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 5.71 (s, 2H), 6.S1 (d, J-7.46 Hz, IH), 7.17 (t, J=7.63 Hz, IH), 7.26-7.28 (m, IH), 7.32 (s, IH), 7.36-7.39 ' (m, IH), 7.41 (d, J-8.81 Hz, 2H), 7.50 (s, IH), 7.62 (d, J=8.48 Hz, 2H), 7.89 (s, IH), 8.39-8.44 (m, IH), S.67 (s, IH), 8.87 (s, IH), MS (ESI(-)) m/e 486 (M-H)". Example 163 N-{4-[4-amino-7-(4-isoquinolinyl)thieno[3,2-c]pyridin-3-yl]pbenyl)-N'-[2-fluoro-5- (trifluoromethyl)pheny1] urea The desired product was prepared by substituting Example 158 for Example 121 in Example 122. 1H NMR (300 MHz, DMSO-dc) δ 5.69 (s, 2H)5 7.39-7.74 (m, IH), 7.46 (d, J=8.48 Hz, 2H), 7.51 (d, J=11.19 Hz, IH), 7.56 (s, IH), 7.64 (s, IH), 7.67 (d, J-2.37 Hz, IH), 7.70 (d, J=7.S0Hz, IH), 7.79-7.84 (m, IH), 8.0S (s, IH), 8.11 (d, J=2.03 Hz, IH), 8.12 (s, IH), 8.64 (d, J=2.03 Hz, IH), S.65 (d, J=2.03 Hz, IH), S.9S (d, J=2.71 Hz, IH), 9.22 (d, J=2.37 Hz, IH), 9.40 (s, IH). MS (ESI(-)) m/e 572 (M-H)". Example 164 N-{4-[4-amino-7-(4-isoqumolinyl)thieno[3,2-c]pyridin-3-yl]phenyl}-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 158 and l-isocyanato-3- methylbenzene for Example 121 and l-fluoro-2-isocyanato-4-(trfluoromethy)benzene, respectively, in Example 122. lH NMR (300 MHz, DMSO-d6) δ 2.30 (s, 3H), 5.70 (s, 2H)5 6.81 (d, J=7.46 Hz, IH), 7.18-7.21 (m, IH), 7.27-7.29 (m, IH), 7.33 (s, IH), 7.43 (d, J=8.82 Hz, 2H), 7.54 (s, IH), 7.63 (d, J=8.4S Hz, 2H), 7.70 (d, J=7.80 Hz, IH), 7.79-7.85 (m, IH), 8.08 (s, IH), 8.12 (s, 2H), 8.65 (d, J=2.37 Hz, IH), 8.68 (s, IH), S.S9 (s, IH), 9.22 (d, J=2,37 35 Hz, IH). MS (ESI(+)) m/e 502 (M+H)+. Example 165 -101- WO 2005/010009 PCT/US2004/024003 N-(4-[4-amino-7-(3-pvridinyl)tbieno[3,2-c]pyridin-3-vl]phenvn-N'-[2-fluoro-5- (trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 124 for Example 121 in Example 122. 1H NMR (300 MHz, DMSO-d6)'δ 5.63 (s, 2H), 7.39-7.47 (m, 3H), 7.53-7.58 (m, 3H), 7.64 (d, J=8.81 Hz, 2H), 7.97 (s, IH), 8.10 (m, J-8.48, 2.03,1.70 Hz, IH), 8.63-8.66 (m, 2H), 8.SS (d, J=1.70 Hz, IH), 8.98 (d, J-3.05 Hz, IH), 9.39 (s, IH). MS (ESI(+)) m/e 524 (M+H)+. Example 166 N-(4-[4-amino 7-(3-pyridinyl)thieno[3,2-c]pyridin-3-yl]phenyn-N'-[2-fluoro-5- methylphenyl)urea The desired product was prepared by substituting Example 124 and l-fluoro-2-isocyanato-4-methylbenzene for Example 121 and 1-fluoro-2-isocyanato-4-(trfluoromethy)benzene, respectively, in Example 122. 1H NMR (300 MHz, DMSO-d6) 5 2.29 (s, 3H), 5.63 (s, 2H), 6.82-6.85 (m, IH), 7.12 (dd, J=11.53, 8.48 Hz, IH), 7.42 (d, J=8.4S Hz, 2H), 7.52 (s, IH), 7.55 (dd, J=S.14, 5.09 Hz, IH), 7.62 (d, J=8.48 Hz, 2H), 7.96 (s, IH), 8.00 (dd, J=7.97,1.S6 Hz, IH), 8.10 (ddd, J=8.14, 2.03, 1.70 Hz, IH), 8.56 (d, .1=2.71 Hz, IH), 8.62 (dd, J-4.75, 1.36 Hz, IH), S.8S (d, J-1.70 Hz, IH), 9.27 (s, IH). MS (ESI(+)) m/e 470 (M+H)+. Examples 167-170 were prepared substituting the appropriate boronic acid (X) for 4-chlorophenylborom'c acid in Example 21C. Example 167 (2E)-3 - {4-amino-3 - R4-(hydroxymethyl)phenyl] thieno [3,2-c]pyridin-7-yI} -N- methylacrylamide X=4-(hydroxymethyl)phenylboronic acid. 1H NMR (300 MHz, DMSO-d5) δ 2.73 (d, J=4.4 Hz, 3H), 4.60 (d, J=5.7 Hz, 2H), 5.31 (t, J=5.7 Hz, IH), 5.81 (s, 2H), 6.58 (d, J=15.9 Hz, IH), 7.43-7.50 (m, 4H), 7.58 (d, W5.9 Hz, IH), 7.64 (s, IH), S.12 (s, IH), 8.15 (q, 1=4.4 30 Hz, IH), MS (ESI(+)) m/e 340.1 (M+H)+. Example 168 (2E)-3-[4-amino-3-(3,4-dimethoxyphenyl)thieno[3,2-c]pyridm-7-yl]-N-methylacrylamide X = 3,4-dimethoxyphenylboronic acid. :H NMR (300 MHz, DMSO-d6) 8 2.73 (d, J=4.7 Hz, 3H), 3.79 (s, 3H), 3.83 (s, 3H), 5.88 (s, 2H), 6.57 (d, J=15.9 Hz, IH), 7.00 (dd, J=8.1,2,0Hz, 1H),7.05 (d, J=2.0 Hz, 1H),7.11 (d, J=8.5Hz, IH), 7.57 (d, J=15.9Hz, IH), 7.62 (s, IH), 8.11 (s, IH), 8.15 (q, J=4.7 Hz, IH), MS (ESI(+)) m/e 370.1 (M+H)+. -102- WO 2005/010009 PCT/US2004/024003 Example 169 (2E)-3-[4-amino-3-[3-chlorophenyl)thieno[3,2-c]pyridin-7-yl]-N-methylacrylarnide X = 3-chlorophenylboronic acid. 1H NMR (300 MHz, DMSOdJ δ 2.73 (d, J=4.4 Hz, 3H), 5.83 (s, 2H), 6.58 (d, J=15.9 Hz, IH), 7.-[4-7.48 (in, IH), 7.53-7.61 (m, 4H), 7.76 (s, IH), S.14 (s, IH), 8.15 (q, J=4.4 Hz, IH), MSJESI(+))'m/e 3-R4.0, 346.2 (M+H)+. Example 170 (2E)-3-[4-amino-3-[3-chloro-4-fluorophenyl)thieno[3,2-c]pvridin-7-yl]-N-methylacrylaniide X =3-chloro-4-fluorophenylboronic acid. 1H NMR (300 MHz, DMSO-d6) δ 2.73 (d, J=4.7 Hz, 3H), 5.88 (s, 2H)3 6.57 (d, W5.9 Hz, IH), 7.49 (ddd, 1=8.5, 4.9, 2.2 Hz, IH), 7.56 (t, J-8.S Hz, IH), 7.58 (d, J=15.9 Hz, IH), 7.74 (dd, J-7.1, 2.0 Hz, IH), 7.75 (s, IH), 8.14 (s, IH), 8.14 (q, J=4.7 Hz, IH), MS (ESI(+)) m/e 362.0, 364.2 (M+H)+. Example 171 (2E)-3-[4-ammo-3-(4-bromophenyl)thieno[3,2-c]pyridin-7-yl]-N-(4- pyridinylmethyl) acrylanride Example 171A (2E)-3-[4-amino-3-(4-bromophenyl)tl'deno[3,2-c]pyridin-7-ynacrylic acid The desired compound was prepared by substituting Example IB for Example 10A in Example 10B, then substituting the product and methylamine for Example 11A and piperazin-2-one, respectively, in Examples 11A-B. Example 171B (2E)-3-[4-amino-3-(4-bromophenyl)thieno[3,2-c]pyridin-7-vn-N-(4- pyridinylmethyl") aery lamide The desired prodict was prepared as the bis(trifluoroacetate) salt substituting l-(4-pyridinyl)methanamine and Example 171A for methylamine and Example 13, respectively, in Example 14, then purifylng the product by HPLC using the conditions described in Example 82. 1H NMR. (300 MHz, DMSO-d6) 8 4.59 (d, J=5.8 Hz, 2H), 6.57 (s, 2H), 6.81 (d, H5.9 Hz, IH), 7.48 (d, JMS.5 Hz, 2H), 7.61 (d, J=5.4 Hz, 2H), 7.68 (d, J-15.9 Hz, IH), 7.75 (d, J-8.5 Hz, 2H), 7.90 (s, IH), 8.25 (s, IH), 8.69 (d, J=6.1 Hz, 2H), 9.02 (t, J=5.S Hz, IH). MS (ESI(+)) m/e 465.0,467.0 (M+H)+. Examples 172-174 were prepared as the bis (trifluoro acetate) salts by substituting the appropriate amine (X) for l-(4-pyridinyl)methanamine in Example 171B. Example 172 -103- WO 2005/010009 PCT/US2004/0 24003 3-[4-bromophenyl)-7-[(lE)-3-(4-morpliolinvl)-3H)xo-l-propenvl]tbieno[3,2-c]pyridin amine X = morpholine. !H NMR (300 MHz, DMSO-d6) 5 3.59-3.67 (m, SH), 5.87 (s, 2H), 7.06 (d, H5.3 Hz, IH), 7.45 (d, J=8.5 Hz, 2H), 7.67-7.74 (m, 4H), 8.32 (s, IH). Example 173 (2E)-3-[4-arnmo-3-[4-bromophenyl)thieno[3,2-c]pyridin-7-vl]-N-f'3--(lH-imidazQl-l- yppropyl]acrylamide X - 3-(lH-imidazol-l-yl)-l-propanamine. 1H NMR (300 MHz, DMSO-d,) δ 2.05 (p, J=7.I, Hz, 2H), 3.23 (q, J=6.2 Hz, 2H), 4.25 (t, J=7.1 Hz, 2H), 6.41 (s, 2H), 6.66 (d, J=15.9 Hz, IH), 7.47 (d, J=8.5 Hz, 2H), 7.61 (d, J=15.9Hz, IH), 7.71 (t, J=1.7 Hz, IH), 7.75 (d, J=8.5 Hz, 2H), 7.84 (t, J=1.7 Hz,' IH), 7.86 (s, IH), 8.20 (s, IH), 8.41 (t, J=5.8 Hz, IH), 9.14 (s, IH). MS (ESI(+)) m/e 482.0, 4S3.8 (M+H)+. Example 174 (2E)-3-[4-amino-3-(4-bromophenyl)thieno[3,2-c]pyridm-7-yn-N-[2-(diethylamino)ethyl]acrylamide X = N,N-diethyl-l,2-ethanediamine. 1H NMR. (300 MHz, DMSO-dJ 5 1.22 (t, J=7.3 Hz, 6H), 3.17-3.26 (m, 4H), 3.55 (q, J=5.8 Hz, 4H), 6.37 (s, 2H), 6.65 (d, J=15.9 Hz; IH), 20 7.46 (d, J=S.5 Hz, 2H), 7.66 (d, JH5.9 Hz, IH), 7.75 (d, J=S.5 Hz, 2H), 7.84 (s, IH), 8.22 (s, IH), 8.58 (t, J=5.6 Hz, IH), 9.17 (s, IH, TFA salt-H). MS (ESI(+)) m/e 473.0,474.9 (M+H)+ Example 175 N-[2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl]-l-methyl-lH-indole-3- carboxamide Example 175 A 4-bromo-2-rnethoxvaniIine A mixture of o-anisidine (27.1g, 219 mmol) and dichloromethane (500 mL) was stirred under an atmosphere of nitrogen and treated with 2,4,4,6-tetrabromo-2,5-cyclohexadienone (90.0g, 219 mmol) in four roughly equal portions over the course of 20 minutes. The temperature of the reaction was maintained between 10 and 15 °C by cooling with a cold water bath during the addition of the 2,4,4,6-tetrabromo-2,5-cyclohexadienone. The mixture" was warmed to ambient temperature and stirred for an additional 1.5 hours at which time HPLC [Hypersil HS C18, 5 um, 100A, 250 x 4.6 mm; 25-100% acetonitrile/O.lM ammonium acetate over 10 minutes, ImL/min) o-anisidine =7.63 min, 4-bromo-2-methoxyaniline R, = 9.77 min] indicated very little o-anisidine remaining. The mixture was -104- WO 2005/010009 PCT/US2O04/O24O03 ashed with 0.67N NaOH (300 mL) and IN aqueous sodium hydroxide (300 mL). The combined aqueous washes were extracted with dichloromethane (150 mL) and the combined organic solutions were then washed with water (2 x 200 mL) and brine (200 mL), dried (MgS04)7 filtered, and concentrated to provide about 48g of the desired product. Example 175B tert-butyl 4-bromo-2-methoxyphenylcarbamate A mixture of Example 175A (36.4g, 180 mmol), and di-tert-butyl dicarbonate (47.2g, 216 mmol) in THF (500 mL) was heated to reflux for 20 hours and cooled to ambient temperature. HPLC (using the conditions from Example 175A, product R, = 13.55 min and TLC (8:2 heptane/ethyl acetate, Rf of product = 0.53, Rr of 4-bromo-2-methoxyaniline = 0.27) indicated approximately 10% starting material was remaining. Additional di-tert-butyl dicarbonate (3.9g, 18 mmol) was added and heating was continued for another 5 hours. The mixture was cooled and evaporated under reduced pressure. The residue was applied to a 400 gram silica gel column and eluted with 8:2 heptane/ethyl acetate. The fractions showing the desired product were combined and washed w,ith saturated NaHC03 and then brine. The organic solution was dried (MgS04), filtered, and concentrated to provide 61.3g of a mixture of the desired product and di-tert-butyl dicarbonate which Was used directly in the next step.- Example 175C tert-butyl 2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2--dioxaborolan-2-yl)phenylcarbamate A mixture of Example 175B (61.3g, 203 mmol), 4,4,4,,4',5,5,5',5'-octamethyl2,2,-bi-1,3,2-dioxaborolane (51.6g, 203 mmol), [l.T-bis(diphenylphosphino)ferrocene]dichloropalladium (II) complex with dichloromethane (1:1) (3.2g, 3.9 mmol), and potassium acetate (59.7g, 609 mmol) in DMF (1.0 L) was heated to 80 °C under an atmosphere of nitrogen for 16 hours, cooled to ambient temperature, and concentrated. Dichloromethane (500 mL) was added to the residue and the resulting.solid was removed by filtration through a pad of diatomaceous earth (Celite®). The pad was washed with dichloromethane (4 x 50 mL) and the-combined filtrates were concentrated, applied to a 550 gram silica gel column, and quickly eluted with heptane/ethyl acetate (85:15) The fractions showing product [Rt with conditions described in Example 175A = 14.33 minutes, Rf of product = 0.33 TLC (85:15 heptane/ethyl acetate), Rrof tert-butyl N-(4-bromo-2-methoxyphenyl)carbamate = 0.48]. This material was treated with heptane (300 mL ) and stirred at ambient temperature for 30 minutes. The mixture was cooled to about 5 °C for 3 hours and the resulting precipitate was collected by filtration to provide 24.4g of the desired product. The filtrate was evaporated and the residue was purified by flash chromatography on a 400 gram silica gel column with 9:1 heptane/ethyl acetate to give an additional S.Sg of the desired product. -105- . Example 175D tert-butyl 2-methoxy-4-(4T4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenylcarbamate A mixture of Example 175C (45.0g, 0.129 mole) in dichloromethane (270 mL) was cooled to <5 °C in an ice bath and treated with a 1:1 solution of TFA/dichloromethane (500 niL) while maintaining the reaction temperature below 5 °C. The reaction was warmed to ambient temperature and stirred for 2 hours. The solvents were removed by evaporation at a pressure of 30 Torr and a bath temperature of <30 °C. The residue was dissolved in dichloromethane (250 mL) and carefully washed with 2.5N sodium hydroxide (300 mL). The organic layer was extracted with brine (100 mL), dried (MgS04), filtered, and concentrated to provide the desired product (21.7g, 6S%). 1H NMR (DMSO-d6, 400 MHz) δ 7.05 (d, 1H), 6.98 (d, 1H), 6.59 (d; 1H); 5.13 (s, 2H), 3.75 (s, 3H), 1.25 (s, 12H); reverse phase HPLC (Hypersil HS, 5um, 100A, 4.6 x 250 mm; 25%-100% acetonitrile/0.05M ammonium acetate over 10 minutes, 1 mL/rnin) Rt 11.03 rnin. Example 175E N-[2-methoxy-4-(4,4,5>5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl]-l-methyl-lH-indole-3- carboxamide A mixture of Example 175D (19.75g, 79.3 mmol) in dichloromethane (150 mL) was treated with N,N-diisopropylethylamine (12.3g, 95.2 mmol), cooled to <5 °C with an ice bath, and treated slowly with a solution of 1-methyl-lH-indole-2-carbonyl chloride (87.3 mmol) in dichloromethane (300 mL) while maintaining the reaction temperature below 5 °C. The mixture was warmed to ambient temperature, stirred for 12 hours, extracted twice with water (150 mL, 100 mL), once with brine (100 mL), dried (MgS04), filtered, and 25 concentrated. The material was purified by flash cliromatography using 400g of silica gel and 3:1 heptane/ethyl acetate to provide the desired product (30.3g, 94%). 1H NMR (DMSO-d6, 400 MHz) S 9.35 (s, 1H), 8.03 (d, 1H), 7.69 (d; 1H), 7.57 (d, 1H), 7.1-7.3 (m, 4H), 7.12 (t, 1H), 4.02 (s, 3H), 3.91 (s, 3H), 1.31 (s, 12H); RP-HPLC (Hypersil HS, 5 um, 100A, 4.6 x 250 mm; 25%-100% acetonitrile/0.05M ammonium acetate over 10 min, 1 mL/rnin) B 14.65 30 min. Example 176 N-(4-{4-ammo-7-rdE)-3-oxo-l-propenyl]thieno[3,2-c]pyridin-3-yl)-2-methoxyphenyl)-l- methyl-lH-indole-2-carboxamide Example 176A 3-bromo-7-[(lE)-3,3-diethoxy-l-propenyl]thieno[3,2-c]pyridin-4-amine A mixture Example 21A (200mg, 0.56 mmol), 2-[(lE)-3,3-diethoxy-l-propenyl]- -106- WO 2005/01000!) PCT/US2004/024003 4,4,5,5-tetramethyl-l,3,2-dioxaborolane;(175mg) 0.67 mmol), Pd(PPh3)4 (40mg, 0.03 mmol) and N CO-i (120mg, 1.13 mmol) in 1,2-dimethoxyethane (10 mL) and water (5 mL) was heated in an 85 °C oil bath for 15 hours. The mixture was cooled to room temperature and concentrated under reduced pressure. The mixture was extracted with dichloromethane and the extract was dried (MgS04), filtered, and concentrated. The "residue was purified by flash column chromatography on silica gel to provide the desired product (150mg, 75%). EH NMR (DMSO-d,, 400 MHz) 5 S.02 (s, IH), 7.88 (s, IH), 6.74 (d, IH), 6.09 (dd, IH), 5.09 (d, IH), 3.62 (m, 2H), 3.48 (m, 2H), 1.15 (t, 6H); MS m/e 357.1, 359.1 (M+H)+. Example 176B N-(4-{4-amino-74(lE)-33"diethoxy4-propenyl]thieno[3,2-c]pyridin-3-yl}-2- methoxypheny 1)-1 -methyl-1 H-indole-2-carboxamide A mixture of Example 176A (150mg, 0.42 mmol), Example 175E, 255mg, 0.63 mmol), Pd(PPh3)4 (35mg, 0.03 mmol) and Na C (90mg, 0.84 mmol) in 1,2- dimethoxyethane (6 mL) and water (3 mL) was heated at reflux for 18 hours. The mixture was cooled to room temperature and concentrated under reduced pressure. The mixture was extracted with dichloromethane then the extract was dried (MgS04), filtered, and concentrated. The residue was purified by flash chromatography on silica gel to provide the desired product (178mg, 76%). 1H NMR (DMSO-d6, 400 MHz) 8 9.5 (s, IH), 8.03 (m, 2H), 20 7.7 (d, IH), 7.59 (m, 2H), 7.33 (m, 2H), 7.21 (s, IH), 7.14 (t, IH), 7.09 (d, IH), 6.82 (d, IH), 6.17 (dd, IH), 5.14 (d, IH), 4:03 (s, 3H), 3.91 (s, 3H), 3.65 (m, 2H), 3.53 (m, 2H), 1.17 (t, 6H); MS m/e 557.3 (M+H)+. Example 176C N-(4-{4-amino-7--['(,lE)-3-oxo-l--propenyl]thieno[3,2-c]pyridin-3-yl}-2-methoxyphenyn-l- methyl-lH-indole-2-carboxamide A mixture of Example 176B (90mg, 0.16 mmol) in acetone (9 mL) and water (1 mL) was treated with p-toluenesulfonic acid (5mg, 0.016 mmol) then stirred for 30 minutes. The solvent was evaporated under reduced pressure then the residue was partitioned between dichloromethane and water. The organic layer was concentrated and the residue was purified by flash chromatography on silica gel to provide the desired product (77 mg). 1H NMR (DMSO-d,, 400 MHz) δ 9.67 (d, IH), 9.52 (s, IH), 8.34 (s, IH), 8.03 (d, IH), 7.91 (d, IH), 7.75 (s, IH), 7.70 (d, IH), 7.32 (m, 2H), 7.25 (s, IH), 7.10 (m, 3H), 6.69 (m5 IH), 4.04 (s, 3H), 3.92 (s, 3H); MS m/e 483.3. General Procedure for Reductive Animations Example 176C (40mg, 0.083 mmol), sodium triacetoxyborohydride (35mg, 0.166 mmol) and the appropriate amine (0.166 mmol) in 1,2-dichloromethane (2 mL) were stirred -107- WO 2(105/010009 PCT/US2004/024003 for 2 to 72 hours at' ambient temperature! The mixture was1 concentrated and the product wa" purified by normal or reverse phase chromatography. Example 177 N-(4-{4-amino-7-[(lE)-3-(,diethylamino)-l-propenyl]thienol-3,2-c]pyridin'3-yl)-2- methoxyphenyl)-l-metliyl-lH-indoIe-2-carboxamide amine: diethylamine. Reverse phase HPLC (5% to 95% acetonitrile over 25 minutes, 1 mL/min, 254 nm, Hypersil HS 100 A, CIS, 5 urn, 250 x 4.6 column) Rt=19.32 min. 1H NMR (DMSO-dfi, 400 MHz) 6 9.50 (s, IH), 8.00 (rn, IH), 7.94 (m, IH), 7.69 (d, IH), 7.60 10 (m, 2H), 7.32 (m, 2H), 7.18 (s, IH), 7.13 (t, IH), 7.06 (d, IH), 6.67 (d, IH), 6.22 (in, IH), 5.6 (br s, 2H), 4.02 (s, 3H), 3.89 (s, 3H), 3.32 (d, 2H), 2.52 (q, 4H), 1.01 ft 6H); MS m/e 540.3 (M+H)+, 538.3 (M-H)+ Example 178 N-(4-(4-amino-74(lE)-3-(ethylarnmo)-l-propenyl]thieno[-3,2-c]pyridin-3-yl}-2- methoxyphenyl)-1 -methyl-1 H-indole-2-carboxamide amine': ethylarmne. Reverse phase HPLC (5% to 95% acetonitrile over 25 minutes, 1 mL/min, 254 nm, Hypersil HS 100 A, CIS, 5 urn, 250 x 4.6 column) R IS.46 min. 1H NMR (DMSO-d6, 400 MHz) 6 9.50 (s, IH), 8.01 (m, IH), 7.94 (s, IH), 7.70 (d, IH), 7.61 (s, IH), 7.58 (d, IH), 7.35 (s, IH), 7.33 (m, IH), 7.20 (s, IH), 7.15 ft IH), 7.07 (d, IH), 6.65 (d, IH), 6.2S (m, IH), 5.60 (br s, 2H), 4.03 (s, 3H), 3.91 (s, 3H), 3.37 (d, 2H), 2.59 (q, 2H), 1.05 (t, 3H); MS m/e 512.4 (M+H)+, 510.5 (M-H)+ Example 179 N-[4-(4-ammo-7-{flE)-3-rr2-(dimethylamino)ethyl]fmethyl)aminol-l-propenyl)thienor3.2-c]pyridin-3-yl)-2-methoxyphenyl]-l-memyl-lH-indole-2-carboxamide amine: N ,N,-trimethyl-l,2--ethanediamine. 1H NMR (DMSO-d6, 400MHz) δ 9.50 (s, IH), 7.99 (d, IH), 7.96 (s, IH), 7.72 (d, IH), 7.6 (m, 2H), 7.35 (m, 2H), 7.33 (m, 2H), 7.21 (s, IH), 7.14 ft IH), 7.07 (d, IH), 6.24 (m, IH), 5.64 (br s, 2H), 4.04 (s, IH), 3.91 (s, 3H), 30 3.22 (d, 2H), 2.48 (m, 2H), 2.37 (m, 2H), 2.23 (s, 3H), 2.14 (s, 6H); MS m/e 569.4 (M+H)+, 568.5 (M-H)+ Example 180 N-(4-[4-ammo-7-((lE)-3-{[3-(5-memyl-lH-pvrazol-4-yl)propyl]amino}-l-propenyl) thieno[3,2-c]pyridin-3-yl.1-2-methoxyphenyl}-l-memyl-lH-mdole-2-carboxamide amine: 3-(5-methyl-lH-pyrazol-4-yl)-l-propanamine. 1HNMR (DMSO-d6,400 MHz) 6 9.50 (s, IH), 8.00 ft IH), 7.93 (s, IH), 7.71 (d, IH), 7.61 (s, IH), 7.58 (d, IH), 7.33 (m, 3H), 7.2 (s, IH), 7.15 ft, IH), 7.08 (d, IH), 6.65 (d, IH), 6.28 (m, IH), 5.59 (br s, 2H), -108- WO 2005/010009 PCT/US2004/024003 4.05 (s, 3H), 3.91 (s, 3H), 3.36 (d, 2H), 2.56 (t/2H); 2:3'7 (t, 2H), 2.11 (W3H),-:1.64 (lii, 2H); MS m/e 606.3 (M+H)+, 604.3 (M-H)+ Example 181 N-T4-[4-amino-7-((lE)-3-{[(5-methyl-2-pyrazinvl)methvl]amnio}-l-propenvl)thieno[3,2-c]pyridin-3-yl]-2-metlioxyphenyl}-l-methyl-lH indole-2-carboxamide amine: (5-methyl-2-pyrazinyl)methylamine. 1H NMR (DMSO-d*, 400 MHz) δ 9.49 (s, IH), 8.59 (s, IH), 8.46 (s, Hi), S.OO (t, IH), 7.94 (s, IH), 7.69 (d, IH), 7.61 (s, IH), 7.57 (d, IH), 7.35 (s, IH), 7.32 (d, IH), 7.20 (d, IH), 7.15 (t, IH), 7.08 (dd, IH), 6.67 (d, IH), 6.28 (m, IH), 5.61 (br s3 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.88 (s, 2H), 3.43 (d, 2H), 2.47 (s, 3H); MS m/e 590.3 (M+H)+ 58S.4 (M-H)+ Example 182 N-(4-{4-amino-7-[(lE)-3-(4-phenyl-l-piperazinyl)-l-prQpenyl]thieno[-3,2-c]pyridin-3-yl}-2- methoxyphenyl)-1 -methyl-1 H-indole-2-carboxamide amine: 1-phenylpiperazine. 1H NMR (DMSO-d6, 400 MHz) δ 9.50 (s, IH), 7.99 (m, 2H), 7.69 (d, IH), 7.62 (s, Hi), 7.58 (d, IH), 7.33 (m, 2H), 7.20 (m, 3H), 7.15 (t, IH),.7.08 (d, IH), 6.93 (d, 2H), 6.72 (m, 2H), 6.27 (m, IH), 5.65 (br s] 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.24 (d, 2H), 3.17 (m, 4H), 2.60 (m, 4H); MS m/e 629.4 (M+H)+, 627.4 (M-H)+ Example 183 N-[4-(4-ammo-7-|(lE)-3-[(3-pyridmymiethyl)amino1-l-prQpeayl}thieno[3,2-c]pyridin-3-yl)-2-methoxyphenYl]-l -methyl-1 H-indole-2-carboxamide amine: l-(3-pyridinyl)methanamine. 1H NMR (DMSO-d6, 400 MHz) δ 9.49 (s, IH), 25 8.56 (s, IH), 8.45 (d, IH), S.OO (m, IH), 7.95 (s, IH), 7.78 (d, IH), 7.71 (d, IH), 7.61 (s, IH), ' 7.57 (d, IH), 7.34 (m, 3H), 7.20 (d, IH), 7.14 (t, IH), 7.07 (dd, IH), 6.66 (d, IH), 6.30 (m, IH), 5.61 (br s, 2H), 4.03 (s, 3H), 3.91 (s, 3H), 3.77 (s, 2H), 3.38 (d, 2H); MS m/e 575.3 (M+H)+, 573.5 (M-H)+ Example 184 NH4-(4-ammo-7-{(lE)-34(2-pyridmylmethy amino1-l-prQpeayl}thieno[3,2-c]pyridin- 2-methoxyphenyl]-l-methyl-lH-indole-2-carboxamide amine: l-(2-pyridinyl)methanamine. lH NMR (DMSO-d6, 400 MHz) 8 9.50 (s, IH), 8.51 (s, IH), 8.0 (m, IH), 7.96 (s, IH), 7J7 (m, IH), 7.71 (m,lH), 7.60 (m, 2H), 7.49 (m, IH), 7.3 (m, 4H), 7.14 (m, IH), 7.09 (m, IH), 6.67 (d, IH), 6.34 (m, IH), 5.6 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.87 (s, 2H), 3.42 (d, 2H); MS m/e 575.4 (M+H)+, 573.4 (M-H)+ Example 185 -109- WO 2005/010009 PCT/US2004/024003 N-{4-[4-amino-7-(nEV3-(f2-(2-pyridinyl) amino1-l-prQpeayl}thieno[3,2-c]pyridin- yl]-2-methoxyphenyl}-l-methyl-lH-mdole-2-carboxarrude amine: 2-(2-pyridinyl)ethanamine. 1H NMR (DMSO-d , 400 MHz) δ 9.50 (s, IH), 8.47 (m, IH), S.OO (m, IH), 7.93 (s, IH), 7.69 (m, 2H), 7.59 (m, 2H), 7.35 (s, IH), 7.31 (m, 2H), 7.2 (m, 3H), 7.07 (m, IH), 6.65 (d, IH), 6.28 (m, IH), 5.60 (br s, 2H), 4.03 (s, 3H), 3.91 (s, 3H), 3.45 (m, 2H), 3.42 (d, 2H), 2.S5 (m, 2H); MS m/e 587.3 (M+H)+, 588.8 (M-H)+ Example 186 N-{4-[4-ammo-7-((lE)-3-{ 2-(lH-mdolo-yl)ethyl]animo}-l-propenyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl}-l-methyl-lH-mdole-2-carboxamide amine: 2-(lH-indol-3-yl)ethanamine. !H NMR (DMSO-d* 400 MHz) 5 10.82 (s, IH), 9.51 (s, IH), 8.01 (m, IH), 7.93 (m, IH), 7.72 (m, IH), 7.58 (m, 3H), 7.36 (m, 3H), 7.20 (m, 3H), 7.08 (m, 2H), 6.9S (m, IH), 6.67 (d, IH), 6.32 (m, IH), 5.6 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3-3.6 (m, 6H); MS m/e 627.4 (M+H)+, 625.6 (M-H)+ Example 187 N-(4-{4-amino-7-[(lE)-3-(4-morpholinyl)-l-propenvl]thieno[3,2-c]pyridin-3-yl)-2-methoxyphen yl)-1 -methyl-1 H-indole-2-Carboxamide amine: moipholine. Reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 ran, hypersil HS 100 A, CIS, 5 urn, 250 x 4.6 column) R1=13 min. 1H NMR (DMSO-d6, 400 MHz) δ 9.51 (s, IH), 8.00 (d, IH), 7.95 (s, IH), 7.71 (d, IH), 7.58-7.62 (m, 2H)} 7.05-7.21 (m, 3H), 6.65 (d, IH), 6.25 (dt, IH), 5.62 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.61 (t, 4H), 3.19 (d, 2H), 2.44 (m, 4H); MS m/e 554.3 (M+H)+ Example 188 N-(4-{4-ammo-7-[(lE)-3-(4-hydroxy-l-piperidinyl)-l-propenyl]thieno[3,2-c]pyridin-3-yl}-2-methoxyphenyl)-1 -methyl- lH-indole-2-carboxamide amine: 4-piperidinol. Purification by reverse phase HPLC using ammonium acetate buffer followed by lyophilization provided the desired product as the diacetate salt. Reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, CI 8, 5 nm, 250 x 4.6 column) Rt=10.2 min. 'H.NMR (DMSO-d6,400 MHz) 8 9.47 (s, IH), 7.98 (d, IH), 7.94 (s, IH), 7.68 (d, IH), 7.55-7.62 (m, 2H), 7.30-7.32 (m, 2H), 7.04-7.17 (m, 3H), 6.63 (d, IH), 6.23 (dt, IH), 5.61 (br s, 2H), 4.0i (s, 3H), 3.89 (s, 3H), 3.12 (d, 2H), 2,73 (m, 2H), 2.06 (t, 2H), 1.85 (s, 6H), 1.70 (m, 2H), 1.38 (q, 2H); MS m/e 568.9 (M+H)+. Example 189 N-[4-(4-ammo-7-{(lE)-3-rethyl(2-hydroxyethyl)ammo1-l-propenyl}thieno[3,2-c]pyridin-3- yl)-2-methoxyphenyl]-l-methyl-lH-indole-2-carboxamide -110- WO 2005/010009 PCT/US2004/024003 amine: 2-(ethylamino)etlianol. Purification by reverse phase HPLC using ammonium acetate buffer followed by lyophilization provided the desired product as the acetate salt. Reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 run, hypersil HS 100 A, CIS, 5 urn, 250 x 4.6 column) R 10.4 min. lH NMR (DMSO-d6> 40° MHz) 9.51 (s, IH), 8.00 (d, IH), 7.96 (s, IH), 7.71 (d, jH), 7.58-7.62 (in, 3H), 7.33-7.35 (m, 2H), 7.07-7.21 (m, 2H), 6.68 (d, IH), 6.26 (dt, IH), 5.62 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.50 (t, 2H), 3.32 (d, 2H), 2.56-2.59 (m, 3H), 1.88 (s, 3H), 1.02 (t, 3H); MS m/e 556.4 (M+H)+. Example 190 N-[4-(4-ammo-7-((lE)-3-[4-(2-hydroxyethyl)-l-piperidinyl]-l-propenYl}thieno[3,2-c]pvridin-3-yl)-2-metlioxyphenyl]-l-methyl-lH-indole-2--carboxamide amine: 2-(4-piperidinyl)ethanol. Purification by reverse phase HPLC using ammonium acetate buffer followed by lyophilization provided the desired product as the diacetate salt. Reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 run, hypersil PIS 100 A, C18, 5 pin, 250 x 4.6 column) R IO.3 min. 1H NMR (DMSO-d6, 400 MHz) δ 9.51 (s, IH), 8.00 (d, IH), 7.96 (s, IH), 7.71 (d, IH), 7.5S-7.62 (m, 2H), 7.33-7.35 (m, 2H), 7.05-7.21 (m, 3H), 6.65 (d, IH), 6.25 (dt, 1H);5.62 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.43 (t, 2H), 3.15 (d, 2H), 2.90 (d, 2H), 1.93 (t, 2H), 1.88 (s, 6H), 1.62 (d, 2H), 1.36 (t, 2H), 1.18 (m, IH); MS m/e 596.8 (M+H)+. Example 191 N-(4-{7-[(lE)-3-(4-aceryl-l-piperazinyl)-l-propenyl]-4-aminothieno[3,2-c]pyridin-3-yl}-2- methoxyphenylH-niethyl-lH-indole-2-carboxamide amine: 1-acetylpiperazine. Purification by reverse phase HPLC using ammonium acetate buffer followed by lyophilization provided the desired product as the acetate salt. Reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, CIS, 5 pm, 250 x 4.6 column) R,=l 1.3 min. lH NMR (DMSO-d6, 400 MHz) δ 9.52 (s, IH), 8.01 (d, IH), 7.98 (s, IH), 7.71 (d, IH), 7.5S-7.62 (m, 2H), 7.33-7.35 (m, 2H), 7.05-7.21 (m, 3H), 6.65 (d, IH), 6.25 (dt, IH), 5.62 (br s, 2H), 4.04 (s, 3H), 3.92 (s, 3H), 3.46 (t, 4H), 3.22 (d, 2H), 2.42 (dt, 4H), 2.00 (s, 3H), 1.91 (s, 3H); MS m/e 595.4 (M+H)+. Example 192 N-(4-{4-amino-7-[(lE)-3-(4-methyl-l-piperazinyl)-l-propenyl]thienor3;2-c]pyridin-3-yl}-2- methoxyphenyl)-l-methyl-lH-indole-2-carboxamide amine: 1-methylpiperazine. Reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, C18, 5 urn, 250 x 4.6 column) Rt=l0.6 min. 1H NMR (DMSO-d6, 400 MHz) δ 9.51 (s, IH), 8.01 (d, IH), 7.97 (s, IH), 7.71 (d, IH), 7.58- -111- WO 2005/010009 PCT/US2004/024003 7.62 (m, 2H), 7.32-7.35 (m; 2H), 7.05-7.21 (m, 3H), 6.68 (d, IH), 6.23 (dt, IH), 5.64 (br s, 2H), 4.04 (s, 3H), 3.92 (s, 3H), 3.17 (d, 2H), 2.36-2.46 (m3 4H), 2.17 (s, 3H); MS m/e 567.4 (M+H)+. Example 193 N-{4-[4-ammo-7-((lE)-3-{[2-(l-pyn-olidinyl)ethyl]amino}-l-propenvl)tfaieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl}-l-methvl-lH-indoIe-2-carboxamide amine: 2-(l-pyrrolidiny])ethanamine. Purification by reverse phase HPLC using ammonium acetate buffer followed by lyophilization provided the desired product as the - diacetate salt. Reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/mih, 254 nm, hypersil HS lOOA, C18, 5 um, 250 x 4.6 column) R-l 1 min. 1H NMR (DMSO-d6, 400 MHz) δ 9.51 (s, IH), S.OO (d, IH), 7.95 (s, IH), 7.71 (d, IH), 7.62 (s, IH), 7.59 (d, IH), 7.33-7.35 (m, 2H), 7.10-7.21 (m, 3H), 6.65 (d, IH), 6.28 (dt, IH), 5.64 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.41 (d, 2H), 2.67 (t, 2H), 2.51-2.54 (m, 3H), 2.44 (t, 4H), 1.88 (s, 3H), 1.67 (s, 4H); MS m/e 5S1.0 (M+H)+. Example 194 N-(4-[4-amino-7-((lE)-3-{[2-(2-oxo-l-imidazolidinyl)ethyl]ammo}-l-propenyl)tmeino[3,2-c]pyridin-3-yl]-2-methoxyphenyl} -1 -methyl-1 H-indole-2-carboxamide amine: l-(2-aminoethyl)-2-imidazolidmone. 1H NMR (DMSO-d6, 400 MHz) δ 9.51 (s, IH), 8.00-S.02 (m, 2H), 7.71 (d, IH), 7.5S-7.62 (m, 2H), 7.05-7.21 (m, 3H), 6.75 (d, IH), 6.34 (dt, IH), 5.64 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.37-3.46 (m, 3H), 3.21-3.31 (m, 3H), 3.17 (m, 2H), 2.70 (t, IH); Rf=0.3 (dichloromethane/methanol/ammonium hydroxide = 9:1:0.003). Example 195 N-(4-[4-amino-7-((lE)-3-{[2-(2-oxo-l-imidazolidinyl)ethyl]ammo}-l-propenyl)tmeino[3,2-c]pyridin-3-yl]-2-methoxyphenyl} -1 -methyl-1 H-indole-2-carboxamide amine: 2-(l-methyl-2-pyrrolidinyl)ethanamine. Purification by reverse phase HPLC using ammonium acetate buffer followed by lyophilization provided the desired product as the diacetate salt. Reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, CIS, 5 um, 250 x 4.6 column) R=l 1 min. 1H NMR (DMSO-d6, 400 MHz) 6 9.51 (s, IH), 8.00 (d, IH), 7.95 (s,-lH), 7.71 (d, IH), 7.62 (s, IH), 7.59 (d, IH), 7.33-7.35 (m, 2H), 7.07-7.21 (m, 3H), 6.65 (d, IH), 6.28 (dt, IH), 5.62 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.40 (d, 2H), 2.90 (m, IH), 2.55-2.70 (m, 2H), 2.21 (s, 3H), 2.02 (m, 2H), 1.8S (s, 6H), 1.75-1.85 (m, 2H), 1.5S-1.6S (m, 2H), 1.35-1.45 (m, 2H); MS m/e 581.0 (M+H)+. -112- WO 2005/010009 PCT/US2004/024003 Example 196 N-[4-(4-amino-7-((lE)-3-[(4-pyridinylmethyl) ammo}-l-propenyl)tmeino[3,2-c]pyridin-3-yl] 2-methoxyphenyl]4-methyl-lH-indole-2-carboxarnide amine: l-(4-pyridinyl)rnethanarnine. Purification by reverse phase HPLC using ammonium acetate buffer followed by lyophilization provided the desired product as the diacetate salt. Reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, C18, 5 |im, 250 x 4.6 column) R,=10.6 min. 1H NMR (DMSO-d6, 400 MHz) δ 9.51 (s, IH), 8.48-8.52 (m, 4H), 8.00 (d, IH), 7.95 (s, IH), 7.58-7.72 (ru, 3H), 7.07-7.40 (m, 6H), 6.70 (d, IH), 6.30 (d, IH), 5.62 (br s, 2H), 4.27 (d, 2H), 4.04 (s, 3H), 3.92 (s, 3H), 3.39 (d, 2H), 1.90 (s, 3H); MS m/e 575.4 (M+H)+. Example 197 N-(4-{4-amino-7-[(lE)-3-amino-l-propenyl]thieno[3,2-c]pyridin-3-vU-2-methoxyphenyl)-l- methyl-lH-indole-2-carboxamide Example 197 A tert-but (2E)-3-(4-amino-3-bromothieno[3,2-c]pyridin-7-yl)-2-propenylcarbamate A mixture of Example 21A (l.Og, 2.8 mmol), tert-buryl (2E)-3-(tributyl stannyl)-2- propenylcarbamate (prepared according to the procedure described in Synthesis, 1991, (12), 1201,1.5g, 3.36 mmol), and potassium flouride (l95nig, 3.36 mmol) in toluene (10 mL) was degassed, treated with Pd(PPh3)4 (194mg, 0.17 mmol), degassed, and heated to 110°C for 14 hours under a nitrogen atmosphere. The mixture was concentrated and purified by flash chromatography on silica gel with dichloromethane/ethyl acetate (6:4) to provide the desired 25 product (1.3g, 3.36 mmol). 1H NMR (DMSO-d6,400 MHz) 5 7.93 (s, IH), 7.35 (s, IH), 6.55 (d, IH), 6.21 (dt, IH), 5.81 (br s, 2H), 4.73 (br s, IH), 3.98 (s, 2H), 1.48 (s, 9H); reverse phase HPLC (5% to 95% acetonitrile over 25 minutes, 1 rnL/min, 254 nm, hypersil HS 100 A, C18, 5 \xm, 250 x 4.6 column) R-15.5 minutes; MS m/e 385.1. Example 197B tert-butyl (2E)-3-[4-amino-3-(3-methoxy-4-{[(l-methyl-lH-indol--2-yl)carbonyl]amino}phenyl)thieno[3,2-c]pyridm-7-yl]-2-propenylcarbaxnate A mixture of Example 197A (275mg, 0.716 mmol), Example 175E (436mg, 1.074 mmol), Na2C03 (151mg, 1.43 mmol), and Pd(PPh3)„ (SOmg, 0.043 mmol) in 1,2-dimethoxyethane/water (12:6 mL) was heated to 95 °C for 20 hours and partitioned between water (30 mL) and dichloromethane (40 mL). The organic layer was separated and the aqueous layer was further extracted with dichloromethane (2 x 40 mL). The organic layer was filtered to provide some desired product (117 mg). The filtrate was dried (MgS04),' -113- WO 2005/010009 PCT/US2004/02-I003 filtered, concentrated, dissolved in dichloromethane (10 mL), and'filtered to provide additional desired product (107 mg). The remaining filtrate was purified by flash-.. chromatography on silica gel with dichloromethane/methanol (97:3). Product-containing fractions were filtered to provide another 25 mg of the desired product to provide a total of 249mg (0.430 mmol). 1H NMR (DMSO-d6, 400 MHz) 6 9.51 (s, IH), 8.01 (t, IH), 7.95 (s, IH), 7.70-7.72 (d, IH), 7.58-7.62 (m, 2H), 7.30-7.35 (m, 2H), 7.07-7.21 (m, 3H), 6.59 (d, IH), 6.21 (dt, IH), 5.62 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.7S (t, 2H), 1.42 (s, 9H); reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, CIS, 5 pm, 250 x 4.6 column) R=19.2 min. MS m/e 5S4.3 (M+H)+. Example 197 C N-(4- (4-amino-7-[(l E)-3-amino-1 -propenyl]thienof 3,2-c1pyridm-3-yl)-2-methoxyphenyl)-l - Methyl 1H-indole-2-carboxamide A mixture of Example 197B (250mg, 0.43 mmol), 6N HC1 (2.5 mL), and acetone (5 mL) was stirred for 3 hours at ambient temperature and heated to 40 °C for 4 hours. The mixture was partitioned between 2N NaOH (10 mL) and dichloromethane (20 mL). The organic layer was separated and the aqueous layer was further extracted with dichloromethane (2 x 20 mL). The organic layer was dried CMgS04), filtered, and concentrated to provide the desired product (146 mg): 1H NMR (CDCI3, 400 MHz) 5 8.66 (s, IH), 8.5S-8.60 (d, IH), 7.95 (m, IH), 7.70-7.72 (d, IH), 7.00-7.52 (m, 6H), 6.69 (d, IH), 6.46 (m, IH), 4.89 (br s, 2H), 4.14 (s, 3H), 3.98 (s, 3H), 3.60-3.61 (d, 2H); reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, CIS, 5 urn, 250 x 4.6 column) R lO.i min. MS m/e 482.4 (M-H)+ General Procedure for the Preparation of Amides, Sulfonamides, Carbamates and Ureas from Example 197C A mixture of Example 197C (30mg, 0.062 mmol) in dichloromethane (2 mL) and pyridine (0.1 mL) was treated with the appropriate acid chloride, sulfonyl chloride, or alkylchloroformate (1.2 eq) at ambient temperature. Ureas were prepared in the same manner 30 from Example 197C and the appropriate isocyanate, but pyridine was omitted from the reaction mixture. The mixtures were stirred for 2 hours at ambient temperature and concentrated. The products were purified by normal or reverse phase chromatography. Example 198 N-(4-{7-[(lE)-3-(acetvlammo)-l-propenyl]-4-aminothieno[3,2 1pyridm-3-vl)-2-. methoxyphenyl)-l-methyHH-indole-2-carboxamide starting reagent: acetyl chloride. Reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, CIS, 5 urn, 250 x 4.6 column) R=11.5 -114- WO 2005/010009 PCT/US2004/024003 min. 1H NMR (DMSO-d5,400 MHz) 6 9.51 (s,TH), 8.17 (t, 1H), 8.00 (s, 1H), 7.96 (s, 1H), 7.71 (d, HI), 7.62 (s, 1H), 7.58 (d, 1H), 7.30-7.35 (m, 2H), 7.21 (s, 1H), 7.07-7.15 (m, 2H), 6.63 (d, 1H), 6.20 (dt, 1H), 5.64 (br s, 2H), 4.04 (s, 3H), 3.93 (br s, 5H), 1.88 (s, 3H); MS m/e 524.2 (M-H)+ 5 Example 199 N-[4-(4-amino-7-inE)-34(methylsulfonyl)amino1-l-propeiiyl}thieno[-3,2-c1pyTidin-3-yl)-2-methoxyphenyl]-1-methyl-lH-indole-2-carboxaniide starting reagent: methylsulfonyl chloride. Reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, CIS, 5 urn, 250 x 4.6 column) Rrl2.3 min. 1H NMR (DMSO-d6, 400 MHz) 6 9.51 (s, 1H), S.02 (t, 1H), 8.00 (s, 1H), 7.71 (d, 1H), 7.64 (s, 1H), 7.59 (d, 1H), 7.30-7.35 (m, 2H), 7.21 (s, 1H), 7.07-7.15 (m, 2H), 6.75 (d, 1H), 6-20 (dt, 1H), 5.65 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.84 (t, 2H), 2.96 (s, 3H); MS m/e 562.3 (M+H)+. 15 Example 200 methyl (2E)-3-[4-amino-3-(3-methoxy-4-{[(Umethyl-lH-indol-2-yl)carbonyl]amino)phenyl)thieno[3,2-c]pyridin-7-yl]-2-propenylcarbamate starting reagent: methyl chloroformate. Reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, CIS, 5 [ira, 250 x 4.6 column) Rj-12.8 min. ]H NM[(DMSO-d6,400 MHz) 6 9.51 (s, 1H), 8.02 (t, 1H), 7.96 (s, 1H), 7.71 (d, 1 ,7.58-7.62 (m, 2H), 7.50 (t, 1H), 7.30-7.35 (m, 2H), 7.08-7.21 (m, 3H), 6.63 (d, 2H), 6.22 (dt, 1H); 5.65 (br s, 2H), 4.04 (s, 3H), 3.92 (s, 3H), 3.88 (t, 2H), 3.57 (s, 3H); MS m/e 542.3. Example 201 N-{4-[4-amino-7-((lE)-3-{[(emylammo)carbonyl]aminol-l-propenynthieno[3,2-c]pyridin-3-yl]-2-methoxvphenyU-l-methyl-lH-indole-2-carboxamide starting reagent: isocyanatoethane. Reverse phase HPLC (5% to 95% acetonitrile 30 over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, C18, 5 jam, 250 x 4.6 column) R.-9.9 iriin. lH NMR (DMSO-d6, 400 MHz) δ 9.51 (s, 1H), 8.0 (d, 1H), 7.95 (s, 1H), 7.71 (d, 1H), 7.62 (s, 1H), 7.58 (d, 1H), 7.30-7.35 (m, 2H), 7.07-7.21 (m, 3H), 6.60 (d, 1H), 6.23 (dt, 1H), 6.11 (t, 1H), 5.S9 (t, 1H), 5.62 (br s, 2H), 4.04 (s, 3H), 3.93 (s, 3H), 3.87 (t, 2H), 3.05, (p, 2H), 1.02 (t, 3H); MS m/e 555.4 (M+H)+. Example 202 N-[4-(4-ammo-7-{(lE)-3-[(3-pyridmylcarbonyl)aminol-Lpropenyl)thieno[3,2-c]pyridin-3- yl)-2-methoxyphenyl]-l-methyl-lH-indole-2-carboxamide -115- WO 2005/010009 PCT/US2004/024003 starting reagent: nicotinyl chloride. Reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 rnL/min, 254 ran, hypersil HS 100 A, CIS, 5 um, 250 x 4.6 column) R,=l 1.7 min. 1H NMR (DMSO-d6, 400 MHz) δ 9.49 (s, IH), 9.10-9.18 (m, 2H), 8.75, (d, IH), S.25 (d, IH), 8.14 (t, IH), 8.10 (s, IH), 7'.97 (s, IH), 7.71 (d, IH), 7.55-7.62 (m, 2H), 7.5S (d, IH), 7.29-7.35 (m, 3H), 7.16 (t, 2H), 7.00 (br s, IH), 6.75 (d, IH), 6.58 (dt, IH), 4.2: (t, 2H), 4.04 (s, 3H), 3.93 (s, 3H); MS m/e 587.1 (M-H)+ Example 203 N-(4-{4-animo-7-[(lE)-3-(isomcotmovlammo)-l-propenyl]thieno[3,2-c]pyridin-3-yl}-2-- methoxyphenyl)-l-methyl-IH-indole-2-carboxamide starting reagent: isonicotinyl chloride. Reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, CIS, 5 um, 250 x 4.6 column) R,=l 1.8 min. lH NMR (DMSO-d6, 400 MHz) 6 9.50 (s, IH), 9.16 (t, IH), 8.75, (m, 2H), 8.00 (d, 2H), 7.83 (m, 2H), 7.71 (d, IH), 7.58-7.62 (m, 2H), 7.31-7.35 (m, 2H), 7.21 (s, IH), 7.07-15 7.16 (m, 3H), 6.73 (d, IH), 6.33 (dt, IH), 4.19 (t, 2H), 4.04 (s, 3H), 3.92 (s, 3H); MS m/e 587.7 (M-H)+ Example 204 N-(4-[4-ammo-7-((lE)-3-{[3-(dimethylanimo)benzoyl]amino}-l-propenyl)thieno[3,2- c1pvridin-3-yl]-2-methoxyphenyl} -1 -methyl- lH-indoIe-2-carboxamide starting reagent: 3-(dimethylamino)benzoyl chloride. Reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, CIS, 5„um, 250 x 4,6 column) R=13.S min. 1HNMR (DMSO-dfi, 400 MHz) δ 9.47 (s, IH), 8.74 (t, IH), S.00 (m, 2H), 7.6S (d, IH), 7.55-7.59 (ra, 2H), 7.05-7.32 (m, 7H), 6.84-6.S6 (m, IH), 6.67 (d, IH), 25 6.30 (dt, IH), 5.62 (brs, 2H), 4.12 (t, 2H), 4.06 (s, 3H), 3.83 (s, 3H), 2.92 (s, 6H); MS m/e 629.4 (M-H)+ Example 205 N-(4-(4-animo-7-{(lE)-3-[(am mocarbonyl)amino1-l-propenyl}thieno[3,2-c]pyridin-3-yl)-2- methoxyphenyl]-1 -methyl-1 H-indole-2-carboxamide starting reagent: isocyanatobenzene. 1H NMR (DMSO-d6, 400 MHz) 6 9.49 (s, IH), S.56 (s, IH), 8.00 (d, IH), 7.96 (d, IH), 7.69 (d, IH), 7.61 (s, IH), 7.57 (d, IH), 7.41 (d, IH), 7.33 (s, IH), 7.32 (m, IH), 7.22 (m, 3H), 7.14 (t, IH), 7.07 (m, IH), 6.89 (t, IH), 6.67 (d, IH), 6.43 (t, IH), 6.28 (m, IH), 4.02 (s, 3H), 3.96 (m, 2H), 3.90 (s, 3H); MS m/e 603.4 35 (M+H)+. Example 206 N-(4-{4-ammo-7-[(lE)-3-(berizoylammo)-l-propenyl]thieno[3,2-c]pyridin-3-yl}-2- -116- WO 2005/010009 PCT/US2004/024003 methoxyphenyl)-l-methyl-lH-mdole-2-carboxamide starting reagent: benzoyl chloride. 1H NMR (DMSO-d6, 400 MHz) δ 9.43 (s, IH), 8.79 (t, IH), 7.94 (m, 2H), 7.76 (m, 2H), 7.64 (s, IH), 7.55 (s, IH), 7.40-7.53 (m, 4H), 7.26 (m, 2H), 7.13 (s, IH), 7.08 (t, IH), 7.01 (ra, 1H),6.64 (d, IH), 6.27 (m, IH); 5.57 (br s, 2H), 4.09 (t, 2H), 3.97 (s, 3H), 3.85 (s, 3H); MS m/e 588.4 (M+H)+. Example 207 N-[4-(4-amino-7-[(lE)-3-[(phenylsulfonyl)ammo1-l'-propenyl)thieno[3,2-c]pyridin--3-yl)-2- methoxyphenyl]-l-methyl-lH-indole-2-carboxamide starting reagent: benzenesulfonyl chloride. lH NMR (DMSO-d6, 400 MHz) δ 9.49 (s, IH), 8.0 (t, IH), 7.85 (m, 3H), 7.69 (d, IH), 7.60 (m, 5H), 7.34 (s, IH), 7.32 (d, IH), 7.19 (d, IH), 7.14 (t, IH), 7.06 (d, IH), 6.60 (d, IH), 6.02 (m, IH), 5.65 (br s, 2H), 4.03 (s, 3H), 3.90 (s, 3H), 3.68 (d, 2H); MS m/e 624.3 (M+H)+. Example 208 benzyl (2E)-3-[4-amino-3'-(3-methoxy-4-{ff l-methyl-lH-indol-2-yncarbonvl]amino}phenyl)thieno[3,2 1pyridin-7-yn-2-propenylcaibamate starting reagent: benzyl chloroformate. 1H NMR (DMSO-d6, 400 MHz) δ 9.49 (s, IH), 8.01 (t, IH), 7.94 (s, IH), 7.71 (d, IH), 7.62 (m, 2H), 7.58 (d, IH), 7.31-7.39 (m, 5H), 20 7.21 (s,.lH), 7.15 (t, IH), 7.08 (d, IH), 6.63 (d, IH), 6.23 (m, IH), 5.64 (br s, 2H), 5.07 (s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.S9 (t, IH); MS m/e 618.4 (M+H)+. Example 209 N-[4-(4-amino-7-{(lE)0-[(5-isoxazolylcarbonyl)amino-l-propenyl]thieno[3,2-c]pyridin-3-- yl)-2-methoxyphenyl]-l-methyl-lH-indole-2-carboxamide starting reagent: 5-isoxazolecarbonyl chloride. lH NMR (DMSO-d6, 400 MHz) δ 9.49 (s, IH), 9.32 (t, IH), 8.76 (d, IH), 7.98 (m, 2H), 7.71 (s, IH), 7.69 (d, IH), 7.58 (d, IH), 7.34 (s, IH), 7.32 (m, IH), 7.20 (d, IH), 7.14 (d, 1H), 7.12 (d, IH), 7.08 (dd, IH), 6.70 (d, IH), 6.30 (m, IH), 5.66 (br s, 2H), 4.15 (t, IH), 4.03 (s, 3H), 3.91 (s, 3H); MS m/e 579.3 (M+H)+ General Procedure for Suzuki Coupling in Southern Domain A mixture of Example 21A (0.250g, 0.74 mmol) in 1,2-dimethoxyethane (10 mL) and water (5 mL) was treated with the appropriate boronic acid (0.85 mmol), Na2C03 (0.179g, 1.69 mmol) and Pd(PPh3)„ (0.08 lg, 0.07 mmol) at SO °C for 18 hours. The organic solvent was removed in vacuo and the solid was isolated by filtration and purified by flash column chromatography on silica gel with 2% methanol/dichloromethane to provide the desired product in 40-88 % yield. -117- WO 2005/010009 PCT/US2004/024003 Example 210 3-bromo-7-(3-mryl)thieno[3,2-c]pyridin-4-amine boronic acid: 3-fuiylboronic acid. lH NMR (DMSO-d6, 400MHz) 5 8.09 (d, 2H), 8.0S (t, IH), 7.S9 (s, IH), 7.82 (t, IH), 6.99 (dd, IH), 6.62 (br s, 2H); reverse phase HPLC (Delta Pak CIS, 5 urn, 300 A, 15 cm; 5%-95% acetonitrile/O.IM ammonium acetate over 10 minutes, then isocratic 3 minutes, ImL/min) R, =1.50 mm.; MS m/e 295, 297. Example 211 3-bromo-7-[4-pyrtdinyl)thieno[3,2-cTpvridin-4-amine boronic acid: 4-pyridinylboronic acid. 1H NMR (DMSO-d6, 400MHz) 5 8.65 (d, 2H), 8.07 (s, IH), 7.88 (s, IH), 7.65 (d, 2H), 6.86 (br s, 2H); reverse phase HPLC (Delta Pak CIS, 5 urn, 300 A, 15 cm; 5%-95% acetonitrile/O. IM ammonium acetate over 10 minutes, ImL/min) R,=9.77 minutes; MS m/e 306, 308 (M+H)+. Example 212 3-bromo-7-(3-pridinyl)thieno[-3,2-c]pyridin-4-amine boronic acid: 3-pyridinylboronic acid. 1H NMR (DMSO-d6, 400MHz) 5 8.81 (dd, IH), 8.60 (dd, IH), 8.01-8.05 (m, IH), 7.96 (s, IH), 7.86 (s, IH), 7.51-7.55 (m, lH),-6.75 (br 20 s, 2H); reverse phase HPLC (Delta Pak CI 8, 5 im, 300 A, 15 cm; 5%-95% acetonitrile/O. IM ammonium acetate over 10 minutes, ImL/min) Rt=9.S4 minutes; MS m/e 306, 308 (M+H)+. Example 213 3-bromo-7-(3-thienyl)thieno[3,2-c]pyridin-4-amme boronic acid: 3-thienylboronic acid. Reverse phase HPLC (Delta Pak CIS, 5 \xm, 300 A, 15 cm; 5%-95% acetonitrile/O. IM ammonium acetate over 10 minutes, then isocratic 3 minutes, ImL/min) R,=12.09 min. 1H NMR (DMSO-d6, 400MHz) 5 8.07 (s, IH), 7.87 (s, IH), 7.65-7.78 (m, IH), 7.69-7.73 (m, IH), 7.50 (dd, IH), 6.64 (brs,2H); MSm/e311,313 (M+H)+. Example 214 3-bromo-7-(2-thienyl)thieno[3,2-c]pyridin-4-amine boronic acid: 2-thienylboronic acid. Reverse phase HPLC (Delta Pale CIS, 5 urn, 300 A, 15 cm; 5%-95% acetonitrile/O.IM ammonium acetate over 10 minutes, then isocratic 3 minutes, ImL/min) 3 =12.09 min. 1H NMR (DMSO-dg, 400MHz) 5 8.07 (s, IH), 7.87 (s, IH), 7.65-7.78 (m, IH), 7.69-7.73 (m, IH), 7.50 (dd, IH), 6.64 (br s, 2H); MS m/e 311,313 (M+H)+. -118- WO 2005/010009 PCT/US2004/024003 Example 215 3-bromo-7-(6-methoxy-3-pyridinyl)thierio[3,2-c]pyridm-4-amine boronic acid: 6-methoxy-3-pyridinylboronic acid. Reverse phase HPLC (Delta Pak C18, 5 urn, 300 A, 15 cm; 50%-l00% acetonitrile/O.lM ammonium acetate over 10 min, ImL/min) =6.60 min. 1H NMR (DMSO-dG, 400MHz) 5 8.37 (dd, 1H), 7.93 (dd, 1H), 7.88 (s, 1H), 7.85 (s, 1H), 6.96 (dd, 1H), 6.66 (br s, 2H), 3.9l (s, 1H); MS m/e 336, 338 (M+H)+- General Procedure for Suzuki Coupling in Northern Domain A mixture of the 3-bromothienyl compound (Examples 210-212) (1.0 eq) in 1,2- dimethoxyethane (10 mL) and water (5 mL) was reacted with Example 175E (1.2 eq), NajCC}, (2.4 eq), and Pd(PPh3)4 (0.06 eq) at 95 °C for 18 hours. The organic solvent was removed in vacuo and the the mixture was extracted with dicliloromethane. The extract was dried (MgSO<), filtered, and concentrated. The residue was purified by preparative reverse phase HPLC (Rainin C18, 8 mm, 300 A, 25 cm; 40% acetonitrile/O.lM ammonium acetate isocratic for 5 minutes, then 40-100% acetonitrile/O.lM ammonium acetate over 30 minutes, 21 nxL/min). The acetonitrile was removed in vacuo and the aqueous mixture was lyophilized to provide the desired product. Example 216 N-{4-[4-amino-7-(4-pyridinyl)thieno[3,2--clpyridin-3-yl)-2-methoxyphenyl}-l-methyl-lH- indole-2-carboxamide bromide: Example 211. !H NMR (DMSO-d6) 400MHz) δ 9.52 (s, 1H), 8.69 (d, 2H), 8.12 (s, 1H), S.03 (t, 1H), 7.68-7.76 (m, 3H), 7.65 (s, 1H), 7.59 (d, 1H), 7.29-7.37 (m, 2H), 7.24 (s, 1H), 7.08-7.18 (m, 2H), 5.75-5.90 (br s, 2H), 4.04 (s, 3H), 3.92 (s, 3H); LCMS (Thermoquest AQA single-quad MS, Genesis Cl 8 column, 3mm particle size, 33 x 4.6mm; 30-95% acetonitrile/0.050M ammonium acetate over 3 minutes, then isocratic 95% acetonitrile/0.050M ammonium acetate over 1.5 minutes, 0.8 mL/min): MS m/e 506 (M+H)+,RT = 3.95 min. Example 217 N-(4-[4-ammo-7-(3-miryl)thieno[3,2-c]pyridin"3-yl]-2-methoxYphenyl)-l-methyl-lH-indole- 2-carboxamide bromide: Example 210. lH NMR (DMSO-d6, 400MHz) δ 9.52 (s, 1H), 8.69 (d, 2H), 8.12 (s, 1H), S.03 (t, 1H), 7.68-7.76 (m, 3H), 7.65 (s, 1H), 7.59 (d, 1H), 7.29-7.37 (m, 2H), 7.24 (s, 1H), 7.08-7.18 (m, 2H), 5.75-5.90 (br s, 2H), 4.04 (s, 3H), 3.92 (s, 3H); reverse phase HPLC (Delta Pale C18, 5 urn, 300 A, 15 cm; 5%-95% acetonitrile/O.lM amraonium acetate over 10 min, ImL/min) R=S.75 minutes; MS m/e 495 (M+H)+. -119- WO 2005/010009 PCT/US2004/024003 Example 218 N-(4-[4-amko-7-(3-pyridhyl)tb no[3,2-c] pyridin"3-yl]-2-methoxphenyl)-l-methyl-lH-indole- indole-2-carboxamide bromide: Example 212. 1H NMR (DMSO-d6, 400MHz) δ 9.52 (s, IH), 8.8S (d, IH), 8.63 (dd; IH), 8.08-8.13 '(m, IH), S.02 (t, IH), 7.99 (s, IH), 7.71 (d, IH), 7.54-7.63 (ra, 3H), 7.30-7.37 (m, 2H), 7.24 (d, IH), 7.09-7.18 (m, 2H), 5.67-5.76 (br s, 2H), 4.04 (s, 3H), 3.92 (s, 3H); reverse phase HPLC (Delta Pale CIS, 5 pm, 300 A, 15 cm; 50%-100% acetonitrile/O.lM ammonium acetate over 10 minutes, lmL/min) [(=8.50 minutes; MS m/e 506 (M+H)+. Example 219 3-(4-phenoxvphenyl)thieno[3,2-c]pvridin-4-amine Example 219A 3-bromothieno[3,2-c]pyridin-4-amine A mixture of 3-bromo-4-chlorothieno[3,2-c]pyridine (prepared according to the procedure described in Bull. Soc. Chim. Beiges 1970, 79, 407-414, 3g, 12 mrnol), concentrated aqueous NH4OH (100 mL), and p-dioxane (100 mL) was sealed in a stainless steel, high-pressure reactor and stirred for 18 hours at 150 °C.-The mixture was concentrated to half its original volume, diluted with water, and extracted with ethyl acetate. The combined organic extracts were washed with brine, dried (MgS04), filtered, and concentrated to provide 2.6g (94%) of the desired product. lH NMR (DMSO-d6, 400MHz) 5 7.S3 (d, IH), 7.77 (s, IH), 7.26 (d, IH), 6.48 (br s, 2H); MS m/e 229 (M+H)+. Example 219B 3-(4-phenoxyphenyl)thieno[3,2-c]priidin-4-amine A mixture of Example 219A (5.43g, 23.7 mmol), 4-phenoxyphenylboronic acid (6g, 28.03 mmol), Na2C03 (3.7g, 34.9 mmol), PdlTPig, (5.4g, 4.7 mmol), DMF (96 mL), and water (24 mL) was stirred for 18 hours at 80 °C under nitrogen, poured into 10% aqueous NaCl (400 mL), and extracted with ethyl acetate (3 x 70 mL). The combined organic extracts were washed with brine, dried (MgSOJ, filtered, and concentrated under reduced pressure. The residue was dissolved in 300 mL of dichloromethane. Silica gel (90g) was added to the solution and the mixture was concentrated under vacuum. The residual silica gel with the absorbed crude product was transferred to a silica gel column (600g) and chromatographed (eluent 40% ethyl acetate/heptane) to provide 5.61g (75%) of the desired product lH NMR (DMSO-d6,400MHz) 8 7.85 (d, IH), 7.49-7.44 (m, 5H), 7.29 (d, IH), 7.22 (t, IH), 7.16-7.12 (m, 4H), 5.44 (br s, 2H); 13C NMR (DMSO-d6,100 MHz) 5 156.9, 156.1,154.5, 148.3, 141.8, 136.1,130.9, 130.1, 123.9, 123.0, 119.2, 118.4, 118.1, 107.8. -120- WO 2005/010009 PCT/US2U04/024003 Example 220 N-[4-(4-armnothieno[3,2-c]pyridin-3-yl) -2- methoxyphenyl}-l-methyl-lH-indole carboxamide The desired product was prepared by substituting Example 175E for 4- phenoxyphenylboronic acid in Example.219B. LCMS m/e 429.3 (M+H)+; R,: 4.05 min. Example 221 tert-butyl (2E)-3-[4-amino-3-(4-phenoxyphenyl)thienQl3,2-c]pyridin-7-yl[acrylate Example 221A 7-iodo-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amine A solution of Example 219B (5g, 15.7 mmol) in DMF (100 mL) was treated with N-iodosuccinimide (4.23g] 18.8 mmol), stirred at ambient temperature for 2 hours, concentrated to half the original volume, and poured into 5% sodium thiosulfate (400 mL). The mixture was filtered and the filter cake was washed with water and dried. The solids were dissolved in dichlorornethane (300 mL), treated with silica gel (80g), and concentrated. The residue was transferred to a silica gel column (600g) and chromatographed with ethyl acetate/heptane (1:6) to provide 5.2 g (75%) of the desired product. 1H NMR (CD2C12, 400 MHz) 5 7.95 (s, 1H), 7.33-7.29 (m, 4H), 7.12 (s, 1H), 7.10 (t, 1H), 7.02-6.99 (m, 4H), 4.76 (br s, 1H); ,3C NM[(CD2Cl2,400MHz)5 158.4,156.8,154.7,154.4,14S.6,138.4,131.3,131.2,130.4, 124.4,122.9,120.0,119,9,118.8,72.0. Example 221B tert-butyl (2E)-3-[4-amino-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]acrylate A mixture of Example 221A (2g, 4.5 rnrnol), tert-butyl acrylate (1.3 mL, 8.8 mmol), Pd(OAc)2 (100mg, 0.44 mmol), PPh3 (236mg, 0.89 mmol), Na2C03 (0.95g, 3.9 mmol), and DMF (40 mL) was stirred for 18 hours at 80 °C under a nitrogen atmosphere. The mixture was concentrated to half its original volume and poured into 10% NaCl (300 mL). The product was extracted with ethyl acetate (3 x 70 mL). The combined organic extracts were washed with brine, dried (MgSO,,), filtered, and concentrated. The residue was dissolved in dichlorornethane (300 mL), treated with silica gel (25g), and concentrated. The preabsorbed silica gel was subsequently transferred to a silica gel (200 g) column and chromato graphed with ethyl acetate/heptane (1:6) to provide 1.52 g (76%) of the desired product. lH NMR (CD2C12, 400 MHz) 8 8.13 (s, 1H), 7.78 (d, 1H), 7.49-7.43 (m, 4H), 7.32 (s51H), 7.22 (t, 1HT 7.15 (d, 4H), 6.46 (d, 1H), 5.18 (br s, 2H), 1.59 (s, 9H); l3CNMR (CD2C12,100 MHz) 8 166.8,158.5,156.8,155.5, 147.1,146.9,139.8,137.5, 131.3,130.7,130.4,124.4,123.8, 119.9,119.7,118.8,118.7,117.2, 80.6, 2S.4. -121- WO 2005/010009 PCT/US2004/024003 Example 222 butyl (2E)-3-[4-amino-3-(4-phenoxyphenyl)thino[3,2-c]pyridin-7-yl]acrylate The desired product was prepared by substituting butyl acrylate for tert-butyl acrylal in Example 221. LCMS m/e 445.5 (M+H)+; retention time: 5.00 mm. Example 223 ethyl (2E)0-[4-amino-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-ynacrylate The desired product was prepared by substituting ethyl acrylate for tert-butyl acrylat in Example 221. Example 224 (2E)-3-[4-amino-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]-2-propen-l-ol A solution of Example 223 (0.45g, 10.8 mmol) in THF at -7S °C was treated with 5.4 mL DIBAL-H solution (1.0M in toluene, 5.4 mmol) and methanol (1 mL), warmed to room temperature, and concentrated. The residue was dissolved in methanol (100 mL), treated with silica gel (5g), and concentrated. The preabsorbed silica gel was subsequently transferred to a silica gel column and chromato graphed (ethyl acetate/heptane 3:1) to provide 200 mg (49%) of the product. Example 225 (2E)-3-R4-ammo-3-(4-phenoxyphenyl)thieno[3,2-c]pyridui-7-yl]acrylicacid A solution of Example 22 IB (1.5g, 3.4 mmol) in dichlorom ethane and trifluoroacetic acid (10 mL) was stirred for 2 hours at ambient temperature, treated with toluene (200 mL), and concentrated to provide 1.7g (100%) of the desired product as the trifluoroacetate salt. 1HNMR (DMSO-d 400 MHz) 6 8.42 (s, IH), 7.95 (s, IH), 7.76 (d, IH), 7.54 (dd, 2H), 7.46 (dt, 2H), 7.21 (t, IH), 7.16 (dd, 4H), 6.61 (d, IH); l3C NMR (DMSO-dd, 100 MHz) 5 167.0, 159.0,158.6, 157.6, 156.0, 148.8,137.7, 137.5, 131.0, 130.1, 128.2, 127.6, 124.0,120.3, 119.4,119.2,118.7,115.7. Example 226 (2E")-3-[4-amino-3-(4-pIienoxyphenyl)tbieno[3,2-c]pyridin-7-yl]acrylicacid A solution of Example 225 (1.2g, 2.3 mmol) and p-dioxane (50 mL) was treated with 2.5M HC1. The mixture was stirred for 20 minutes at ambient temperature and concentrated. The process was repeated once more after which the residue was azeotropically dried with toluene (2 x 100 mL) to provide the desired product as the hydrochloride salt. General Procedure for Amide Formation Amixtuxe of Example 226 (50mg, 0.12 mmol), N,N-diisopropyl ethyl amine (90 μL, -122- WO 2005/010009 PCT/US2004/024003 5.1 nimol), the amine (0.24 mniol), and DMF (2.5 mL) was treated sequentially with 0.5M KBTU in DMF and 0.5M HOBT in DMF. The reaction was stirred for 18 hours at ambient temperature, diluted with water, and extracted with ethyl acetate. The combined organic extracts were dried (NajSO,,), filtered, and concentrated. The residue was purified using normal or reverse phase chromatography. Example 227 tert-butvI 3-[({(2E)-3-R4-ainmo-3-(4-phenoxvphenvl)thieno[3,2-c]pyridin-7-yl]-2- propenoyl}amino)methyl]-l-pyrrolidinecarboxylate amine: tert-butyl 3-(aminomethyl)-l-pyrrolidinecarboxylate. Example 228 (2E)-3-[4-amino-3-(4-phenoxyphenvl)thieno[3,2-c]pyridin-7-yll-N-(3- pyrrolidinylmethy 1) acrylamide The desired product was prepared by dissolving Example 227 in dichloromethane (8 mL) and adding TFA (2 mL). The mixture was stirred for 4 hours at room temperature and concentrated to provide the desired product. Example 229 (2E)-3-14-ammo-3-(4-phenoxvphenyl)thieno[3,2-c]pyridin-7-yl]-N-[(3S)-3- pyrrolidinylmethyl] acrylamide Example 229A tert-butvl(3R)-34({(2E)-3-[4-ammo-3-(4-phenoxvphenvl)thieno[3,2-c]pyridin-7-ylV2- propenoyl)amino)methyl]-l-pyrrolidinecarboxylate amine: tert-butyl (3R)-3-(aminomethyl)-l-pyrrolidmecarboxylate. Example 229B (2E)-3-[4-amino-3-(4-phenoxvphenyl)thieno[3,2-c]pvridin-7-yl]-N-[(3S)-3- pyrro lidinylmethyl] aery lamide Example 229A was dissolved in dichloromethane (8 mL), treated with TFA (2 mL), stirred for 4 hours at room temperature, and concentrated to provide the desired product. Example 230 (2E)-3-[4-amino-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]-N-[(3R)-3- pyrrolidinylmethyl]acrylamide Example 230A -123- WO 2005/010009 PCT/US2004/024003 tert-butyl (3S)-3-[({(2E)-3-[4-amko-3-(4-phenoxvphenvl)thieno[3,2-c]pyridin-7-yl]-2- propenovl}amino)methyl]-l-pyrrolidinecarboxvlate amine: tert-butyl (3S)-3-(airwiomethyl)-l-pyrrolMinecarboxylate. 1H NMR (CD2C12, 400 MHz) 5 8.07 (s, IH), 7.73 (d, IH), 7.43-7.37 (m, 4H), 7.25 (s, IH), 7.16 (t, IH), 7.09 (d, 4H), 6.47 (d, IH), 5.94 (br d: IH), 5.07 (s, 2H), 3.49 (dd, IH), 3.30-3.26 (m, IH), 3.04 (m, IH), 2.45 (m, IH), 1.99 (m, IH), 1.70-1.65 (m, 4H), 1.42 (s, 9H). Example 230B (2E)-3-[4-amino-3-[4-phenoxypheny1)thieno[3,2-c]pvridin-7-yl]-N-[(3R)-3- pyrrolidinylmethyl]acrylamide Example 230A was dissolved in dichloromethane (S mL), treated with TFA (2 mL), stirred for 4 hours at room temperature, and concentrated to provide the desired product. 1H NMR (DMSO-d6,400 MHz) 5 8.31 (m, IH), 8.12 (s, IH), 7.67 (s, IH), 7.64 (d, IH), 7.57-7.43 (m, 4H), 7.21 (t, IH), 7.15-7.12 (m, 4H), 6.63 (d, IH), 5.87 (brs, 2H), 4.15-4.12 (m, 15 IH), 3.24-3.13 (m, 2H), 2.97-2.S7 (m, IH), 2.S2-2.60 (m, 2H), 2.35-2.14 (m, 2H), 1.90-1.80 (m, IH), 1.80-1.70 (m, IH); MS m/e 471. Example 231 (2E)-3-[4-amino-3-(4-phenoxyphenyl)tln'eno[3,2-c]pyridin-7-yl]-N-methylacrylamide amine: methylamine. 1H NMR (DMSO-d6, 400MHz)6 8.16 (q, IH), 8.13 (s, IH), 7.66 (s, IH), 7.58 (d, IH), 7.51-7.43 (m, 4H), 7.21 (t, IH), 7.15-7.12 (m, 4H), 6.5S (d, IH),' 5.87 (br s, 2H), 2.73 (d, 3H); MS m/e 402. Example 232 tert-butyl 3-[({(2E)-3-[4-ammo-3-(4-phenoxyphenyl)thieno[3,2-c]pvridin-7-y11-2- propenoyl}amino)methyl]-l-pyrTolidinecarboxylate amine: tert-butyl 3-(arniiiomethyl)-l-pyrrolidinecarboxylate. Example 233 (2E)-3-[4-animo-3-(4-phenoxyphenyl)tlueno[3,2-c]pyridin-7-yl]-N-(3- pyrrolidinylmethyl) acryl ami de The desired product was prepared by substituting Example 232 for Example 229A in Example 229B. Example 234 tert-butyl 4-({(2E)-3-[4-amino-3-(4-phenoxvphenyl)thieno[3,2-c]pyridm-7-yl]-2-propenoyl)ammo)-l-piperidinecarboxylate amine: tert-butyl 4-amino-l-piperidinecarboxylate. -124- WO 2005/010009 PCT/DS2004/024003 Example 235 (2E)-3-[4-amino-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]-N-4-piperidinylacrylamide The desired product was prepared by substituting Example 234 for Example 229A in Example 229B. MS m/e 471.3 (M+H)+ Example 236 tert-butyl 2-[2-({(2E)-3-[4-amino-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl] propenoyl}amino)ethyl]-l-piperidinecarboxylate amine: tert-butyl 2-(2-aminoethyl)-l-piperidinecarboxylate. Example 237 (2E)-3-[4-amino-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]-N-[2-(2- piperidinyl)ethyl]acry]amide The desired product was prepared by substituting Example 236 for Example 229A in Example 229B. MS m/e 499.4 (M+H)+ Example 238 tert-butyl 3-[({(2E)-3-[4-amino:-3-[4-phenoxyphenyl)thieao[3,2-c]pyridin-7-yl]-2- propenoyl}amino)methyl]-l-piperidmecarboxylate . amine: tert-butyl 3-(amuiomethyl)-l-piperidinecarboxylate. Example 239 (2E)-3-[4-amino-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]-N-(3- piperidinylmethypacrylarnide The desired product was prepared by substituting Example 238 for Example 229A in Example 229B. MS m/e 4S5.3 (M+H)+. Example 240 tert-butyl 3-({(2E)-3-[4-ammo-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]-2- propenoyl)amino)-l-pyrrolidinecarboxylate. amine: tert-butyl 3-amino-l-pyrrolidinecarboxylate. Example 241 ('2E)-3-[4-ammo-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]-N-3-pyrrolidmylac The desired product was prepared by substituting Example 241 for Example 229A in Example 229B. MS m/e 4573 (M+H)+. -125- WO 2005/010009 PCT/US2004/0240 Example 242 (2E)-3-[4-amino-3-[4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]-N-[(3S)-3- pyrrolidinyl]acrylamide The desired product was prepared by substituting tert-butyl (3S)-3-amino-l- pyrrolidinecarboxylate into the general procedure for amide formation, then substituting the resulting amide for Example 229A in Example 229B. MS m/e 457.2 (M+H)+. Example 243 (2E)-3 4-ainino-3-(4-phenoxvphenYl)thienor3<2-c1pvridin-7-vl]-N- [3R)-3- pyrrolidmyl]acrylamide The desired product was prepared by substituting tert-butyl (3S)-3-amino-l-pyrrolidinecarboxylate into the general procedure for amide formation, then substituting the resulting amide for Example 229A in Example 229B. MS m/e 457.1 (M+H)+ Example 244 C2E)-3-[4-amino-3-C4-plienoxyphenyl)thieno[3,2-c]pvridm-7-yl]-N-[3-(4-morpholinyppropyriacrylamide amine: 3-(4-morphou"nyl)-l-propanamine. Example 245 (2E)-3-[4-ammo-3-(4-phenoxvphenyl)thieno[3,2-c]pyridin-7-vl1-N-|'2-(2-p dinyletlivl]acrvIamide amine: 2-(2-pyridinyl)ethanamine. Example 246 (2E)-3-[4-amino-3-[4-phenoxvphenvl)thieno[3,2-c]pyridin-7-yl]-N-[2-(l-methyl-2- pyrTolidinvl)ethyl] acrylamide amine: 2-(l -methyl-2-pyrrolidinyl)ethanamine. Example 247 (2E)-3-[4-ammo-3-(4-phenoxyphenyl')thieno[3,2-c]pyridin-7-vl1-N-[3-(dimethylamino)propy 11 acrylamide amine: N,N-dimethyl-l,3-propanediarmne. Example 248 (2E).-3-[4-ammo-3-(4-phenoxyphenvl) thieno[3,2-c]pyridm-7-vl1-N-[3-(lH-imidazol-l- yl)propyl]acrylamide amine: 3-(lH-imidazol-l-yl)-l-propanamine. -126- WO 2005/010009 PCT/US2004/024003 Example 249 (2E)-3-[4-amino-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yn-N-[3-(l- piperidinyl)propyl]acrylamlde amine: 3-(l-piperidinyl)-l-propanamine. Example 250 (2E)-3-[4-amino-3-(4-plienoxyphenyl)thieno[3,2-c]pyridin-7-yl]-N-(3- pyridinylmethypacrylamide amine: l-(3-pyridinyl)methanamine. Example 251 (2E)-3-[4-amino-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]-N42-(4- morpholinyl)ethyl] aery lamide amine: 2-(4-morpholinyl)ethanamine. Example 252 (2E)-3-[4-amino-3-(R4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]-N-[2-(l- pyrroIidinyl)ethyl]acrylamide amine: 2-(l-pyrrolidiuyl)ethanamine. Example 253 (2E)-3-[4-amino-3-(4-phenoxyphenvl)thieno[3,2-c]pyridin-7-yl]-N-[(l-ethyl-2- pyrrolidinyl)methyl] acrylamide amine: (l-ethyl-2-pyrrolidinyl)metliylamine. Example 254 (2E)-3-[4-amino-3-(4-phenoxyphenvl)thieno[3,2-c]pyridin-7-yl]-N-[2- (dimediylamino)ethyl] acrylamide amine: N,N-dimethyl-l,2-ethanediamine. Example 255 (2E)-3-[4-amino-3-(4-phenoxyphenyl)tfaieno[3,2-c]pyridin-7-yl]-N42-(l- piperidinypethyl]acry lamide amine: 2-(l-piperidinyl)ethanamme. Example 256 -127- WO 2005/010009 PCT/US2004/024003 (2E)-3-[4-amino-3-(4-phenoxvphenyl)thieno[3,2-c]pyridin-7-vl]-N-(2-pyridinylmethyQacrylamide amine: l-(2-pyridinyl)methanamine. Example 257 2E)-3-[4-amino-3-(4-phenoxyphenvl)thieno[3,2-c]pyridin-7-yll-N-[4-pyridinyhnethyl)acryl amide amine: l-(4-pyridinyl)methanamine. Example 258 (2E)-3-[4-amino-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]-N-3-piperidinylacrylamide The desired product was prepared by substituting tert-butyl 3-amino-l-piperidinecarboxylate into the general procedure for amide formation, then substituting the resulting amide for Example 229A in Example 229B. 5 Example 259 (2E)-3-[4-amino-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yn-N-[[3R)-3- piperidinyl]acrylamide The desired product was prepared by substituting tert-butyl (3R)-3-(methylamino)-l-pipendinecarboxylate into the general procedure for amide formation, then substituting the resulting amide for Example 229A in Example 229B. Example 260 (2E)-3-[4-amino-3-(4-phenQxyphenyl)thieno[3,2-c]pyridin-7-yl]-N-(4- ' piperidinylmethyl)acrylamide The desired product was prepared by substituting tert-butyl 4-(aminomethyl)-l-piperidinecarboxylate into the general procedure for amide formation, then substituting the resulting amide for Example 229A in Example 229B. General Procedure for Suzuki Coupling A mixture of Example 10B (50mg, 0.11 mmol), a substituted boronic acid (1.5 equiv.), palladium(II) acetate (2.5mg, 0.011 mmol), PPh3 (12mg, 0.045 mmol), sodium acetate (35mg, 0.033 mmol), and DMF (2.5 mL) was stirred at 100 °C for 18 hours under a nitrogen atmosphere. The mixture was poured to 50 mL of 10% NaCl in water and the product was extracted with ethyl acetate (3 x 25 mL). The combined organic extracts were washed with brine, dried (MgSO,,), filtered, and concentrated. The residue was dissolved in dichloromethane (100 mL), treated with 2.5g of silica gel, and concentrated. The residue was transferred onto a silica gel column (10 g of silica) and eluted with ethyl acetate/heptane -12S- WO 2005/01000!) PCT/US2004/024003 mixtures, typically 1:3, depending on the substrate. Example 261 7-(2-furyl)-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amine boronic acid: 2-fiirylboronic acid. MS m/e 385.3 (M+H)+. Example 262 7-(3-fiiryl)-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amine boronic acid: 3-furylboronic acid. MS m/e 385.3 (M+H)+. Example 263 7-(l-benzofuran"2-yl)-3-(4"phenoxyphenyl)thieno[3,2-c]pyridin-4-amine boronic acid: l-benzofuran-2-ylboronic acid, MS m/e 435.2 (M+H)+. Example 264 5-[4-anrnio-3"(4-phenoxyphenyl)thieno[3,2-c]pyridin-7-yl]-2-furaldehyde boronic acid: 5-fonnyl-2-furylboronic acid. MS m/e 413.3 (M+H)+. Example 265 3-(4-phenoxyphenyl)-7-("lH-pyn-ol-3-yl)trueno[3,2-c]pyridm-4-amine The desired product was prepared by substituting l-(tert-butoxycarbonyl)-lH-pyrrol-3-ylboronic acid into the general procedure for Suzuki couplings, then substituting the resulting product for Example 229A in Example 229B. MS m/e 384.2 (M+H)+. Example 266 3-(4-phenoxyphenyl')-7-(lH-pyrrol-2-yl)thieno[3,2-c]pyridin-4-amine The desired product was prepared by substituting l-(tert-butoxycarbonyl)-lH-pYTrol-2-ylboronic acid into the general procedure for Suzuki couplings, then substituting the resulting product for Example 229A in Example 229B. MS m/e 384.2 (M+H)+. Example 267 7-(lH-indol-2-yl)-3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amine The desired product was prepared by substituting l-(tert-butoxycarbonyl)-lH-indol-2 ylboronic acid into the general procedure for Suzuki couplings, then substituting the resulting product for Example 229A in Example 229B. MS m/e 534.3 (M+H)+ (BOC protected compound). Example 268 -129- WO 2005/010009 PCT/US200J/024003 tert-butyl (2E)-3-(4-amino-3-broDiothieno[3,2-c]pyridin-7-yl)acrylate A solution of Example 21A (2.50g; 7.04 mmol), PPh3 (0.370g, 1.41 mmol), and Na2CO3 (1.49g, 14.1 mmol) in DMF (35 mL) was treated with tert-butyl acrylate (2.00 mL, 14.1 mmol) and palIadium(H)acetate (0.158g, 01704 mmol). The reaction was heated to 80 °C under an atmosphere of nitrogen for 16 hours. The reaction was cooled to ambient temperature and partitioned between ethyl acetate (100mL) and brine. The organic phase was washed with brine (2 x 100 mL), dried (Na>S04), filtered, and concentrated. The compound was purified by flash chromatography on silica gel using heptane/ethyl acetate (6:1) to (3:1) to provide the desired product (1.70g, 3.01 mmol). 1HNMR (DMSO-d6, 400MHz) 5 S.24 (s, IH), 7.94 (s, IH), 7.62 (d, IH), 7.17 (br s, 2H), 6.22 (d, IH), 1.4S (s, 9H); MS m/e 355/357 (M+H)+ Example 269 tert-butyl (2E)-3-[4-armno-3-(3-methoxy-4-{rri-methyl-lH-indol-2- yl)carbonyl]amino}phenyl)thieno[3,2-c]pyridin-7-yl]acry]ate A mixture of Example 268 (1.70g, 4.79 mmol), Example 175E (2.91g, 7.1S mmol), Na,C03 (l.Olg, 9.57 mmol), and Pd(PPh3)4 (0.332g, 0.287 mmol) was heated in a mixture of DME (60 mL) and water (30 mL) at 95 °C for 15 hours under an atmosphere of nitrogen. The reaction was cooled to ambient temperature, treated with additional Example 175E 20 (0.91$, 2.39 mmol) and Pd(PPh3)4 (0.332g, 0.2S7 mmol), heated to 95 °C for another 5 hours, and cooled to ambient temperature. The resulting precipitate was collected by Alteration and washed with diethyl ether (40mL). The precipiate was dissolved in dichloromethane (200mL), dried (NajSOJ, filtered, and concentrated to provide the desired product (I.98g, 3.57 mmol). 1HNMR (DMSO-d6, 400MHz) 6 9.49 (s, IH), S.24 (s, IH), 8.01 (d, IH), 7.72 (d, IH), 7.69 (s, 2H), 7.57 (d, IH), 7.31 (m, 2H), 7.22 (d, IH), 7.10,(m, 2H), 6.32 (d, IH), 6.10 (br s, 2H), 4.03 (s, 3H), 3.91 (s, 3H), 1.51 (s, 9H); MS m/e 555 (M+H)+. Example 270 (2E)-3-[4-amino-3-(3-metfaoxy-4--{[(l-metfayl-lH-indol-2- yl)carbonyl]amino}phenyl)thieno[3,2-c]pyridin-7-yl]acrylic acid The desired product was prepared as the trifluoro acetate salt by substituting Example 269 for Example 221B in Example 225. LCMS m/e 499.2; retention time: 2.08 min. Example 271 (2E)-3-[4-amino-3-(3-methoxy-4-{[(l-methyl-lH-indol-2- yl)carbonynamino)phenyl)thieno[3,2-c]pyridm-7-yl]acrylic acid The desired product was prepared as the hydrochloride salt by substituting Example 270 for Example 225 in Example 226. -130- WO 2005/010009 PCT/US2IKI4/024003 Example 272 N-(4-[4-amino-7-(('lE)-3-oxo-3-{[2-(l-piperidinvl')ethyl]amino}-l-propenyl)thieno[3,2- c]pyridin-3-yl]-2-rnethoxyphenyl}-l"methyl-lH-indole-2-carboxamide A mixture of Exmaple 271 (30.6mg, 0.044 mmol), N,N-diisopropylethylamine (35 μL, 0.20 mmol), 2-piperidin-l-ylethylamine (14.3 pL, 0.10 mmol), and DMF (1 mL) was treated sequentially with 0.5M (0.09 mL) of HBTU in DMF and 0.5M (0.09 mL) of HOBT in DMF. The reaction was stirred for 24 hours at ambient temperature and partitioned between IN NaOH and ethyl acetate. The combined extracts were dried (Na2SO3, filtered, and concentrated to provide the desired product (20.4mg, 0.034 mmol). LCMS m/e 609.2; retention time: 2.93 min. Example 273 N-(4-{4-amino-7-[(lZ)-3-oxo-3-(4-piperidinylamino)-l-propenyl]thieno[3,2-c]pyridin-3-yl}- 2-methoxyphenyl)-l-methyl-lH-mdole-2-carboxamide Amixture of Example 272 (50mg, 0.12 mmol), N,N-diisopropylethylamine (90 JAL, 5.1 mmol), 4-piperidinamine (0.24 mmol), and DMF (2.5 mL) was treated sequentially with 0.5M HBTU in DMF and 0.5M HOBt-in DMF. The reaction was stirred for 18 hours at ambient temperature, diluted with water, and extracted with ethyl acetate. The combined organic extracts were dried (Na2SOJ, filtered, and concentrated. The residue was purified using normal or reverse phase chromatography. LCMS m/e 581.3; [( = 2.67 min. Example 274 N-[4-(4-amino-7-{(lZ)-3-oxo-3-[(3-piperidinylmethyl)amino1-l-propenyl)thieno[3,2- clpyridin-3-yl)-2-methoxyphenyl]l-methyl-lH-indole-2-carboxamide A mixture of Example 270 (1 lmg, 0.020 mmol), tert-butyl 3-(aminomethyl)-l-piperidinecarboxylate (5mg, 0.024 mmol), and Na Oj (0.060 mmol, 6 mg) in dichloromethane (1 mL) and water (0.5 mL) was treated with a solution of tetramethylfiuoroformadinium hexafluorophosphate (TFFH, Smg, 0.030 mmol) in dichloromethane (0.5 mL), stirred for 3 days at ambient temparature, treated with additional amine (12mg, 0.056 mmol), stirred another day, treated with additional TFFH (30mg, 0.11 mmol), and partitioned between dichloromethane and saturated NaHC03. The combine organic phases were dried (Na SOJ, filtered, and concentrated. The residue was purified by reversed phase HPLC. The acetonitrile was removed under vacuum and the residue was lyophilized to provide the BOC-protected amine which was dissolved in dichloromethane (1 mL), triethylsilane (0.2 mL), and trifluoroacetic acid (0.5 mL). The mixture was stirred at room temperature for 1 hour and concentrated. The residue was purified by reverse phase HPLC. The acetonitrile was removed under vacuum and die desired product was isolated by -131- lyophylization (1:9 mg). LCMS m/e 595.2; K, = 2.67 min. Example 275 (2E)-3-[4-ammoO-(4-bromophenyl)thieno[-3,2-c]pyridin-7-yl]-N-3-pyridinylacrylaniide The desired product was prepared as the tris(trifluoroacetate) salt by substituting 3- pyridinamine for l-(4-pyridinyl)methanamine in Example 171B. 1H NMR (300 MHz, DMSO-dg) 5 6.75 (s, 2H), 6.93 (d, J=15.9 Hz, 1H), 7.50 (d, J=S.l Hz, 2H), 7.56 (dd, J=8.5, 4.7 Hz, 1H), 7.76 (d, J=8.1 Hz, 2H)3 7.S4 (d, J-15.9 Hz, 1H), 7.97 (s, 1H), 8.25-S.28 (m, IE 8.33 (s, 1H), 8.39 (dd, JM5.1,1.0 Hz, 1H), 9.00 (d, J=2.0 Hz, 1H), 10.76 (s, 1H). MS (ESI(+)) m/e 450.9, 452.8 (M+H)+. Example 276 3-(lH-indol-5-yl)thieno[3,2-c]pyridin-4-amine The desired product was prepared by substituting lH-indol-5-ylboronic acid and Example IB for 4-chlorophenylboronic acid and Example 2 IB, respectively, in Example 21C.1H NMR (300 MHz, DMSO-d6) δ 5.37 (s, 2H), 6.50 (ddd, J=3.0, 2.0,1.0 Hz, 1H), 7.13 (dd, J=8.5,1.7 Hz, 1H), 7.24 (d, J=5.4 Hz, 1H), 7.38 (s, 1H), 7.45-7.46 (m, 1H), 7.52 (dt, J-8.5, 1.0 Hz, 1H), 7.60-7.61 (m, 1H), 7.81 (d, >6.1 Hz, 1H), 11.31 (s, 1H), MS (ESI(+)) m/e 265.9 (M+H)+. Example 277 N-{4-{4-amino-7-(hydroxymethy])thieno['3,2-c]pyridin-3-yl]phenyl)-N'-(3- methylphenyQurea Example 277A 3-(4-bromo-2-thienyl)-2-butenoicacid A solution of ethyl (diethoxyphosphino)acetate (34 mL, 171 mmol) in THF (35 mL) was added dropwise via addition funnel, over 20 minutes, to a 0 °C suspension of NaH (6.9g, 60% oil dispersion, 172 mmoI)'in THF (200 mL). The resulting mixture was stirred at 0 °C for 30 minutes, then treated with asolution of l-(4-bromo-2-thienyl)ethanone (23.6g, 115 mmol) in THF (75 mL). The reaction was warmed to room temperature, stirred for 4 hours, quenched with water, neutralized with 2N HC1, and extracted three times with ethyl acetate. The combined extracts were washed with brine, dried (NajSOJ, filtered, and concentrated. The concentrate was dissolved in ethanol (350 mL) and THF (190 mL), treated with" 2N LiOH (115 mL), stirred overnight at room temperature, and concentrated. The remaining aqueous solution was washed with diethyl ether, acidified with 2N HCI, and filtered. The filter cake was washed with water and dried to provide 22.38 g (79% yield) of the desired product as a mixture of E and Z isomers. MS (ESI(+)) m/e 244.7, 246.7 (M+H)+. -132- WO 2005/010009 PCT/US2004/024003 Example 277B 3-bromo-7-methylthieno[3I2-clpyridiri--4(5H)-one The desired product was prepared by substituting Example 277A for (2E)-3-(4-bromo-2'-tnienyl)acrylic acid in Example 1 A. MS (ESI(+)) m/e 244, 246 (M+H)+. Example 277C 3-bromo-4-chloro-7-methylthieno[3,2-c]pyridine A solution of Example 277B (10,25g, 42.1 mmol) in POCl3 (50 mL) was stirred at reflux for 2 hours, cooled to room temperature, diluted with ice water, and stirred vigorously resulting in a precipitate which was collected by filtration. The filter cake was further purified by silica gel chromatography on silica gel with dichloromethane to provide 7.14g (64% yield) of the desired product. MS (ESI(+)) m/e 261.9, 263.9 (M+H)+ Example 277D (3-bromo-4-chlorothieno[3,2-c]pyridm-7-yl)methyl acetate A solution of Example 277C (lg5 3.81 mmol) in CC14 (30 mL) was treated with NBS (0.755g, 4.24 mmol) and benzoyl peroxide (0.093g, 0.3S mmol), heated to reflux for 24 hours, cooled to room temperature, and filtered. The filtrate was concentrated to provide 3- bromo-7-(bromomethyl)-4-chlorothieno[3,2-c]pyridineJ which was used directly. MS (ESI(+)) m/e 339.5, 341.6, 343.4 (M+H)+. The crude product was dissolved in DMF (7.5 mL), treated with sodium acetate (1.6g, 19.5 mmol), heated to 100 °C overnight, and partitioned between water and ethyl acetate. The organic extract was washed with brine, dried (Na2S04), filtered, and concentrated. The residue was purified by silica gel chromatography with 10% ethyl acetate/hexanes to provideO.65 g (53% yield) of the desired product. MS (ESI(+)) m/e 319.7, 321.7, 323.7 (M+H)+. Example 277E (4-amino-3 -bromothieno \3,2-c]pyridin-7-yl)methanol A mixture of Example 277D (3.1g, 9.7 mmol), concentrated NH4OH (62 mL), and dioxane (62 mL) was heated to 150 °C in a sealed tube for 36 hours, filtered, and concentrated to provide a soid which was triturated with water (20 mL), collected and dried to give 2.1g (84% yield) of the desired product. MS (ESI(+)) m/e 258.9, 260.8 (M+H)+. Example 277F N-{4-[4-ammo-7-(hydroxvmethyl)thieno[3,2-c]pvridin-3--vl]phenyl}-N'-(3- methylphenyl)'urea -133- WO 2005/010009 PCT/US2004/024003 The desired product was prepared by substituting Example 277E and Example 66D for Example IB and 4-phenoxyphenylboronic acid respectively, in Example 10A. 1H NMR (300 MHz, DMSO-d,) δ 2.29 (s, 3H), 4.61 (d, J=5.4 Hz, 2H), 5.15 (t, J=5.3 Hz, 1H), 5.37 (s, 2H), 6.80 (d, J=7.5 Hz, 1H), 7.17 (t, 3=7.6 Hz,' 1H), 7.25 (d, J-8.8 Hz, 1H), 7.32 (s, 1H), 7.36 (d, J=8.5 Hz, 2H), 7.44 (s, 1H), 7.60 (d, J=8.5 Hz, 2H), 7.75 (s, 1H), 8.67 (s, 1H), 8.87 (s, 1H).. MS (ESI(+)) ni/e 405.1 (M+H)+. Example 278 N-{4-(4-amino-7-(4-morpholiiwbiethyl)thieno[3,2-c]pyTidiri-3-yl]phenyl)-N'-(3- methylphenyflurea Example 27SA 4-amino-3-bromothieno[3,2-c]pyridine-7-carbaldehyde A solution of Example 277E (lg, 3.86 mmol) in THF (100 mL) was treated with MnO, (2.66g, 42.1 mmol), stirred overnight at room temperature, and filtered through diatomaceous earth (Celite®). The pad was washed with THF and dichloromethane and the combined filtrates were concentrated to provide O.SSg (89% yield ) of the desired product. MS (ESI(+)) m/e 256.8,25S.S (M-KHf. Example 278B 3-bromo-7-(4-morpholinylmemyl)thieno[3,2-c]pyridm-4-amine A solution of Example 27SA (0.048g, 0.187 mmol) in THF (15 mL) and dichloromethane (15 mL) was treated with acetic acid (0.012 mL, 0.21 mmol), morpholine (0.02 mL, 0.23 mmol), and sodium tnacetoxyborohydride (0.063g, 0.3 mmol), stirred at room temperature overnight, treated with additional morpholine (0.08 mL), acetic acid (0.05 mL) and sodium tnacetoxyborohydride (0.23g), and stirred an additional 8 hours. The reaction was quenched with IN NaOH and extracted three times with ethyl acetate. The combined organic extracts were dried (Na SC),,), filtered, and concentrated and the residue was purified by preparative HPLC on a Waters Symmetry C8 column (25mm x 100mm, 7pm particle size) using a gradient of 10% to 90% acetonitrile: 0.1% aqueous TFA over 30 minutes to provide 0.045 g (55% yield) of the desired product MS (ESI(+)) m/e 327.9, 329.8 (M+H)+. Example 278C N-{4-[4-amino-7-(4-morpholinyJmethyl)thieno[3,2-c]pvridin-3-yl]phenyl|--N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 278B and Example 66D for Example IB and 4-phenoxyphenylboronic acid respectively, in Example 10A. -134- WO 2005/010009 PCT/TJS2004/024003 1H NMR (300 MHz, DMSO-d ) δ 2.29 (s, 3H)S 2.37-2.40 (m, 4H), 3.56-3.63 (m, 6H), 5.36 (s, 2H), 6.80 (d, J=7.8 Hz, 1H), 7.14-7.19 (m, 1H), 7.24-7.27 (ms 1H), 7.31 (s, 1H), 7.36 (d, J-8.5 Hz, 2H), 7.40 (s, 1H), 7.58 (d, J=8.8 Hz, 2H), 7.70 (s, 1H), 8.66 (sf 1H), 8.84 (s, 1H); MS (ESI(+)) m/e 474.1 (M+H)+, Example 279 . N-(4-{4-amino-7-[(3-oxQ-l-piperazinyl)memyl]thieno[3,2-c]pvridin-3-vl)phenvl)-N'-(3- methylphenyl)urea The desired product was prepared substituting piperazin-2-one for moipholine in Examples 278B-C. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (s, 3H), 2.58 (t, J=5.1 Hz, 2H), 2.95 (s, 2H), 3.13-3.20 (ni, 2H), 3.67 (s, 2H), 5.40 (s, 2H), 6.80 (d, J-7.5 Hz, 1H), 7.17 (t, J=7.8 Hz, 1H), 7.25 (d, J=8.1 Hz, 1H), 7.31 (s, 1H), 7.37 (d, J=8.5 Hz, 2H), 7.40 (s, 1H), 7.59 (d, J=8.5 Hz, 2H), 7.72 (s, 1H), 7.77 (s, 1H), 8.68 (s, 1H), 8.86 (s, 1H); MS (ESI(+)) m/e 487.1 (M+H)+. Example 280 N-[4-(4-amino-7-{[(2-methoxyemyl)ammo]methyl)thieno[3,2-c]pyridin-3-yl)plienyl]-N,-(3- methylphenyl)urea The desired product was prepared substituting 2-methoxyethylamine for morpholine in Examples 278B-C. lH NMR (300 MHz, DMSO-ds) δ 2.29 (s, 3H), 2.65 (t, J=5.6 Hz, 2H), 3.25 (s, 3H), 3.42 (t, J=5.6 Hz, 2H), 3.86 (s, 2H), 5.31 (s, 2H), 6.80 (d, J=7.6 Hz, 1H), 7.17 (t, J=7.6 Hz, 1H), 7.25 (d, J=8.5 Hz, 1H), 7.31 (s, 1H), 7.36 (d, J=8.5 Hz, 2H), 7.40 (s, 1H), 7.59 (d, J=8.8 Hz, 2H), 7.73 (s, 1H), 8.65 (s, 1H), S.84 (s, 1H); MS (ESI(+)) m/e 462.1 (M+H)+. Example 281 N- (4- R4-amino-7-(6-methoxy-3-pyridmyl)thieno [3,2-c]pyridin-3 -yl]-2-methoxyphenyl) -1 - methyl-1 H-indole-2-carboxamide A mixture of Example 215 (1.0 eq) in 1,2-dimethoxyethane (10 mL) and water (5 mL) was reacted with N-[2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl]-l-30 methyl-lH-indole-2-carboxamide (1.2 eq), NajC03 (2.4 eq), and Pd(PPh3)4 (0.06 eq) at 95 °C , for 18 hours. The organic solvent was removed in vacuo and the the mixture was extracted with dichloromethane. The extract was dried (MgSOJ, filtered, and concentrated. The residue was purified by preparative reverse phase HPLC (Rainin CIS, S nun, 300-. A, 25 cm; 40% acetonitrile/0.lM ammonium acetate isocratic for 5 minutes, then 40-100% acetonitrile/0.lM ammonium acetate over 30 minutes, 21 mL/min). The acetonitrile was . removed in vacuo and the aqueous mixture was lyophilized to provide the desired product. 1HNMR (DMSO-d,, 400MHz) δ 9.52 (s, 1H), 8.45 (s, 1H), 8.02 (t, 1H), 7.91 (s, 1H), 7.71 (d, 1H), 7.55-7.63 (m, 2H), 7.2S-7.38 (m, 2H), 7.23 (s, 1H), 7.08-7.18 (m, 2H), 7.03 (d, 1H), -135- WO 2005/010009 PCT/US2004/024003 5.57-5.69 (br s, 2H); 4.'04{sr;3H), 3.93 (s, 3H), 3.92 (s, 3H); reverse phase HPLC (Delta Pak, C18, 5 urn, 300 A, 15 cm; 50%-100% acetonitrile/O.lM ammonium acetate over 10 min, lmL/min) R,=9.30 min.; MS m/e 536 (M+H)+ Example 282 N-{4-[4-ammo-7-(3-tm nvI)thieno[3,2-c]pvridm-3-vl]-2-memoxyphenyl)-l-rnethyl-lH-- indole-2-carboxamide A mixture of Example 213 (1.0 eq) in 1,2-dimethoxyethane (10 mL) and water (5 mL) 10 was reacted with Example 175E (1.2 eq), Na COj (2.4 eq), and Pd(PPh3)4 (0.06 eq) at 95 °C for IS hours. The organic solvent was removed in vacuo and the the mixture was extracted with dichloromethane. The extract was dried (MgS04), filtered, and concentrated. The residue was purified by preparative reverse phase HPLC (Rainin CIS, 8 mm, 300 A, cm; 40%.acetonitrile/0.1M ammonium acetate isocratic for 5 minutes, then 40-100% 15 acetonitrile/0.1M ammonium acetate over 30 minutes, 21 mL/min). The acetonitrile was removed in vacuo and the aqueous mixture was lyophilized to provide the desired product. 1H NMR (DMSO-d6, 400MHz) 6 9.52 (s, IH), 8.11 (s, IH), 8.01 (t, IH), 7.80-7.85 (m, IH), 7.72-7.77 (m, IH), 7.70 (d, IH), 7.62 (s, IH), 7.55-7.61 (m, 2H), 7.29-7.36 (m, 2H), 7.22 (d, IH), 7.07-7.17 (m, 2H), 5.56-5.67 (brs, 2H), 4.04 (s, 3H), 3.92 (s, 3H); RP-HPLC (Delta Pak 20 C18, 5 um, 300 A, 15 cm; 50%-100%, acetonitrile/0.1M ammonium acetate over 10 min, 1 mL/min) R, =1.82 min.; MS m/e 511 (M+H)+. Example 283 N-{4-[4-ammo-7-(24hienyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl}-l-methyl-lH- indoIe-2-carboxamide A mixture of Example 214 (1.0 eq) in 1,2-dimethoxyethane (10 mL) and water (5 mL) was reacted with Example 175E (1.2 eq), NajCOj (2.4 eq), and Pd(PPh3)4 (0.06 eq) at 95 °C for 18 hours. The organic solvent was removed in vacuo and the the mixture was extracted with dichloromethane. The extract was dried (MgSO„), filtered, and concentrated. The residue was purified by preparative reverse phase HPLC (Rainin Cl 8, 8 mm, 300 A, 25 cm; 40% acetonitrile/0.1M ammonium acetate isocratic for 5 minutes, then 40-100% acetonitrile/O.lM ammonium acetate over 30 minutes, 21 mL/min). The acetonitrile was removed in vacuo and the aqueous mixture was lyophilized to provide the desired product. 1H NMR (DMSO-d6,400MHz) δ 9.51 (s, IH), 8.12 (s, IH), 8.02 (t, IH), 7.70 (d, IH), 7.65 (s, IH), 7.61 (dd, IH), 7.59 (d, IH), 7.49 (dd, IH), .7.30-7.37 (m, 2H), 7.21-7.26 (m, 2H), 7.15 (t, IH), 7.11 (dd, IH), 5.68-5.77 (br s, 2H), 4.04 (s, 3H), 3.92 (s, 3H); reverse phase HPLC (Delta Pak CIS, 5 um, 300 A, 15 cm; 50%-100% acetonitrile/O.lM ammonium acetate over 10 min, lmL/min) R-9.61 min.; MS m/e 511 (M+H)+. -136- WO 2005/010009 PCT/US2004/024003 Example 2 84 N-{4-[4-amino-7-(lH-indol-5-yl)thieno[3,2-c]pvridin-3-vIlphenvl]-N'-[2-fluoro-5- (trifluoromethylphenyl]urea 5 Example 284A 3-(4-aminophenyl)-7-(lH-indol-5-yl)thieno[3,2-c]pyridin-4-amine The desired product was prepared by substituting Example 77B and lH-indol-5-ylboronic acid for Example 77A and 4-pyridylboronic acid, respectively, in Example 121A. MS (ESI(+)) m/e 357 (M+H)+. Example 284B N-R4-[4-ammo-7-(lH4ndol-5-yl)tlueno[3,2-c]pyridm-3-vl]phenvl-N'-[2-fluoro-5- (trifluorornethyl)phenyl]urea The desired product was prepared by substituting Example 284A for Example 121B in Example 122. 1H NMR (300 MHz, DMSO-d δ 5.43 (s, 2H), 6.51 (s, IH), 7.37-7.39 (m, IH), 7.42-7.44 (m, 3H), 7.47-7.50 (m, 2H), 7.53-7.55 (m, 2H), 7.64 (d, J=S.4S Hz, 2H), 7.80 (d, J-1.70 Hz, IH), 7.S9 (s5 IH), 8.65 (dd, J=7.29, 2.20 Hz, IH), 8.9S (d, J=3.05 Hz, IH), 9.39 (s, IH), 11.22 (s, IH); MS (ESI(+)) m/e 562 (M+H)+. Example 285 N-{4-[4-amino-7-(lH-mdol-5-yl)thieno[3,2-c]p pyridm-3-vl]phenvl-N'-[2-fluoro-5- The desired product was prepared by substituting Example 284A and l-isocyanato-3-methylbenzene for Example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene, respectively in Example 122. JH NMR (300 MHz, DMSO-d6) 8 2.29 (s, 3H), 5.42 (s, 2H), 6.51 (s, IH), 6.81 (d, J=7.12 Hz, IH), 7.17 (t, J=7.63 Hz, IH), 7.26-7.28 (m, IH), 7.32 (s, IH), 7.36 (dd, J=8.31,1.87 Hz, IH), 7.41-7.43 (m, 3H), 7.45 (s, IH), 7.53 (d, J=8.14 Hz, IH), 7.62 (d, J=8.82 Hz, 2H), 7.79 (d, J=1.36 Hz, IH), 7.88 (s, IH), 8.66 (s, IH), 8.86 (s, IH), .11.21 (s, IH); MS (ESI(+)) m/e 490 (M+H)+. Examples 286-288 were prepared by substituting the appropriate boronic acid (X) for 4-chloro-phenylboronic acid in Example 21C. Example 286 (2E)-3-[4-ammo-3-(lH-mdol-6-vl)thieno[3,2-c]pyridm-7-yl]-N-memvlacrvlamide X= lH-indol-6-ylboronic acid, 1H NMR (300 MHz, DMSO-d6) δ 2.74 (d, J=4.4 Hz, 3H), 5.84 (s, 2H), 6.53-6.55 (m, IH), 6.59 (d, J=15.9 Hz, IH), 7.07 (dd, J=8.1,1.4 Hz, IH), -137- WO 2005/010009 PCT/US2004/024003 7.45-7.48 (m, 2H), 7.59 (d, J=15.9Hz, 1H), 7.62 (s, 1H), 7.69 (d, J=8.1 Hz, 1H), 8.11 (s, 1H)> 8.16 (q, J=4.4Hz, 1H), 11.32 (s, 1H); MS (ESI(+)) m/e 349.0 (M+H)+. Example 287 (2E)-3-[4-animo-3-(l-memyl-lH-indo]-6-yl) thieno[3,2-c]pyridm-7-yl]-N-memvlacrvlamide X= l-methyHH-indol-6-ylboronic acid. 1H NMR (300 MHz, DMSO-dg) δ 2.74 (d, J-4.4 Hz, 3H), 3.87 (s, 3H), 5.81 (s, 2H), 6.51 (dd, J=3.4, 0.7 Hz, 1H), 6.58 (d, J=15.9 Hz, 1H), 7.22 (dd, J=8.1,1.7 Hz, 1H), 7.46 (d, J=3.4 Hz, 1H), 7.56-7.64 (m, 4H), 8.10 (s, 1H), 8.15 (q, J=4.4 Hz, 1H); MS (ESI(+)) m/e 363.0 (M+H)+. Example 288 (2E)-3-[4-ammo-3-(2-memyl-lH-mdol-5-yl) thieno[3,2-c]pyridm-7-yl]-N-memvlacrvlamide X= 2-methyl-lH-indol-5-ylboromc acid. 1H NMR (300 MHz, DMSO-d6) δ 2.42 (s, 3H), 2.73 (d, J=4.4 Hz, 3H), 5.82 (s, 2H), 6.20 (s, 1H), 6.58 (d, J-15.9 Hz, 1H), 7.05 (dd, 15 J=8.5,1.7 Hz, 1H), 7.41 (d, J=8.5 Hz, 1H), 7.47 (d, J=1.4 Hz, 1H), 7.56 (s, 1H), 7.58 (d, J=15.9 Hz, 1H), S.09 (s, 1H), 8.15 (q, J=4.4 Hz, 1H), 11.17 (s, 1H); MS (ESI(+)) m/e 463.0 (M+H)+. Example 289 4-(R4-amino-3-(lH-mdol-5-yl)thieno[3,2-c]pyridin-7-yl]methyl}-2-piperazinone The desired product was prepared by substituting piperazin-2-one for morpholine in Example 27SB, then substituting the product for Example 21B in Example 29. 1H NMR (300 MHz, DMSO-d6) δ 2.63 (t, J=5.3 Hz, 2H), 2.98 (s, 2H), 3.17-3.22 (m, 2H), 3.71 (s, 2H), 5.82 (s, 2H), 6.51 (m, 1H), 7.15 (dd, J=8.5,1.7 Hz, 1H), 7.46-7.47 (m, 1H), 7.51 (s, 1H), 7.53 (d, 25 J=8.5 Hz, 1H), 7.63 (s, 1H), 7.74-7.79 (m, 2H), 11.33 (s, 1H); MS (ESI(+)) m/e 378.1 (M+H)+. Example 290 N-(4-(4-ammo-7-[(3-oxo-]-pipe:razmyl)memyl] thieno[3,2-c]pyridm-7-yl]-N-methevl]acrvlamide (trifluoromethyl)phenyl]urea The desired product was prepared substituting piperazin-2-one for morpholine in Example 278B, then substituting the product and N-R4,-(4J4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl]-N'-[3-(trifluoromethyl)phenyl]urea for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1H NMR (300 MHz, DMSO-d6) δ 2.57-2.60 (m, 2H), 2.95 (s, 2H), 3.15-3.19 (m, 2H), 3.67 (s, 2H), 5.40 (s, 2H), 7.32 (d, J=7.8 Hz, 1H), 7.39 (d, J=8.5 Hz, 2H), 7.41 (s, 1H), 7.53 (t, J=8.0 Hz, 1H), 7.58-7.63 (m, 3H), 7.72 (s, 1H), 7.77 (s, 1H), 8.03 (s, 1H), 9.00 (s, 1H), 9.13 (s, 1H); MS (ESI(f)) m/e 541.1 (M+H)+ -138- WO 2005/010009 PCT/US2004/024003 Example 291 (2E)-3-[4-amino-3-(lH-indol-5-vl)thieno[3,2-c]pyridin-7-yl]-N-(4-pyridmytoiethypacrylamide Example 291A (2E)-3-(4-amino-3-bromothieno[3,2-c]pyridin-7-yl)acryhc acid The desired product was prepared substituting Example IB for Example 10A in Example 10B, then substituting the product for Example 10B in Examples 11A-B. MS (ESI(+)) m/e 298.8, 300.8 (M+H)+. Example 291B (2E)-3-[4-amino-3-(lH-uidol-5-vnthieno[3,2-c]pvridin-7-yl]-N-(4-pyridinylmethyl)acrylamide The desired product was prepared substituting Example 291A for Example 78 in Example 90, then substituting the product for Example 21B in Example 29. 1H NMR (300 MHz, DMSO-d6) 5 4.46 (d, J=6.0 Hz, 2H), 5.87 (s, 2H), 6.51-6.53 (m, IH), 6.70 (d, J=15.9 Hz, IH), 7.16 (dd, 1=8-1,1.7 Hz, IH), 7.32 (d, J=5.8 Hz, 2H), 7.47-7.49 (m, IH), 7.55 (d, J=8.5 Hz, IH), 7.60 (s, IH), 7.65 (m, 2H), 8.13 (s, IH), 8.52{d, J=5.8 Hz, 2H), 8.83 (t, J=6.0 Hz, IH), 11.35 (s, IH). Example 292 (2E)-3-K-armno-3-(lH-mdol-5-vl)thieno[3a-clpvridm-7-yl]-N-[3-(lH-irnidazol-l- yppropyl] acrylamide The desired product was prepared substituting Example 291A for Example 78 in Example 96, then substituting the product for Example 21B in Example 29. 1H NMR (300 MHz, DMSO-d6) 6 1.88-1.97 (m, 2H), 3.15-3.21 (m, 2H), 4.03 (t, J-7.0 Hz, 2H), 5.83 (s, 2H), 6.52 (m, IH), 6.60 (d, J=15.9 Hz, IH), 6.90 (t, J-1.0 Hz, IH), 7.16 (dd, J=8,5,1.7 Hz, IH), 7.22 (t, J=1.2 Hz, IH), 7.46-7.48 (m, IH), 7.55 (d, J=8.5 Hz, IH), 7.59 (s, IH), 7.61 (d, J=15.9 Hz, IH), 7.63-7.64 (m, IH), 7.67 (s, IH), 8.11 (s, IH), 8.29 (t, J=5.6 Hz, IH), 11.34 30 (s, IH); MS (ESI(+)) m/e 443,1 (M+H)+. Example 293 (2E)-3-[4-amino-3-(lH-indol-5-vnthieno[3,2-c]pyridin-7-yl]-N-[2- (diethylamino)ethyn acrylamide The desired product was prepared by substituting Example 291A for Example 78 in Example 86, then substituting the product for Example 21B in Example 29. 1H NMR (300 MHz, DMSO-d6) 5 0.98 (t, J=7.0 Hz, 6H), 2.48-2.55 (m, 6H), 3.23-3.29 (m, 2H), 5.81 (s, 2H), 6.51-6.52 (m, IH), 6.61 (d, J=15.6 Hz, IH), 7.15 (dd, J=8.1,1.7 Hz, IH), 7.46-7.48 (m, -139- WO 2005/010009 PCI7US2004/024003 1H), 7.54 (d, J=8.1 Hz, IH), 7.58 (d, J=15.6 Hz, IH), 7.58 (s, IH), 7.63-7.64 (m, IH), 8.10 1H), 8.13 ft J=5.4Hz, IH), 11.34 (s, IH); MS (ESI(+)) m/e 434.1 (M+H)+. Example 294 N-[4-(4-ammo-7-iodottono[3,2-c]pvridin -3 phenvl-N'-[2-fluoro-5- (trifluorornethyl)phenyl]urea carboxamide Example 294A tert-butvtyl 4-(4-aminofcieno[3,2-c]pvridin-3-vl)-2-methoxvphenylcarbamate A solution of Example IB (l.Og, 4.365 mmol) in ethyleneglycol dimethyl ether (20 mL) was treated with tert-butyl 2-methoxy-4-(4,4,5,5-tetramethyl-l,3 -dioxaborolan-2-yl)phenylcarbamate (1.83g, 5.238 mmol), Pd(PPh3)4 (0.303g, 0.262 mmol), and a solution of sodium carbonate (1.1 lg, 10.473 mmol) in water (10 mL), stirred at 85 °C for 16 hours under nitrogen, concentrated, and treated with dichloromethane. The organic layer was dried (MgSOJ, filtered, and concentrated. The concentrate was purified by flash column chromatography on silica gel with 100% ethyl acetate to provide 1.62g (100%) of the desired product. !H NMR (DMSO-d6,400 MHz) 6 8.1 (s, IH), 7.8 (m, 2H), 7.41 (s, IH), 7.2 (m, IH), 7.1 (s, IH), 7-6.95 (m, IH), 3.8 (s, 3H), 1.458 (s, 9H); LCMS (Thermoquest AQA 1 single-quad MS, Genesis CI 8 column, 3 urn particle size, 33 x 4.6mm; 70% 50 mM ammonium acetate in water to 95% acetonitrile over 6 min, 0.8 to 0.5 mL/min) 1 =3.73 min (95%), MS m/e 372.2 (M+H)+. Example 294B tert-butyl 4-(4-ammo-7-iodo thieno[3,2-c]pyridin-3-yl)-2-methoxyphenylcarbamate A solution of Example 294A (1.49g, 4.01 mmol) in dimethylformamide (20 mL) was treated portionwise with N-iodosuccinimide (1.083g, 4.813 mmol), stirred at room temperature for 2 hours, treated with saturated sodium thiosulfate, stirred for 30 minutes, and filtered. The filter cake was washed with water and dried in a vacuum oven to provide 1.884g (94%) ofthe desired product. 1H NMR (DMSO-d6, 400 MHz) 8 8.111 (s, IH), 8.018 (s, IH), 7.8 (m, IH), 7.566 (s, IH), 7.086-7.082 (m, IH), 7.0 (m, IH), 5.6 (s, 2H), 3.841 (s, 3H), 1.478 (s, 9H); LCMS (Thermoquest AQA single-quad MS, Genesis CIS column, 3um particle size, 33 x 4.6mm; 70% 50 mM ammonium acetate in water to 95% acetonitrile over 6 min, O.S to 0.5 mL/min) 1 =4.42 min (95%), MS m/e 498.2 (M+H)+. Example 294C 3-(4-animo-3-memoxyphenvI)-7-iodomieno[3,2-c]pyridm-4-amine A solution of Example 294B (S.641g, 17.374 mmol) in dichloromethane (100 mL) at 0 °C was treated dropwise with trifluoroacetic acid (30 mL) in dichloromethane (20 mL), -140- WO 2005/010009 PCT/US2004/024003 stirred at 0 °C for 1 hour and at room temperature for 3 hours, concentrated, and dried under high vacuum. The residue was treated with dichloromethane and 6N HC1. The layers were partitioned and the organic layer was extracted with 6N HCI. The combined aqueous layers were cooled to 0 °C. The aqueous layer was basified to pH 11 and the resulting precipitate was collected by filtration to provide 4.787g of the desired product. The filtrate was extracted three times with ethyl acetate and the combined extracts were dried (MgSOJ, filtered, and concentrated to provide 2.41g of additional product. 1H NMR (DMSO-d6, 400 MHz) 8 8.1 (s, 1H), 7.67 (s, 1H), 6.93 (s, 1H), 6.8 (s, 2H), 6.5 (s, 2H), 3.8 (s, 3H); LCMS (Thermoquest AQA single-quad MS, Genesis CIS column, 3jam particle size, 33 x 4.6mm; 70% 50 mM ammonium acetate in water to 95% acetonitrile over 6 min, 0.8 to 0.5 mL/rnin) R,=3.25 min (95%), MS m/e 398.0 (M+H)+. Example 294D l-methyl-lH-indole-2-carbonyl chloride A suspension of l-methyl-lH-2-indolecarboxylic acid (0.4S5g, 2.769 mrnol) in dichloromethane (10 mL) at 0 °C was treated with oxalyl chloride (0.369g, 2.91 mrnol) and one drop of dimethyl formamide. The reaction mixture was stirred at 0 °C for 1 hour and at room temperature for 2 hours. The solvent was removed under reduced pressure and dried on the high vacuum for 1 hour. The residue was used directly in the subsequent reaction without 20 further purification or analysis. Example 294E N-[4-(4-ammo-7-iodo thieno[3,2-c]pyridui-3-yl)-2-methoxyphenyl]-l-methyl-lH-indoIe-2- carboxamide A solution of Example 294C (l.Og, 2.517 mrnol) in pyridine (10 mL) at 0 °C was treated dropwise with a solution of Example 294D (0.536g, 2.769 mrnol) in dichloromethane (5 mL), stirred at 0 °C for 1 hour and at room temperature for 2 hours, treated with IN NaOH, stirred for 15 minutes, and concentrated. Dichloromethane was added and the layers were partitioned. The aqueous layer was extracted with dichloromethane. The combined organic layers were washed with water, dried (MgSOJ, filtered, and concentrated. The solid was dried on the high vacuum to remove residual pyridine to provide 0.906g (65%) of the desired product. 1H NMR (DMSO-d6,400 MHz) δ 9.5 (s, 1H), 8.042-7.993 (m, 2H), 7.72-7.70 (m, 1H), 7..641-7.637 (m, 1H), 7.602-7.581 (m, 1H), 7.337-7.317 (m, 2H), 7.212 (m, 1H), 7.174-7.136 (m, 1H), 7.095-7.075 (m, 1H), 5.673 (s, 2H), 4.043 (s, 3H), 3.916 (s, 3H); LCMS (Thennoquest AQA single-quad MS, Genesis CIS column, 3um particle size, 33 x 4.6mm; 70% 50 mM ammonium acetate in water to 95% acetonitrile over 6 min, 0.8 to 0.5 rnL/min) R=4.33 min (95%), MS m/e 553.11 (M-H)+ -141- WO 2005/010009 PCT/US2004/024003 General Procedure for Sonogashira Couplings A Milestone® microwave tube was charged with Example 294E (0.050g to 0.065g, -0.09 mmol), the appropriately fiinctionalized alkyne (0.27 mmol), Pd(PPh3)4 (0.005g, 0.0045 mmol), cuprous iodide (O.OOlg, 0.0045 mmol), and piperidine (3 mL). The reaction mixture was stirred at 85 °C under Milestone® microwave conditions for 5 minutes and concentrated. The concentrate was purified by flash chromatography on silica gel or by preparative HPLC. LCMS (Thermoquest AQA single-quad MS, Genesis C18 column, 3|im particle size, 33 x 4.6mm; 70% 50 mM ammonium acetate in water to 95% acetonitrile over 6 min, 0.8 to 0.5 mL/min). The following compounds were prepared following this procedure using the indicated alkyne. Example tonal Product Starting Alkyne Amt. (mg) (Yield%) US m/z 29b N-{4-|4-amino-'/- (phenylethynyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl}-l-methyl-lH-indole-2-carboxamide ethynylbenzene 11(23%) 529.4 296 s JM-{4-L4-ammo-7-(3-ammo-3-memyl-l-butynyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl}-l-methyl-lH-indole-2-carboxamide l,l-dimethyl-2-propynylamine 18(30%) 510.4 -142- WO 2005/010009 PCT/US 2004/0 24003 "297 " N -(4- {4-amino- 7-[i-(dimethylaminoJ-1 -propynyl]thieno[3,2-c]pyridin-3-yl}-2-methoxyphenyl)-l-methyMH-indole-2-carboxaraide N,N-dimethyl-N-2-propynylamine 17(28%) 510.4 298 N-{4-L4-amino-7-(3-iiydroxy-3-metiiyl-l-butynyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl} -1 -methyl-1 H-indole-2-carboxamide 2-methyl-3-butyn-2-ol "27 (45%) 511.4 299 N-{4-|4-amino-7-(2- pyridinylethynyl)thieno[3)'2-c]pyridin-3-yl]-2-methoxyphenyl}-l-methyl-lH-indole-2-carboxamide 2-ethynylpyndme T6 (27%) 530.4' 300 N-{4-[4-amino-7-(3-methoxy-l-propynyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl}-l-methyl-lH-indole-2-carboxamide 3-methoxy-l-propyne 21 (36%) 497.4 301 N-{4-[4-amino-7-(i>-hydroxy-l-pentynyl)thieno[3J2-c]pyridin-3-yl]-2-methoxyphenyl} -1 -methyl-1 H-indole-2- ■ carboxamide 4-pentyn-l-ol 22 (37%) 511.4 -143- WO 2005/010009 PCT/US2004/02400J 302' N-(4-{4-ammo-7-L(l- ■ •'• aminocyclohexy])ethynyl]thieno[3,2-c]pyridm-3-yl}-2-methoxyphenyl)-l-methyl- lH-indole-2-carboxamide 1- .-.," ethynylcyclohexana mine 36 (}&%) 533.5 303 5-l4-amino-3-(3-metIioxy-4-{[(l-methyl-lH-indol-2- yl)carbonyl]ammo}phenyl)thieno[3,2-c]pyridin-7-yl]-4-pentynoic acid 4-pentynoic acid 12 (20%) 525.3 -304 N- {4-|4-ammo-/-(4-hydroxy-1 -butynyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl} -1 -methyl-1 H-indole-2-carboxamide 3-butyn-I-ol 10(17%) 497.4 305 N-(4-{4-ammo-/-[3-(methylamino)-l-propynyl]thieno[3)2-c]pyridin-3-yl}-2-methoxyphenyl)-1 -methyl-1 H-indoIe-2-carboxamide M-methyl-N>2-propynylamine 3 (<1%) 49b.b 306 N-(4-{4-ammo-7-[3-(diethylamino)-l-propynyl]thieno[3,2-c]pyridin-3-yl}-2-methoxyphenyl)-l-methyl-lH-indole-2-carboxamide N M-diethyl-N-2-propynylamine 34 (64%) 53S.6 " 307 N- {4-|4-amino- /-(3-hydroxy-1-3ropynyl)thieno[3,2-c]pyridin-3-yl]-2-metiioxyphenyl}-l-methyl-lH-indole-2-carboxamide (acetate salt) 2-propyn-l-ol 15 (27%) 483.4 -1-[4- WO 2005/010009 PCT/US2004/0 24003 "" 308 tert-butyl -ainmo-J- -methoxy -IKl- tert-butyl 2- ■ 100 - 5B2:5- methyl-lH-indol - yl)carbonyl]amino}phenyl)thieno[3,2- c]pyridin-7-yl]-2-propynylcarbamate propynylcarb amate (95%) 309 tert-butyl S-llA-airuno- i-methoxy -tKl-methyl-lH-indoW-yl)carbonyl]amino}phenyl)tbieno[3,2-c]pyridin-7-yl]ethynyl} -2-pyridinylcarbamate tert-butyl 5- ethynyl-2- pyridinylcarbamate 93 (yl%) 645.6 Example 310 N-{4-[4-amino-7-(3-amino-l-propynyl)theno[3,2-c]pyridiD-3-vl]-2-methoxyphenyU--l- methyl-lH-indole-2-carboxamide A solution of Example 308 (0.095g, 0.163 mmol) in dichloromethane (10 mL) at 0 °C was treated with a solution of trifluoroacetic acid (4 mL) in dichloromethane (5 mL). The reaction mixture was stirred at 0 °C for 35 minutes and at room temperature for 15 hours. The solvent was removed under reduced pressure and the residue was dried under high vacuum. Ethyl acetate and 5N NaOH were added. The layers were partitioned and the organic layer 10 was washed with NaOH, dried (MgS04), filtered and concentrated to provide 0.039g (49%) of the desired product. lH NMR (DMSO-d6, 400 MHz) δ 9.518 (s, 1H), 8.015-7.995 (m, 2H), 7.719-7.699 (m, 1H),-7.632-7.581 (m, 2H), 7.352-7.314 (m, 2H), 7.213 (m, 1H), 7.172-7.15 (m, 1H), 7.134-7.076 (m, 1H), 5.85 (br s, 2H), 4.038 (s, 3H), 3.915 (s, 3H), 3.681 (s, 2H); LCMS (Thermoquest AQA single-quad MS, Genesis C18 column, 3y.m particle size, 33 x 15 4.6mm; 70% 50 mM ammonium acetate in water to 95% acetonitrile over 6 min, 0.8 to 0.5 mL/min) R=3.12 min (100%), MS m/e 482.5 (M+H)+. Example 31-1 N-(4-[4-amino-7-[(6-ammo-3-pvridinyl)emwvnthieno[3,2-c]pyridin-3-vU-2- methoxyphenyl)-l-methyl-lH-uidole-2-carboxamide A.solution of Example 309 (O.OSOg, 0.12 mmol) in dichloromethane (5 mL) at 0 °C . was treated with a solution of trifluoroacetic acid (2 mL) in dichloromethane (5 mL). The reaction mixture was stirred at 0 °C for 35 minutes and at room temperature for 15 hours. The solvent was removed under reduced pressure and the residue was dried under high vacuum. Ethyl acetate and 5N NaOH were added. The layers were partitioned and the organic layer was washed with NaOH, dried (MgS04), filtered, and evaporated under reduced pressure. The crude material was purified by preparative HPLC to provide 0.003g (1%) of -145- WO 2005/010009 PCT/US2004/024003 the desired product. 1H NMR (DMSO-d , 400 MHz) δ 9.517 (s, 1H), 8:15-8.146 (m,lH); 8.06-8.005 (m, 2H), 7.72-7.701 (m, 1H), 7.647 (s, 1H), 7.604-7.583 (m, 1H), 7.554-7.527 (m, 2H), 7.356-7.315 (m, 2H), 7.233 (m, 1H), 7.173-7.091 (m, 2H), 6.494-6.459 (m, 2H), 5.8 (br s, 2H), 4.041 (s, 3H), 3.923 (s, 3H); LCMS (Thermoquest AQA single-quad MS, Genesis 5 CIS column, 3y.m particle size, 33 x 4.-6mm; 70% 50 mM ammonium acetate in water to 95% acetonitrile over 6 rnin, 0.S to 0.5 mL/min) R=3.65 min (100%), MS m/e 545.5 (M+H)+. Example 312 N-[4-{4-ammo-7-[6-(l,3-dioxo-l,3-dmydro-2H-isomdol-2-yl)4-hexynyl]thieno[3,2- c]pyridin-3-vl)-2-methoxvphenvl)-l-methyl-lH-indole-2-carboxamide A microwave tube charged with Example 294E (0.100g, 0.18 mmol), 2-(5-hexynyl)-lH-isoindole-l,3(2H)-dione (0.123g, 0.541 mmol), PdCl2(PPh3)2 (0.006g, 0.009 mmol), cuprous chloride (0.002g, 0.009 mmol), triethylamine (0.054g, 0.541 mmol), and DMF (4 mL) was stirred at 85 °C for 5 minutes under microwave conditions and concentrated. The residue was purified by flash chromatography on silica gel using 1:1 ethyl acetate/heptane then 100% ethyl acetate to provide 0.078g (66%) of the desired product 1H NMR (DMSO-d6, 400 MHz) δ 9.479 (s, 1H), 7.988-7.957 (m, 1H), 7.878-7.763 (m, 5H), 7.686-7.666 (m, 1H), 7.57-7.549 (m, 2H), 7.319-7.28 (m, 2H), 7.175-7.171 (m, lH)r7.139-7.101 (m, 1H), 7.059-7.034 (m, 1H), 5.673 (br s, 2H), 4.006 (s, 3H), 3.882 (s, 3H), 3.654-3.62 (m, 2H), 2.572 (m, 2H), 1.S39-1.776 (m, 2H), 1.619-1.546 (m, 2H); LCMS (Thermoquest AQA single-quad MS, Genesis C'18 column, 3u.m particle size, 33 x 4.6mm; 70% 50 mM ammonium acetate in water to 95% acetonitrile over 6 min, 0.8 to 0.5 mL/min) 1 =4.6 min (95%), MS m/e 654.6 (M+H)+. Example 313 N-[4-{4-ammo-7-r6-(l,3-dioxo-l,3-dmydro-2H-isomdol-2-yl)4-hexynyl]thieno[3,2- c]pyridin-3-vl)-2-methoxvphenvl)-l-methyl-lH-indole-2-carboxamide A mixture of Example 294E (0.120g, 0.217 mmol), 3-formyl-2-furylboronic acid (0.033g, 0.236 mmol), Pd(PPh3)4 (0.012g, 0.010 mmol), and sodium carbonate (0.057g, 0.538 30 mmol) in DMF (2 mL) and water (1 mL) was heated at 80 °C for 16 hours, cooled to ambient temperature, and concentrated. The residue was partitioned between water (20 mL) and methanol/dichloromethane (1:9, 20 mL). The layers were separated and the aqueous layer was extracted further with methanol/dichloromethane (1:9, 2 x 20 mL). The organic layers were combinedj dried (MgSO<), filtered, and concentrated. The residue was purified by flash column chromatography on silica gel deactivated with triemylamine, using methanol/dichloromethane (1:24) as the mobile phase to provide the desired product (0.017g, 0.032 mmol). 1H NMR (DMSOA400MHZ) δ 9.48 (s, 1H), 7.96 (d, 1H), 7.82 (d, 1H), 7.68 (d, 1H), 7.57 (m, 2H), 7.51 (s, 1H), 7.33 (s, 1H), 7.29 (m, 1H), 7.26 (d, 1H), 7.17 (m, 1H), -146- WO 2005/010009 PCT/US2004/02400J 7.13 (t, IH); 7.05(m, IH),4.04(s, 3H), 3.91 (s, 3H);.MSm/e 521 (M-H)+ Example 314 tert-butyl(2E)-3-[4-ammo-3-(3-rnethoxv-4-{[(l-methyl-lH-indol-2- vl)carbonyl]ammo)phenyl)thieno[3,2-c]pvridin-7-yl]-2-propenylcarbamate Example 314A tert-butyl allylcarbamate A solution of copper cyanide (1.15g, 12.9 mmol) in THF (30 mL) at -78 °C was 10 treated slowly with n-butyl ]ithium (16.9 mL, 27.1 mmol), stirred for 15 minutes at -78 °C, treated with tributyl tin hydride (7.88g, 7.30 mL, 27.1 mmol) over a period of 5 minutes, stirred for 15 minutes, treated with tert-butyl 2-propynylcarbamate (2.00g, 12.9 mmol) in tetrahydrofuran (7 mL), stirred at -78 °C for 1 hour, and treated with a 9:1 aqueous solution of ammonium chloride:ammonium hydroxide (250 mL) and dichloromethane (200 mL). The suspension was filtered through a short pad of diatomaceous earth (Celite®). The organic phase of the filtrate was washed with brine and concentrated. The residue was purified on silica gel using 1-2% ethyl acetate/heptane to provide the desired product (3.66g, 63%). ]H NM[(400MHz,CDC13)66.08 (dt,B partofanAB system,J=19.3 Hz, 1.3 Hz, IH); 5.93 (dt, A part of an AB system, J=19.3 Hz, 4.8 Hz, IH), 4.59 (br s, IH), 3.7S (br s, 2H)51.45 (s, 20 9H), 1.32-1.26, (m, 12H), 0.90-0.85 (m, 15H). Example 314B tert-butyl (2E)-3-[4-amino-3-(3-methoxv-4-{rq--methvl-lH-indol-2- yl)carbonvl1arnmo}phenyl)thieno[3,2-c]p din-7-yl]-2-propenylcarbamate A degassed suspension of Example 294E (2.50g, 4.51 mmol), Example 314A (2.62g, 5.87 mmol), and potassium fluoride (0.340g, 5.87 mmol) in toluene (45 mL) was treated with Pd(PPh3)4 (0.360g, 0.316 mmol), degassed twice more, and then heated to 115 °C for 14 hours. The suspension was cooled to room temperature and the solvent was removed under reduced pressure. The resulting solid was triturated with ethanol/dichloromethane (10:1) (100 mL) and collected by vacuum filtration provide the desired product (2.3g, 90%). LCMS (Thermoquest AQA single-quad MS, Genesis C18 column, 3 um particle size, 33 x 4.6mm; 70% 50 mM ammonium acetate in water to 95% acetonitrile over 6 rnin, 0.8 to 0.5 mL/min); MS m/e 5S4.6 (M+H)+, R, = 4.1 minutes; 1H NMR (DMSO-d6, 400 MHz) 8 9.51 (s,lH), 7.99 (d, J=8.0 Hz,lH), 7.95 (s, IH), 7.70 (d, J=8.0 Hz, IH), 7.63 (s, IH), 7.58 (d, J-8.4 Hz, IH), 7.35 (s, IH), 7.32 (d, J=8.4 Hz, IH), 7.21 (d, J=1.5 Hz, IH), 7.15 (dd, J=7.8 Hz, 7.0 Hz, IH), 7.08 (dd, J=8.0 Hz, 1.9 Hz, IH), 6.58 (d, J=16.2 Hz, IH), 6.21 (td, J=16.2 Hz, J=5.5 Hz, IH), 5.65 (br s, IH), 4.04 (s, 3H), 3.91 (s, 3H), 3.80 (brm, 2H), 1.42 (s, 9H). -147- WO 2005/010009 PCT/US2004/024003 Example 315 tert-butyl (2E)-3-[4-amino-3-(3-methoxv-4-{rq--methvl-lH-indol-2- yl)carbonvl1arnmo}phenyl)thieno[3,2-c]p din-7-yl]-2-propenylcarbamate A suspension of Example 314B (0.625g, 1.07 mmol) in dichloromethane (9 mL) at 0 °C was treated with a solution of trifluoroacetic acid (2.4g, 21.4 mmol) in dichloromethane (2 mL). The solution was slowly warmed to room temperature, stirred for 4 hours, and concentrated. The resulting trifluoroacetate salt was treated with 50% NaOH and extracted with 10:1 dichloromethane/methanol (4 x 200 mL). The solvents were removed under reduced pressure to provide the crude product which was purified by silica gel chromatography using 10% methanol/dichloromethane to 25% methanol (with 2.5% ammonium hydroxide)/dichloromethane to provide the desired product (0.330g, 58%): LCMS (Thermoquest AQA single-quad MS, Genesis CI 8 column, 3 im particle size, 33 x 4.6mm; 70% 50 mM ammonium acetate in water to 95% acetonitrile over.6 min, 0.8 to 0.5 mL/min); MS m/e 484.6 (M+H)+; R, = 3.0 minutes; 1H NMR (DMSO-d6,400 MHz) 6 9.50 (s, IH), 7.98 (d, J=8.0 Hz, IH), 7.94 (s, IH), 7.69 (d, J=7.8 Hz, IH), 7.62 (s, IH), 7.58 (d, J=8.6 Hz, IH), 7.34 (s, IH), 7.31 (d, J=7.2 Hz, IH), 7.20 (d, J=1.9 Hz, IH), 7.14 (dd, J=7.8 Hz, 8.0 Hz, IH), 7.08 (dd, J=8.2 Hz, 1.9 Hz, IH), 6.67 (d, J=16.2 Hz, IH), 6.33 (td, >16.2 Hz, 5.5 Hz, IH), 5.60 (or s, IH), 4.03 (s, 3H), 3.91 (s, 3H), 3.44 (dd, JF5.6 Hz, 1.3 Hz, 2H). General Procedure for Reductive Animation with Example 315 A suspension of Example 315 (0.050g, 0.104 mmol) and the appropriate ketone/aldehyde (0.087 mmol) in dichloroethane (1.5 mL) was treated with sodium triacetoxyborohydride (0.036g, 0.173 mmol), stirred at room temperature for 2-12 hours, treated with 10% NaOH (3 mL) and dichloromethane (3 mL), stirred for 15 minutes, filtered through an Empore® cartridge, and concentrated. The crude product was purified in one of three ways: Method A: Triturated in ethanol and collected by filtration. Method B: Purified by preparative reverse phase HPLC (Rainin CIS, 8 mm, 300 A, 25 cm; 40% acetonitrile -0.1M ammonium acetate isocratic for 5 minutes, then 40-100% acetonitrile/O.lM ammonium acetate over 30 min? 21 mL/min) followed by lyopbilization. Method C: Purified by reverse phase HPLC .(Rainin CI 8, 8 mm, 300 A, 25 cm; 40% acetonitrile - 0.1M ammonium acetate isocratic for 5 minutes, then 5 -100% acetonitrile/O.lM ammonium acetate over 30 min, 21 mL/min) then lyophilized.. LCMS conditions: LCMS (Thermoquest AQA single-quad MS, Genesis CI8 column, 3 urn particle size, 33 x 4.6mm; 70% 50 mM ammonium acetate in water to 95% acetonitrile over 6 min, 0.8 to 0.5 mL/min). The following examples were prepared by this procedure using the indicated ketone or aldehyde. -148- WO 2005/010009 PCT/US 2004/024003 Example . i-inal Froduct "Starting Ketone/Aldehyde Yield% MS m/e 316 N-[4-(7-{(lli)-3-LU-acetyl-4-piperidinyl)amino]-l -propenyl} -4-aminothieno[3,2-c]pyridin-3 -yl)-2-methoxypheny 1]-1 -methyl- 1H-indole-2-carboxamide l-acetyl-4-pipendmone . 25 ooy.i 317 N-(4-{4-ammo-7-l(lJi)-3-(tetxahydro-2H-pyran-4-ylamino)-l-propenyl]thieno[3,2-c]pyridin-3-yl} -2-methoxyphenyl)-1 -methyl-lH-indole-2-carb ox amide (acetate salt) tetrahydro-4h.-pyran-4-one 31 568.1 318 M-(4-(4-amino-7-L(lii)-3-( 1,4-dioxaspiroR4.5]dec-8-ylamino)-l-propenyl]thieno[3,2-c]pyridin-3-yl}-2-methoxyphenyl)-l-methyl-1 H-indole-2-carboxamide 1,4- dioxaspiroR4.5]decan-8- one 48 624.3 319 M-L4-(4-amuio-7-{(lli)-3-[(3,3- dimethyl-1,5- dioxaspiro[5.5]undec-9-yl)amino]- 1 -propenyl} thieno[3,2-c]pyridin- 3-yl)-2-methoxyphenyl]-l-methyl- lH-indole-2-carboxamide (acetate salt) 3,3-tiimethyl-ip-dioxaspiro[5.5]undecan-9-one bO 666.3 320 N-{4-[4-amino-7-((lli)-3-U(6- methyl-2- pyridinyl)methyl] amino }-1 - propeny thieno -clpyridin-S- yl]-2-methoxyphenyl}-l-methyl- ■ lH-indole-2-carboxamide (acetate salt) 6-methyl-2-pyridinecarb aldehyde 10 ' 589.5"' 321 N-{4-[4-amino-7-((lH)-3-{l2,3- dihydroxypropyl]amino}-l- propenyl)thieno[3,2-c]pyridin-3- 2,3-cuhydroxypropanal 2 5b8.1 yl]-2-methoxyphenyl}-l-methyl- -149- WO 2005/010009 PCT/US2004/0 24003 1 H-indoIe-2-carboxamide rrr't— rrrr - i •_■ — j 322 N-L4-(4-ammo-7-{(lb)-3-L(l-isopropyl-4'piperidinyl)amino]-l-propenyl}thieno[3,2-c]pyridin-3-yl)-2-methoxyphenyl]-l-methyl-1 H-indole-2-carboxamide l-isopropyl-4-piperidinone 2t> 609.7 Purification Methods and Spectral Data Example 316 Purification Method: A; !H NMR (400 MHz, DMSO-d6) δ 9.51 (s, IH), 8.01-7.99 (m, 2H), 7.70 (d, J=7.4 Hz, IH), 7.66 (s, IH), 7.58 (d, J=8.2 Hz, IH), 7.35 (s, IH), 7.32 (d, J-7.4 Hz, IH), 7.20 (d, J=1.9 Hz, IH), 7.15 (dd, J=7.6 Hz, 8.0 Hz, IH), 7.08 (dd, J=6.5 Hz, 1.9 Hz, IH), 6.89 (d (br), IH), 6.27 (td, J=16.0 Hz, 6.2 Hz, IH), 5.76 (brs, IH), 4.04 (s, 3H), 3.91 (s, 3H), 3.70 (m, 2H), 3.07 (m, 2H), 2.62 (m, 2H), 2.01 (s, m, 4H), missing signals for 4 aliphatic protons that are under residual solvent and water signals. Example 317 Purification Method: B; 1H NMR (400 MHz, DMSO-d*) δ 9.51 (s, IH), 8.00 (t, J=8.0 Hz, IH), 7.70 (d, J=7.70 Hz, IH), 7.62 (s, IH), 7.58 (d, J=8.6 Hz, IH), 7.34 (s, IH), 7.31 (d, J=7.2 Hz, IH), 7.19 (d, J=1.9 Hz, IH), 7.14 (t, J=7.2 Hz, IH), 7.08 (dd, J«S.O Hz, 1.8 Hz, IH), 6.68 (d, J=16.4 Hz, IH), 6.28 (td, M6.2 Hz, 6.2 Hz, IH), 5.62 (br s, IH), 4.04 (s, 3H), 3.91 (s, 3H), 3.84 (m, 2H), 3.45 (m, 2H), 3.27 (m, 2H), 2.32 (m, IH), 1.86 (m, 2H), 1.30 (m, 2H), 1.91 (s,3H, acetate). Example 318 Purification Method: B; 1H NMR (400 MHz, DMSO-d,) δ 9.51 (s, IH), 7.99 (d, J=8.0 Hz, IH), 7.93 (s, IH), 7.69 (d, J=7.8 Hz, IH), 7.61 (s, IH), 7.58 (d, J=7.6 Hz, IH), 7.34 (s, IH), 7.31 (d, J-8.4 Hz, IH), 7.20 (d, J=1.8 Hz, IH), 7.14 (dd, J=8.0 Hz, 7.2 Hz, IH), 7.07 (dd, J=7.6 Hz, 1.9 Hz, IH), 6.65 (d, JM16.0 Hz, IH), 6.28 (td, J-16.2 Hz, 6.0 Hz, IH), 5.60 (br s, IH), 4.04 (s, 3H), 3.91 (s, 3H), 3.84 (m, 4H), 3.39 (m, 2H), 2.54 (m, IH), 1.79 (m, 2H), 1.68 (m, 2H), 1.48-1.34 (m, 4H). Example 319 Purification Method: C; !H NMR (400 MHz, DMSO-dg) 8 9.51 (s, IH), 7.99 (dd, (J=8.0 Hz, 8.2 Hz, IH), 7.93 (s, IH), 7.69 (d, J=8.2 Hz,lH), 7.61 (s, IH), 7.57 (d, J=8.4 Hz, IH), 7.34 (s, IH), 7.31 (d, J=7.2 Hz,lH), 7.20 (d, J=1.8 Hz, IH), 7.14 (dd, J=S.O Hz, 7.8 Hz, IH), 7.07 (dd, J=S.O Hz, 1.8 Hz, IH), 6.65 (d, J=16.1 Hz, IH), 6.27 (td, J-16.2 Hz, 6.0 Hz, -150- WO 2005/010009 PCT/US2004/024003 IH), 5.59 (br s, IH), 4.03 (s, 3H), 3.91 (s; 3H); 3:42-3:39 (ri, 6H), 2.32'(m, IH), 2.08 (m, 2H), 1.71 (m, 2H), 1.38-1.22 (m, 4H), 0.886 (s, 6H), 1.89 (s, 3H, acetate). Example 320 Purification Method: C; !H NMR (400 MHz, DMSO-d6) 6 9.50 (s, IH), 7.99 (dd, J=8.2 Hz, 7.8 Hz, IH), 7.96 (s, IH), 7.70-7.67 (m, 2H), 7.63 (s, IH), 7.58 (d, J=8.4 Hz, IH), 7.34 (s, IH), 7.31 (d, J=8.2 Hz, IH), 7.27 (d, J=7.4 Hz, IH), 7.19 (d, J=1.9 Hz, 1H),7.15 -7.12 (m, 2H), 7.07 (dd, J=7.8 Hz, 1.8 Hz, IH), 6.73 (d (br), J=16.0 Hz, IH), 6.30 (td, J=16.0 Hz, 6.0 Hz, IH), 4.03 (s, 3H), 3.91 (s, 3H), 3.54 (br s, 2H), 2.47 (s, 3H), 2.33 (m, 2H), 1.90 (s, 3H, acetate). Example 321 Purification Method: C; 1H NMR too dilute for definitive analysis. Analytical HPLC (Rainin CIS, 8 mm, 300 A, 25 cm; 5 -100% acetonitrile over 15 minutes then isocratic 5 minutes - 1.0 mL/min): R, = 11.9 minutes. Example 322 Purification Method: A; 1H NMR (400 MHz, DMSO-d.) 8 9.51 (s, IH), 8.00 (dd, J=8.2 Hz, 8.0 Hz, IH), 7.94 (s, IH), 7.70 (d, J=8.0 Hz; IH), 7.61 (s, IH), 7.59 (d, J=8.0 Hz; 20 IH), 7.35 (s, IH), 7.32 (d, J=7.4 Hz, IH), 7.20 (d, J=1.8 Hz, IH), 7.15 (t, J=7.6 Hz, IH), 7.08 (dd, J=8.2 Hz, 1.8 Hz, IH), 6.65 (d, J=16.2 Hz, IH), 6.28 (td, J=16.2 Hz, 6.0 Hz, IH), 5.59 (br s, IH), 4.04 (s, 3H), 3.91 (s, 3H), 3.39 (m, 2H), 2.74 (m, 2H), 2.65(m, IH), 2.40 (m, IH), 2.08 (m, 2H), 1.84 (m, 2H), 1.27-1.17 (m, 2H), 0.940 (d, 6H). General Procedure for Reductive Animations with Example 176C A mixture of Example 176C (40 mg, 0.083 mmol), sodium triacetoxyborohydride (35 mg, 0.166 mmol) and the appropriate amine (0166 mmol) in 1,2-dichloromethane (2 mL) was stirred for 2 to 72 hours at ambient temperature. The mixture was concentrated and the residue was purified by normal or reverse phase chromatography. Where necessary a Boc- protected diamine was used for the reductive amination then the protecting group was removed by stirring the reaction mixture in a 2:1 mixture of acetone and 6N hydrochloric acid for 2 hours followed by concentration and purification of the residue. The following examples were prepared by this general method using the indicated amines: Example 323 N-[4-(4-amino-7-{(lE)-3-[4-(2-methoxyetriyl)-l-piperazinyl]-l-propenyl)thienof'3,2- clpyridin-3-yl)"2-metlioxvphenvl14-mettiyl-lH-iridole-2--carboxainide -151- WO 2005/010009 PCT/US2004/024003 Prepared as the diacetate salt from N,N -dimethyl N-[2-(l-piperazinyl)ethyl]amine. H NMR (DMSO-d6,400 MHz) 8 9.50 (s, IH), 8.00 (d, IH), 7.96 (s, IH), 7.69 (d, IH), 7.C (s, IH), 7.59 (d, IH), 7.34 (s, IH), 7.33 (d, IH), 7.19 (s, IH), 7.15 (t, IH), 7.07 (d, IH), 6.t (d, IH), 6.21 (m, IH), 5.63 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.16 d, 2H), 2.2-2.5 (m, 12H), 2.13 (s, 6H), 1.87 (s, 6H); MS m/e 624.5 (M+H)+, 622.6 (M-H)+ Example 324 N-[4-(4-amino-7-{(lE)-3-[4-(2-methoxyetriyl)-l-piperazinyl]-l-propenyl)thieno[3,2- clpyridin-3-yl)-2-metlioxvphenvl14-mettiyl-lH-iridole-2-carboxainide Prepared from l-(2-methoxyethyl)piperazine. 1H NMR (DMSO-dg, 400 MHz) 5 9 (s, IH), 7.99 (d, IH), 7.95 (s, IH), 7.69 (d, IH), 7.60 (s, IH), 7.57 (d, IH), 7.34 (s, IH), 7.3 (d, IH), 7.19 (s, IH), 7.14 ft IH), 7.06 (d, IH), 6.66 (d, IH), 6.20 (m, IH), 5.62 (br s, 2H), 4.03 (s, 3H), 3.90 (s, IH), 3.41 ft 2H), 3.22 (s, 3H), 3.16 (d, 2H), 2.3-2.5 (m, 10H), MS mA 611.5 (M+H)+. Example 325 N-[4-(4-amino-7-{(lE)-3-[4-(2-methoxyetriyl)-l-piperazinyl]-l-propenyl)thieno[3,2- clpyridin-3-yl)-2-metlioxvphenvl]4-mettiyl-lH-iridole-2--carboxainide Prepared as the triacetate salt from N,N-dmiemyl-N-[3-(l-piperazmyl)propyl]anune. 1H NMR (DMSO-d6, 400 MHz) δ 9.50 (s, IH), 7.99 (d, IH), 7.96 (s, IH), 7.69 (d, IH), 7.60 (s, IH), 7.5S (d, IH), 7.35 (s, IH), 7.32 ft IH), 7.20 (s, IH), 7.14 ft IH), 7.06 (d, IH), 6.65 (d, IH), 6.21 (m, IH), 5.62 (br s, IH), 4.03 (s, 3H), 3.90 (s, 3H), 3.16 (d, 2H), 2.39 (m, SH), 2.26 ft 2H), 2.19 (m, 2H), 2.09 (s, 6H), 1.85 (s, 9H), 1.53 (m, 2H); MS m/e 638.8 (M+H)+, 636.7 (M-H): Example 326 N- (4-[4-amino-7-(( 1 E)-3 - (4-f (2-pyrirmdinylamino)methyl]-1 -piperidinyl) -1 -propenyl)thieno[3,2-c]pyridin-3-yl]-2-memoxypte Prepared as the acetate salt from N-(4-piperidmylmethyl)-2-pyrimidmaimae. 3H 30 NMR (DMSO-d6, 400 MHz) δ 9.50 (s, IH), 8.00 (d, IH), 7.96 (s, IH), 7.71 (d, IH), 7.61 (s, IH), 7.32 ft IH), 7.19 (s, 2H), 7.15 ft IH), 7.07 (d, IH), 6.65 (d, IH), 6.51 ft IH), 6.22 (m, IH), 5.63 (br s, 2H), 4.03 (s, 3H), 3.91 (s, 3H), 3.15 (d, 2H), 2.91 (d, 2H), 2.63 (m, 2H), 1.6-2.0 (m, 12H); MS m/e 659.5 (M+H)+, 657.5 (M-H)+ Example 327 N-[4-(4-ammo-7-((lE)-3-[4-(aminocarbonyl)-l-piperidiriyl]-l-propeDvl}triierjo[3,2-c]pyridiri-3-vl)-2-memoxypheDyl]-l-memvl-lH-indole-2-carboxamide Prepared as the diacetate salt from 4-piperidinecarboxarnide. 1H NMR (DMSO-d6 -152- WO 2005/010009 PCT/US2004/024003 400 MHz) δ 9.50 (s, IH), 8.00 (d, IH), 7.97 (s, IH), 7.70 (d, IH), 7.62 (s,'lH), 7.58 (d, lH), 7.35 (s, IH), 7.33 (t, IH), 7.21 (m, 2H), 7.15 (t, IH), 7.07 (d, IH), 6.74 (s, IH), 6.66 (d, IH), 6.24 (m, IH), 5.63 (br s, 2H), 4.04 (s, 3H), 3.92 (s, 3H), 3.16 (d, 2H), 2.95 (m, IH), 1.85-2.09 (m, 4H), 1.89 (s, 6H), 1.53-1.74 (m, 4H); MS m/e 595.5 (M+H)+, 593.2 (M-H)+ 5 Example 328 N-[4-(4-amino-7-{(lE)-3-[[3-(diinethylamino)propyl](methyl)aminoI-l-propenvn clpyridin-3-yl)-2-rnethoxyphenylI-l-rnethyl-lH-indole-2-carboxamide Prepared as the diacetate salt fromN,N,N'4iraemyl-l,3-propanediarnine. 1H NMR (DMSO-d6, 400 MHz) δ 9.50 (s, IH), 8.00 (d, IH), 7.96 (s, IH), 7.71 (d, IH), 7.61 (s, IH), 7.59 (d, IH), 7.35 (s, IH), 7.32 (t, IH), 7.19 (s, IH), 7.14 (t, IH), 7.07 (d, IH), 6.67 (d, IH), 6.23 (m, IH), 5.63 (br s, 2H), 4.03 (s, 3H), 3.91 (s, 3H), 3.19 (d, 2H), 2.38 (t, 2H), 2.23 (t, 2H), 2.20 (s, 3H), 2.11 (s, 6H), 1.86 (s, 6H), 1.58 (m, 2H); MS m/e 583.0 (M+H)+, 581.3 (M-H)+ 15 Example 329 N -[4-(4-ammo-7-((lE)-3-[4-(aminocarbonyl)-l-piperidiriyl]-l-propeDvl}triierjo[3,2-c]pyridiri-3-vl)-2-memoxypheDyl]-l-memvl-lH-indole-2-carboxamide Prepared as the triacetate salt from tert-butyl 4-armno-l-piperidinecarboxylate and '20 deprotected. lH NMR (DMSO-d6, 400 MHz) 6 9.50 (s, IH), 7.98 (d, IH), 7.94 (s, IH), 7.69 (d, IH), 7.60 (s, IH), 7.57 (d, IH), 7.34 (s, IH), 7.32 (t, IH), 7.19 (s, IH), 7.14 (t, IH), 7.08 (d, IH), 6.67 (d, IH), 6.28 (m, IH), 5.61 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.41 (d, 2H), 3.02 (m, IH), 2.59 (m, 4H), 1.89 (s, 9H), 1.85 (m, 2H), 1.32 (m, 2H); MS m/e 567.0 (M+H)+, 565.3 (M-H)+ Example 330 N-[4-(4-ammo-7-((lE)-3-[4-(aminocarbonyl)-l-piperidiriyl]-l-propeDvl}triierjo[3,2-c]pyridiri-3-vl)-2-memoxypheDyl]-l-memvl-lH-indole-2-carboxamide Prepared as the tetraacetate salt from tert-butyl 4-piperidinylmethylcarbamate and 30 deprotected. 1H NMR (DMSO-d6,400 MHz) 6 9.51 (s, IH), 7.99 (d, IH), 7.96 (s, IH), 7.69 (d, IH), 7.61 (s, IH), 7.58 (d, IH), 7.35 (s, IH), 7.33 (t, IH), 7.19 (d, IH), 7.14 (t, IH), 7.06 (dd, IH), 6.66 (d, IH), 6.22 (m, IH), 5.65 (br s, 2H), 4.03 (s, 3H), 3.91 (s, 3H), 3.16 (d, 2H), 2.94 (m, 2H), 2.64 (d, 2H), 1.94 (m, 2H), 1.87 (s, 12H), 1.72 (m, 2H), 1.50 (m, IH), 1.20 (m, 2H); MS m/e 581.5 (M+H)+, 579.5 (M-H)". Example 331 l-((2E)-3-[4-amino-3-(3-methoxy-4-([(l-methyl-lH-indol-2- yl)carbonyl]amino)phenyl)thieno[3,2-c]pyridin-7-yn-2-propenvl)-4-piperidinecarboxylic -153- WO 2005/010009 PCT/US2004/024003 acid Prepared as the diacetate salt from 4-piperidinecarboxylic acid. 1H NMR (DMSOd6, 400 MHz) 8 9.52 (s, IH), 8.00 (d, IH), 7.97 (s, IH), 7.72 (d, IH), 7.61 (s, IH), 7.59 (d, IH), 7.35 (s, IH), 7.33 (m, IH), 7.20 (s, IH), 7.15 (t, IH), 7.07 (d, IH), 6.67 (d, IH), 6.24 (m, IH), 5.65 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.16 (d, 2H), 2.86 (m, 2H), 2.15 (m, IH), 2.02 (m, 2H), 1.88 (s, 6H), l.SO (m, 2H), 1.57 (m, 2H); MS m/e 596.5 (M+H)+, 594.5 (M-H)'. Example 332 N-[4-(4-ammo-7-((lE)-3-[(4-arm ocvcl6hexyl)ammo1-l-propenyl)thieno[3,2-c]pyridin-3-vl)-2-methoxyphenyl]-1 -methyl-1 H-indole-2-carboxamide Prepared as the triacetate salt from tert-butyl 4-aminocyclohexylcarbamate and deprotected. 1H NMR (DMSO-d 400 MHz) δ 9.52 (s, IH), 7.98 (d, IH), 7.94 (s, IH), 7.70 (d, IH), 7.62 (s, IH), 7.59 (m, IH), 7.35 (s, IH), 7.33 (m, IH), 7.20 (s, IH), 7.15 (t, IH), .7.09 (d, IH), 6.66 (d, IH), 6.29 (m, IH), 5.62 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.42 (d, 2H), 2.76 (m, IH), 2.40 (m, IH), 1.89 (m, 4H), 1.83 (s, 9H), 1.03-1.28 (m, 4H); MS m/e 681.6 (M+H)+, 679.6 (M-H)-. Example 333 N-[4-R4-ammo-7-{(lE)-3-rmemyl(l-memyl-4-piperidmyl)ammo1-l-propenvl}thie c]pyridin-3-yl)-2-methoxyphenyn-l-memyl-lH-indole-2-carboxamide Prepared as the tetraacetate salt from N,l-dimethyl-4-piperidinamine. 1H NMR (DMSO-d6, 400MHz) 6 9.52 (s, IH), 7.99 (d, IH), 7.95 (s, IH), 7.70 (d, IH), 7:61 (s, IH), 7.59 (d, IH), 7.35 (s, IH), 7.33 (t, IH), 7.20 (s, IH), 7.15 (t, IH), 7.08 (d, IH), 6.67 (d, IH), 6.22 (m, IH), 5.63 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.29 (d, 2H), 2.82 (m, 2H), 2.36 (m, IH), 2.21 (s, 3H), 2.13 (s, 3H), 1.84 (s, 12H), 1.82 (m, 2H), 1.73 (m, 2H), 1.49 (m, 2H); MS m/e 595.5 (M+H)+, 593.6 (M-H)". Example 334 N-[4-(4-aim o-7-{(lE)-3-[4-(6-oxo4,6-dmydro-2-pyridmyl)-l-piperaziiiyl]-l- propenyl| thieno[3,2-c]pvridm-3-yl)-2-memoxyphenyn-l-memyl-lH-mdole-2-carboxamide Prepared as the acetate salt from 6-(l-piperazmyl)-2(lH)-pyridinone. 1H NMR (DMSO-d6,400 MHz) 8 9.53 (s, IH), 7.99 (m, 2H), 7.71 (d, IH), 7.62 (s, IH), 7.58 (d, IH), 7.33 (m, 3H), 7.20 (m, IH), 7.15 (t, IH), 7.08 (m, IH), 6.72 (d, IH), 6.27 (m, IH), 6.05 (d, IH), 5.85 (d, IH), 5.67 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.39 (m, 4H), 3.23 (d, 2H), 2.53 (m, 4H), 1.89 (s, 3H); MS m/e 646.6.6 (M+H)+, 644.7(M-H)+ Example 335 N-[4-(4-ammo-7-((lE)-3-[4-(aminocarbonyl)-l-piperidiriyl]-l-propeDvl}triierjo[3,2-c]pyridiri-3-vl)-2-memoxypheDyl]-l-memvl-lH-indole-2-carboxamide -154- WO 2005/010009 PCT/US2004/024003 yl)-2-methoxyph'enyl']i-l-methvl-lH-indole-2-carboxamide Prepared as the acetate salt from l-methyl-l,4-diazepane. ]H NMR (DMSO-d6,400 MHz) 8 9.52 (s, IH), 8.00 (d, IH), 7.96 (s, IH), 7.72 (d\ IH), 7.61 (s, IH), 7.58 (d, IH), 7.35 (s, IH), 7.33 ft IH), 7.19 (s, IH), 7.15 (t, IH), 7.07'(d, IH), 6.67 (d, IH), 6.24 (m, IH), 5.64 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.29 (d, 2H), 2.68 (m, 4H), 2.56 (m, 4H), 2.25 (s, 3H), 1.86 (s, 3H), 1.73 (m, 2H); MS m/e 581.5 (M+H)+ 579.4 (M-H)+ Example 336 N-[4-(4-ammo-7-((lE)-3-[4-(aminocarbonyl)-l-piperidiriyl]-l-propevl}triierjo[3,2-c]pyridiri-3-vl)-2-memoxyphe3-yl]-l-memvl-lH-indole-2-carboxamide Prepared from 2-(l-piperazinyl)pyrazine. 1H NMR (DMSO-d* 400 MHz) 6 9.52 (s, IH), 8.33 (d, IH), 8.08 (m, IH), 8.01 (d, IH), 7.99 (s, IH), 7.S4 (d, IH), 7.72 (d, IH), 7.62 (s, IH), 7.59 (d, IH), 7.33 (m, 2H), 7.20 (m, IH), 7.15 ft IH), 7.08 (dd, IH), 6.73 (d, IH), 6.28 (m, IH), 5.67 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.59 (m, 4H), 3.25 (d, 2H), 2.56 (m, 4H); 15 MS m/e 631.6 (M+H)+. Example 337 N-{4-[4-ammo-7-((lE)-3-{[2-(2-hy(froxvemoxy)ethyl]amiDoVl-propenyl)tme clpyridin-3 41-2-memoxyphenyl}4-memyl-lH-indole-2-carboxamide Prepared as the diacetate salt from 2-(2-aminoethoxy)ethanol. 1H NMR (DMSO-d6, 400 MHz) δ 9.51 (s, IH), 8.00 (d, IH), 7.95 (s, IH), 7.70 (d, IH), 7.58-7.62 (m, 2H), 7.07-7.35 (m, 5H), 6.70 (d, IH), 6.30 (dt, IH), 5.62 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.40-3.53 (m, 8H), 2.73 ft 2H), 1.87 (s, 6H); reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, C18, 5 um, 250 x 4.6 column) R,=10.2 min; MS m/e 570.5 (M+H)+. Example 338 N-[4-(4-ammo-7-((lE)-3-[4-(aminocarbonyl)-l-piperidiriyl]-l-propeDvl}triierjo[3,2-c]pyridiri-3-vl)-2-memoxypheDyl]-l-memvl-lH-indole-2-carboxamide Prepared as the diacetate salt from 2-[(2-ammoethyl)(2-hydroxyethyl)amino]ethanol. 1H NMR (DMSO-d6,400 MHz) δ 9.51 (s, IH), 8.00 (d, IH), 7.95 (s, IH), 7.70 (d, IH), 7.58-7.62 (m, 2H), 7.07-7.35 (m, 5H), 6.70 (d, IH), 6.30 (dt, IH), 5.62 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.39-3.44 (m, 6H), 2.53-2.61 (m, 8H), 1.87 (s, 6H); reverse phase.HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, C18, 5 uni, 250 x 35 4.6 column) Rt=10.0 min; MS m/e 613.5 (M+H)+. Example 339 N-(4-[4-ammo-7-((lE)-3-[2-(4-piperid yl)ethyl]amino)-l-propenvl)thieno[3,2 1pyridin-3- -155- WO 2005/010009 PCT/US2004/024003 yl]-2-methoxypheftyn -1 -methyl- lH-indole-2-carboxamide Prepared as the trihydrochloride salt from tert-butyl 4-(2-aminoethyl)-l-piperidinecarboxylate and deprotected. 'HMMR (DMSO-d6) 400 MHz) 6 9.49 (s, 1H), 8.1! (m, 2H), 8.01 (s, IE), 7.71 (d, 1H), 7.60 (d, 1H), 6.98-7.35 (m, 6H), 6.55 (m, 1H), 4.04 (s, 3H), 3.93 (s, 3H), 3.84 (m, 2H), 2.27 (d, 2H), 2.89 (m/4H), 2.07 (m, 1H), 1.28-1.46 (m, 4H reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, C18, 5 nm, 250 x 4.6 column) Rf=12.6 rnin; MS m/e 679.6 (M-H)+ Example 340 N-{4-[4-ainino-7-((lE)-3-{[2-('4-pyridinyl)emyl]ammo)-l-propenyl)thieno[3,2-c]pyridm yl]-2-memoxyphenyl}-l-methyl-lH-mdole-2-carboxamide Prepared as the acetate salt from 2-(4-pyridinyl)ethanamine. 1H NMR (DMSO-d6, 400 MHz) δ 9.51 (s, 1H), 8.46 (s, 2H), 8.00 (d, 1H), 7.94 (s, 1H), 7.71 (d, 1H), 7.58-7.62 (m 3H), 7.08-7.35 (m, 6H), 6.65 (d, 1H), 6.27 (dt, 1H), 5.62 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H 2.81 (dt, 4H), 1.87 (s, 3H); reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, CIS, 5 um, 250 x 4.6 column) R IO.4 min; MS m/e 587.5 (M-H)+ Example 341 N-[4-(4-animo-7-(flE)-3-[4-(2-cyanoemyl)-l-piperazmyl]-l-propenyl|thiePo[3,2-c]pyridin 3-vl)-2-methoxyphenyl]-l-methyl-lH-indole-2-carboxamide Prepared as the acetate salt from 3-(l-piperazinyl)propanenitrile. !H NMR (DMSO-d6, 400 MHz) 8 9.51 (s, 1H), 8.00 (d, 1H), 7.97 (s, 1H), 7.70 (d, 1H), 7.58-7.62 (m, 2H), 7.0' 7.35 (m, 5H), 6.70 (d, 1H), 6.25 (dt, 1H), 5.65 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.34 (t 2H), 3.19 (br s, 2H), 2.68 (t, 2H), 2.57 (t, 2H), 1.91 (s, 3H); reverse phase HPLC (25% to 100% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, CIS, 5 u.m, 250 > 4.6 column) Rf=9.9 min; MS m/e 604.5 (M-H)+ Example 342 N-[4-(4-ammo-7-((lE)-3-[4-(aminocarbonyl)-l-piperidiriyl]-l-propenvl}thierjo[3,2-c]pyridiri-3-vl)-2-memoxyphe3-yl]-l-memvl-lH-indole-2-carboxamide 'Prepared as the diacetate salt from tert-butyl 4-piperidinylcarbamate and deprotected, 1H NMR (DMSO-d 400 MHz) δ 9.51 (s, 1H), 8.00 (d, 1H), 7.98 (s, 1H), 7.70 (d, 1H), 7.58-7.62 (m, 2H), 7.07-7.35 (m, 5H), 6.70 (d, 1H), 6.25 (dt, 1H), 5.65 (br s, 2H), 4.04 (s, 3H), 35 3.92 (s, 3H), 3.20 (d, 2H), 2.82-2.95 (m, 3H), 2.03 (t, 2H), 1.91 (s, 3H), 1.85 (d, 2H), 1.50 (q, 2H); reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, C18, 5 um, 250 x 4.6 column) R,=l 1.3 min; MS m/e 565.5 (M-H)+ -156- WO 2005/010009 PCT/US2004/024003 Example 343 N –[4-(4 aipino-7-{(lE)-3-[4-(3-airdno-3-oxopropvn-l-piperazmvl1-l-propenvl)thienQ[3.2-clpvridin-3-yl-2-methoxyphenvl1-l-methvl-lH-indole-2-carboxairiide Prepared as the diacetate salt from 3-(l-piperazinyl)propanamide. 1H NMR (DMSO-d6, 400 MHz) δ 9.52 (s, IH), 8.00 (d, IH), 7.97 (s, IH), 771 (d, IH), 7.58-7.62 (m, 2H), 7.07-7.38 (m, 6H), 6.80 (d, IH), 6.23 (dt, IH), 5.65 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.17 (d, 2H), 2.49 (br s, 2H), 2.21 (t, 2H), 1.88 (s, 6H); reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/rnin, 254 run, hypersil HS 100 A, C18, 5 μm, 250 x 4.6 column) R,=9.7 min; MS m/e 622.7 (M-H)+ Exaniple 344 N-('4-(4-amino-7-[(lE)-3-(3-oxo-l-piperazinyl)-l-propenvl1thieno[3,2-c]pvridin-3-vl)-2-methoxyphenyl)-l-methyl-lH-indole-2-carboxamide Prepared as the acetate salt from 2-piperazinone. 1H NMR (DMSO-d6, 400 MHz) 5 9.52 (s, IH), 7.99-8.01 (m, 2H), 7.97 (s, IH), 7.71 (d, IH), 7.58-7.63 (m, 2H), 7.07-7.38 (m, 5H), 6.71 (d, IH), 6.23 (dt, IH), 5.65 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.13-3.26 (m, 4H), 2.63 (m, 2H), 1.87 (s, 3H); reverse phase HPLC (5% to 95% acetonitrile over 25 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, CIS, 5 urn, 250 x 4.6 column) R,=1S.9 min; MS m/e 567.5 (M+H)+. 20 Example 345 N-('4-(4-amino-7-[(lE)-3-(3-oxo-l-piperazinyl)-l-propenvl1thieno[3,2-c]pvridin-3-vl)-2- 3-yl-2-methoxyphenyl]-l-methyl-lH-indole-2-carboxamide Prepared as the acetate salt from N-(2-furylmethyl)-N-memylamine. 1H NMR (DMSO-d6, 400 MHz) 6 9.52 (s, IH), 7.99-8.01 (m, 2H), 7.72 (d, IH), 7.58-7.63 (m,'2H), 7.07-7.38 (m, 5H), 6.71 (d, IH), 6.23-6.45 (m, 3H), 5.65 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.6 (s, 2H), 3.22 (d, 2H), 2.21 (s, 3H), 1.91 (s, 3H); reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/mins 254 nm, hypersil HS 100 A, CIS, 5 urn, 250 x 4.6 column) R,=13.5 min; MS m/e 578.3 (M+H)+. Example 346 N-('4-(4-amino-7-[(lE)-3-(3-oxo-l-piperazinyl)-l-propenvl1thieno[3,2-c]pvridin-3-vl)-2- 2-methoxyphenyl]-l-methyl-lH-indole-2-carboxamide Prepared from l-(2-furoyl)piperazine. 1H NMR (DMSO-d 400 MHz) 8 9.52 (s, IH), 35 7.99-8.01 (m, 2H)5 7.84 (s, IH), 7.70 (d, IH), 7.58-7.63 (m, 2H), 6.99-7.38 (m, 6H), 6.62-6.73 (m, 2H), 6.23 (dt, IH), 5.65 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.70 (br s, 4H), 3.24 (d, 2H); reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 iruVrnin, 254 nm, hypersil HS 100 A, C18, 5 urn, 250 x 4.6 column) R.-12.7 min; MS m/e 645.4 (M-H)+ -157- WO 2005/010009 PCT/US2004/0 24003 Example 347 N-(4-[4-amino-7-(nE)-3-(4-[2-('4-mQrpholmvl)ethvn-l-piperazmvU-l-propenvl')tb>no[3,2- clpyridm-3-yl]-2-metboxyphenyl)-l-methyl-lH-indQle-2-carboxamide Prepared as the acetate salt from 4-[2-(l-piperazinyl)ethyl]morpholine. 1H NMR (DMSO-dg, 400 MHz) δ 9.52 (s, IH), 8.00 (d, IH), 7.99 (s, IH), 7.71 (d, IH), 7.58-7.62 (m, 2H), 7.07-7.36 (m, 5H), 6.67 (d, IH), 6.22 (dt, IH), 5.65 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.54 (t, 4H), 3.16 (d, 2H), 2.37-2.50 (m, 16H), 1.86 (s, 6H); reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, C18, 5 urn, 250 x 4.6 10 column) Rt-17.1 min; MS m/e 664.7 (M-H)'. Example 348 N-{4-[4-arnino-7-((lE)-3-{4-[3-('ajemylammo)propyn-l-piperazinyl|-l-propenylthieno[3,2- c1pvridin-3-yl]-2-methoxyphenyl)-l-methyl-lH-indole-2-carboxaniide Prepared as the triacetate salt from N,N-diethyl-N-[3-(l-piperazmyl)propyl]amine. 'H NMR (DMSO-d6,400 MHz) 6 9.52 (s, IH), 8.01 (d, IH), 7.96 (s, IH), 7.71 (d, IH), 7.58-7.62 (m, 2H), 7.07-7.36 (m, 5H), 6.67 (d, IH), 6.23 (dt, IH), 5:64 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.16 (d, 2H), 2.35-2.45 (m, 10H), 2.27 (t, 2H), 1.86 (s, 9H), 1.74 (m, 2H), 0.94 (t, 6H); reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 irdVmin, 254 nm, 20 hypersil HS 100 A, CIS, 5 m, 250 x 4.6 column) R.-9.9 min; MS m/e 664.6 (M-H)+ Example 349 N-[4-(4-aim o-7-{(lE)-3-[4-(l-methyl-4-piperidinyl)-l-piperazmvn-l-propenyl)thienor3.2- c1pvridin-3-yl)-2-methoxyphenyl]-l-methvl-lH-indole-2-carboxamide Prepared as the tetraacetate from l-(l-methyl-4-piperidinyl)piperazine. lH NMR (DMSO-d6, 400 MHz) δ 9.52 (s, IH), 8.01 (d, IH), 7.96 (s, IH), 7.71 (d, IH), 7.58-7.62 (m, 2H), 7.07-7.36 (m, 5H), 6.67 (d, IH), 6.22 (dt, IH), 5.64 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.16 (d, 2H), 2.79 (d, 2H), 2.12 (s, 3H), 2.08 (m, IH), 1.85 (s, 12H), 1.68-1.72 (m, 2H), 1.37-1.40 (m, 2H); reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 rnI7min, 254 nm, hypersil HS 100 A, CIS, 5 um, 250 x 4.6 column) R,=9.4 min; MS m/e 648.7 (M-H)'. Example 350 N-{4-[4-ammo-7 (lE)-3-(4-[2-(l-piperidinvI)emyl]-l-piperazmvI)-l-propenyl)thieno[3,2- c]pyridin-3-yl]-2-methoxyphenyl) -1 -methyl-1 H-indole-2-carboxamide Prepared as the triacetate from l-[2-(I-piperidinyl)ethyl]piperazine. 1H NMR (DMSO-d6, 400 MHz) 6 9.52 (s, IH), 8.01 (d, IH), 7.97 (s, IH), 7.71 (d, IH), 7.58-7.62 (m, 2H), 7.07-7.35 (m, 5H), 6.6S (d, IH), 6.22 (dt, IH), 5.64 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.16 (d, 2H), 2.32-2.41 (m, 14H), 1.85 (s, 9H), 1.48 (m, 4H)3 1.35 (m, 2H); reverse phase • -158- WO 2005/010009 PCTAJS2004/024003 HPLC' (5% 5ho 95% acetbnitrile oyer 10 minutes, 1 mL/min, 254 nm, hypersil HS 100-A, C18,; 5 μm, 250 x 4.6 column)R=9.9 min; MSm/e 664.7 (M-H)+ Example 351 N-{4-[4-amino-7-((lE)-3-{4-[2-(2-thienyl)ethvl]l-piperazmvl}-l-propenyl)thieno[3,2- clp yridm-3-y]1-2-methoxyphenvl) -1 -methyl-1 H-indole-2-carboxamide Prepared from l-[2-(2-thienyl)ethyl]piperazine. ]H NMR (DMSO-d6) 400 MHz) 6 9.52 (s, IH), 8.00 (d, IH), 7.98 (s,'lH), 7.5S-7.72 (m, 4H), 7.29-7.35 (in, 3H), 7.07-7.20 (m, 3H), 6.40-6.90 (m, 2H), 6.70 (d, IH), 6.24 (dt, IH), 5.64 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.20 (d, 2H), 2.96 (t, 2H), 2.50-2.57 (m, 10H), 2.65-2.76 (m, 3H), 2.28-2.50 (m, 2H), 2.10 (s, 6H), 1.85 (s, 12H), 1.59-1.65 (m, IH); reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, C18, 5 urn, 250 x 4.6 column) 1 =13.0 min; MS m/e 661.6 (M-H)+ Example 352 N-{4-[4-aramo-7-((lE)-3-(4-[(2R)-tetrahy propenyl) thieno[3,2-c]pyridin-3-yl]-2-methoxyphenvli-l-methyl-lH-indole-2-carboxamide Prepared as the diacetate salt from l-[(2R)-tetrahydro-2-furanylmethyl]piperazine. 1H NMR (DMSO-d6,400 MHz) 8 9.52 (s, IH), 8.00 (d, IH), 7.97 (s, IH), 7.71 (d, IH), 7.58-20 7.62 (m, 2H), 7.07-7.36 (m, 5H), 6.68 (d, IH), 6.23 (dt, IH), 5.64 (br s, 2H), 4.04 (s, 3H), 3.91 (m, 4H), 3.56-3.73 (dq, 2H), 3.16 (d, 2H), 2.35-2.50 (m, 7H)51.89 (m, 8H), 1.72-1.80 (m, 2H), 1.41-1.49 (m, IH); reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, CIS, 5 urn, 250 x 4.6 column) R==20.0 min; MS m/e 635.5 (M-H)-. Example 353 N-{4-[4-amino-7-((lE)-3-{4-[2-(2-thienyl)ethvl]l-piperazmvl}-l-propenyl)thieno[3,2- c1pvridm-3-yl]-2-memoxyphenyl)-l-memyl-lH-mdole-2-carboxamide Prepared as the tetraacetate salt from 3-(4-methyl-l-piperazinyl)-l-propanamine. 'H 30 NMR (DMSO-o 400 MHz) δ 9.52 (s, IH), 8.00 (d, IH), 7.96 (s, IH), 7.71 (d, IH), 7.58-7.62 (m, 2H), 7.07-7.36 (m, 5H), 6.70 (d, IH), 6.28 (dt, IH), 5.64 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.42 (d, 2H), 2.62 (t, 2H), 2.32-2.34 (m, 8H), 2.30 (s, 3H), 1.83 (s, 12H), 1.60 (m, 2H); reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, C18, 5 urn, 250 x 4.6 column) Rt=9.0 min; MS m/e 666.2 (M+H+CH3CN)+. Example 354 N-(4-[4-amino-7-((lE)-3-{4-[3-('4-morpholinyl')propyl]-l-piperazinyl)-l-. -159- WO 2005/010009 PCT/US 20 04/0 24003 propepyl)thieno[3,2-c]pyridm-3-yl]-2-methox Prepared from 4-[3-(l -piperazinyl)propyl]morpholine as the tetraacetate salt. lH NMR (DMSO-d6, 400 MHz) δ 9.52 (s, 1H), 8.01 (d, 1H), 7.96 (s, 1H), 7.71 (d, 1H), 7.58-7.62 (m, 2H), 7.07-7.36 (m, 5H), 6.66 (d, 1H), 6.25 (dt, 1H), 5.64 (br s, 2H), 4.04 (s, 3H), 5 3.91 (s, 3H), 3.55 (t, 4H), 3.15 (d, 2H), 2.24-2.32 (m, 14H), 1.88 (t, 12H), 1.56 (p, 2H); reverse phase HPLC (5% to 95% acetonitrile over 25 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, CIS, 5 urn, 250 x 4.6 column) R=17.1 min; MS m/e 67S.7 (M-H)+ Example 355 N-{4-[4-amino-7-((lE)-3-{4-[3-(l-pyrrohdinyl)propyl]-l-piperazinyl}-l- propenyl)liiieno[3,2-c]pvridm-3-yl]-2-methoxyphenyl)-l-methyl-lH-indole-2-carboxarpide Prepared as the diacetate salt from l-[3-(l-pyrrolidinyl)propyl]piperazine. 1H NMR (DMSO-d6 400 MHz) δ 9.52 (s, 1H), 8.01 (d, 1H), 7.96 (s, 1H), 7.71 (d, 1H), 7.58-7.62 (m, 2H), 7.07-7.36 (m, 5H), 6.66 (d, 1H), 6.23 (dt, 1H), 5.64 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H), 3.15 (d, 2H), 2.26-2.39 (m, 16H), 1.88 (s, 6H), 1.59-1.66 (m, 6H); reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 run, hypersil HS 100 A, C18, 5 fim, 250 x 4.6 column) Rt=9.4 min; MS m/e 662.5 (M-H)+ Example 356 N-[2-(((2E)-3-[4-amino-3-(3-methoxy-4-([(l-methyl-l-H-indol-2- yl)carbonyl]animo)phenyl) thieno[3,2-c]pyridm-7-vI1-2-propenyl)amino)ethynglycine Prepared as the acetate salt from N-(2-aminoethyl)glycine. 1H NMR (DMSO-dfiJ 400 MHz) 8 9.52 (s, 1H), 8.01 (d, 1H), 8.00 (s, 1H), 7.79 (s, 1H), 7.71 (d, 1H), 7.58-7.62 (m, 2H), 7.07-7.36 (m; 5H), 6.73 (d, 1H), 6.25 (dt, 1H), 5.67 (br s, 2H),-4.04 (s, 3H), 3.91 (s, 3H), 3.20-3.28 (m, 6H), 3.00 (s, 2H), 2.64 ft 2H), 1.88 (s, 3H); reverse phase HPLC (5% to 95% acetonitrile over 10 minutes, 1 mL/min, 254 nm, hypersil HS 100 A, C18, 5 um, 250 x 4.6 column) R=l 1.0 min; MS m/e 565.7 (M-H20)+. Example 357 N-{4-[4-amino-7-((lE)-3-{4-[2-(2-thienyl)ethvl]l-piperazmvl}-l-propenyl)thieno[3,2- c]pvridm-3-yl)-2-memoxvphenyl]-l-memyl-lH-mdole-2-carboxamide Prepared as the tetraacetate salt from (3S)-N -dimethyl-3-pyrrolidinamine. 1H NMR (DMSO-d6, 400 MHz) δ 9.51 (s, 1H), 8.00 (d, 1H), 7.96 (s, 1H), 7.70 (d, 1H), 7.58-7.61 (m, 2H), 7.07-7.36 (m, 5H), 6.68 (d, 1H), 6.23 (dt, 1H), 5.64 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3H),. 35 3.18-3.34 (m, 4H), 2.65-2.76 (m, 3H), 2.28-2.50 (m, 2H), 2.10 (s, 6H), 1.85 (s, 12H), 1.59-1.65 (m, 1H); reverse phase HPLC (5% to 95% acetonitrile over 25 minutes, 1 mL/min, 254 nm- hvnfirsil RS 1 on A Pis 5 um, 250 x 4.6 column) R=20.0 min; MS m/e 579.5 (M-H)'. -160- WO 2005/010009 PCT/US2004/024003 - Example 358 N-{4-[4-amino-7-((lE)-3-{4-[2-(2-thienyl)ethvl]l-piperazmvl}-l-propenyl)thieno[3,2- cbvridin-3-yl]-2-metiioxyphenvn-l-metfavl-lH-indole-2-carboxamde Prepared from N3N-dimethyl-l,4-benzenediamine. 1H NMR (DMSO-d6,400 MHz) 8 9.50 (s, IH), 7.99 (d, IH), 7.94 (s, IH), 7.70 (d, IH), 7.60 (s, IH), 7.58 (d, IH), 7.35 (s, IH), 7.33 (m, IH), 7.19 (m, IH), 7.15 (t, IH), 7.GT(dd, IH), 6.74 (d, IH), 6.62 (m, 4H), 6.33 (m, IH), 5.62 (br s, 2H), 5.3 (br s, IH), 4.03 (s, 3H), 3.90 (s, 3H), 3.86 (d, 2H), 2.71 (s, 6H); MS m/e 603.7 (M+H)+ 601.8 (M-H)+ Example 359 N-[4-(4 amino-7-((lE)-3-[(4-bylroxyGyclohexyl)amino1-l-propenyl)tHeno[3,2-c]pvridin-3-yl)-2-methoxypbenyl]-l-methyl-lH-indole-2-carboxamide Prepared as the diacetate salt from 4-aminocyclohexanol. ]H NMR (DMSO-d , 400 MHz) δ 9.51 (s, IH), 8.00 (d, IH), 7.94 (s, IH), 7.69 (d, IH), 7.62 (s, IH), 7.58 (d, IH), 7.35 15 (s, IH), 7.33 (m, IH), 7.21 (s, IH), 7.15 (t, IH), 7.08 (d5 IH), 6.65 (d, IH), 6.27 (m, IH), 5.61 (br s, 2H), 4.04 (s, 3H), 3.91 (s, 3B), 3.41 (d, 2H), 3.36 (m, IH), 2.4 (m, IH), 1.7-1.9 (m, 4H), 1.89 (s, 3H), 1.11 (m, 4H); MS m/e 582.7 (M+H)+ 580.8 (M-H)+ Example 360' N-{4-[4-amino-7-((lE)-3-{4-[2-(2-thienyl)ethvl]l-piperazmvl}-l-propenyl)thieno[3,2- Example 360A N-{4-[4-amino-7-((lE)-3-{4-[2-(2-thienyl)ethvl]l-piperazmvl}-l-propenyl)thieno[3,2- A mixture of Example 176A (250 mg, 0.70 mmol), 4-phenoxyphenylboronic acid (180 mg, 0.84 mmol), Pd(PPh3)4 (50 mg, 0.04 mmol), and sodium carbonate (150 mg, 1.4 mmol) in 1,2-dimethoxyethane (8 mL) and water (4 mL) was heated to reflux for 15 hours. The mixture was cooled to room temperature and concentrated under reduced pressure. The mixture was extracted with dichloromethane and the extract was dried (MgS04), filtered, and concentrated. The residue was purified by flash column chromatography on silica gel to 30 provide the desired product (170 mg, 55%). 1H NMR (DMSO-dg, 400 MHz) 5 8.00 (s, IH), 7.56 (s, IH), 7.47 (m, 4H), 7.20 (t, IH), 7,13 (m, 4H), 6.81 (d, IH), 6.17 (dd, IH), 5.67 (br s, 2H), 5.13 (d, IH), 3.57 (m, 4H), 1.18 (t, 6H); MS m/e 447.3 (M+H)+. Example 360B (2E)-3-[4-ammo-3-(4-phenoxyphenyl)thieno[3,2 1pvridm-7-yl]acrylaldehyde A mixture of Example 360A (170 mg, 0.38 mmol), p-toluenesulfonic acid (10 mg), acetone (9 mL), and water (1 mL) was stirred for 1.25 hours and concentrated. The residue partioned between saturated aqueous sodium bicarbonate and dichloromethane. The organic -161- WO 2005/010009 PCT/US2004£02-f003 layer was dried (MgS04), filtered, and:Concentrated to provide the desjred product (150 mg). lH NMR (DMSO-d6,400 MHz) δ 9.66 (d, IH), 8.32 (s, IH), 7.89 (d, IH), 7.68 (s, IH), 7.47 (m, 4H), 7.20 (t, IH), 7.14 (m, 4H), 6.65 (dd, IH); MS m/e 373.3'(M+H)+ 371.1 (M-H)+ - Example 360C 7-[(lE)-3-({2-[(2R)4-methyl-2-pyrrolidinvne]thynamino)-l-propenyl]-3-(4- A mixture of Example 360B (30 mg, 0.080 mmol), sodium triacetoxyborohydride (35 mg, 0.16 mmol), 1 drop of acetic acid, and diethylamine (12 mg, 0166 mmol) in 1,2-dichloroethane (2 mL) was stirred for 2 hours at ambient temperature. The mixture was 10 ' concentrated and the residue was purified by reverse phase chromatography followed by lyophilization to provide the desired product as the acetate salt. 1H NMR (DMSO-d 400 MHz) 5 7.94 (s, IH), 7.55 (s, IH), 7.44. (m, 4H), 7.20 (t, IH), 7.11 (m, 4H), 6.67 (d, IH), 6.22 (m, IH), 5.55 (br s, 2H), 3.28 (d, 2H), 2.52 (q, 4H), 1.87 (s, 3H), 1.00 (t, 6H); MS m/e 430.4 (M+H)+ 15 Example 361 7-[(lE)-3-({2-[(2R)4-methyl-2-pyrrolidinvne]thynamino)-l-propenyl]-3-(4- phenoxvphenyl)thieno[3,2-c]pvridm -amine The desired product was prepared as the acetate salt by substituting 2-[(2R)-l-methyl-2-pym)hdmyl]ethanarnine for diethylamine in Example 360. 1H NMR (DMSO-c , 400 MHz) 5 7.96 (s, IH), 7.58 (s, IH), 7.45 (m, 4H), 7.21 (t, IH), 7.13 (m, 4H), 6.76 (d, IH), 6. (m, IH), 5.61 (br s, 2H), 3.54 (d, 2H), 2.95 (m, IH), 2.71 (m, 2H), 2.24 (s, 3H), 2.16 (m, 2H), 1.89 (s, 3H), 1.85 (m, 2H), 1.35-1.67 (m, 4H); MS m/e 483.4 (M+H)+ Example 362 2-(l-{(2E)-3-[4-anmio-3-(4-phenoxvphenyl)thieno[3,2-c]pyridm-7-Yl]-2-propenyl)-4- piperidinyl) ethanol The desired product was prepared as the acetate salt by substituting 2-(4- . 1 piperidinyl)ethanol for diethylamine in Example 360. lH NMR (DMSO-d6, 400 MHz) S 7.94 (s, IH), 7.55 (s, IH), 7.46 (m, 4H), 7.20 (t, IH), 7.12 (m, 4H), 6.64 (d, IH), 6.21 (m, IH), 5.56 (br s, 2H), 4.35 (br s, IH), 3.42 (t, 2H), 3.14 (d, 2H), 2.89 (m, 2H), 1.92 (m, 2H), 1.87 (s, 3H), 1.62 (m, 2H), 1.34 (m, 3H), 1.14 (m, 2H); MS m/e 485.4 (M+H)+ Example 363 2-[((2E)-3-[4-arrmio-3-(4-phenoxvphenyl)thieno[3,2-c]pvriom-7-yl]-2- propenyl}(ethyl)arnino1ethanol The desired product was prepared as the diacetate salt by substituting 2-(emylamino)ethanol for diethylamine in Example 360. 1H NMR (DMSO-d6J 400 MHz) δ -162- WO 2005/010009 PCT/US2004/024003 7.94 (s, 1H), 7.55 (s, 1H), 7.46 (m, 4H), 7.20 ft 1IQ,-7,13-(mj-4H); 6.67 -172- WO 2005/010009 PCTYUS2004/024003 " 384' N-|4-(4-amino-7- {(lE)-3-|.(2'-; hydroxyemyl)amino]-3-oxo-l- propenyl}thieno[3,2-c]pyridin- 3 -yl)-2-methoxyphenyl]-1 - methyl-lH-indole-2- carboxamide 2-atninoetoanol 39.8 2.63 '542.1)' 2,UA 385 N- {4-|4-ammo-7-Ul b>3- {[I-(dimethylamino)ethyl]amino}-3 -oxo-1 -propenyl)thieno [3,2-c]pyridin-3-yl]-2-methoxyphenyl} -1 -methyl-1 H-indole-2-carboxamide N,N-dimethyl- 1,2- ethanediamine 50.5 2.43 569.2 2,1;A 386 M-[4-(4-amino-7-{(lli)-3-L(3-hy droxypropy l)amino] -3 -oxo-l-propenyl}thieno[3,2-c]pyridin-3-yl)-2-methoxyphenyl] -1 -methyl-1H-indole-2-carboxamide 3-ammo-1-propanol 40.5 2.68 556.2 2,1,A 387 N-{4-i4-amuio-7-((lli)-3-{i3- (lH-imidazol-1- yl)propyl]amino} -3 -oxo-1 - propenyl)thieno[3J2-c]pyridin- 3-yl]-2-methoxyphenyl}-l- methyl-lH-indole-2- carboxamide 3-UH- imidazol-1-yl)- 1-propanamine "42.T 2.49 606.0 2,1, A 388 i t N-{4-L4-amino-7-((lH)-3-{[(2S)-2- - dimethylamino)propyl] amino •-3-OXO-1- oropenyl)thieno [3,2-c]pyridin-3-yl]-2-methoxyphenyl} -1 -uethyl-lH-indole-2-;arboxamide N-l(lS)-2- amino-1- methylethyl]- N,N- dimethylamine 50.2 2.40 "583.2 2,1,A -173- WO 2005/010009 PCT/US2004/024003 389 iN-(4-[4-amino-/-((l]ij-i oxo- 3-{[3-(l- pyrrolidinyl)propyl] amino} -1 - prop enyl)thieno[3,2-c]pyridin- 3-yl]-2-methoxyphenyl}-l- methyl-lH-indole-2- carboxamide 3-(l- *-'■ pyrrolidinyl)-!-propanamine 44.2 2.48 609.2 2,1>A 390 i»-{4-L4-amino-7-((lii)-3-{L3- (4- moipholinyl)propyl]amiiio} -3-oxo-1 -prop enyl)thieno [3,2-cJpyridin-3-yl]-2-methoxyphenyl} -1 -methyl-lH-indole-2-carboxamide 3-(4- moipholinyl)-l- propanamine 32.5 2.24 62S.iT 2,1,A 391 jN-{4-[4-amino-7-((lK)-3-{[l- (2,6-dimethoxyb enzyl)-4- piperidinyl]amino} -3-oxo-1 - propenyl)tbieno[3,2-c]pyridin- 3-yl]-2-methoxyphenyl}-l- methyl-lH-indole-2- carboxamide 1-146- dimethoxy- benzyl)-4- piperidinamine 27.0 2.80 731.D 2,1,A 392 N-(4-{4-amino-7-l(lb)-3- ({[(2R)-l-ethyl-2- pyrrolidinyl]methyl}amino)-3- oxo-1 -propenyl]thieno[3,2- c]pyridin-3-yl}-2- methoxyphenyl)-1 -methyl- 1H- indole-2-carboxamide l(2R)-i-ethyl-2- pyrrolidinyl]- methylamine 40.6 2.54 609.2" 2,1,A ■- 393 N-l4-{4-airuno-7-{(lE)-3-l(l-3enzyl-4-piperidinyl)amino] -3-oxo-1 -propenyl} thieno[3,2-c]pyridin-3-yl)-2-methoxyphenyl]-l-methyl-lH-mdole-2-caiboxamide l-benzyl-4-piperidinamine 38.0 2.71 671.0' 2,U. WO 2005/010009 PCT/US2004/024003 394 N-(4-{4-amino-7-L(iJi>3-(Ul-(2-methoxyphenyl)-4- piperidinyl]methyl} amino)-3- oxo-l-propenyl]thieno[3,2- c]pyridin-3-yl}-2- methoxyphenyl)-1 -methyl- 1H- indole-2-carboxamide [I-(2- methoxyphenyl )-4- piperidinyl]-methylamine 21.9 3.5l 701.0 2,1,A 395 N-{4-[4-amino-7-((lJi>3- {[2,3- dihydroxypropyl]amino}-3- oxo-l-propenyl)thieno[3,2- c]pyridin-3-yl]-2- methoxyphenyl} -1 -methyl- lH-indole-2-carboxamide j}-amino-l,2-propanediol 37.5 2.5l y72.0 2,1,A 396 N-{4-[4-amino-'/-((lJti)-3-{[3-(di ethy lamino)propyl] amino} -3-oxo-l-propenyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl} -1 -methyl -lH-indole-2-carboxamide N.N-diethyl- 1,3- propanediamine 31.3 2.56 611.2" 231,A ' 397 N-{4-[4-ammo-7-((lii)-3-U'2- (diethylamino)ethyl]amino}-3- oxo-1 -propenyl)thieno [3,2- c]pyridin-3-yl]-2- methoxyphenyl}-l-methyl- lH-indole-2-carboxamide N,N-diethyl-1,2-ethanedi amine 46.0 2.60 597.2 2,1,A 398 N-(4-{4-amino-7-[(lH)-3- ({[(2S)-l-ethyl-2- pyrroIidinyl]methyl} amino)-3- oxo-l-propenyl]thieno[3,2- c]pyridin-3-yl}-2- methoxyphenyl)-l-methyl-lH- indole-2-caxboxami de [(2S)-l-ethyl-2- pyrrolidinyl]- methylamine 44.2 2.64 609.2 2,1,A -175- WO 2005/0 ] 0009 PCT/US2004/02400. 399 N-{4-[4-ammo-7-((lH)-3-{[2: (dimethylamino)-1 -methylethyl]amino} -3-oxo-l-propenyl)thieno[3J2-c]pyridin-3 -y]]-2-methoxyphenyl} -1 -methyMH-indole-2-carboxamide N-|2- aminopropyl]-N,N-dimethylamine "46.0 2.49 583.2 2,U 400 M- {4-[4-amino-7-((l K)-3-oxo- 3-{[2-(l- pylrolidinyl)ethyl]amino}-l- propenyl)thieno[3,2-c]pyridin- 3-yl]-2-methoxyphenyl} -1 - methyl-lH-indole-2- carboxamide 2-(l- pyrrolidinyl)- ethanamine 43.1 2.53 S95.2 2,U 401 M-{4-[4-anuno-7-((lli)-3-oxo-3-{[2-(2-oxo-l-imidazolidiDyl)ethyl]amino} -1 -propenyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl} -1 -methyl-1 H-indole-2-carboxamide H2- aminoethyl)-2-imidazol-idinone 27.9 2.60 610.0 2,1,A 402 M-{4-l4-amino-7-((lJiJ-3-{L3- (4-methyl-l- piperazinyl)propyl]amino}-3- oxo-1 -propenyl)thieno[3',2- c]pyridin-3-yl]-2- methoxyphenyl} -1 -methyl- lH-indole-2-carboxamide 3-(4-raethyl-l-piperazinyl)-l-propanamine 50.1 2:39 638.2 2, LA 403 N-L4-(4-ammo-7-{(lH)-3-ll- azabicyclo[2.2.2]oct-3- ylamino]-3-oxo-l- propenyl}thieno[3,2-c]pyridin- 3-yl)-2-methoxyphenyl]-1 - methyMH-indole-2- quinucHdin-3-amine 8.1 2.52 607.0 2,1,A :arboxamide -176- WO 2005/010009 PCT/US 2004/0 24003 404 N-(4-{4-ammo-7-L(lE)-3-({2-[l-methyl-2- pyrrolidinyl]ethyl}amino)-3-oxo-1 -propenyl]thieno[3,2-c]pyridin-3-yl}-2-methoxypheoyl)-1 -methyl-1H-indol e-2-carboxamide 2-[l-methyl-2- pyrrolidinyl]- ethanamine 48.9 2.5 609.0 2,1,A 405 N-{4-[4-amino-7-((lii)-3-l[2- (2,4-dioxo-l,3-thiazolidin-3- yl)ethyl]amino}-3-oxo-l- propenyl)thieno[3,2-c]pyridin- 3-yl]-2-methoxyphenyl}-l- methyl-lH-indole-2- carboxamide 3-( -atninoethyl)- 1,3- thiazolidine-2,4-dione 30.0 2.97 641.0 2,1,A 406 N-{4-[4-aimno-7-UlJi>3-{|> (1 -methyl-1 H-pyrrol-2- yl)ethyl]atnino}-3-oxo-l- propenyl)thieno[3,2-c]pyridin- 3-yl]-2-methoxyphenyl}-l- methyl-lH-indole-2- carboxamide 2-(L-methyl-lH-pyrrol-2-yl)etHanamine 30.5 3.27 605.0 1,A 407 N-(4-{4-ammo-7-[(IJbi)-3-((2- [methyl(phenyl)amino]- ethyl)amino)-3-oxo-l- propenyl]thieno[3,2-c]pyridin- 3 -yl} -2-methoxyphenyl)-1 - methyl-lH-indole-2- carboxamide N-(2- aminoethyl)-N-methyl-N-phenylamine 33.6 3. 2 631.0 iw 408 ' N-{4-[4-amino-7-((iK)-3-{|3-(methy lamino)propyl] amino } -3-oxo-l-propenyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl} -1 -methyl- tert-butyl 3-aminopropyl-(methyl)-carbamate 64.7 2.42 569.0 2,1,A 1 H-indole-2-carboxamide 1 -177- WO 2005/010009 PCT/US2004/024003 409 NH4-{4-amrao-7-l(lJj)-3-oxo- 3-({2-[2- piperidinyl]ethyl}amino)-l- propenyl]thieno[3,2-c]pyridin- 3-yl} -2-methoxyphenyl)-1 - methyl-lH-indole-2- carboxamide tert-butyl 2-(2-aminoethyl)-l-piperidine-carboxyl'ate 43.1 "2T6' 609.0 2,1,A ' 410 N-{4-[4-ammo-7-((lls>3-U2-(methylamino)ethyl]amino}-3-oxo-l-propenyl)thieno[3,2-c]pyridin-3-yl]-2-methoxyphenyl} -1 -methyl-1 H-iudole-2-carboxamide tert-butyl 2-aminoethyl-carbamate 55.1 2.41' 555.0 2,1,A 411 N-{4-L4-amino-7-((lii)-3-oxo- 3-{[(3R)-3- pyrrolidinylmethyl]amino}-l- prop enyl)thierio[3,2-cjpyridin- 3-yl]-2-methoxyphenyl} -1 - methyl-lH-indole-2- carboxamide tert-butyl (3i>)- 3- (aminomethyl)- 1-pyrrolidine- carboxylate 66.3 2.42 581'.0 2,1 A' 412 JN-{(2ii>3-L4-amino-3-(3- methoxy-4-{[(l-methyl-lH- indol-2- yl)carbonyl]ammo}phenyl)- thieno[3,2-c]pyridin-7-yl]-2- propenoyl} glycinamide (acetate salt) glycinamide 41.0" '2.47' Wi.i 2,2,B 413 N-(4-{4-amino-7-[(lJbi)-3-amino-3-oxo-l-propenyl]thieno[3,2-c]pyridin-3-yl} -2-metboxyphenyl)-1 -methyMH-indole-2-carboxamide (acetate salt) ammonium hydroxide 21.0 2.92 49S.4 1,2,B 414 " N-(4-{4-amino-y-[(ll±)-3--methylamino)-3 -oxo-1 -propenyl]thieno[3,2-c]pyridin-3-yl} -2-methoxyphenyl)-l - ■nnthvl.1 ET inrlnin 1 , methylamine 22.0 3.1 512.3 1,23 -178- WO 2005/010009 PCT/US2004/024003 methyl-lH-incloie- -carboxamide (acetate salt) - it :i... 415 N-(4-{4-ammo-7-L(lb)-3- (dimethylamino)-3-oxo-l - propenyl]thieno[3,2-c]pyridin- 3-yl}-2-methoxyphenyl)-l- methyl-lH-indole-2- carboxamide N,N-dmetbylamine" 21.0 3.5 526.4 1,2,3 416 ethyl N-{(2bh3-L4-amino-3- (3-methoxy-4-{[(l-7.5, 2.4 Hz, 1 H) 8.97 (s, 1 H) 9.36 (s, 1 H) MS (ESI(+)) m/e 532.1 (M+H)+. Example 424 N-{4-[4-arnmo-7-(l,4-m xa-8-a2aspiroR4.51dec-8-ylmemyl)1hiepo[3,2-c]pyridin-3-yl]phenyl)-N'-[2-fluoro-5-(trirluoromethyl')phenyl]urea Example 424A 3-bromo-7-(l,4-dioxa-8-azasphoR4.51dec-g-ymiemvntheno[3,2-c]pytidm-4-arnine The desired product was prepared substituting l,4-dioxa-8-azaspiroR4.5]decane for morpholine in Example 278B. -181- WO 2005/010009 PCT/US2004/024003 Example 424B N-(4-{4-amino-7-[(diethylamino)methyl]thieno[3,2-c]pyridin-3-yl}phenyl')-N'-[2-fluoro-5- yl]phenyl} -N'-f 2-fluoro-5-(trifluoromethy])phenyl]urea The desired product was prepared substituting Example 424A and N-[4-(4,4,5,5-5 tetramemyl-l,3,2 oxaborolan-2-yl)phenyl]-N'-[2-fluoro-5-(triiluoromethyl)plienyl]ureafor Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1H NMR (300 MHz, DMSO-D6) 6 ppm 1.64 (t, J=5.3 Hz, 4 H) 2.45-2.50 (m, "4 H) 3.61 (s, 2 H) 3.87 (s, 4 H) 5.33 (s, 2 H) 7.39-7.43 (m, 4 H) 7.51 (m, 1 H) 7.60 (d, J=S.5 Hz, 2 H) 7.68 (s, 1 H) 8.64 (dd, J=7.3,2.2 Hz, 1 H) 8.97 (d, J=2.7 Hz, 1 H) 9.35 (s, 1 H) MS (ESI(-)) m/e 10 600.3 (M-H)+ Example 425 N-{4-[4-ammo-7-(lH-ipdol-5-yl)mieno[3,2-c]pyrim -3-yllphenv]}-N'-(3-methylphenyl)urea Example 425A 3-(4-aminophenyl)-7-("lH-mdol-5-yl) thieno[3,2-c]pyridm-4-amine The desired product was prepared substituting Example 77B, indole-5-boronic acid and PdCl,(dppf) for Example 21A, 2-[(lE)-3,3-diethoxy-l-propenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane and Pd(PPh3)4, respectively, in Example 176A. MS (ESI(+)) m/e 357.0 (M+H)+. Example 425B N-{4-[4-ammo-7-(lH-ipdol-5-yl)mieno[3,2-c]pyrim -3-yllphenv]}-N'-(3-methylphenyl)urea The desired product was prepared by substituting Example 425A and l-isocyanato-3- methylbenzene for Example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene, respectively, in Example 122. ]H NMR (300 MHz, DMSO-D6) 6 ppm 2.29 (s, 3 H) 5.42 (s, 2 H) 6.50-6.51 (m, 1 H) 6.81 (d, J=7.1 Hz, 1 H) 7.17 (t, J=7.6 Hz, 1 H) 7.24-7.27 (m, 1 H) 7.32 (s, 1 H) 7.35-7.45 (m, 5 H) 7.53 (d, J=8.1 Hz, 1 H) 7.62 (d, J=8.8 Hz, 2 H) 7.79 (d, J=1.4 Hz, 1 H) 7.88 (s, 1 H) 8.66 (s, 1 H) 8.86 (s, 1 H) 11.21 (s, 1 H) MS (ESI(+)) m/e 490.1 (M+H)+. Example 426 3-(4-ammophenvl)-7-[3-(diemylamino)prop-l-wyl] thieno[3,2H 1pyridin-4- amine The desired product was prepared substituting Example 77B and diethyl-prop-2-I ynylamine for Example 144A and 3-butyn-l-ol, respectively, in Example 144B. 1H NMR (300 MHz, DMSO-D6) 6 ppm 1.06 (t, J=7.1 Hz, 6 H) 2.59 (q, J=7.1 Hz, 4 H) 3.70 (s, 2 H) 1 5.37 (s, 2 H) 5.79 (s, 2 H) 6.67 (d, J=8.5 Hz, 2 H) 7.08 (d, J-8.5 Hz, 2 H) 7.36 (s, 1 H) 7.92 (s, 1 H) MS (ESI(+)) m/e 351.0 (M+H)4". -182- WO 2005/010009 PCT/US2004/024003 Example 427 3-(4-ammophenvl)-7-[3-(diemylamino)prop-l-wyl] thieno[3,2H 1pyridin-4-amine The desired product was prepared substituting Example 77B and dipropyl-prop-2-5 ynylamine for Example 144A and 3-butyn-l-ol, respectively, in Example 144B. 1H NMR (300 MHz, DMSO-D6) δ ppm0.S9 (t, J=7.3 Hz, 6 H) 1.41-1.54 (m, 4 H) 2.46-2.51 (m, 4 H) 3.66 (s, 2 H) 5.37 (s, 2 H) 5.78 (s, 2 H) 6.67 (d, J=8.5 Hz, 2 H) 7.0S (d, J=8.5 Hz, 2 H) 7.36 (s, .1 H) 7.91 (s, 1 H) MS (ESI(+)) m/e 379.1 (M+H)+. Example 428 3"(4-arninopbenyl)-7-[3-(oUmetfaylammo)prop-l-ynyl]thieno[3,2-c]pyridin-4-amnie The desired product was prepared substituting Example 77B and dimethyl-prop-2-ynylamine for Example 144A and 3-butyn-l-ol, respectively, in Example 144B. 1H NMR (300 MHz, DMSO-D6) δ ppm2.33 (s, 6 H) 3.61 (s, 2 H) 5.38 (s, 2 H) 5.81 (s, 2 H) 6.67 (d, J-8.1 Hz, 2 H) 7.09 (d, J=8.1 Hz, 2 H) 7.37 (s, 1 H) 7.95 (s, 1 H) MS (ESI(+)) m/e 323.0 (M+H)+. Example 429 N-(4-{4-amino-7-[3-(m thylammo)prop-l-vnyl]thieno[3,2-c]pyridin-3-vl)plienyl)-N'-[2- fluoro-5-(trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 426 for Example 121B in Example 122. 1H NMR (300 MHz, DMSO-D6) δ ppm1.06 (t, J=7.1 Hz, 6 H) 2.59 (q, J=7.1 Hz, 4 H) 3.70 (s, 2 H) 5.74 (s, 2 H) 7.38-7.43 (m, 3 H) 7.48-7.55 (m, 2 H) 7.62 (d, J=8.8 Hz, 2 H) 7.96 (s, 1 H) 8.63 (dd, J=7.3, 2.2 Hz, 1 H) 8.97 (d, J=2.7 Hz, 1 H) 9.38 (s, 1 H) MS - (ESI(+)) m/e 556.1 (M+H)+. Example 430 N-(4- {4-amino-7-[3-(diethylamino")prop-1 -ynyl]thienof 3,2-c]pyridin-3 - yl} phenyl)-N'-(2- fluoro-5-methylphenyl)urea The desired product was prepared by substituting Example 426 and l-fluoro-2- isocyanato-4-methylbenzene for Example 12 IB and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene, respectively, in Example 122. 1H NMR (300 MHz, DMSO-D6) δ ppm1.06 (t, J=7.1 Hz, 6 H) 2.28 (s, 3 H) 2.59 (q, J=7.1 Hz, 4 H) 3.70 (s, 2 H) 5.75 (s, 2 H) 6.82 (ddd, J=7.8, 5.3, 2.0 Hz, 1 H) 7.12 (dd, J=l 1.2, 8.5 Hz, 1 H) 7.39 (d, J=8.5 Hz, 2 H) 7.51 35 (s, 1 H) 7.61 (d, J=8.5 Hz, 2 H) 7.96 (s, 1 H) 8.00 (dd, J-8.1, 2.0 Hz, 1 H) 8.55 (d, J=2.4 Hz, 1 H) 9.27 (s, 1 H) MS (ESI(+)) m/e 502.1 (M+H)+. -183- WO 2005/010009 PCT/US2004/024003 Example 431 N-(4- {4-amino-7-[3-(diethylamino")prop-1 -ynyl]thienof 3,2-c]pyridin-3 - yl} phenyl)-N'-(2- fluoro-5-methylphenyl)urea The desired product was prepared by substituting Example 426 and l-chloro-3-5 isocyanatobenzene for Example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene, respectively, in Example 122. 1H NMR (300 Ivfflz, DMSO-DJ 8 ppm 1.06 (t, J=7.1 Hz, 6 H) 2.59 (q, J=7.1 Hz, 4 H) 3.70 (s, 2 H) 5.75 (s, 2 H) 7.03 (td, J=4.4, 2.0 Hz, 1 H) 7.29-7.32 (m, 2 H) 7.3S (d, J-8.5 Hz, 2 H) 7.51 (s, 1 H) 7.61 (d, J=8.5 Hz, 2 H) 7.72-7.73 (m, 1 H) 7.96 (s, 1 H) 8.96 (s, 1 H) 8.97 (s, 1 H) MS (ESI(+)) m/e 504.1 (M+H)+. i Example 432 N-(4-{4-ammo-7-[3-(dipropylanimo)prop-l-ynyl]thieno[3,2-c]pyridin-3-yl}phenvl)-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 427 and l-isocyanato-3- methylbenzene for Example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene, respectively, in Example 122. lH NMR (300 MHz, DMSO-DJ 8 ppm 0.90 (t, J=7.5 Hz, 6 H) 1.42-1.54 (m, 4 H) 2.29 (s, 3 H) 2.47-2.52 (m, 4 H) 3.67 (s, 2 H) 5.75 (s, 2 H) 6.81 (d, J=7.8 Hz, 1 H) 7.17 (t, J=7.8 Hz, 1 H) 7.25 (d, J=8.5 Hz, 1 H) 7.3Z& 1 H) 7.37 (d, J-8.5 Hz, 2 H) 7.51 (s, 1 H) 7.60 (d, J=8.5 Hz, 2 H) 7.96 (s, 1 H) 8.66 (s, 1 H) 8.86 (s, 1 H) MS (ESI(+)) m/e 512.2 (M+H)+. i Example 433 N-(4- {4-amino-7-[3-(diethylamino")prop-1 -ynyl]thienof 3,2-c]pyridin-3 - yl} phenyl)-N'-(2- fluoro-5-methylphenyl)urea The desired product was prepared by substituting Example 427 for Example 121B in Example 122. lH NMR (300 MHz, DMSO-D6) 8 ppm 0.90 (t, J-7.3 Hz, 6 H) 1.42-1.54 (m, 4 H) 2.47-2.52 (m, 4 H) 3.67 (s, 2 H) 5.74 (s, 2 H) 7.38-7.43 (m, 3 H) 7.52 (dd, J=11.2, 8.5 Hz, 1 H) 7.53 (s, 1 H) 7.62 (d, J=8.8 Hz, 2 H) 7.96 (s, 1 H) 8.63 (dd, J=7.5, 2.0 Hz, 1 H) 8.98 (s, 1 H) 9.39 (s, 1 H) MS (ESI(+)) m/e 584.1 (M+H)+. 30 Example 434 N-(4- {4-amino-7-[3-(diethylamino")prop-1 -ynyl]thienof 3,2-c]pyridin-3 - yl} phenyl)-N'-(2- fluoro-5-methylphenyl)urea The desired product was prepared by substituting Example 427 and l-fluoro-2-isocyanato-4-methylbenzene for Example 121B and l-fluoro-2-isocyanato-4- (trifluoromethyl)benzene, respectively, in Example 122. 1H NMR (300 MHz, DMSO-D6) 8 ppm 0.90 (t, J=7.3 Hz, 6 H) 1.42-1.54 (m, 4H) 2.28 (s, 3 H) 2.47-2.52 (m, 4 H) 3.67 (s, 2 H) -184- WO 2005/010009 PCT/US2004/024003 5.74 (s, 2 H) 6.79-6.84 (m, 1 H) 7.11 (dd, J=11.4, 8.3 Hz, 1 H) 7.38 (d, J=8.5 Hz, 2 H) 7.52 (s, 1 H) 7.60 (d, J=8.5 Hz, 2 H) 7.95 (s, 1 H) 8.00 (dd, J=7.S, 2.0 Hz, 1 H) 8.54 (d, J=2.7 Hz, 1 H) 9.26 (s, 1 H) MS (ESI(+)) m/e 530.2 (M+H)+. Example 435 N-(4- {4-amino-7-[3-(diethylamino")prop-1 -ynyl]thienof 3,2-c]pyridin-3 - yl} phenyl)-N'-(2- fluoro-5-methylphenyl)urea The desired product was prepared by substituting Example 427 and l-chloro-3-isocyanatobenzene for Example 121B and l-fluoro -isocyanato trifluoromethy benzene, respectively, in Example 122. ]H NMR (300 MHz, DMSOD6) δ ppm0.90 (t, J=7.5 Hz, 6 H) 1.42-1.54 (m, 4 H) 2.47-2.52 (m, 4 H) 3.67 (s, 2 H) 5.74 (s, 2 H) 7.03 (td, J=4.4, 2.0 Hz, 1 H) 7.29-7.32 (m, 2 H) 7-38 (d, J=8.5 Hz, 2 H) 7.52 (s, 1 H) 7.61 (d, J-8.5 Hz, 2 H) 7.72-7.73 (ms 1 H) 7.96 (s, I H) 8.96 (s, 1 H) 8.97 (s, 1- H) MS (ESI(+)) m/e 532.1 (M+H)+ Example 436 N-(4-{4-amino-7-[3-(dipropylammo)prop-l-ynyl]mieno[3,2-c]pyridin-3-yl] phenyl)-N'-[3-(trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 427 and l-isocyanato-3-(trifluoromethyl)benzene for Example 121B and l-fluoro-2-isocyanato-4-(trifluorornethyl)benzene, respectively, in Example 122. ]H NMR (300 MHz, DMSO-Dfi) δ ppm0.90 (t, J=7.3 Hz, 6 H) 1.42-1.54 (m, 4 H) 2.47-2.52 (m, 4 H) 3.67 (s, 2 H) 5.75 (s, 2 H) 7.33 (d, J-7.5 Hz, 1 H) 7.39 (d, J=S.5 Hz, 2 H) 7.50-7.55 (m, 2 H) 7.59-7.64 (m, 3 H) 7.96 (s, 1 H) 8.03 (s, 1 H) 9.02 (s, 1 H) 9.13 (s, 1 H); MS (ESI(+)) m/e 566.2 (M+H)+. Example 437 N-(4- {4-amino-7-[3-(diethylamino")prop-1 -ynyl]thienof 3,2-c]pyridin-3 - yl} phenyl)-N'-(2- fluoro-5-methylphenyl)urea The desired product was prepared substituting Example 77B, pyrimidine-5-boronic acid andPdCl2(dppf) for Example 21 A, 2-[(lE)-3,3-diethoxy-l-propenyl]-4,4,5,5-tetrarhethyl-l,3,2-dioxaborolane and Pd(PPh3)4, respectively, in Example 176A. lH NMR (300 MHz, DMSO-Dg) δ ppm5.40 (s, 2 H) 5.80 (s, 2 H) 6,69 (d, J=8.5 Hz, 2 H) 7.11 (d, J=8.5 Hz, 2 H) 7.39 (s, 1 H) 8.01 (s, 1 H) 9.13 (s, 2 H) 9.22 (s, 1 H) MS (ESI(+)) m/e 320.0 (M+H)+. ' Example 438 N-(4- {4-amino-7-[3-(diethylamino")prop-1 -ynyl]thienof 3,2-c]pyridin-3 - yl} phenyl)-N'-(2-fluoro-5-methylphenyl)urea The desired prepared by substituting Example 437 product was and l-chloro-3-isocyanatobenzene for Example 121B and l-fluoro -isocyanato trifluoromethytybenzene, WO 2005/010009 PCT/US2004/024003 respectively, in Example 122. 1H NMR (300 MHz, DMSO-D6) 6 ppm 5.74 (s, 2 H) 7.04 (dt J=6.1, 2.4 Hz, 1 H) 7.30-7.33 (m, 2 H) 7.42 (d, J=8.5 Hz, 2 H) 7.55 (s, 1 H) 7.63 (d, J=8.5 Hz, 2 H) 7.73 (s, 1 H) 8.04 (s, 1 H) 8.98 (s, 1 H) 9.00 (s, 1 H) 9.14 (s, 2 H) 9.23 (s, 1 H) MS ;BSI(+)) m/e 473.0 (M+H)+ Example 439 N-[4-(4-ammo-7-pvrinn'dm-5-yl]thieno[3,2-c]pvridin-3-vl')pheriyl]-N'-[3-(trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 437 and l-isocyanato-3-(trifluorornethyl)benzene for Example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene, respectively, in Example 122. 1H NMR (300 MHz, DMSO-D6) δ ppm5.74 (s, 2 H) 7.33 (d, J=7.5 Hz, 1 H) 7.42 (d, J-8.S Hz, 2 H) 7.53 (t, J-8.0 Hz, 1 H) 7.55 (s, 1 H) 7.59-7.66 (m, 3 H) 8.03-8.04 (m, 2 H) 9.03 (s, 1 H) 9.14 (app. s., 3 H) 9.23 (s, 1 H) MS (ESI(+)) m/e 507.0 (M+H)+. Example 440 3-(4-animopheayl)-7-(2-memoxypyrimidin-5-vl)thieno[3,2-c]pyridm The desired product was prepared substituting Example 77B, 2-memoxypyrimidine-5-boronic acid and PdCl2(dppf) for Example 21 A, 2-[(lE)-3,3-diethoxy-l-propenyl]-4,4,5,5-tetramethyl-l,3,2-dioxaborolane and Pd(PPh3)4, respectively, in Example 176A. 1H NMR (300 MHz, DMSO-D6) δ ppm4.00 (s, 3 H) 5.39 (s, 2 H) 5.70 (br. s., 2 H) 6.69 (d, J=8.5 Hz, 2 H) 7.10 (d, J=8.5 Hz, 2 H) 7.37 (s, 1 H) 7.90 (s, 1 H) 8.88 (s, 2 H) MS (ESI(+)) m/e 350.0 (M+H)+. Example 441 N-(4-{4-ammo-7-[3-(dimemylammo)prop-l-vnyl]tlu no[3,2-c]pvridm-3 yl)ph methylphenyl)urea The desired product was prepared by substituting Example 42S and l-isocyanato-3-methylbenzene for Example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene, respectively, in Example 122. lH NMR (300 MHz, DMSO-DJ δ ppm2.29 (s, 3 H) 2.30 (s, 6 H) 3.56 (s, 2 H) 5.75 (s, 2 H) 6.80 (d, J=7.1 Hz, 1 H) 7.17 (t, J=7.8 Hz, 1 H) 7.25 (d, J-8.5 Hz, 1 H) 7.31 (s, 1 H) 7.38 (d, J=8.5 Hz, 2 H) 7.51 (s, 1 H) 7.60 (d, J=S.5 Hz, 2 H) 7.98 (s, 1 H) 8.67 (s, 1 H) 8.87 (s, 1 H) MS (ESI(+)) m/e 456.1 (M+H)+ Example 442 N-(4- {4-amino-7-[3-(diethylamino")prop-1 -ynyl]thienof 3,2-c]pyridin-3 - yl} phenyl)-N'-(2- fluoro-5-methylphenyl)urea -186- WO 2005/010009 PCT/US2004/024003 The desired product was prepared by substituting Example 428-and l-isocyanato-3-(trifluoromethyl)benzene for Example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene, respectively, in Example 122. 1HNMR (300 MHz, DMSO-D6) δ ppm2.30 (s, 6 H) 3.56 (s, 2 H) 5.75 (s, 2 H) 7.33 (d, J=7.5 Hz, 1 H) 7.40 (d, J-8.5 Hz, 2 H) 5 7.51 (s, 1 H) 7.53 (t, J=7.8 Hz, 1 H) 7.58-7.64 (m, 3 H) 7.98 (s, 1 H) 8.03 (s, 1 H) 9.02 (s, 1 H) 9.13 (s, 1 H) MS (ESI(+)) m/e 510.1 (M+H)+. Example 443 N-(4-{4-ammo-7-[3-(dimethylaimno)prop-l-vnynthieno[3,2-c]pyridm-3-yl}phenyl)-N'-[2- fluoro-5-(trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 428 for Example 121B in Example 122. 1H NMR (300 MHz, DMSO-D6) 8 ppm 2.30 (s, 6 H) 3.56 (s, 2 H) 5.75 (s, 2 H) 7.38-7.44 (m, 3 H) 7.48-7.55 (m, 2 H) 7.62 (d, J-8.8 Hz, 2 H) 7.98 (s, 1 H) 8.63 (dd, J=7.3, 2.2 Hz, 1 H) 8.97 (d, J=2.4 Hz, 1 H) 9.38 (s, 1 H) MS (ES1(+)) m/e 528.0 (M+H)+. 15 Example 444 N-(4-{4-arnino-7-[3-(diethylamino)propyl]thieno[3,2-c]pvridin-3-yl}phenyl)-N'-(3- methylphenyl)urea A mixture of Example 153 (185 mg, 0.53 mmol) and 10% Pd/C (37 mg) in MeOH . (10 mL) was stirred under hydrogen (60 psi) for 16 h. The catalyst was removed by filtration through Celite, and the filtrate was concentrated to dryness. The residue was purified by flash chromatography on silica gel to give the desired product (107 mg, 72%). 1H NMR (300 MHz, DMSO-De) δ ppm0.95 (t, J=7.1 Hz, 6 H) 1.73-1.82 (m, 2 H) 2.29 (s, 3 H) 2.41-2.50 (m, 6 H) 2.6S-2.73 (m, 2 H) 5.25 (s, 2 H) 6.80 (d, J=7.5 Hz, 1 H) 7.17 (t, J=7.8 Hz, 1 H) 7.25 25 (d, J-8.5 Hz, 1 H) 7.31 (s, 1 H) 7.36 (d, J=8.5 Hz, 2 H) 7.43 (s, 1 H) 7.59 (d, J=8.5 Hz, 2 H) 7.68 (s, 1 H) 8.66 (s, 1 H) 8.85 (s, 1 H) MS (ESI(+)) m/e 4SS.1 (M+H)+. Example 445 N-[4-(4-amino-7-pyridm-2-vlthieno[3,2-c]pvridin-3-yl')phenyl]-N'-(3-methylphenvl)urea Example 445A tert-butyl 4-(4-ammo-7-pYridb-2-vlthieno[3,2-c]pyridin-3-yl)phenylcarbamate A suspension of Example 77A (734 mg, 1.6 mmol) and pyridyl-2-trimethylstannane (418 mg, 1.72 mmol) in DME (12 mL) was degassed with nitrogen, and PdCl2(o-tol3P)2 (62 35 mg, 0.078 mmol) and Cul (15 mg, 0.078 mmol) were added. The reaction vessel was sealed and the reaction was heated to 90°C for 16 h. After cooling, the mixture was partitioned between EtOAc and H20. The extracts were dried (Na2S04) and concentrated, and the -187- WO 2005/010009 PCT/US2004/024003 residue was purified by flash chromatography on silica gel; eluting' with40-75% fitOAc/ hexanes to give the desired product (222 mg). MS (ESI(+)) m/e 419.0 (M+H)+. Example 445B 3-(4-aminophenyl)-7-pyridm-2-ylthieno[3,2-c]pyridm-4-arnine The desired product was prepared by substituting Example 445A for Example 76B in Example 76C. MS (ESI(+)) m/e 319.0 (M+H)+. Example 445C N-[4-(4-amino-7-pyridin-2-yl thieno[3,2-c]pyridin-3-vl)phenyl]-N'-(3-meuivlphenyl)urea The desired product was prepared by substituting Example 445B for Example IC in Example ID. The product was purified by preparative HPLC on a Waters Symmetry C8 column (25 mm x 100 mm, 7 urn particle size) using a gradient of 10% to 100% acetomtrile.'0.1 % aqueous TFA over 8 min (10 min run time) at a flow rate of 40 ml/min to give the desired product as the tnfluoroacetic acid salt. 1H NMR (300 MHz, DMSO-DJ δ ppm2.29 (s, 3 H) 6.81 (d, J=7.5 Hz, 1 H) 6.89 (br. s., 2 H) 7.17 (t, J=7.6 Hz, 1 H) 7.27 (d, J=8.5 Hz, 1 H) 7.33 (s, 1 H) 7.-[4-7.48 (m, 3 H) 7.66 (d, J=8.5 Hz, 2 H) 7.85 (s, 1 H) 8.00 (td, J=7.8, 1.7 Hz, 1 H) 8.21 (d, J=8.1 Hz, 1 H) 8.70 (s, 1 H) 8.78-S.82 (m, 2 H) 9.05 (s, 1 H) MS (ESI(+)) m/e 452.1 (M+H)+. Example 446 N-[4-(4-ainmo-7-pyridm-2-yltrieno[3,2-cfc (trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 445B and l-fluoro-2- isocyanato-4-(trifluoromethyl)benzene for Example IC and l-isocyanato-3-methylbenzene, respectively, in Example ID. The product was purified by preparative HPLC on a Waters Symmetry CS column (25 mm x 100 mm, 7 |im particle size) using a gradient of 10% to 100% acetonitrile:0.1% aqueous TFA over 8 min (10 min run time) at a flow rate of 40 ml/min to give the desired product as the tnfluoroacetic acid salt. ]H NMR (300 MHz, 30 DMSO-Dg) δ ppm7.03 (br. s., 2 H) 7.39-7.45 (m, 1 H) 7.46-7.56 (m, 4 H) 7.68 (d, J=S.5 Hz, 2 H) 7.90 (s, 1H) 8.02 (td, J=7.8,1.7 Hz, 1 H) 8.22 (d, J=8.1 Hz, 1 H) 8.63 (dd, J=7.3,2.2 Hz, 1 H) 8.71 (s, 1 H) 8.80 (ddd, J=4.8, 1.8, 0.9 Hz, 1 H) 9.02 (d, J=3.1 Hz, 1 H) 9.48 (s, 1 H) MS (ESI(+))-m/e 524.0 (M+H)+. Example 447 N-[4-(4-ammo-7-pyrife-2-yl thieno[3,2-c]pyridin-3-yl)phenyl]-N'-[3-(trifluoromethyl)phenyl]urea 488- WO 2005/010009 PCT/US2004/024003 The desired product was prepared by substituting Example 445B and l-isocyanato-3-(trifluoromethyl)benzene for Example 1C and l-isocyauato-3-methylbenzene, respectively, in Example ID. The product was purified by preparative HPLC on a Waters Symmetry C8 column (25 mm x 100 mm, 7 um particle size) using a gradient of 10% to 100% acetonitrile:0.1 % aqueous TFA over 8 min (10 min run time) at a flow rate of 40 ml/min to give the desired product as the trifluoroacetic acid salt. 1H NMR (300 MHz, DMSO-D6) δ ppm6.99 (br. s, 2 H) 7.33 (d, J=7.8 Hz, 1 H) 7.45-7.50 (m, 3 H) 7.54 (t, J=7.8 Hz, 1 H) 7.62 (d, J=8.1 Hz, 1 H) 7.69 (d, J=8.5 Hz, 2 H) 7.90 (s, 1 H) 8.02 (td, J=7.8, 2.0 Hz, 1 H) 8.06 (s, 1 H) 8.22 (d, J=8.1 Hz, 1 H) S.71 (s, 1 H) 8.80 (ddd, J=4.S, 1.7,1.0 Hz, 1 H) 9.26 (s, 1 H) 9.33 10 (s, 1 H) MS (ESI(+)) m/e 506.0 (M+H)+. Example-448 3-[4-amino-3-(lH-mdol-6-yl)thieno[3,2-c]pyridin-7-yl]-N-methylpropanamide The desired product was prepared by substituting Example 286 for Example 14 in Example 15. 1H NMR (300 MHz, DMSO-D6) 8 ppm 2.49 (m, 2H), 2.58 (d, J=4.8 Hz, 3H), 2.93 (t, J=7.6 Hz, 2H), 5.25 (br s, 2H), 6.52 (m, 1H), 7.04 (dd, J=8.14, 1.4 Hz, 1H), 7.44 (m, 3H), 7.66 (m, 2H), 7.81 (q, J-4.8 Hz, 1H), 11.28 (s, 1H); MS ESI(+)) m/e 351 (M+H)+. Example 449 . 3-[4-amino-3-(lH-indol-5-vl) thieno[3,2-c]pyridin-7-yl]-N-methylpropanamide The desired product was prepared by substituting Example 29 for Example 14 in Example 15. 1H NMR (300 MHz, DMSO-D6) 6 ppm 2.49 (m, 2H), 2.57 (d, J=4.8 Hz, 2H), 2.92 (t, J=7.6 Hz, 1H), 5.23 (br s, 2H), 6.48 (m: 1H), 7.12 (dd, J=8.1,1.7 Hz, 1H), 7.40 (s, 1H), 7.45 (m, 1H), 7.52 (d, J=8.1 Hz, 1H), 7.59 (s, 1H), 7.63 (s, 1H), 7.S1 (q, J-3.7 Hz, 1H), 1131 (br s, 1H); MS ESI(+)) m/e 351 (M+H)+. Example 450 3-[4-arnmo-3-(4-ammophenyl)thieno[3,2-c]pyridm-7-yl]-N-methylpropanamide The desired product was prepared by substituting Example 112B for Example 14 in Example 15. 1H NMR (300 MHz, DMSO-D6) 6 ppm 2.45 (m, 2H), 2.56 (d, J=4.4 Hz, 3H), 2.90 (t, J=7.6 Hz, 2H), 5.34 (s, 4H), 6.66 (d, J=8.5 Hz, 2H), 7.07 (d, J=8.5 Hz, 2H), 7.29 (s, 1H), 7.61 (s, 1H), 7.79 (q, J=4.41 Hz, 1H); MS ESI(+)) m/e 327 (M+H)+. Example 451 7-(3-ammophenyl)-3-(4-ammophenyl) thieno[3,2-c]pyridin-4-amine The desired product was prepared by substituting Example 77B and 3-aminophenylboronic acid for Example IB and 4-phenoxyphenylboronic acid, respectively, -189- WO 2005/010009 PCT/US2004/0 24003 in Example 10A, I:HNMR (300 MHz, DMSO-D6) δ ppm5.22 (brs, 2H), 5.35 (brs; 2H), 5.52 (br s, 2H), 6.57 (m, IH), 6.68 (d, J=8.5 Hz, 2H), 6.77 (d, J=8.1 Hz, IH), 6.83 (m, IH), 7.12 (m, 3H), 7.31 (s, IH), 7.78 (s, IH); MS ESI(+)) m/e 333 (M+H)+. Example 452 3,7-bis(4-aminophenyl)thienor3,2-c]pyridm-4-amine The desired product was prepared by substituting Example 77B and 4-aminophenylboronic acid for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1H NMR (300 MHz, DMSO-D δ ppm5.23 (br s, 2H), 5.35 (br s, 2H), 5.42 (br s, 2H), 6.68 (d, J=7.8 Hz, 4H), 7.10 (d, J=8.5 Hz, 2H), 7.29 (m, 3H), 7.73 (s, IH); MS ESI(+)) m/e 333 (M+H)+. Example 453 N-{3-[4-arm o-3-(4-aminophenvl)tlueno[3,2-c]pyridm-7-yl]phenyl}acetarhide The desired productwas prepared by substituting Example 77B and 3-acetamidophenylboronic acid for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1H NMR (300 MHz, DMSO-D6) δ ppm2.07 (s, 3H), 5.38 (br s, 2H), 5,60 (br s, 2H), 6.68 (d, J=8.5 Hz, 2H), 7.11 (d, J=8.5 Hz, 2H), 7.30 (d, J=8.1 Hz, IH), 7.34 (s, IH), 7.42 (t, J=8.0 Hz, IH), 7.58 (d, J=8.8 Hz, IH), 7.84 (s, IH), 7.95 (m, IH), 10.06 (s, IH); MS ESI(+)) m/e 375 (M+H)+. Example 454 N-(4-[4-arru o-3-(4-arnmophenyl)thieno[3,2-c]pyridin-7-yl]phenvl]acetamide The desired product was .prepared by substituting Example 77B and 4-acetamidophenylboronic acid for Example IB and 4-phenoxyphenylboronic acid, . respectively, in Example 10A. 1H NMR (300 MHz, DMSO-D6) δ ppm2.08 (s,3H), 5.36 (br s, 2H), 5.55 (br s, 2H), 6.68 (d, J=8.5 Hz, 2H), 7.10 (d, J=8.5 Hz, 2H), 7.32 (s, IH), 7.57 (m, 2H), 7.70 (m, 2H), 7.83 (s, IH), 10.05 (s, IH); MS ESI(+)) m/e 375 (M+H)+. Example 455 N-(4-[4-arru o-3-(4-arnmophenyl)thieno[3,2-c]pyridin-7-yl]phenvl]acetamide The desired product was prepared by substituting Example 77B and phenylboronic if acid for Example IB and 4-phenoxyphenylboronic acid, respectively, in.Example 10A. 1H NMR (400 MHz, DMSO-DJ 6 ppm 5.36 (br s, 2H), 5.58 (br s, 2H), 6.69 (d, J=8.3 Hz, 2H), 7.12 (d, J=8.3 Hz, 2H), 7.32 (s, IH), 7.40 (t, J=7.4 Hz, IH), 7.51 (t, J=7.7 Hz, 2H), 7.66 (d, J=7.4 Hz, 2H), 7.87 (s, IH); MS ESI(+)) m/e 318 (M+Hf. -190- WO 2005/010009 PCT/US2004/024003 Example 456 4-[4-ammo-3-(4-aminophenyl)thieno[3,2-c]pylidm-7-yl]benzonitrile The desired product was prepared by substituting Example 77B and 4-cyanophenylboronic acid for Example IB and 4-phenoxyphenylboronic acid, respectively in Example 10A. 1H NMR (300 MHz, DMSO-D6) 8 ppm 5.39 (s, 2H), 5.76 (br s, 2H), 6.69 (d, J=8.5 Hz, 2H), 7.11 (d, J=8.5 Hz, 2H), 7.3S (s, IH), 7.89 (d, J=8.1 Hz, 2H), 7.97 (d, J=7. Hz, 3H); MS ESI(+)) m/e 343 (M+H)+. Example 457 N-{3-[4-arm o-3-(4-aminophenvl)tlueno[3,2-c]pyridm-7-yl]phenyl}acetarhide The desired product was prepared by substituting Example 77B and 3-(methylsulfonylamino)phenylbororiic acid for Example IB and 4-phenoxyphenylboronic acid, respectively, in' Example 10A. !H NMR (300 MHz, DMSO-D6) δ ppm3.07 (s, 3H), 5.37 (s, 2H), 5.62 (br s, 2H), 6.68 (m, 2H), 7.11 (d, J=S.5 Hz, 2H), 7.22 (m, IH), 7.37 (m, 2H), 7.47 (t, J=9.0 Hz, IH), 7.53 (t, J=1.9 Hz, IH), 7.86 (s, IH), 9.91 (s, IH); MS ESI(+)) m/e411(M+H)+. Example-458 N-{4-[4-ammo-3-(4-animophenvl)thieno[3,2-c]pyridm-7-vHphenyl}mem The desired product was prepared by substituting Example 77B and 4-(methylsulfonylamino)phenylboronic acid for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. ]H NMR (300 MHz, DMSO-Dg) δ ppm3.06 (s, 3H), 5.37 (s, 2H), 5.57 (br s, 2H), 6.68 (d, J=8.5 Hz, 2H), 7.10 (d, J=8.5 Hz, 2H), 7.33 (t, J-4.2 Hz, 3H), 7.63 (d, J=8.8 Hz, 2H), 7.84 (s, IH), 9.88 (s, IH); MS ESI(+)) m/e 411 (M+H)+. Example 459 3-(4-animophenyl)-7-[2-phenylvmvl1thieno[3,2-c]pyridm -amine The desired product was prepared by substituting Example 77B and phenylethyleneboronic acid for Example IB and 4-phenoxyphenylboronic acid, respectively in Example 10A. 1H NMR (300 MHz, DMSO-D6) δ ppm5.38 (s, 2H), 5.71 (br s, 2H), 6.65 (d, J-8.5 Hz, 2H), 7.13 (m, 3H), 7.26 (t, J=7.3 Hz, IH), 7.39 (m, 4H), 7.62 (d, J=7.5 Hz, 2H 8.11 (s, IH); MS ESI(+)) m/e 3-R4(M+H)+. Example 460 N-{4-[4-amino-7-(4-arm ophenyl)thieno[3-,2-c]pyridin-3-yl]phenyl}-N'-(3- methylphenyl)urea -191- WO 2005/010009 PCTYUS2004/024003 Example 460A N-[4-(4-ammo-7-iodotaienor3J-c]pyridin-3-vl)pheiivl1-N'-(3-methvlphenyl)urea The desired product was prepared by substituting Example 77B for Example 1C in Example ID. ]H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3H), 5.59 (s, 2H), 6.81 (d, J=7.1 Hz, IH), 7.17 ft J=7.6 Hz, IH), 7.25 (m, IH), 7.31 (s, IH), 7.37 (d, J= S.5 Hz, 2H), 7.53 (s, IH), 7.60 (d, J=8.8 Hz, 2H), 8.01 (s, IH), 8.65 (s, IH), 8.86 (s, IH); MS ESI(+)) m/e 501 (M+H)+. Example 460B N-{4-[4-ammo-7-(4-aim ophenvl)thieno[3,2-c]pyridin-3-vl1pheayl)-N1-(3- methylphenyl)urea The desired product was prepared by substituting Example 460A and 4-aminophenylboronic acid for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1H NMR (300 MHz, DMSO-Dg) 8 ppm 2.29 (s, 3H), 5.41 (m, 4H), 6.69 (d, J=8.5 Hz, 2H), 6.81 (d, J=7.5 Hz, IH), 7.17 ft J=7.8 Hz, IH), 7.29 (m, 4H), 7.39 (d, J=8.5 Hz, 2H), 7.45 (s, IH), 7.61 (d, J=8.5 Hz, 2H), 7.77 (s, IH), 8.67 (s, IH), 8.87 (s, IH); MS ESI(+))m/e466(M+H)+. Example 461 N-{4-[4-arjimo-7-(3-animophenyl)theno[3,2-c]pyridin-3-yl]phenyl)-N'--(3- methylphenyl)urea The desired product was prepared by substituting Example 460A and 3-aminophenylboromc acid for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3H), 5.23 (s, 2H), 5.47 (s, 2H), 6.59 (dd, J-8.1,1.4 Hz, IH), 6.79 ft J=7.S Hz, 2H), 6.84 (m, J=2.0 Hz, IH), 7.16 (m, 2H), 7.26 (m, IH), 7.31 (m, IH), 7.40 (d, J=8.8 Hz, 2H), 7.45 (s, IH), 7.61 (d, J=8.5 Hz, 2H), 7.82 (s, IH), 8.66 (s, IH), 8.86 (s, IH); MS ESI(+)) m/e 466 (M+H)+. Example 462 N-{4-[4-arjimo-7-(3-animophenyl)theno[3,2-c]pyridin-3-yl]phenyl)-N'--(3- methylphenyl)urea The desired product was prepared by substituting Example 460A and 4-(N,N-dimethylamino)phenylboromc acid for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. ]H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3H), 2.96 (s, 6H), 5.40 (br s, 2H), 6.81 (d, J=7.5 Hz, IH), 6M (d, J=8.8 Hz, 2H), 7.17 ft J=7.6 Hz, IH), 7.26 (m, IH), 7.32 (s, IH), 7.39 (d, J=S.S Hz, 2H), 7.44 (m, IH), 7.48 (d, J=8.8 Hz, 2H), 7.61 (d, J-8.8 Hz, 2H), 7.81 (s, IH), 8.66 (s, IH), 8.85 (s, IH); MS ESI(+)) m/e 494 (M+H)+: -192- WO 2005/010009 PCT/US2004/024003 Example 463 N-{4-[4-amino-7-(4-formylphenyl)thieno [3,2-c]pyridm-3-vl1phenvl}-N’-(3- methylpheiryDurea The desired product was prepared by substituting Example 460A and 4-formylphenylboronIclicid for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1HNMR (300 MHz, DMSO-D,) 6 ppm 2.29 (s, 3H), 5.71 (br s, 2H), 6.81 (d, J=7.1 Hz, IH), 7.17 (t, J=7.6 Hz, IH), 7.26 (m, IH), 7.32 (s, IH), 7.41 (d, J=8.5 Hz, 2H), 7.52 (s, IH), 7.62 (d, J=8.5 Hz, 2H), 7.94 (d, J=8.5 Hz, 2H), 8.06 (m, 3H), 8.68 (s, IH), 8.88 (s, IH), 10.07 (s, IH); MS ESI(+)) m/e 479 (M+H)+. Example 464 N-(4-{4-animo-7-[3-oxoprop-l-enyl]thieno[3,2-c]pvridin-3-yUphenyl')-N'"(3- methylphenyl)urea Example 464A N-(4-{4-amino-7-[3,3-diethoxyprop4-enyl]thieno[3,2-c]pyTidin-3-yl]plienyl')-N,-(3- methylphenyl)urea The desired product was prepared by substituting Example 460A for Example 21A in Example 176A. 1HNMR(300 MHz, DMSO-Dg) δ ppm1.19 (m, 6H), 2.29 (s, 3H), 3.54 (m, 2H), 3.65 (m, 2H), 5.13 (d, JM5.1 Hz, IH), 5.65 (br s, 2H), 6.18 (t, J=4.6 Hz, IH), 6.83 (m5 2H), 7.17 (t, J=7.8 Hz, IH), 7.25 (m, IH), 7.32 (s, IH), 7.38 (d, J=S.S Hz, 2H), 7.52 (s, IH), 7.60 (d, J=8.8 Hz, 2H), 7.99 (s, IH), 8.65 (s, IH), 8.86 (s, IH); MS ESI(+) m/e 503 (M+H)+. Example 464B N-(4-{4-amino-7-[3-oxoprop-l-enyl]thieno[3,2-c]pyridin-3-yUphenyl)-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 464A for Example 176B in Example 176C. !H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3H), 6.66 (dd, J=16.0, 7.46 Hz, IH), 6.81 (d, J=7.5 Hz, IH), 7.17 (t, J=7.8 Hz, IH), 7.26 (m, IH), 7.32 (s, IH), 7.40 (d, J=8.5 Hz, 2H), 7.63 (apparent d, J=8.8 Hz, 3H), 7.89 (d, J=16.0 Hz, IH), 8.31 (s, IH), 8.67 (s, IH), 8.88 (s, IH), 9.66 (d, J=7.5 Hz, IH); MS ESI(+)) m/e 429 (M+H)+. Example 465 N-{4-[4-arjimo-7-(3-animophenyl)theno[3,2-c]pyridin-3-yl]phenyl)-N'--(3- methylphenyl)urea -193- WO 2005/010009 PCT/US2004/024003 The desired product was prepared by substituting Example 464B for Example 176C in Example 177. 1H NMR (300 MHz, DMSO-D6) 6 ppm 1.03 (t, J=7.1 Hz, 6H), 2.29 (s, 3H) 2.57 (br m, 4H) 5.56 (br s, 2H), 6.24 (dt, J=1S.0,6.0 Hz, IH) 6.77 (d, J=1S.0 Hz, IH) 6.80 (d, J=7.1 Hz, IH), 7.17 (t, J=7.6 Hz, IH), 7.32 (s, 1H),'7.26 (d, J=9.0 Hz, IH) 7.37 (d, J=8.5 Hz, 2H), 7.50 (s, IH), 7.60 (d, J=8.8 Hz, 2H), 7.93 (s, IH), 8.69 (s, IH), 8.90 (s, IH); MS ESI(+)) m/e486(M+H)+- Example 466 3-[4-amino-3-(2-methyl-lH-mdol-5-yl)thieno[3,2-c]pvridin7-yl]-N-[2- (diethylamino)ethyl]acrylamide Example 466A tert-butyl 3-[4-arnmo-3-brQmothieno[3,2-c]pyridin-7-yl)acrylate The desired product was prepared by substituting Example2lA for Example 10B in Example 11 A. Example 466B 3-(4-arnino-3-bromothieno[-3,2-c]pyridin-7-yl)acrylic acid The desired product was prepared by substituting Example 466A for Example 11A in Example 1 IB. Example 466C 3-[4-amino-3-(2-methyl-lH-mdol-5-yl)thieno[3,2-c]pvridin7-yl]-N-[2-(diethylamino)ethyl]acrylamide The desired product was prepared by substituting Example 466B and N,N-diethylethane-l,2-diamine for Example!IB and piperazin-2-one, respectively, in Examples 11C. MS ESI(+)) m/e 397.0, 398.6 (M+H)+. Example 466D 3-[4-animo-3-(2-memyl4H-mdol-5-vl)thieno[3,2-c]pyridm-7-vl]-N-[2- (diethylamino)ethyl]acrylamide The desired product was prepared by substituting Example 466C and 2-methyl-lH-indol-5-ylboronic acid for Example 2IB and 4-chlorophenylboronic acid in Example 21C. 1H NMR (300 MHz, DMSO-D δ ppm1.23 (t, J=7.3 Hz, 6H), 2.43 (s, 3H), 3.18-3.27 (m, 5H), 3.57 (q, J=5.8 Hz, 2H), 6.22 (s, IH), 6.71 (d, J-15.9 Hz, IH), 7.08 (dd, J=8.3,1.5 Hz, IH), 7.44 (d, J-8.1 Hz, IH), 7.51 (s, IH), 7.67 (d, J=15.9 Hz, IH), 7.79 (s, IH), 8.22 (s, IH), J.62 (t, J=5.4 Hz, IH), 9.11-9.19 (m, IH), 11.24 (s, IH); MS'(ESI(+)) m/e 448.2 (M+H)+. Example 467 -194- VO 2005/010009 PCT/US2004/024003 N-{-4[4-amino-7-(2-memy1-1H-indol-5-vl)thino[3,2-c]phenyl}-N-(3- Methylphenyl)urea Example 467A 2-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-vl)-lH-mdole A solution of 5-bromo-2-methyl-lH-indole (5.04 g, 24 mmol) in THF (25 mL) was added dropwise to a suspension of potassium hydride (3.2 g, 24 mmol) in THF at 0 °C. After fifteen minutes at 0 °C, the solution was cooled to -78 °C and a t-butyl lithium solution (1.7 M in pentane, 28.2 mL, 48 mmol) was added dropwise via syringe while maintaining the temperature below -55 °C. After an additional 15 minutes, the solution was cooled to -78 °C and treated with a 2-isopropoxy-4,4,5,54etramethyl-[l,3,2]dioxaborolane (9.8 mL, 48 mmol) dropwise via syringe. The solution was stirred at -78 °C for 1.5 hours, allowed to warm to room temperature and quenched with saturated aqueous ammonium chloride. The solution was diluted with ethyl acetate and filtered to remove inorganic material. The filtrate was extracted with ethyl acetate. The combined organics were washed with brine, dried (MgSOJ and concentrated. The concentrate was purified by flash chromatography on silica gel using 10% ethyl acetate/hexanes to give 3.9 g (63% yield) of the desired product. MS (ESI(+)) m/e 258 (M+H)+. Example 467B 3-(4-ammophenyl)-7-(2-methyl-1H-indol-5-yl)thieno[3,2-c]pyrim 4-amine The desired product was prepared by substituting Example 77B, Example 467 A, and PdCl,(dppf) for Example 21A, 2-[(lE)-3,3-diethoxy-l-propenyl]-4,4I5,5rtetramethyl-l,3,2-dioxaborolane and Pd(PPh3)4, respectively, in Example 176A. MS ESI(+)) m/e 371.1 (M+H)+. Example 467C N-R4-[4-ammo-7-(2-methyl-lH-mdol-5-yl)thieno[3,2-c]pyridm-3-yl]phenyl)-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 467B-and l-isocyanato-3- methylbenzene for Example 121B and l-fluoro-2-isocyanato-4-(tricluoromethyl)benzene, respectively in Example 122. 1H NMR (300 MHz, DMSO-D6) 8 ppm 2.29 (s, 3H), 2.42 (s, 3H), 5.40 (s, 2H), 6.19 (s, IH), 6.81 (d, J=7.5 Hz, IH), 7.17 (t, J=7.8 Hz, IH), 7.25-7.28 (m, 2H), 7.32 (s, IH), 7.39 (d, >8.1 Hz, IH), 7.40 (d, J=8.5 Hz, 2H), 7.44 (s, IH), 7.61 (d, J=8.5 Hz, 2H), 7.64 (d, J=1.4 Hz, IH), 7.86 (s, IH), 8.67 (s, IH), 8.87 (s, IH), 11.03 (s, IH); MS (ESI(+)) m/e 504.2 (M+H)+. -195- WO 2005/010009 PCT/US2004/0240I Example 468 N-R4-[4-ammo-7-(2-methyl-lH-mdol-5-yl)thieno[3,2-c]pyridm-3-yl]phenyl)-N'-(3- methylphenyl)urea Example 468A 3-fluoro-4-rutrophenyltrifluoromemanesulfonate A solution of 3-fluoro-4-nitro-phenol (2.0 g, 12;7 mmol) in dichloromethane (100 roL) at 0 °C was treated with trifluoroaceticmetiianesulfonic anhydride (5.0 g, 17.7 mmol), I followed by the slow addition of triethylamine (7.1 mL. 50.9 mmol). The solution was stirred at room temperature for three hours, poured into water, extracted with dichloromethane. The combined organic layers were dried (NajSO,,), filtered and concentrated. The residue was purified by flash chromatography on silica gel using 10% ethyl acetate/hexanes to provide 3.5 g (95% yield) of the desired product. MS (ESI(+)) m/e 288.(M+H)+. Example 468B 7-fluoro-lH-indol-5-yltrifluoromethanesulfonate A solution of 468A (1.5 g, 5.2 mmol) in THF (65 mL) at-40 °C was treated dropwis with a solution of vinylmagnesium bromide (1.0 M solution in THF, 15.6 mL, 15.6 mmol). The solution was stirred at -40 °C for two hours, quenched with saturated ammonium chloride, warmed to room temperature, partitioned between water and ethyl acetate. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried (Na2S04), filtered and concentrated. The residue was purified by flash chromatography on silica gel using 5-15% ethyl acetate/hexanes to provide 270 mg (18% yield) of the desired product. MS (ESI(-)) m/e 282 (M-H)". Example 468C 7-fluoro-5-('4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indoIe A solution of Example 468B (270 mg, 0.95 mmol), bis(pinacolato)diboron (292 mg, 1.15 mmol) and potassium acetate (262 mg, 2.66 mmol) in DMF was purged with nitrogen, treated with PdCl2(dppf), heated to 90 °C overnight, cooled to room temperature, filtered through celite, washing with ethyl acetate and concentrated. The residue was purified bv -196- WO 2005/010009 PCT/US 2004/024003 flash chromatography on silica gel using 3-5% ethyl acetate/hexanes to give 160 mg (65% yield) of the desired product. MS (ESI(-)) m/e 260 (M-H)+ Example 468D 3-[4-ammo-3-(7-fluoro-lH4ndol-5-yl)thino[3,2-c]p Tidin-7-yl]-N-methylacrylamide The desired product was prepared by substituting Example 468C for 4-chlorophenylboronic acid in Example 21C. 1H NMR (300 MHz, DMSO-D6) δ ppm2.73 (d, J=4.S Hz, 3H), 5.78-5.87 (br. s, 2H), 6.56-6.63 (m, 2H), 7.04 (dd, J=11.9,1.4 Hz, IH), 7.48 (d, J=1.4 Hz, IH), 7.54 (d, J=3.4 Hz, IH), 7.58 (d, J-15.6 Hz, IH), 7.64 (s, IH), 8.11 (s, IH), 8.13-8.17 (m, IH), 11.85 (s, IH); MS (ESI(+)) m/e 367.2 (M+H)+. Example 469 N-{4-[4-ammo-7-(2-methyl-lH-mdol-5-vl)thieno[3,2-c]pyridin-3-yllphenyl|-N'-[3- (trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 467B and l-isocyanato-3- (trifluoromethyl)benzne for Example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene, repectively, in Example 122. 1H NMR (300 MHz, DMSO-DJ δ ppm2.42 (s, 3H), 5.40 (s, 2H), 6.19 (s, IH), 7.26 (dd, J=8.1, \J Hz, IH), 7.33 (d, J=7.8 Hz, IH), 7.39 (d, JN8.1 Hz, IH), 7.42 (d, J=S.5 Hz, 2H), 7.45 (s, IH), 7.53 (t, J=8.0 Hz, IH), 7.60-7.64 (m, 4H), 7.86 (s, IH), 8.04 (s, IH), 9.04 (s, IH), 9.16 (s, IH), 11.04 (s, IH); MS (ESI(+)) m/e 558.2 (M+H)+ Example 470 N-{4-[4-ammo-7-(2-methyl-lH-mdol-5-vl)thieno[3,2-c]pyridin-3-yllphenyl|-N'-[3- (trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 467B and l-fluoro-2-isocyanto-4-(trifluoromethyl)benzene for Example 1C and l-isocyanato-3-methylbenzene, respectively, in Example ID. 1H NMR (300 MHz, DMSO-D6) δ ppm2.42 (s, 3H), 539 (s, 2H), 6.19 (s, IH), 7.26 (dd, J-8.48,1.70 Hz, IH), 7.42 (m, 5H), 7.54 (m, IH)," 7.63 (m, 3H), 7.86 (s, IH), 8.64 (dd, J=7.12, 2.03 Hz, IH), 8.98 (d, J-2.71 Hz, IH), 9.38 (s, IH), 11.03 (s, IH); MS (ESI(+)) m/e 576.1 (M+H)+. . Example 471 N-{4-[4-ammo-7-(2-methyl-lH-mdol-5-vl)thieno[3,2-c]pyridin-3-yllphenyl|-N'-[3- methyrphenypurea The desired product was prepared by substituting Example 467B for Example 121B in Example 122. 1H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3H), 2.42 (s, 3H), 5.39 (s, 2H), 6.19 (s, IH), 6.79-6.84 (m, IH), 7.12 (dd, J=11.2, 8.5 Hz, IH), 7.26 (dd, J-8.5, 1.9 Hz, -197- WO 2005/010009 PCT/US2004/024003 IH), 7.37-7.44 (m, IH), 7.42 (d, J=S:S Hz, 2H), 7.44 (s, IH), 7:61 {d, J=8.8 Hz, 2H), 7.64 (d, J=1.7 Hz, IH), 7.86 (s, IH), 8.01 (dd, J=7.8,2.0 Hz, IH), 8.56 (d, J=2.7 Hz, IH), 9.27 (s, IH), 11.03 (s, IH); MS (ESI(+)) m/e 522.2 (M+H)+. Example 472 3-[4-amino-3-(7-fluoro-2-metliyl-lH-indol-5-vl)thieno[3,2-c]pyridin-7-yl]-N- methylacrylamide Example 472A 3-[4-aminoo-3-(7-fluoro-2-metliyl-lH-indol-5-vl)thieno[3,2-c]pyridin-7-yl]-N- The desired product was prepared by substituting isopropenylmagnesium bromide for vinyknagnesium bromide in Example 468B. MS (ESI(-)) m/e 296 (M-H)+ Example 472B 7-fluoro-2-methyl-5-(4,4,5,5-tetrametbYl-l,3,2-dioxaborolan-2-vn-lH-indole The desired product was prepared by substituting Example 472A for Example 468B in Example 468C. MS ESI(+)) m/e 276.1 (M+H)+. Example 472C 3-[4-amino-3-(7-fluoro-2-metliyl-lH-indol-5-vl)thieno[3,2-c]pyridin-7-yl]-N- methylacryl]amide The desired product was prepared by substituting Example 472B for 4-chlorophenylboronic acid in Example 21C. 1H NMR (300 MHz, DMSO-D6) 6 ppm 2.43 (s, 3H), 2.73 (d, J=4.8 Hz, 3H), 5.82 (s, 2H), 6.30 (br. s., IH), 6.58 (d, J=15.9 Hz, IH), 6.94 (dd, J=11.9, 1.4 Hz, IH), 7.32 (s, IH), 7.58 (d, J=15.9 Hz, IH), 7.62 (s, IH), 8.10 (s, IH), 8.15 (q, J=4.8 Hz, IH), 11.64 (s, IH); MS (ESI(+)) m/e 3S1.3 (M+H)+. Example 473 3-[4-amino-3-(7-fluoro-2-metliyl-lH-indol-5-vl)thieno[3,2-c]pyridin-7-yl]-N- methylacryl]amide Example 473 3-[4-amino-3-(7-fluoro-2-metliyl-lH-indol-5-vl)thieno[3,2-c]pyridin-7-yl]-N- methylacryl]amide The desired product was prepared by substituting Example 291A for Example 78 in Example 96. Example 473B 3-[4-amino-3-(7-fluoro-2-metliyl-lH-indol-5-vl)thieno[3,2-c]pyridin-7-yl]-N- methylacryl]amide -198- WO 2005/010009 PCT/US2004/024003 The desired product was' prepared by substituting Example 473A and Example 467A for Example 21B and 4-chlorophenylboronic acid in Example 21C. 1H NMR (300 MHz, DMSO-D6) δ ppm2.01-2.10 (m, 2H), 2.43 (s, 3H), 3.24 (q, J=6.0 Hz, 2H), 4.26 (t, J=7.1 Hz, 2H), 6.23 (s, IH), 6.73 (d, J=15.9 Hz, IH), 7.03 '(dd, J=S.5,1.7 Hz, IH), 7.44 (d, J-8.1 Hz, IH), 7.52-7.53 (m, IH), 7.63 (d, J=15.9 Hz, IH), 7.72 (t, J=1.7 Hz, IH), 7.84-7.85 (m, 2H), 8.21 (s,"lH), 8.46 (t, J=5.4 Hz, IH), 9.14 (s, IH), 11.24 (s, IH); MS (ESI(+)) m/e 457.2 (M+H)+. Example 474 N-{4-[4-amino-7-(lH-indol-6-yl)thieno[3,2-c]pyridin-3-yl]phepyl)-N'-(3-methylphenyl)urea Example 474A lH-mdol-6-ylboronic acid A solution of 6-Bromo-lH-indole (1.5 g, 7.65 mmol) in THF (10 mL) was added dropwise to a suspension of potassium hydride (0.31 g, 7.65 mmol) in THF at 0 °C. After fifteen minutes at 0 °C, the solution was cooled to -78 °C and a t-butyl lithium solution (1.7 M in pentane, 9.0 mL, 15.3 mmol) was added dropwise via syringe while maintaining a temperature below -55 °C. After 15 minutes, the solution was cooled to -78 °C and treated with a tributyl borate (4.14 mL, 15.3 mmol). The solution was stirred at -78 °C for 2 hours and then allowed to warm to -10 °C. The solution was the added 75 mL of 1 M HC1, warmed to room temperature and separated. The aqueous phase was extracted with diethyl ether (3x75 mL) and the combined organics were extracted with 1 M NaOH (4x40 mL). The aqueous layers were combined, adjusted to pH -2 with 6 M HC1 and extracted with diethyl ether (4x50 mL). The combined organic layers were washed with brine (20 mL), dried (MgS04), filtred and concentrated. The concentrate was purified by flash chromatography on silica gel using 3.5-5% methanol/dichloromethane to give 838 mg (68% yield) of the desired product. MS (ESI(+))m/e 161 (M+H)+. Example 474B 3-(4-animophenvl)-7-(lH-mdol-6-Ynthieno[3,2-c]pvridm-4-amine The desired product was prepared by substituting Example 77B, Example 474A, and PdCl2(dppf) for Example 21A,2-[(lE)-3,3-diethoxy-l-propenyl]-4,4,5J5,-tetramethyl-l,3,2-dioxaborolane and Pd(PPh3)4, respectively, in Example 176A. 1H NMR (300 MHz, DMSO-D6) 6 ppm 5.36 (s, 2H), 5.50 (s, 2H), 6.48 (ddd, J=3.0,1.93 0.9 Hz, IH), 6.69 (d, J=8.5 Hz, 2H), 7.12 (d, J=8.5'Hz, 2H), 7.27 (dd, J=8.3,1.5 Hz, IH), 7.32 (s, IH), 7.39-7.41 (m, IH), 7.64-7.66 (m, 2H), 7.87 (s, IH), 11.20 (s, IH); MS (ESI(+)) m/e 357.2 (M+H)+. Example 474C -199- WO 2005/010009 PCT/US2004/02400J N-{4-[4-amino-7-(lH-mdol-6-yl)thieno[3,2-c]pyridin-3-yllplienyl}-N'-[3-(trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 474B and l-isocyanato-3-methylbenzene for Example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene, respectively, in Example 122. 1H NMR (300 MHz, DMSO-D6) 6 ppm 2.29 (s, 3H), 5.45 (s, 2H), 6.49 (ddd, J=3.0, 2.1, 0.7Hz, IH), 6.81 (d, J=7.1 Hz, IH), 7.17 ft J=7.6Hz, IH), 7.25 (s, IH), 7.29 (dd, J=8.3, 1.5 Hz, IH), 7.32-7.33 (m, IH), 7.40-7.43 (m, 3H), 7.46 (s, IH), 7.62 (d, J=8.8 Hz, 2H), 7.66-7.67 (m, IH), 7.66 (d, J-8.1 Hz, IH), 7.91 (s, IH), 8.68 (s, IH), 8.88 (s, IH), 11.21 (s, IH); MS (ESI(+)) m/e 490.2 (M+H)+. Example 475 N-{4-[4-airuno-7-(lH-mdol-6-yl)thieno[3,2-c]pyridin-3-yllplienyl}-N'-[3-(trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 474B and l-isocyanato-3-(trifluoromethyl)benzene for Example 12IB and I-fluoro-2-isocyanato-4-(trifluoromethyl)benzene, respectively, in Example 122. 1H NMR (300 MHz, DMSO-D6) δ ppm5.45 (s, 2H), 6.4S-6.50 (m, IH), 7.29 (dd, J=8.3,1.5 Hz, IH), 7.33 (d, J=7.8 Hz, IH), 7.40-7.45 (m, 3H), 7.47 (s, IH), 7.53 ft J-S.O Hz, IH), 7.60-7.68 (m, 5H), 7.91 (s, IH), 8.04 (s, IH), 9.02 (s, IH), 9.14 (s, IH), 11.22 (s, IH); MS (ESI(+))"m/e 544.2 (M+H)+. Example 476 N-{4-[4-arm o-7-(lH-indol-6-yl)thieno[3,2-c]pyridin-3-yl]phenyl}-N'-[2-fluoro-5- (trifluoromethyl)phenyl ]urea The desired product was prepared by substituting Example 474B for Example 121B in Example 122. 1H NMR (300 MHz, DMSO-Ds) 6 ppm 5.44 (s, 2H), 6.49 (d, JN2.7 Hz, IH), 7.29 (dd, J=8.3, 1.5 Hz, IH), 7.39-7.42 (m, 2H), 7.45 (d, J-8.5 Hz, 2H), 7.48 (s, IH), 7.49-7.55. (m, IH), 7.64 (d, J=8.5 Hz, 2H), 7.66-7.68 (m, 2H), 7.91 (s, IH), 8.65 (dd, J=7.3, 2.5 Hz, IH), 8.99 (s, IH), 9.39 (s, IH), 11.22 (s, IH); MS (ESI(+)) m/e 562.1 (M+H)+. Example 477 3-[4-amino-3-(7-fluoro-2-metliyl-lH-indol-5-vl)thieno[3,2-c]pyridin-7-yl]-N-methylacryl]amide Example 477A 2-( I -benzothien-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane The desired product was prepared by substituting 5-bromo-benzo[b]thiophene (commercially available) for Example 468B in Example 468C. MS ESI(+)) m/e 277.1 (M+NH/)+. Example 477B -200- WO 2005/010009 PCT/US2004/024003 3-[4-ammo-3-(l-benzothien-5-yl)thieno[3,2-c]pyn in-7-yl]-N-methylacrvlamide The desired product was prepared by substituting Example 477A for 4-chlorophenylboronic acid in Example 21C. 3H NMR (300 MHz, DMSO-D6) δ ppm2.75 (d, J=4.S Hz, 3H), 6.45 (s, 2H), 6.71 (d, J=15.9Hz, IH), 7.48 (dd, J=8.3, 1.5 Hz, IH), 7.56 5 (d, J=5.4 Hz, IH), 7.61 (d, J=15.9 Hz, IH), 7.90 (s, IH), 7.92 (d, J=5.4 Hz, IH), 8.04 (d, J=1.4 Hz, IH), 8.19-8.22 (m, 2H), 8.26 (q, J=4.8 Hz, 1H)TMS (ESI(+)) m/e 366.0 (M+H)+. Example 478 3-{4-airunoO-[2-ftrifluoromethyl)4H-indol-5-yl]thieno[3,2-c]pyridin-7-yl}-N- methylacrylamide Example 47 8 A N-(4-bromo-2-methylphenyl)-2,2,2-trifluoroacetamide A solution of 4-bromo-2-methyl-phenylamine (commercially available, 2.5 g, 13.4 mmol) in dichloromethane (27 mL) was treated with trifluoroacetic anhydride (2.3 mL, 16.3 mmol), stirred at room temperature for one hour and concentrated to dryness to give 3.7 g (98% yield) of the desired product. MS (ESI(-)) m/e 279.8, 281.9 (M-H)+ Example 47 8B N-[4-bromo-2-(bromomethyl)phenyl]-2,2,2-trifluoroacetamide A solution of Example 478A (2.5 g, 8.9 mmol) and N-bromosuccinimide (1.58 g, 8.9 mmol) in carbon tetrachloride (25 rnL) was irradiated with a 100-watt incandescent bulb overnight. The solution was filtered and the filtrate was concentrated. The concentrate was purified by flash chromatography on silica gel using 3-4% ethyl acetate/hexanes to give 2.17 g (6S% yield) of the desired product. MS (ESI(-)) m/e 360, 362 (M-H)'. Example 478C {5-bromo-2-[(trifluoroacetyl)arninolbenzyl}(triphenvl)phosphonium bromide A solution of 478B (2.17 g, 6.01 mmol) in toluene (20 mL) was treated with triphenylphosphine (1.89 g, 7.2 mmol), heated at 60 °C overnight, cooled to room temperature and filtered. The filter cake was washed with diethyl ether to give 3. g(S4% yield) of the desired product. 1H NMR (300 MHz, DMSO-D6) δ ppm5.14 (d, J=15.26 Hz, 2H), 7.08 (t, J=2.20 Hz, IH), 7.16 (m, IH), 7.41 (d, J-8.14 Hz, IH), 7.59 (m, 6H), 7.74 (m, 6H), 7.91 (m,3H), 10.91 (s, IH). Example 478D 5-bromo-2-(trifluoromethyl)-lH-mdole -201- WO 2005/010009 PCT/US2004/024003 A microwave tube charged with Example 478C (1.33 g, 4.25 mmol) and DMF (4 mL) was stirred at 200 °C for 15 minutes under microwave conditions and partitioned between water and ethyl acetate. The organic phase was dried (Na2SO3 and concentrated. The concentrate was purified by flash chromatography on silica gel using 10% ethyl acetate/hexanes to .give 1.1 g (100% yield) of the desired product MS (ESI(-)) m/e 261.8, 263.8 (M-H)+ Example 478E 5-(4,4,5,5-tetramemyl 1-3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)-lH-indole The desired product was prepared by substituting Example 478D for 468B in Example 468C. MS ESI(-)) m/e 310.0 (M-H)+ Example 478F 3-[4-ammo-3-(2-memyl-lH-mdol-5-vl) thieno[3 -clpvridto-7-yl]-N-(pyridin-4- ylmethyl)acrylamide The desired product was prepared by substituting Example 478E for 4-chlorophenylboronic acid in Example 21C. 1H NMR (300 MHz, DMSO-DJ δ ppm2.74 (d, J-4.8 Hz, 3H), 5.77 (s, 2H), 6.59 (d, J=15.9 Hz, IH), 7.11 (s, IH), 7.37 (dd, J=8.8,1.4 Hz, IH), 7.59 (d, J-15.9 Hz, IH), 7.62-7.65 (m, 2H), 7.79 (s, IH), 8.12 (s, IH), 8.16 (q, J=4.5 Hz, IH), 12.53 (s, IH); MS (ESI(+)) m/e 417.0 (M-hH)+. Example 479 3-[4-ammo-3-(2-memyl-lH-mdol-5-vl) thieno[3 -clpvridto-7-yl]-N-(pyridin-4- ylmethyl)acrylamide Example 479A 3-(4-arnmo-3-bromotfa no[3,2-c]pyridm The desired product was prepared substituting Example 291A for Example 78 in Example 90. Example 479B 3-[4-ammo-3-(2-memyl-lH-mdol-5-vl) thieno[3 -clpvridto-7-yl]-N-(pyridin-4- ylmethyl)acrylamide The desired product was prepared substituting Example 479A and Example 467A for Example 21B and 4-chlorophenylboronic acid in Example 21C. 1H NMR (300 MHz, DMSO-D6) 6 ppm 2.42 (s, 3H), 4.49 (d, J=5.8 Hz, 2H), 6.11 (s, 2H), 6.21 (s, IH), 6.74 (d, J=15.9 Hz, IH), 7.07 (dd, 1=8.1,1.7 Hz, IH), 7.39 (d, J=5.8 Hz, 2H), 7.42 (d, J=8.1 Hz, IH), -202- WO 2005/010009 PCT/US2O04/O24O03 7.49 (s, IH), 7.66 (s, 1H),'7.67 (d, J=15.9 Hz, IH), S.16 (s, IH), 8.57 (d, J=5.4 Hz, 2H), 8.89 (t, J-5.8 Hz, IH), 11.20 (s, IH); MS (ESI(+)) m/e 440.0 (M+H)+. Example 480 N-{4-[4-ainino-7-(l"niethv lH-indoI-5-yl)thieno[3,2-cIpyridm-3-vl]pbenyl}-N'-(3- methylphenyl)urea Example 480A l-metbyl-5-R4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indole The desired product was prepared by substituting 5-bromo-l-methyl-lH-indole for 5- bromo-2-methyl-lH-indole in Example 467A. MS (ESI(+)) m/e 258 (M+H)+. Example 480B 3-(4-armnophenyl)-7-(l-memyl-lH-mdol-5-yl)thieno[3,2-c]pyridm-4-amino The desired product was prepared by substituting Example 77B, Example 480A, and PdCl2(dppf) for Example 21A, 2-[(lE)-3,3-diethoxy-l-propenyl]-4,4,5,5,-tetramethyl-l;3,2-dioxaborolane and Pd(PPh3)„, respectively, in Example 176A. MS ESI(+)) m/e 371.0 (M+H)+. Example 480C N-{4-[4-aimno-7-(l-methyl-lH-mdol-5-yl)thieno[3,2-c]pyridm-3-yl]phenyn-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 480B for Example 1C in Example ID. 1H NMR (300 MHz, DMS0-D6) S ppm 2.29 (s, 3H), 3:85 (s, 3H), 5.43 (s, 2H), 25 6.50 (d, J=2.7 Hz, IH), 6.81 (d, J-7.1 Hz, IH), 7.17 (t, J=7.8 Hz, IH), 7.26 (d, 8.5 Hz, IH), 7.32 (s, IH), 7.40-7.45 (m, 5H), 7.57 (d, J=8.5 Hz,- IH), 7.61 (d, J=8.8 Hz, 2H), 7.79 (d, J=1.7 Hz, IH), 7.88 (s, IH), 8.66 (s, IH), 8.86 (s, IH); MS (ESI(+)) m/e 504.1 (M+H)+. Example 481 N-{4-[4-animo-7-(l-memvl-lH-mdol-5-yl)thieno[3,2-c]pyridm-3-yl]phenyl}-N'-(3- chlorophenypurea The desired product was prepared by substituting Example 4S0B and l-isocyanato-3-chlorobenzene for Example 121B and l-fluoro-2-isocyanato -(trifluoromethyl)benzene, respectively, in Example 122. ]H NMR (300 MHz, DMSO-D6) 6 ppm 3.85 (s, 3H), 5.43 (s, 35 2H), 6.50 (dd, J=3.1, 0.7 Hz, IH), 7.02-7.06 (m, IH), 7.30-7.33 (m, 2H), 7.40-7.44 (m, 4H), 7.45 (s, IH), 7.57 (d, J=8.5 Hz, IH), 7.62 (d, J=8.8 Hz, 2H), 7.73 (dd, J=2.5,1.5 Hz, IH), 7.79 (dd, J-1.7, 0.7 Hz, IH), 7.89 (s, IH), 8.97 (app. s, 2H); MS (ESI(+)) m/e 524.1 (M+H)4. -203- WO 2005/010009 PCT/US2004/024003 Example 482 3-[4-ammo-3-(2-memyl-lH-mdol-5-vl) thieno[3 -clpvridto-7-yl]-N-(pyridin-4-ylmethyl)acrylamide Example 482A 2-methyl-5-(4,4T5,54etramemyl-l,3,2-dioxaborolari-2-vl)-l,3-benzothiazole The desired product was prepared by substituting 5-bromo-2-methyl-benzothiazole for 46SB in Example 468C. MS ESI(+)) m/e 276.0 (M+H)+. Example 4S2B 3-[4-ammo-3-(2-methyl-13-ben2otmazol-5-yl)thieno[3,2-c]pyridb-7-yl]-N- methylacrylamide The desired product was prepared by substituting Example 482A for 4-chlorophenylboronic acid in Example 21C. 1H NMR (300 MHz, DMSO-DJ δ ppm2.74 (d, J=4.S Hz, 3H), 2.85 (s, 3H), 5.80 (s, 2H), 6.60 (d, J=15.9 Hz, IH), 7.50 (dd, J=8.1,1.7 Hz, . IH), 7.60 (d, J=15.9 Hz, IH), 7.74 (s, IH), 8.00 (d, J=1.4 Hz, IH), 8.14 (s, IH), 8.14-8.19 (m, IH), 8.19 (d, J=8.1 Hz, IH); MS (ESI(+)) m/e 381.0 (M+H)*. Example 483 3-[4-ammo-3-(2-memyl-lH-mdol-5-vl) thieno[3 -clpvridto-7-yl]-N-(pyridin-4-methylacrylamide Example 483A 5-bromo-1,3-dihydro-2H-indol-2-one A suspension of 1,3-dihydro-indol-2-one (1.3g, 9.76 mmol) in acetonitrile (20 mL) at -5 °C was treated with N-bromosuccmimide, warmed to room temperature, stirred overnight and filtered to give 1.8 g (87% yield) of the desired product. MS (ESI(+)) m/e 209.9,211.9 (M-H)+ Example 483B 5-(4,4,5,5-tetramemyl43,2rdioxaborolan-2-vl)-13-dmydro-2H-mdol-2-one The desired product was prepared by substituting Example 4S3A for 468B in Example 468C. MS ESI(+)) m/e 260 (M+H)+. Example 483C 3-[4-ammo-3-(2-oxo-23-dmydro4H-mdol-5-yl)thieno[3,2-c]pyridin-7-yl]-N- methylacrylamide -204- WO 2005/010009 PCT/US2004/024003 The desired product was prepared by substituting Example 483B for 4-chlorophenylboronic acid in Example 21C. 1H NMR (300 MHz, DMSOD6) δ ppm2.73 (d, J=4.8 Hz, 3H), 3.56 (s, 2H), 5.86 (s, 2H), 6.57 (d, J=15.9 Hz, IH), 6.95 (d, J=7.8 Hz, IH), 7.26 (dd, J-7.8, 1.4 Hz, IH), 7.31 (s, IH), 7.55-7.60 (m, 2H), 8.11 (s, IH), 8.14 (q, J=4.8 Hz, 5 IH), 10.56 (s, IH); MS (ESI(+)) m/e 365.0 (M+H)+ Example 484 3-[4-amino-3-(l-benzofuran-2vl)thieno[3,2-c]pyridion -7-yl]-N-methylacrylamide The desired product was prepared by substituting 2-naphthaleneboronic acid for 4-10 chlorophenylboronic acid in Example 21C. lH NMR (300 MHz, DMSO-D6) 8 ppm 2.75 (d, J=4.S Hz, 3H), 6.30 (s, 2H), 6.69 (d, J=15.9 Hz, IH), 7.59-7.65 (m, 4H), 7.91 (s, IH), 8.01-S.06 (m, 2H), 8.10 (dd, J=1.7, 0.7 Hz, IH), 8.10 (d, J=8.5 Hz, IH), 8.21 (s, IH), 8.24 (q, . J=4.8 Hz, IH); MS (ESI(+)) m/e 360.0 (M+H)+. Example 485 3-[4-amino-3-(l-benzofuran-2yl)thieno[3,2-c]pyridion -7-yl]-N-methylacrylamide The desired product was prepared by substituting benzofuran-2-ylboronic acid for 4-chlorophenylboronic acid in Example 21C. 1H NMR (300 MHz, DMSO-D6) δ ppm2.74 (d, J=4.8 Hz, 3H), 6.47 (s, 2H), 6.60 (d, JM15.9 Hz, IH), 7.28 (d, J=0.7 Hz, IH), 7.34 (td, J=7.5, 1.4 Hz, IH), 7.41 (td, >7.5,1.7 Hz, IH), 7.59 (d, J=15.9 Hz, IH), 7.70 (d, J=7.5 Hz, IH), 7.74-7.77 (m, IH), 8.17 (q, J=4.8 Hz, IH), S.19 (s, IH), 8.21 (s, IH); MS (ESI(+)) m/e 350.0 (M+H)+. Example 486 3-[4-ammo-3 1-benzofuran-5-yl)thieno[3,2-c]pyridin-7-yl]-N-memylaciylarmde Example 486A 5-(4,4,5,5-teLRamemyl-13,2-dioxaborolan-2-yl)-l-berizofuran The desired product was prepared by substituting 5rbromo-benzofuran (commercially available) for Example 468B in Example 468C. MS ESI(+)) m/e 245.1 (M+H)+. Example 486B 3-[4-amino-3-(l-benzofuran-2-vl)thieno[3,2-c]pyridion -7-yl]-N-methylacrylamide The desired product was prepared by substituting Example 486A for 4-chlorophenylboronic acid in Example 21C. 1H NMR (300 MHz, DMSO-D6) 6 ppm 2.75 (d, J=4.8 Hz, 3H), 6.48-6.67 (br. s, 2H), 6.73 (d, J=15.9 Hz, IH), 7.07 (dd, J=2.2,0.9 Hz, IH), 7.44 (dd, £=8.5,2.0 Hz, IH), 7.61 (d, J-15.9 Hz, IH), 7.79 (d, J-8.5 Hz, IH), 7.82 (d, -205- WO 2005/010009 PCT/US2004/024003 J=1.7 Hz, 1H), 7.91 (s, 1H), S.14 (d, =2.0 Hz, 1H), 8.22 (s, 1H), 8.29 (q, J=4.8 Hz, 1H); MS-(ESI(+))m/e 350.0 (M+H)+ Example 487 3-(4-armno-3-qumolin-6-ylthieno[3,2-c]pvridm-7-yl)-N-methylacrvlamide Example 487A 6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-vl)quipoline The desired product was prepared by substituting 6-bromoquinoline (commercially available) for Example 468B in Example 468C. MS ESI(+)) m/e 256.0 (M+H)+. Example 487B 3-(4-amino-3-quinolin-6-yl thieno[3,2-c]pyridin-7-yl)-N-methylacrylamide The desired product was prepared by substituting Example 487A for 4-chlorophenylboronic acid in Example 21C. 1H NMR (300 MHz, DMSO-DJ δ ppm2.74 (d, J=4.8 Hz, 3H), 5.83 (s, 2H), 6.61 (d, J=15.9 Hz, 1H), 7.61 (d, J=15.9 Hz, 1H), 7.63 (dd, J=8.1,4.4 Hz, 1H), 7.82 (s, 1H), 7.86 (dd, J=8.8,1.7 Hz, 1H), 8.14-8.18 (m, 4H), 8.47 (dd, J=S.5,1.7 Hz, 1H), 8.99 (dd, J=4.2, 1.9 Hz, 1H); MS (ESI(+)>m/e 361.0 (M+H)+. Example 488 3-[4-animo-3-(l,2-benzisoxazol-5-yl)tlu no[3,2-c]p din-7-yl]-N-methvlacrylamide Example 48 8 A 5-bromo-l,2-benzisoxazole A solution of 5-bromo-2-hydroxy-benzaldehyde (2.0 g, 10 mmol) in ethanol (10 mL) at room temperature was treated with hydroxylamine-O-sulfonic acid (1.69 g, 15 mmol), stirred for 20 minutes, diluted with dichloromethane (50 mL), cooled to 0 °C and treated with a solution of sodium bicarbonate (3 g) in water (25 mL). The solution was stirred at 0 °C for 30 minutes. The organic layer was removed and the aqueous layer was extracted with dichloromethane. The aqueous layer was treated with additional dichloromethane (50 mL) and stirring was continued for one hour. The layers were separated and the aqueous layer was extracted with dicloromethane. The combined organic layers were washed with brine, dried (MgSOJ and concentrated. The concentrate was recrystallized from ethanol to give 970 mg (49%) yield of the desired product. MS (ESIQ) m/e 195.9,197.9 (M-H)+ Example 488B 5-(4,4,5.5-tetramethyl-l,3,2-dioxaborolan-2-yl')-l,2-beD2isoxazole -206- WO 2005/010009 PCT/US2004/024003 The desired product was prepared by substituting Example 488A for Example 468B in Example 468C. MS (ESI(-)) m/e 244.0486 (M-H)+ Example 488C 3-[4-amino-3-(l-benzofuran-2yl)thieno[3,2-c]pyridion -7-yl]-N-methylacrylamide The desired product was prepareci by substituting Example 488B for 4-chlorophenylboronic acid in Example 21C. 1H NMR (300 MHz, DMSO-Dfi) 8 ppm 2.73 (d, J=4.S Hz, 3H), 5.S6 (s, 2H), 6.57 (d, J=15.9 Hz, 1H), 7.11 (d, J=8.8 Hz, 1H), 7.54-7.58 (m, 1H), 7.57 (d, >15.9 Hz, 1H), 7.66 (s, 1H), 7.72 (d, J=2.0 Hz, 1H), 8.12 (s, 1H), S.14 (q, 10 J=4.8 Hz, 1H), 11.45 (s, 1H); MS (ESI(+)) m/e 351.0 (M+H)+. Example 489 3-[4-ammo-3-(23-dmylro4H-mdol-5-yntrdeno[3,2-c]pvridm-7-vl1-N-methylacrylamide Example 489 A tert-butyl 5-bromoindoline-l-carboxylate A suspension of 5-bromo-2,3-dihydro-lH-indole (1.0 g, 5.05 mmol) in diethyl ether (50 mL) was treated with di-tert-butyl -dicarbonate (1.32 g, 6.o5 mmol), stirred overnight at room temperature and filtered. The filtrate was diluted with hexanes and concentrated in vacuo until crystal formed. The crystals were collected via filtration to give 1.05 g (70% yield) of the desired product. 1H NMR (300 MHz, DMSO-Dg) 6 ppm 1.50 (s, ?H), 3.06 (t, J=8.S2 Hz, 2H), 3.90 (m, 2H), 7.30 (dd, J=S.4S,2.03 Hz, 1H), 7.37 (m, 1H), 7.56 (s, 1H). Example 489B tert-butvl5-(4,4,5,54etramemyl-13,2-dioxaborolan-2-yl)mdoline-l-carboxylate The desired product was prepared by substituting Example 489A for Example 468B in Example 46SC. MS (ESI(+)) m/e 246 (M+H-Boc)+. Example 489C . tert-butyl 5-{4-amino-7-[3-(memylammo)-3-oxoprop-l-enyl]thieno[3,2-c]pyridin-3- yl]indoline-1-carboxylate The desired product was prepared by substituting Example 489B for 4-chlorophenylboronic acid in Example 21C. MS ESI(+)) m/e 451.1 (M+H)+. Example 489D 3-[4-amino-3-(l-benzofuran-2yl)thieno[3,2-c]pyridion -7-yl]-N-methylacrylamide The desired product was prepared by substituting Example 489C for Example 76B in Example 76C. 1H NMR (300 MHz, DMSO-D6) 6 ppm 2.73 (d, J=4.S Hz, 3H), 2.98 (t, J=8.5 -207- WO 2005/010009 PCT/US2OO4/024O03 Hz, 2H), 3.50 (td, J=8.5,1.4 Hz, 2H), 5.80 (s, 1H), 5.96 (s, 2H), 6.55 (d, J=15.9 Hz, 1H), 6.6tf (d, J=8.5 Hz, 1H), 6.98 (dd, J=8.0,1,9 Hz, 1H), 7.10 (s, 1H), 7.48 (s, 1H), 7.56 (d, J=15.9 Hz, 1H), 8.08 (s, 1H), 8.14 (q, J=4.3 Hz, 1H); MS (ESI(+)) m/e 351.0 (M+H)+. Example 490 3-[4-amino-3-(2-methvl-13-benzothiazoI-6-yl)thieno[3,2-c]pyridin-7-yl]-N- methylacrylami de Example 490A 6-bromo-2-methyM 3-benzothiazole A solution of 4-bromo-2-iodo-phenylamine (1.5 g, 5.0 mmol), thiacetamide (381 mg, 5.0), cupric oxide (280 mg, 3.5 mmol), dppf (56 mg, 0.10 mmol), Pd2(dba)3(48 mg, 0.052 mmol) in DMF was heated at 60 °C for 1 hour, cooled to room temperature, partitioned between water and ethyl acetate. The organic phase was dried (NajSOJ and concentrated. The concentrate was purified by flash chromatography on silica gel using 20% hexanes/methylene chloride to give 550 mg (40% yield) of the desired product. MS (ESI(+)) m/e 227.8,229.8 (M+H)+. -Example 490B 2-methyl-6-R4,4,5,5"tetramethyl-l,3 oxaborolan-2-yl)-l,3-benzothiazole The desired product was prepared by substituting Example 490A for Example 468B in Example 468C. MS ESI(+)) m/e 276 (M+H)+. Example 490C 3-[4-amino-3-(l-benzofuran-2yl)thieno[3,2-c]pyridion -7-yl]-N-methylacrylamide methylacrylamide The desired product was prepared by substituting Example 490B for 4-chIorophenylboronic acid in Example 21C. 1H NMR (300 MHz, DMSO-Ds) 6 ppm 2.75 (d, J==4.8 Hz, 3H), 2.86 (s, 3H), 6.57 (s, 2H), 6.72 (d, J-16.3 Hz, 1H), 7.59 (dd, J-8.5,1.7 Hz, 30 1H), 7.61 (d, J 16.3 Hz, 1H), 7.94 (s, 1H), 8.06 (d, J-8.5 Hz, 1H), S.22 (app. s, 2H), 8.27 (q, J=4.8 Hz, IE); US (ESI(+)) m/e 380.9 (M+H)+. -208- WO 2005/010009 PCT/US2004/024003 Example 491 3-(2-methyl-lH-mdol-5-vl)-7-pyridin-4-ylthino[3,2-c]pyridin-4-amine The desired product was prepared by substituting Example 467A for Example 175E in Example 216. 1H NMR (300 MHz, DMSO-D6) δ ppm2.42 (s, 3H), 5.70 (s, 2H), 6.21 (s, 1H), 7.06 (dd, J=8.14,1.70 Hz, 1H), 7.41 (d, J-8.14Hz, 1H), 7.4S (m, 2H), 7.73 (d, J=6\10 Hz, 2H), 8.07 (s, 1H), S.68 (d, J=6.10 Hz, 2H), 11.17 (s, 1H); MS (ESI(+)) m/e 357.0 (M+H)*. Example 492 7-(4-ammophenyl)-3-(2-meniyl-lH-indol-5-yl)tl eno[3,2-c]pylidm amine Example 492A 7-(4-aminophenyl)-3-bromothieno[3,2-c]pyridin-4-amine The desired product was prepared by substituting Example 21 A, 4-(4,4,5)5- tetramethyl-l,3,2-dioxaborolan-2-yl)aniline and PdCl2(dppf) for Example IB, 4-phenoxyphenylboronic acid, and Pd(PPh3)4, respectively, in Example 10A. MS (ES1(+)) m/e 319.9, 321.9 (M+H)+. Example 492B 7-(4-aminophenyl)3-(2-memyl-lH-indol-5-yl)thieno[3,2-c]pyridm-4-amine The desired product was prepared by substituting Example 492A and 467A for Example 21B and 4-chlorophenylboronic acid, respectively, in Example 21C. 1H NMR (300 MHz, DMSO-D6) δ ppm 2.42 (s, 3H), 5.23 (s, 2H), 5.31 (s, 2H), 6.20 (s, 1H), 6.69 (d, J=8.5 Hz, 2H), 7.05 (dd, J=S.l, 1.7 Hz, 1H), 7.32 (d, J=8.5 Hz, 2H), 7.37 (s, 1H), 7.39 (d, J=8.1 Hz, 1H), 7.46 (d, J=0.7 Hz, 1H), 7.75 (s, 1H), 11.14 (s, 1H); MS (ESI(+))m/e 37.1.0 (M+H)+. Example 493 N-{3-[4-ammo-3-(2-memyl-lH-mdol-5-yl)thieno[3,2-c]pyridm-7-yl]phenyl}acetamide Example 493A -209- WO 2005/010009 PCTYUS2004/02400 N-[3-(4-amino-3-bromothieno[3,2-c]pvridiii-j-7-vl)phenvl]acetamide The desired product was prepared by substituting Example 21A and 3-acetamidophenylboronic acid for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. MS ESI(+)) m/e 361.9, 363.7 (M+H)+. , Example 493B N-(3-[4-ammo-3-[2-memyl-lH-mdol-5-yl)mieno[3,2-c]pyridm-7-yl]phenYl}acetamide The desired product was prepared by substituting Example 493A and 467A for Example 21B and 4-chlorophenylboronic acid, respectively, in Example 21C. 1H NMR (300 MHz, DMSO-D6) 8 ppm 2.09 (s, 3H), 2.43 (s, 3H), 6:24 (dd, J=1.9,1.2 Hz, IH), 6.64-6.81 (br. s, 2H), 7.12 (dd, J=8.1,1.7 Hz, IH), 7.35 (ddd, J=3.0, 2.0,1.4 Hz, IH), 7.46 (d, J-S.l Hz, IH), 7.52 (d, J-7.8 Hz, IH), 7.55-7.56 (m, IH), 7.58-7.61 (m, IH), 7.82 (s, IH), 7.93 (s, IB), 8.13 (dd, J=2.6,1.2 Hz, IH), 10.17 (s, IH), 11.25 (s, IH); MS (ESI(+)) m/e 413.0 (M+H)+ Example 494 N-{4-[4-amino-7-(,4-fluorophenvl)thieno[3,2 1pyridin-3-yl]phenyl}-N'-('3- methylphenyl)urea The desired product was prepared by substituting Example 460A and 4-fluorophenylboronic acid for Example IB and 4-phenoxyphenylboronic acid, respectively, 20 in Example 10A. 1H NMR (300 MHz, DMSO-D6) 6 ppm 2.29 (s, 3H), 6.78 (s, 2H), 6.81 (d, J=7.1 Hz, IH), 7.17 (t, J=7.6 Hz, IH), 7.25-7.28 (m, IH), 7.32 (s, IH), 7.41-7.47 (m, 4H), 7.66 (d, J=S.S Hz, 2H), 7.75 (dd, J=8.S, 5.4 Hz, 2H), 7.84 (s, IH), 7.96 (s, IH), 8.77 (s, IH), 9.02 (s, IH); MS (ESI(+)) m/e 469.0 (M+H)+. Example 495 N-{4-[4-ammo-7-(4-cyanophenyl)thieno[3,2-c]pyridin-3-yl]phenyl) -N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 460A and 4-cyanophenylboronic acid for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3H), 6.66 (s, 2H), 6.81 (d, J=7.5 Hz, IH), 7.17 (t, J=7.8 Hz, IH), 7.26 (d, J=8.5 Hz, IH), 7.32 (s, IH), 7.44 (d, J=8.5 Hz, 2H), 7.66 (d, J=S.5 Hz, 2H), 7.80 (s, IH), 7.93 (d, J=8.5 Hz, 2H), 8.06 (d, J=8.5 Hz, 2H), 8.06 (s, IH), 8.72 (s, IH), 8.97 (s, IH); MS (ESI(+)) m/e 476.0 (M+H)+: Example 496 N-(4-[4-ammo-7-[4-methoxyphenyl)thieno[3,2-c]pyridin-3-yl]phenyl)-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example tuuA ouu 4-methoxyphenylboronic acid for Example IB and 4-phenoxyphenylboronic acid, -210- WO 2005/010009 PCT/US2004/024003 wspectively, in Example 10A. 1H NMR {300 MHz," DMSO-D6) δ ppm2.29 (s, 3H), 3.83 (s, 3H), 5.47 (s, 2H), 6.81 (d, J=7.5 Hz, 1H), 7.09 (d, J=8.8 Hz, 2H), 7.17 (t, J=7.6 Hz, 1H) 7.26 (d, J-S.5 Hz, 1H), 7.32 (s, 1H), 7.40 (d, J=8.5 Hz, 2H), 7.46 (s, 1H), 7.57-7.63 (m, 4H), 7.84 (s, 1H), 8.67 (s, 1H), 8.87 (s, 1H); MS (ESI(+)) m/e 481.1 (M+H)+. Example 497 N{4-[4-amino-7-(3-chlorophenyl)thieno[3,2-c]pyridin-3-yl]phenyl)-N'-(3-- Methyrphenyl)urea The desired product was prepared by substituting Example 460A and 3-chlorophenylboronic acid for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3H), 6.72 (s, 2H), 6.81 (d, J=7.5 Hz, 1H), 7.15-7.20 (m, 1H), 7.27 (d, >8.5 Hz, 1H), 7.32 (s, 1H), 7.45 (d, J=S.5 Hz, 2H), 7.60-7.68 (m, 4H), 7.71 (dt, J=7.0,1.7 Hz, 1H), 7.77 (t, J=1.5 Hz, 1H), 7.S1 (s, 1H), 8.03 (s, 1H), 8.75 (s, 1H), 9.00 (s, 1H); MS (ESI(+)) m/e 485.0 (M+H)+. Example 498 N-{4-[4-ammo-7-(13-benzodioxol-5-yl)thieno[3,2-c]pyridm-3-yl]phenyl)-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 460A and 3,4-methylenedioxyphenylboronic acid for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1H NMR (300 MHz, DMSO-D5) δ ppm2.29 (s, 3H)5 6.14 (s, 2H), 6.67 (s, 2H), 6.81 (d, J=7.1 Hz, 1H), 7.12 (d, J=7.S Hz, 1H), 7.15-7.19 (m, 1H), 7.19 (d, J=7.S Hz, 1H), 7.25-7.28 (m, 2H), 7.32 (s, 1H), 7.44 (d, J=S.S Hz, 2H), 7.65 (d, J=8.8 Hz, 2H), 7.81 (s, 1H), 7.90 (s, 1H)S 8.72 (s, 1H), 8.97 (s, 1H); MS (ESI(+)) m/e 495.1 (M+H)+. Example 499 N-{4-[4-ammo-7-(13-benzodioxol-5-yl)thieno[3,2-c]pyridm-3-yl]phenyl)-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 460A and 3-acetamidophenylboronic acid for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1H NMR (300 MHz, DMSO-D6) 6 ppm 2.09 (s, 3H), 2.29 (s, 3H), 6.81 (d, J=7.1 Hz, 1H), 6.74-6.89 (br. s, 2H), 7.17 (t, J=7.5 Hz, 1H), 7.25-7.28 (m, 1H), 7.31-7.36 (m, 2H), 7.45-7.43 (m, 3H), 7.60 (ddd, J=7.8,1.7,1.0 Hz, 1H), 7.66 (d, J=8.5 Hz, 2H), 7.85 (s, 1H), 7.95 (s, 1H), 8.11 (s, 1H), 8.75 (s, 1H), 9.01 (s, 1H)S 10.17 (s, 1H); MS (ESI(+)) m/e 508.1 (M+H)+. Example 500 -211- WO 2005/010009 PCT/US2004/024003 N-{4-[4-ammo-7-(13-benzodioxol-5-yl)thieno[3,2-c]pyridm-3-yl]phenyl)-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 460A and 4-(trifluoroniethoxy)phenylboromc acid for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1H NMR. (300 MHz, DMSO-D6) δ ppm2.29 (s, 3H), 5.60 (s, 2H), 6.81 (d, J=7.1 Hz, IH), 7.17 (t, J=7.8 Hz, IH), 7.26 (d, J=S.5 Hz, IH), 7.32 (s, IH) 7.40 (d, J=8.5 Hz, 2H), 7.50-7.53 (m, 3H), 7.62 (d, J=8.5 Hz, 2H), 7.80 (d, J=8.S Hz, 2H), 7.93 (s, IH), 8.68 (s, IH), S.S8 (s, IH); MS (ESI(+)) m/e 535.1 (M+H)+. Example 501 N-{4-[4-ammo-7-(13-benzodioxol-5-yl)thieno[3,2-c]pyridm-3-yl]phenyl)-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 460A and 4-(methylsulfonylamino)phenylboronic acid for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. 1H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3H), 3.10 (s, 3H), 6.77 (s, 2H), 6.81 (d, J=7.5 Hz, IH), 7.17 (t, J=7.S Hz, IH), 7.27 (d, J=8.8 Hz, IH), 7.29-7.33 (m, 2H), 7.40 (ddd, J-7.8,1.7, 1.0 Hz, IH), 7.45 (d, J=8.8 Hz, 2H), 7.52-7.58 (m, 2H), 7.66 (d, J=S.8 Hz, 2H), 7.83 (s, IH), 7.97 (s, IH), 8/75 (s, IH), 9.00 (s, IH), 10.05 (s, IH); MS (ESI(+)) m/e 544.0 (M+H)+. Example 502 N-{4-[4-ammo-7-(13-benzodioxol-5-yl)thieno[3,2-c]pyridm-3-yl]phenyl)-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 460A and 4-acetamidophenylboronic acid for Example IB and 4-phenoxyphenylboronic acid, respectively, in Example 10A. !H NMR (300 MHz; DMSO-D6) δ ppm2.10 (s, 3H), 2.29 (s, 3H), 6.76 (s, 2H), 6.81 (d, J=7.5 Hz, IH), 7.17 (t, J=7.8 Hz, IH), 7.27 (d, J=8.5 Hz, IH)., 7.32 (s, IH), 7.46 (d, J=S.5 Hz,"2H), 7.62-7.68 (m, 4H), 7.78 (d, J=8.S Hz, 2H), 7.85 (s, IH), 7.93 (s, IH), 8.76 (s, IH), 9.01 (s, IH), 10.17 (s, IH); MS (ESI(+)) m/e 508.1 (M+H)+. .Example 503 N-{4-[4-ammo-7-(13-benzodioxol-5-yl)thieno[3,2-c]pyridm-3-yl]phenyl)-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 464B and morpholine for Example 176C and diethylamine, respectively, in Example 177. 1H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3H), 2.42-2.45 (m, 4H), 3.18 (d, J=6.4 Hz, 2H), 3.59-3.62 (m, 4H), 5.57 (s, 2H), 6.21 (dt, J-16.3, 6.4 Hz, IH), 6.68 (d, J=I6.3 Hz, IH), 6.80 (d, J=7.5 Hz, IH), 7.17 (t, J=7.8 Hz, IH), 7.25 (d, J=8.5 Hz, IH), 7.32 (s, IH), 7.37 (d, J=8.5 Hz, 2H), 7.50 -212- WO 2005/010009 PCT/US2004/024003 (s, IH), 7.60 (d, J-8.5 Hz, 2H), 7.94 (s, IH), 8.67 (s, IH), 8.88 (s, IH); MS (ESI(+)) m/e '-500.2 (M+H)+. Example 504 3,7-di-lH-indol-6-vlthieno[3,2-c]pvridin-4-amine The desired product was prepared by substituting Example 21A, Example 474A (2.1 equivalents) and PdCl2(dppf) for Example 21B, 4-chlorophenylboronic acid and PdCla(PPh3)4, respectively in Example 21C. lH NMR (300 MHz, DMSO-D6) 6 ppm 6.53-6.57 (m, 4H), 7.14 (dd, J=8.1,1.4 Hz, IH), 7.32 (dd, J=8.1,1.7 Hz, IH), 7.4S-7.52 (m, 2H), 7.55 (s, IH), 7.71-7.73 (m, 2H), 7.75 (d, J=2.4 Hz, IH), 7.S0 (s, IH), 7.95 (s, IH), 11.34 (s, lH),'11.38(s, IH); MS (ESI(+)) m/e 381.0 (M+H)+. Example 505 N-(3-{4-ammo-3-[4-({[(3-methylphenyl)ammo1carbonyl)ammo)phenyl]thieno[3,2-c]pyridin- 7-yl)prop-2-ynyl)-2-(piperidin-l-vlcarbonyl)benzarnide Example 5 05 A N-{3-[4-amino 3-(4-aminophenyl)thieno[3,2-c1pyridm-77yl]prop-2-yjiyl]-2-(pyridin--l- ylcarbonyl)benzamide The desired product was prepared by substituting Example 77B and N-propargylphthalimide for Example 144A and 3-butyn-l-ol in Example 144B. MS (ESI(+)) m/e510(M+H)+. Example 505B N-{3-[4-amino 3-(4-aminophenyl)thieno[3,2-c1pyridm-77yl]prop-2-yl]-2-(pyridin--l- ylcarbonyl)benzamide The desired product was prepared by substituting Example 505A for Example 1C in Example ID. 1HNMR (300 MHz, DMSO-d6) δ ppm1.51 (s, 6H), 2.29 (s, 3H), 3.07-3.09 (m, 2H), 3.54 (s, 2H), 4.36 (s, 2H), 5.78 (s, 2H), 6.81 (d, J=7.12 Hz, IH), 7.17 (t, J=7.80 Hz, 30 IH), 7.23-7.31 (m, 2H), 7.31 (s, IH), 7.37 (d, J=8.82 Hz, 2H), 7.45-7.56 (m, 3H), 7.60 (d, J=S.4S. Hz, 2H), 7.69 (d, J=7.46 Hz, IH), 7.98 (s, IH), 8.66 (s, IH), 8.86 (s, IH), S.96 (t, J=5.43 Hz, IH); MS (ESI(+)) m/e 643 (M+H)+. Example 506 N- (4-f 4-amino-7-(3-pyrrolidin-1 -ylprop-1 -ynyl)thieno[3 ,2-c]pyridin-3-yl]phenyl) -NM3- methylphenylurea Example 506A -213- WO 2005/010009 PCT/US2004/024003 I -prop-2-ynylpyrrolidine A suspension of pyrrolidine (3.71 mL, 44.92 mmol) and cesium carbonate (14.64 g, 44.92 mmol) in acetone was treated with propargyl bromide (5.0 mL, 44.92 mmol) and stirred at room temperature for 2 days. The solution was filtered, washing with acetone. The filtrate was concentrated, taken up in ethyl acetate, washed with aqueous sodium bicarbonate, dried (Na O,,), filtered and concentrated to give 1.67 g of the desired product. MS (ESI(+)) m/ell0(M+H)+. Example 506B 3-(4-ammophenyl)-7-(3-pyrrolidm-l-ylprop-l-ynyl)thieno[3,2 1pyridm-4-arnine The desired product was prepared by substituting Example 77B and Example 506A for Example 144A and 3-butyn-l-ol in Example 144B. MS (ESI(+)) m/e 349 (M+H)+ Example 506C N- {4-[4-amino-7-(3-pyrrolidin-1 -ylprop-1 -ynypthienof 3,2-c]pyridin-3-yl]phenyl) -N-(3 methylphenyl)urea The desired product was prepared by substituting Example 506B for Example 1C in Example ID. 1H NMR (300 MHz, DMSO-D6) δ ppm1.73-1.7.7 (m, 4H), 2.29 (s, 3H), 2.63-2.67 (m, 4H), 3.71 (s, 2H), 5.75 (s, 2H), 6.80 (d, J=7.46 Hz, IH), 7.17 (t, J=7.80 Hz, IH), 7.24-7.26 (m, IH), 7.31 (s, IH), 7.37 (d, J=8.81 Hz, 2H), 7.50 (s, IH), 7.60 (d, J=8.48 Hz, 2H), 7.96 (s, IH), 8.66 (s, IH), 8.86 (s, IH); MS (ESI(+)) m/e 482 (M+H)+- Example 507 N-{4-[4-amino-7-(3-pyn-olidip-l-ylprop-l-ynyl)thieno[3,2-c]pyridin-3-yl]phenyl)-N'-[3-(trifluoromethyl)phenyl]urea The desired product was preparedby substituting Example 506B and l-isocyanato-3-(trifluoromethyl)benzene for Example 1C and l-isocyanato-3-methylbenzene, respectively, in Example ID! 1HNMR(300MHz, DMSO-D 8 ppm 1.73-1.78 (m, 4H), 2.65 (t, J-5.26 Hz, 4H), 3.71 (s, 2H), 5.75 (s, 2H), 7.33 (d, J=7.46 Hz, IH), 7.39 (d, J=8.48 Hz, 2H), 7.51 (s, IH), 7.54 (d, J-7.80 Hz, IH), 7.59 (s, IH), 7.62 (d, J=8.4S Hz, 2H), 7.97 (s, IH), 8.04 (s, IH), 9.02 (s, IH), 9.13 (s, IH); MS (ESI(+)) m/e 536 (M+H)+. Example 508 N-{3-[4-amino 3-(4-aminophenyl)thieno[3,2-c1pyridm-3-yl] ]-3-(pyridin-l- ylcarbonyl)benzamide The desired product was prepared by substituting Example 506B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene for Example 1C and l-isocyanato-3-methylbenzene, respectively, in Example ID. 1H NMR (300 MHz, DMSO-D6) δ ppm1.9S (m, 2H), 2.09 (m, -214- WO 2005/010009 PCT/US2004/024003 2H), 3.24 (m, 2H),:3:64 (m; 2H), 4.54 (s, 2H), 6.32 (s, 2H), 7.41 (m, 3H), 7.52 (m, 1H), 7.65 (m, 3H), 8.15 (s, 1H), 8.62 (dd, J=7.29, 2.20 Hz, 1H), 9.03 (d, J=2.71 Hz, 1H), 9.47 (s, 1H); MS (ESI(+)) m/e 554 (M+H)+. Example 509 N-{4-[4-amino -7-(3-pyrrolidin-l-ylprop-1-ynyl)thieno[3,2-c]pyridm-3-yl]pheny}-N-(2- Fluoro-5-methylphenyl)urea The desired product was prepared by substituting Example 506B and l-fluoro-2-isocyanato-4-rnethylbenzene for Example 1C and l-isocyanato-3-methylbenzene, 10 respectively, in Example ID. 1H NMR (300 MHz, DMSO-D6) 6 ppm 1.99 (m, 4H), 2.28 (s, 3H), 3.25 (m, 2H), 3.63 (m, 2H), 4.54 (s, 2H), 6.44 (s, 2H), 6.82 (m, 1H), 7.12 (dd, J-11.36, 8.31 Hz, 1H), 7.41 (d, J=8.48 Hz, 2H), 7.63 (d, J=8.48 Hz, 2H), 7.69 (s, 1H), 7.98 (dd, J=7.80,1.70 Hz, 1H), 8.16 (s, 1H), 8.61 (d, J=2.03 Hz, 1H), 9.36 (s, 1H); MS (ESI(+)) m/e 500 (M+H)+. Example 510 N-{4-[4-amino -7-(3-pyrrolidin-l-ylprop-1-ynyl)thieno[3,2-c]pyridm-3-yl]pheny}-N-(2- chlorophenyl)urea The desired product was prepared by substituting Example 506B and l-chloro-3-20 isocyanatobenzene for Example 1C and l-isocyanato-3-methylbenzene, respectively, in Example ID. 1H NMR (300 MHz, DMSO-D6) 8 ppm 2.03 (m, 4H), 3.24 (m, 2H), 3.58 (m, 2H), 4.54 (s, 2H), 6.43 (s, 2H), 7.03 (m, 1H), 7.31 (m, 2H), 7.41 (d, J=8.5 Hz, 2H), 7.65 (d, J=8.5 Hz, 2H), 7.6S (s, 1H), 7.75 (s, 1H), 8.16 (s, 1H), 9.29 (s, 1H), 9.31 (s, 1H); MS (ESI(+)) m/e 502 (M+H)+. Example 511 A suspension of Example 77B (0.6 g, 1.63 mmol) in DMF (3 mL) and triethylarnme (2 mL) was degassed by bubbling nitrogen through the suspension for 5 minutes , treated withN-propargylphthalimide (0.45 g, 2.45 mmol), PdCl2(PPh3)4 (57 mg, 0.08 mmol), and Cut (15 mg, 0.08 mmol), then heated to 80 °C for 1 hour. The cooled solution was poured into water, extracted with ethyl acetate and the combined organic layers were washed with brine, dried (Na SOJ, filtered'and concentrated. The residue was purified by flash 35 chromatography on silica gel using 3% methanol/dichloromethane to provide 300 mg (43% yield) of the desired product. 1H NMR (300 MHz, DMSO-D6) δ ppm4.72 (s, 2H), 5.37 (s, 2H), 5.86 (s, 2H), 6.66 (d, J=8.14 Hz, 2H), 7.07 (d, J=8.14 Hz, 2H), 7.35 (s, 1H), 7.87-7.89 (m, 1H), 7.90 (s, 1H), 7.93 (d, J=4.07 Hz, 2H), 7.96 (d, J=5.76 Hz, 1H); MS (ESI(+)) m/e 425 -215- WO 2005/010009 PCT/US2004/024003 (M+H)+ ' Example 512 N-{4-[4-amino -7-(3-diethylamino)prop-1-ynyl)thieno[3,2-c]pyridm-3-yl]pheny}-N-(3- (trifluorometliyl)phenyl] urea Example 512A 3-(4-ammophenyl)-7-[3-(diemylammo)prop-l-ynyl]thieno[3,2-c]pyridm-4-amine The desired product was prepared by substituting Example 77B and 3-diethylamino- 1-propyne or Example 144A and 3-butyn-l-ol in Example 144B. MS (ESI(+)) m/e 351 (M+H)+. Example 512B N-{4-[4-amino -7-(3-pyrrolidin-l-ylprop-1-ynyl)thieno[3,2-c]pyridm-3-yl]pheny}-N-(2- (trifluoromethy l)pheny!1 urea The desired product was prepared by substituting Example 512 A and 1 -isocyanato-3 -(trifluoromethyl)benzene for Example IC and l-isocyanato-3-methylbenzene, respectively, in Example ID. ]H NMR (300 MHz, DMSO-D6) δ ppm1.06 (t, J=7.12 Hz, 6H), 2.60 (q, J=6.89 Hz, 4H), 3.71 (s, 2H), 5.75 (s, 2H), 7.33 (d, J=7.46 Hz, IH), 7.39 (d, J-S.48 Hz, 2H), 20 7.53 (m, 2H), 7.61 (m, 3H), 7.96 (s, IH), 8.04 (s, IH), 9.01 (s, IH), 9.12 (s, IH); MS (ESI(+)) m/e 538 (M+H)+. Example 513 N-{4-[4-amino -7-(3-pyrrolidin-l-ylprop-1-ynyl)thieno[3,2-c]pyridm-3-yl]pheny}-N-(2- The desired product was formed by substituting Example 284A and 3-chloro-l- isocyanatobenzene for Example IC and l-isocyanato-3-methylbenzene, respectively, in Example ID. 1H NMR (300 MHz, DMSO-D6) 6 ppm 6.56 (m, IH), 6.84 (s, 2H), 7.04 (m, IH), 7.32 (d, J-5.43 Hz, 2H), 7.39 (dd, J-8.31,1.87 Hz, IH), 7.49 (m, 3H),7.60 (d, J=S.14 Hz, 1H)„7.69 (d, J=8.48 Hz, 2H), 7.75 (m, IH), 7.86 (m, 2H), 7.94 (s, IH), 9.22 (s, IH), 9.28 (s, IH), 11.37 (s, IH); MS (ESI(+)) m/e 510 (M+H)+. Example 514 N-{4-[4-ammo-7-(lH-mdol-5-vnthieno[3,2-cbvridin-3-vl]phenyl)-N'-[3- (trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 284A and l-isocyanato-3- (triiluoromethyl)benzene for Example IC and l-isocyanato-3-methylbenzene, respectively, in Example ID. lH NMR (300 MHz, DMSO-D6) δ ppm6.56 (m, IH), 6.83 (s, 2H), 7.33 (d, J=7.46 Hz, IH), 7.39 (dd, J=8.14,1.70 Hz, IH), 7.49 (m, 3H), 7.55 (m, IH), 7.61 (m, 2H), -216- WO 2005/010009 PCT/US2004/024003 7.70 (m,2H)37:S6(m,2H), 7:94 (s lH),8.06 9.31(1,H) 9.37(s, IH), 11.36 (s, IH); MS (ESI(+)) m/e 544 (M+H)+. Example 515 N-{44.4-ammo-7-(lH4ndol-5-yl) thieno[3,2-c]pvridin-3-yl]phenvl}-N'-(2-fiuoro-5- methylphenyl)urea The desired product was prepared by substituting Example 284A and l-fluoro-2-isocyanato-4-methylbenzene for Example 1C and l-isocyanato-3-methylbenzene, respectively, in Example ID. 1H NMR (300 MHz, DMSO-D6) 6 ppm 2.29 (s, 3H), 6.56 (s, IH), 6.84 (m, J=5.09, 2.37 Hz, 3H), 7.13 (dd, J=11.36, 8.31 Hz, IH), 7.39 (dd, J=S.48,1.70 Hz, IH), 7.49 (m, 3H), 7.60 (d, J=S.14Hz, IH), 7.67 (d, J=8.81 Hz, 2H), 7.86 (m, 2H), 7.94 (s, IH), 7.99 (dd, J=7.97,1.86 Hz, IH), 8.60 (d, J=2.37 Hz, IH), 9.36 (s, IH), 11.36 (s, IH); MS (ESI(+)) m/e 508 (M+H)+ Example 516 tert-butyl 3-{4-ammo-3-[4-({[(3-memylphenyl)ammolcarbonynammo)phenyl]thieno[3,2-c]pyridin-7-yl)prop-2-ynyl(ethyl)carbamate Example 516A tert-butyl prop-2-ynylcarbamate A solution of propargyl amine (2.32 g, 42.1 mmol) in THF (75 mL) and water (200 mL) was treated with a saturated sodium bicarbonate solution (5 mL), followed by the dropwise addition of a solution of di-tert-butyl -dicarbonate (9.19 g, 42.1 mmol) in THF (20 mL). The solution was stirred overnight at room temperature, concentrated in vacuo to remove THF, extracted with ethyl acetate. The combined organics were washed with brine, dried (MgS04) and concentrated to provide 4.37 g (67% yield) of the desired product. 1H NMR (300 MHz, CHLOROFORM-D) 8 ppm 1.46 (s, 9H), 2.22 (t, J=2.54 Hz, IH), 3.92 (dd, J=5.26,2.20 Hz, 2H), 4.68 (s, IH). Example 516B tert-butyl ethyl(prop-2-vnyl)carbamate A suspension of sodium hydride (354 mg, 14.2 mmol) in DMF (33 mL) at room temperature was treated with a solution of Example 516A (2.0 g, 12.9 mmol) in DMF (10 mL) and stirred for one hour at room temperature. The solution was cooled to 0 °C, treated with ethyl iodide (1.24 mL, 15.5 mmol), stirred for one hour at 0 ° and overnight at room temperature. The solution was diluted with water (25 mL),extracted with diethyl ether (2x50 mL) and the combined organic layers were washed with brine (30 mLO, dried (MgS04), filtered and concentrated. The residue was purified by flash chromatography on silica gel -217- WO 2005/010009 PCT/US2004/024003 using 5-10% ethyl acetate/hexanes to give the 1.1 g (47% yield) of the desired product. MS , (ESI(+))m/el84(M+H)+. Example 516C tert-butyl 3-[4-amino-3-(4-aininophenyl)thieno[3,2-c]pvridin-7-Y-llprop-2- ynyKethypcarbamate The desired product was prepared by substituting'Example 77B and Example 516B for Example 144A and 3-butyn-l-ol, respectively, in Example 144B. 1H NMR (300. MHz, DMSO-D6) 6 ppm 1.17 ft J=6.95 Hz, 3H), 1.44 (s, 9H), 3.36 (q, J=7.12 Hz, 2H), 4.32 (s, 10 2H), 5.38 (s, 2H), 5.83 (s, 2H), 6.67 (d, >8.48 Hz, 2H), 7.08 (d, J=8.48 Hz, 2H), 7.37 (s, IH), 7.93 (s, 1H),MS (ESI(+)) m/e 422 (M+H)+. Example 516D tert-butyl 3-[4-amino-3-(4-aininophenyl)thieno[3,2-c]pvridin-7-Y-llprop-2- c-lpyridin-7-yl) prop-2-ynyl(ethyl)carbamate The desired product was prepared by substituting Example 516C for Example lCin Example ID. 1H NMR (300 MHz, DMSO-D6) δ ppm1.18 ft, J=6.44 Hz, 3H), 1.45 (s, 9H), 2.29 (s, 3H), 3.37 (q, J-7.12 Hz, 2H), 4.33 (s, 2H), 5.79 (s, 2H), 6.80 (d, J=7.46 Hz, IH), 7.17 ft J=7.80 Hz, IH), 7.25 (m, IH), 7.31 (m, IH), 7.37 (d, J=8.48 Hz, 2H), 7.52 (s, IH), 7.60 (d, 20 J-8.48 Hz, 2H), 7.97 (s, IH), 8.66 (s, IH), 8.86 (s, IH); MS (ESI(+)) m/e 556 (M+H)+. Example 517 N-(4-{4-anmio-7-[3-(emylammo)prop-l-Ynvnthieno[3,2-c]pyridm-3-vl}phenyl)-N’-(3- methylphenyl)urea The desired product was prepared by substituting Example 516D for Example 76B in Example 76C. 1H NMR (300 MHz, DMSO-D6) δ ppm1.07 ft, J=7.12 Hz, 3H), 2.29 (s, 3H), ' 2.72 (q, J=7.12 Hz, 2H), 3.65 (s, 2H), 5.74 (s, 2H), 6.81 (d, J-7.46 Hz, IH), 7.17 (t, J=7.80 Hz, IH), 7.25 (m, IH), 7.32 (s, IH), 7.38 (d, J=8.48 Hz, 2H), 7.51 (s, IH), 7.60 (m, J-8.48 Hz, 3H), 7.95 (s, IH), 8.66 (s, IH), S.86 (s, IH); MS (ESI(+)) m/e 456 (M+H)+. Example 518 tert-butyl 3-[4-amino-3-[4-({[(2-fluoro-5- methylphenyl)ammolcarbonyl}amino)phenynthieno[3,2-c]pyridin-7-yl}prop-2- ynylfethyDcarbamate The desired product was prepared by substituting Example 516C and l-fluoro-2- isocyanato 4-methylbenzene for Example 1C and l-isocyanato-3-methylbenzene, respectively, in Example ID. 1H NMR (300 MHz, DMSO-D6) δ ppm1.18 (t, J=7.12 Hz, 3K), 1.45 (s, 9H), 2.28 (s, 3H), 337 (q, J-7.12 Hz, 2H), 4.33 (s, 2H), 5.77 (m, 2H), 6.83 (m, -218- WO 2005/010009 PCT/US2004/024003 IH), 7.12 (dd, W1.36, 8.31 Hz, 1H), 7.39 (d, J=8.82 Hz, 2H), 7.53 (s, IH), 7.60 (d, J=8.82 Hz, 2H), 7.97 (s, IH), 8.00 (dd, J=7.80,2.03 Hz, 1H), 8.55 (d, J=2.37 Hz, IH), 9.26 (s, 1H); MS (ESI(+)) m/e 574 (M+H)+. Example 519 N-(4-{4-amino-7-[3-(emvlamino)prop-l-ynvl]thieno[3,2-c]pyridm-3-vl)phenvl)-N'-(2- fluoro-5 -methy lphenypurea The desired product was prepared by substituting Example 518 for Example 76B in Example 76C. 1H NMR (300 MHz, DMSO-D6) δ ppm1.07 (t, 1=7.29 Hz, 3H), 2.30 (m, 3H), 2.73 (q, J=7.12 Hz, 2H), 3.66 (s, 2H), 5.73 (s, 2H), 6.82 (m, IH), 7.11 (m, IH), 7.38 (m, 3H), 7.51 (s, IH), 7.60 (m, 2H), 7.95 (s, IH), 7.99 (m, IH), 8.55 (d, J-2.37 Hz, IH), 9.26 (s, IH); MS (ESI(+)) m/e 474 (M+H)+. Example 520 N-(4-{4-amino-7-[3-(emvlamino)prop-l-ynvl]thieno[3,2-c]pyridm-3-vl)phenvl)-N'-(2- (trifluoromethyl)phenyl]urea Example 520A tert-butyl 3-(4-amino-3-{4-[({[3- (trifluoromemyl)phenyl]aimno}carbonyl)ammo]phen ynyl(ethyl)carbamate The desired product was prepared by substituting Example 516C and l-isocyanato-3-(trifluoromethyl)benzene for Example IC and l-isocyanato-3-methylbenzene, respectively, in Example ID. Example 520B N-(4-{4-amino-7-[3-(emvlamino)prop-l-ynvl]thieno[3,2-c]pyridm-3-vl)phenvl)-N'-(2- (trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 520A for Example 76B in Example 76C. 1H NMR (300 MHz, DMSO-D6) 6 ppm 1.12 (m, 3H), 2.83 (q, J=6.89 Hz, 2H), 3.82 (s, 2H), 5.79 (s, 2H), 7.32 (m, 2H), 7.39 (d, JM8.48 Hz, 2H), 7.53 (m, 2H), 7.62 (t, J=7.S0 Hz, 3H), 7.98 (s, IH), 8.04 (s, IH), 9.09 (s, IH), 9.20 (s, IH); MS (ESI(+)) m/e 510 (M+H)+. Example 521 tert-butyl 3-{4-arru o-3-[4-f{[(3-cmorophenyl)ammolcarbonyUainmo)phenyl]thieno[3,2-c]pyridin-7-yl} prop-2-vnyl(ethyl')carb amate The desired product was prepared by substituting Example 516C and 3-chloro-l- -219- WO 2005/010009 PCT/US2004/024003 isocyanatobenzene for Example 1C and l-isocyanato-3-methylbenzene, respectively, in Example ID. 1H NMR (300 MHz, DMSO-D,) δ ppm1.18 (t, J-6.95 Hz, 3H), 1.45 (s, 9H), 3.37 (q, J-7.12 Hz, 2H), 4.33 (s, 2H), 5.75 (s, 2H), 7.03 (m, IH), 7.31 (m, 2H), 7.39 (d, J=S.S2 Hz, 2H), 7.52 (s, IH), 7.61 (d, J=8.48 Hz, 2H), 7.73 (m, IH), 7.97 (s, IH), 8.97 (m, 5 2H); MS (ESI(+)) m/e 576 (M+H)+. Example 522 N-(4-{4-arm o-7-[3-(emylammo)prop-l-ynyl]thieno[3,2-c]pyridm-3-yl)pbenyl)-N'-(3- chlorophenyPurea Tbe desired product was prepared by substituting Example 521 for Example 76B in' Example 76C. 1HNMR (300 MHz, DMSO-DJ 6 ppm 1.25 (t, J=7.12 Hz, 3H), 3.13 (m, 2H), 4.32 (m, 2H), 6.76 (s, 2H), 7.03 (m, IH), 7.32 (m, 2H), 7.42 (d, J=8.48 Hz, 2H), 7.67 (d, J-8.48 Hz, 2H), 7.76 (m, 2H), 8.16 (s, IH), 9.18 (s, IH), 9.41 (s, IH), 9.43 (s, IH); MS (ESI(+)) m/e 476 (M+H)+. 15 Example 523 tert-butyl 3-(4-amino-3-{4-[({[2-fluoro-5-(trifluoromemyl)phenyl]animo)carbonyl)ar ynyl(ethyl)carbamate The desired product was prepared by substituting Example 516C and l-fluoro-2- isocyanato-4-(trifluoromethyl)benzene for Example 1C and l-isocyanato-3-methylbenzene, respectively, in Example ID. !H NMR (300 MHz, DMSO-D6) 6 ppm 1.18 (t, J=7.12 Hz, 2H), 1.45 (s, 9H), 3.37 (q, J=7.i2 Hz, 3H), 4.34 (s, 2H), 5.78 (s, 2H), 7.41 (m, 3H), 7.52 (m, 2H), 7.62 (d, J=8.S1 Hz, 2H), 7.97 (s, IH), 8.64 (dd, J=7.29, 2.20 Hz, IH), 8.97"(d, J=3.05 Hz, IH), 9.38 (s, IH); MS (ESI(+)) m/e 628 (M+H)+. Example 524 N-(4-(4-ammo-7-[3-(ethylammo)prop-l-ynyl] thieno[3,2-c]pyridin-3-yl)phenyl)-N,-[2- fluoro-5-(trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 523 for Example 76B in Example 76C. XHNMR (300MHz, DMSO-D*) δ ppm1.25 (m, 3H), 3.13 (s, 2H), 4.32 (s, 2H), 6.48 (s, 2H), 7.42 (m, 3H), 7.52 (m, IH), 7,65 (d, J=8.81 Hz, 2H), 7.71 (s, IH), S.13 (s, IH), 8.62 (dd, J=7.29, 2.20 Hz, IH), 9.04 (d, J=2.71 Hz, IH), 9.14 (s, IH), 9.48 (s, IH), MS (ESI(+)) m/e 528 (M+H)+. Example 525 tert-butyl 3-(4-ammo-3-R4 {[(3-memylphenyl)ammolcarbonyl}arnmo)phenyl]tnieno[3,2- clpyridin-7-yl}prop-2-ynylcarbamate -220- WO 2005/010009 PCT/US2004/024003 Example 525A tert-butyl 3-(4-amino-3-{4-[({[2-fluoro-5-(trifluoromemyl)phenyl]animo)carbonyl)arynyl(ethyl)carbamate The desired product was prepared by substituting pxample 77B and Example 516A for Example 144A and 3-butyn-l-ol, respectively, in Example 144B. MS (ESI(+)) m/e 395 (M+H)+ Example 525B tert-butyl 3-(4-amino-3-{4-[({[2-fluoro-5-(trifluoromemyl)phenyl]animo)carbonyl)ar ynyl(ethyl)carbamate The desired product was prepared by substituting Example 525A for Example 1C in Example ID. 1H NMR (300 MHz, DMSO-De) δ ppm1.42 (s, 9H), 2.29 (s, 3H), 4.06 (d, J-5.09 Hz, 2H), 5.77 (s, 2H), 6.81 (d, J=7.12 Hz, IH), 7.17 (t, J=7.80 Hz, IH), 7.25 (m, IH), 7.32 (s, IH), 7.3S (m, 3H), 7.52 (s, IH), 7.60 (d, J=S.48 Hz, 2H), 7.95 (s, IH), 8.66 (s, IH), S.S6 (s, IH); MS (ESI(+)) m/e 528 (M+H)+. Example 526 N-{4-[4-arnmo-7-(3-aminoprop4-ynyl)thieno[3,2-c]pyridin-3-yl]phenyl}-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 525B for Example 76B in Example 76C. !H NMR (300 MHz, DMSO-D6) 6 ppm 2.29 (s, 3H), 4.14 (d, J=4.75 Hz, 2H), 6.44_(s, 2H), 6.80 (d, J=7.46 Hz, 2H), 7.17 (t, J=7.80 Hz, IH), 7.26 (m, IH), 7.33 (s, IH), 7.39 (d, J=8.48 Hz, 2H), 7.64 (d, J=8.81 Hz, 2H), 7.69 (s, IH), 8.08 (s, IH), 8.37 (s, IH), 8.S< (s, IH), 9.09 (s, IH); MS (ESI(+)) m/e 428 (M+H)*. 25 Example 527 N-{4-[4-ammo-7-(3-ammoprop-l-vnyl)tln no[3,2-c]pyridin-3-yl]phenyl)-N'-(3- chlorophenyl)urea Example 527 A tert-butyl 3-(4-ammo-3-R4 {[(3-memylphenyl)ammolcarbonyl}arnmo)phenyl]tnieno[3,2- c]pvridin-7-vl)prop-2-ynylcarbamate The desired product was prepared by substituting Example 525A and 3-chloro-l-isocyanatobenzene for Example 1C and l-isocyanato-3-methyl benzene, respectively, in Example ID. Example 527B N-{4-[4-arnmo-7-(3-ammoprop-l-ynvl)thieno[3,2-c]pyridin-3-yl]phenyl}-N'-(3- -221- WO 2005/010009 PCT/US2004/024003 chlbrophenyl)urea The desired product was prepared by substituting Example 527A for Example 76B in Example 76C. ]H NMR (300 MHz, DMSO-D6) 8 ppm 4.14 (m, 2H), 6.38 (s, 2H), 7.03 (m, 2H), 7.31 (m, 2H), 7.41 (d, J=8.82 Hz, 2H), 7.65 (m,2H), 7.68 (s, IH), 7.74 (s, IH), 8.07 (s, ' IH), 8.37 (s, IH), 9.23 (s, IH), 9.25 (s, IH); (ESI(+)) m/e 448 (M+H)+. Example 528 N-{4-[4-amino-7-(3-armnoprop-l-ynyl)thieno[3,2-c] pvridin-3-yl} phenyl}-N'-(3-fluro-5- methylphenyl)urea Example 528A tert-butyl 3- {4-amino-3-[4-( (f (2-fluoro-5- memylphenyl)ainino1carbonyl)ammo)phenynthieno[3,2-c]pvriddn-7-ynprop-2- ynylcarbamate The desired product was prepared by substituting Example 525A and l-fluoro-2- isocyanato-4-methylbenzene for Example 1C and l-isocyanato-3-methyl benzene, respectively, in Example ID. Example 528E N-{4-[4-amino-7-(3-armnoprop-l-ynyl)thieno[3,2-c] pvridin-3-yl} phenyl}-N'-(3-fluro-5- methylphenyl)urea The desired product was prepared by substituting Example 528A for Example 76B in Example 76C. 1H NMR (300 MHz, DMSO-DJ δ ppm2.28 (s, 3H), 4.14 (d, J=4.75 Hz, 2H), 6.38 (s, 2H), 6.83 (m, 2H), 7.12 (dd, J=11.36, 8.31 Hz, IH), 7.41 (d, J=8.48 Hz, 2H), 7.63 (d, J=S.81 Hz, 2H), 7.68 (s, IH), 7.9S (dd, J=7.80,2.03 Hz, IH), 8.07 (s, IH), 8.35 (m, IH), 8.59 (d, J=2.37 Hz, IH), 9.33 (s, IH); ESI(+)) m/e 446 (M+H)+. Example 529 tert-butyl 3-(4-amino-3-{4-[(([2-fluoro-5- (trifluoromemyl)phenyl]anmo)carbonyl) pvridin-3-yl} phenyl}-N'-(3-prop-2- ynylcarbamate The desired product was prepared by substituting Example 525A and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene for Example 1C and l-isocyanato-3-methyl benzene, respectively, in Example ID. ]H NMR (500 MHz, DMSO-D6) δ ppm1.41 (s, 9H), 4.05 (d, J-3.74 Hz, 2H), 5.73 (s, 3H), 7.38 (m, 3H), 7.48 (d, J=10.61 Hz, IH), 7.51 (s, IH), 7.61 (d, J=8.42 Hz, 2H), 7.94 (s, IH), 8.62 (dd, J=7.1S, 2.18 Hz, IH), 8.94 (s, IH), 9.35 (s, IH); ESI(+)) m/e 600 (M+H)+. -222- WO 2005/010009 PCI7US2004/024003 Example 530 N-{4-[4-amino-7-(3-armnoprop-l-ynyl)thieno[3,2-c] pvridin-3-yl} phenyl}-N'-(3-fluro-5- (trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 529 for Example 76B in Example 76C. lHNMR (300 MHz, DMSO-D6) S ppm 4.14 (d, J=5.09 Hz, 2H), 6.38 (s, 2H), 7.43 (m, 4H), 7.52 (m, IH), 7.65 (d, J=8.S2 Hz, 2H), 7.d9-(s, IH), S.08 (s, IH), 8.38 (s, IH), 8.62 (dd, J=7.12, 2.03 Hz, IH), 9.04 (d, J=2.71 Hz, IH), 9.47 (s, IH); ESI(+)) m/e 500 (M+H)+. Example 531 tert-butyl 3-(4-amino-3-(4-[({[3-(tri£luoromemyl)phenyl]amino}carbonyl)animo1phenyl) thieno[3 -clpyridin-7-yl')prop-2- ynylcarbamate The desired product was prepared by substituting Example 525A and l-isocyanato-3- (trifluoromethyl)benzene for Example 1C and l-isocyanato-3-methyl benzene, respectively, in Example ID. 1H NMR (500 MHz, DMSO-D δ ppm1.41 (s, 9H), 4.05 (d, J=3.43 Hz, 2H), 5.73 (s, 3H), 7.35 (m, 3H), 7.52 (m, 2H), 7.60 (m, 3H), 7.94 (s, IH), 8.02 (s, IH), 8.98 (s, IH), 9.09 (s, IH); ESI(+)) m/e 582 (M+H)+. Example 532 N-{4 4-ammo-7-(3-airu oprop-l-vnyl)thieno[3,2-c]pyridin-3-yl]phenyU-N’-[3- (trifluoromethyl)phenyl] urea The desired product was prepared by substituting Example 531 for Example 76B in Example 76C. 1HNMR (300 MHz, DMSO-D6) δ ppm4.14 (d, J=5.09 Hz, 2H), 6.46 (s, 2H), 7.33 (d, J-7.80 Hz, IH), 7.42 (d, J=8.4S Hz, 2H), 7.53 (t, J=7.S0 Hz, IH), 7.66 (m, 4H), 8.08 (m, 2H), 8.38 (m, 2H), 9.37 (s, IH), 9.46 (s, IH); ESI(+)) m/e 482 (M+H)+. Example 533 N-{4-[4-amino-7-(3-armnoprop-l-ynyl)thieno[3,2-c] pvridin-3-yl} phenyl}-N'-(3-fluro-5- methylphenyl)urea Example 533 A tert-butyl 1,1 -diethylprop-2-ynylcarbamate The desired product was prepared by substituting 1,1 -diemylpropargylamine for propargylamine in Example 516. 1H NMR (500 MHz, DMSO-D6) δ ppm0.85 (t, J=7.49 Hz, 6H), 1.38 (s, 9H), 1.73 (m, 4H), 3.05 (s, IH), 6.61 (s, IH). Example 533B -223- WO 2005/010009 PCT/US2004/02400: The desired product was prepared by substituting Example 77B and Example 533A .or Example 144A and 3-butyn-l-ol, respectively, in Example 144B. MS (ESI(+)) m/e 451 (M+H)+. Example 53 3C tert-butyl 3-(4-ammo-3-[4-({[(3-memylphenynammo1carbonyl}amino)phenyl]tln yl)o[3,2-c]pyridin-7-yl}-l,l-diethylprop-2-ynylcarbamate The desired product was prepared by substituting Example 533B for Example 1C in Example ID. Example 533D N-(4-[4-ammo-7-(3-ammo-3-ethylpent-l-ynyl)tm o[3,2-c]pyridm-3-yl]plieiiyl)-N1-(3- methyrphenypurea The desired product was prepared by substituting Example 533C for Example 76B in Example 76C. !H NMR (300 MHz, DMSO-D6) 8 ppm 1.14 (t, J=7.29 Hz, 6H), 1.91 (m, 4H) 2.29 (s, 3H), 6.39 (s, 2H), 6.S0 (d, J=7.46 Hz, IH), 7.17 (t, J=7.63 Hz, IH), 7.26 (d, J=8.14 Hz, IH), 7.33 (s, IH), 7.39 (d, J=8.14 Hz, IH), 7.65 (m, 3H), 8.10 (s, IH), 8.56 (s, 3H), 8.86 (s, IH), 9.09 (s, IH); MS (ESI(+)) m/e 484 (M+H)+. Example 534 N-l4-[4-ammo-7-(3-ammo-3-efoylpeiit-l-y fluoro-5 -methylphenyl)urea Example 534A tert-butyl 3-{4-amino-3-[4-({[(2-fluoro-5- memvlphenyl)ammolcarbonyl}arm o)phenyl]tbieno[3,2-c]pyridm-7-vl}-l ,l-diethylprop-2- ynylcarbamate The desired product was prepared by substituting Example 533B and l-fluoro-2-isocyanato-4-methylbenzene for Example 1C and l-isocyanato-3-methylbenzene, respectively, in Example ID. Example 534B N-(4-[4-ammo-7-(3-arruno-3-ethylpent-l-vnvfl fluoro-5-methylphenyr)urea The desired product was prepared by substituting Example 534A for Example 76B ir Example 76C. 1H NMR (300 MHz, DMSO-D6) δ ppm1.14 (t, J=7.46 Hz, 6H), 1.92 (m, 4H -224- WO 2005/010009 PCMJS2004/024003 2!28 (s, 3H), 6.45 (s, 2H), 6.83 (m, IH), 7.12 (dd, J=U.36, 8.31 Hz, IH), 7.41'(d, X=S.48 Hz, 2H), 7.63 (d, J=8.48 Hz, 2H), 7.69 (s, IH), 7.99 (d, J-2.03 Hz, IH), 8.11 (s, IH), 8.58 (m, 3H), 9.33 (s, IH); MS (ES1(+)) m/e 502 (M+H)+. Example 535 N-{4-[4-amino-7-(3-ammo-3-ethylpent4-ynvl)1hieno[3,2-c]pyTidin--3-yl]phenyl}-N'-(3- chlorophenyDurea Example 535A 10 tert-butyl 3-{4-ainmo-3-[4-({[(3-chlorophenyfl clpyridin-7-yU -1J -diethylprop-2-ynylcarbamate The desired product was prepared by substituting Example 533B and 3-chloro-l-isocyanatobenzene for Example IC and l-isocyanato-3-methylbenzene, respectively, in Example ID. 15 Example 535B N-(4-[4-arnino-7-(3-anmo-3-ethylp chlorophenypurea The desired product was prepared by substituting Example 535A for Example 76B in 20 Example 76C. ]H NMR (300 MHz, DMSO-D*) δ ppm1.14 (t, J=7.46 Hz, 6H), 1.91 (m, 4H), 6.36 (s, 2H), 7.03 (m, IH), 7.32 (d, J-5.43 Hz, 2H), 7.40 (d, J=8.4S Hz, 2H), 7.65 (d, J=8.8 Hz, 2 H), 7.67 (s, 1 H), 7.75 (s, IH), 8.10 (s, IH), S.56 (m, 2H), 9.25 (s, IH), 9.28 (s, IH); MS (ESI(+)) m/e 504 (M+H)*. Example 536 N-{4-[4-ammo-7-(3-ammo-3-emylpent-l-ynyl)thieno[3,2pynoKdm fluoro-5-(trifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 542A for Example 76B in Example 76C. 1H NMR (300 MHz, DMSO-D6) 5 p'pm 2.07 (m, 3H), 2.41 (m, IH), 3.38 (q, 5 J=7.12 Hz, 2H), 4.76 (m, IH), 6.61 (s, IH), 7.42 (m, 3H), 7.52 (m, IH), 7.66 (d, J=S.48 Hz, 2H), 7.73 (s, IH), 8.14 (s, IH), 8.62 (dd, J=7.29, 2.20 Hz, IH), 9.05 (d, J-2.71 Hz, IH), 9.52 (m, 3H), MS (ESI(+)) m/e 540 (M+H)+ Example 543 10 N-[4-(4-aminofuro[3,2-c]pyridin-3-yl)phenyl]-N'-([3-methylphenyl)iu-ea Example 543A 3-bromo-4-chlorofiiro[3,2-c]pyridine A solution of 4-chJorofuro[3,2-c]pyridine (commercially available, 10.60 g, 69 mmol) 15 . in carbon tetrachJoride (135 mL) was cooled to -15 °C and bromine (12.13 g, 80 mmol) was added drop-wise over a fifteen minute time period. The mixture was stirred at ambient temperature for eighteen hours. The solvent was removed in vacuo, and the residue was dissolved in methanol (250 mL). A solution of 20% aqueous sodium hydroxide (35 mL) was added and the mixture was stirred 1 hour at ambient temperature. The methanol was 20 removed in vacuo, and the residue was partitioned between water (100 mL) and dichloromethane (50 mL). The combined organic layers were dried over anhydrous 5agnesium sulfate and the solvent was removed in vacuo to give 3-bronio-4-chloro[3,2-c]pyridine 15.45 g, 96%) as a solid. MS (ESI(+)) m/e 232,234 (M+H)+. 25 '' Example 543B 3-bromofuro[3,2-c]pyridin-4-amine The desired product was prepared by substituting Example 543A for 3-bromo-4-chlorothieno[3,2-c]pyridine in Example IB. MS (ESI(+)) m/e 213,215 (M+H)+. 30 Example.543C 3-(4-aminophenyl)furo[3,2-c]pvridm amine The desired product was prepared by substituting Example 543B and 4-bromoaniline for Example IB and 4-bromo-2-fluroraniline, respectively, in Example 1C. :H NMR (300 MHz, DMSO-D6) 8 ppm 5.32 (br s, 2H), 5.50 (br s, 2H), 6.69 (d, J=8.5 Hz, 2H), 6.88 (d, 35 J=6.1 Hz, IH), 7.15 (d, J=8.8 Hz, 2H), 7.76 (s, IH), 7.82 (d, 1=5.76 Hz, IH); MS ESI(+) m/e 226 (M+H)+. Example 543D -230- WO 2005/010009 PCT/US2004/024003 N-[4-(4-ammofurQ[3,2-c]pviidin-3>vl)phenyl]-N'-(3-methylphenyli)urea The desired product was prepared by substituting Example 543C for IC in Example ID. 1H NMR (300 MHz, DMSO-D6) 8 ppm 2.29 (s, 3H), 5.52 (s, 2H), 6.80 (d, J=7.1 Hz, IH), 6.93 (d, J=5.S Hz, IH), 7.16 (t, J=7.8 Hz, 1H)> 7.25 (m, IH), 7.31 (s, IH), 7.43 (m, 2H), 5 7.60 (d, J=S.8 Hz, 2H), 7.88 (m, 2H), 8.64 (s, IH), 8.82 (s, IH); MS ESI(+)) m/e 359 (M+H)+. Example 544 N-[4-(4-aminofuro[3,2-c]pvridin-3-yl)phenyn-N'-(3-chlorophenyl)urea 10 The desired product was prepared by substituting Example 543C and 3-chloro-l- isocyanatobenzene for Example IC and l-isocyanato-3-methylbenzene, respectively, in Example ID. 1H NMR (300 MHz, DMSO-D6) 8 ppm 5.52 (s, 2H), 6.93 (d, J=6.1 Hz, IH), 7.03 (m, IH), 7.31 (m, 2H), 7.45 (d, J=8.5 Hz, 2H), 7.61 (d, J=8.5 Hz, 2H), 7.73 (s, IH), 7.86 (d, J=5.8 Hz, IH), 7.92 (s, IH), 8.94 (s, IH), 8.95 (s,TH); MS ESI(+)) m/e 379 (M+H)+ 15 Example 545 N-[4-(4-animofuro[3,2-c]pyTidm-3-yl)phenyl]-N The desired prqduct was prepared by substituting Example 543C and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene for Example IC and l-isocyanato-3-methylbenzene, 20 respectively, in Example ID. lH NMR (300 MHz, DMSO-DJ 8 ppm 5.52 (br s, 2H), 6.94 (d, J=5.8 Hz, IH), 7.44 (m, 4H), 7.63 (d, J=8.8 Hz, 2H), 7.87 (d, J=5.8 Hz, IH), 7.93 (s, IH), 8.64 (dd, J-7.3, 2.2 Hz, IH), 8.95 (d, J=2.7 Hz, IH), 9.34 (s, IH); MS ESI(+)) m/e 431 (M+H)+. 25 Example 546 N-[4-(4-ammofuro[3,'2-cfayridm-3-vl)pfe The desired product was prepared by substituting Example 543C and l-isocyanato-3-(triiluoromethyl)benzene for Example IC and l-isocyanato-3-methylbenzene, respectively, in Example ID. 1HNMR(300 MHz, DMSO-D6) 8 ppm 5.52 (s, 2H), 6.93 (d, J=5.8 Hz, IH), 30 7.32 (d, J=7.5 Hz, IH), 7.45 (d, J=8.5 Hz, 2H), 7.53 (t, J=7.8 Hz, IH), 7.61 (t, J=8.3 Hz, 3H), 7.87 (d, J=5.8 Hz, IH), 7.92 (s, IH), 8.03 (s, IH), 8.97 (s, IH), 9.10 (s, IH); MS ESI(+)) m/e 413(M+H)+. Example 547 35 N-[4-(4-ammo-7-pyridin-3-ylnu:o[3,2-cfo Example 5 47 A tert-butyl 4-(4-arriinofuro[3,2-c]pyridin-3-vl)phenvIcarbamate -231- WO 2005/010009 PCT/US2004/024003 The desired product was prepared by substituting Example 543C for Example 66C ii Example 72A. MS ESI(+) m/e 326 (M+H)+. Example 547B 5 tert-butyl 4-(4-arm o-74odofUro[-3,2-c]pyridin-3-yl)phenylcarbamate The desired product was prepared by substituting Example 547A for Example 10A in Example 10B. Example 547C 10 S aminophenyn odofiirorS -clpyridm -amine The desired product was prepared by substituting Example 547B for Example 294B in Example 294C. MSESI(+)m/e352 (M+H)+. Example 547D 15 N-[4-(4-ammo-7-iodofuro[3,2-c]pyridin-3-yl)phenyl]-N'-(3-methvlphenYl)urea The desired product was prepared by substituting Example 547C for Example 1C in Example ID. 1H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3H), 5.69 (br s, 2H), 6.80 (d, J-7.1 Hz, IH), 7.17 (t, J-7.S Hz, IH), 7.25 (m, IH), 7.31 (s, IB), 7.43 (d, J-8.5 Hz, 2H), 7.61 (d, J=8.5 Hz, 2H), 8.03 (s, IH), 8.05 (s, IH), 8.64 (s, IH), 8.84 (s, IH); MS ESI(+) m/e 20 485 (M+H)+. Example 547E N-[4-(4-amino-7-pyridm-3-ylfuro[3,2 1p The desired product was prepared by substituting Example 547D and 25 3-pyridylboronic acid for Example 10B and 4-pyridylboronic acid, respectively, in Example IOC. ]H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3H), 5.77 (s, 2H), 6.81 (d, J=7.1 Hz, IH), 7.17 (t, J=7.8 Hz, IH), 7.25 (m, IH), 7.32 (s, IH), 7.50 (m, 3H), 7.63 (d, J=8.5 Hz, 2H), 8.04 (s, IH), 8.19 (m, 2H), 8.56 (dd, J=4.8,1.7 Hz, IH), 8.66 (s, IH), 8.85 (s, IH), 9.02 (d, J=1.4 Hz, IH); MS ESI(+)) m/e 436 (M+H)+. 30 Example 548 N-{4-[4-ammo-7 1H-mdol-5-yl)furor The desired product was prepared by substituting Example 547D and 5-indolylboronic acid for Example 10B and 4-pyridylboronic acid, respectively, in Example 35 IOC. 1H NMR (300 MHz, DMSO-D*) δ ppm2.29 (s, 3H), 5.51 (s, 2H), 6.50 (m, IH), 6.81 (d, J=7.1 Hz, IH), 7.17 (t, J=7.8 Hz, IH), 7.25 (d, J=9.0 Hz, IH) 7.32 (s, IH), 7.39 (m, IH), 7.48 (m, J=8.8 Hz, 4H), 7.63 (d, J=S.S Hz, 2H), 7.94 (s, IH), 8.01 (s, IH), 8.08 (s, IH), 8.65 (s, IH), 8.84 (s, IH), 11.15 (s, 1H);MS ESI(+)) m/e 474 (M+H)+. -232-- WO 2005/010009 PCT/US2004/024003 Example 549 N-[4-(4-arm o-7-pylimidm-5-ylniro The desired product was prepared by substituting Example 547D and pyrimidin-5-5 ylboronic acid for Example 10B and 4-pyridylboronic acid, respectively, in Example IOC. lHNMR (300 MHz, DMSO-D6) 6 ppm 2.29 (s, 3H), 5.89 (or s, 2H), 6.81 (d, J=7.5 Hz, 1H), 7.17 (t, J=7.8 Hz, 1H), 7.26 (m, 1H), 7.32 (s, 1H), 7.47 (d, J=8.5 Hz, 2H), 7.63 (d, J=8.S Hz, 2H), 8.07 (s, 1H), 8.32 (s, 1H), 8.65 (s, 1H), 8.85 (s, 1H), 9.16 (s, 1H), 9.26 (s, 2H); MS ESI(+))ro/e437(M+H)+. 10 Example 550 N-(4-{4-ammo-7-[3-(m thylamino)prop-l-ynyl]fiiro[3,2-c]pyridin-3-yl}pheny methylphenyl)urea The desired product was prepared by substituting Example 547D and N,N-diethyl-N-15 prop-2-ynylamine for Example 144A and 3-butyn-l-ol, respectively, in Example 144B. lH NMR (300 MHz, DMSO-D,) 6 ppm 1.04 (t, J=7.1 Hz, 6H), 2.29 (s, 3H), 2.57 (m, 4H), 3.67 (s, 2H), 5.85 (s, 2H), 6.80 (d, J=7.5 Hz, 1H), 7.16 (t, J=7.6 Hz, 1H), 7.25 (m, 1H), 7.31 (s, 1H), 7.42 (d, J=8.5 Hz, 2H), 7.61 (d, J=8.5 Hz, 2H), 7.97 (s, 1H), 8.00 (s, 1H), 8.65 (s, 1H), 8.84' (s, 1H); MS ESI(+)) m/e 468 (M+H)+. 20 Example 551 N-{4-[4-ammo-7-(3-pylrolidin-l-ylprop-l-Ynyl)furo[3,2-c]p Tidin-3-yl]phenyl)-N'-(3- methylphenvl)urea The desired product was prepared by substituting Example 547D and Example 506A 25 for Example 144A and 3-butyn-l-ol, respectively, in Example 144B. 1H NMR (300 MHz, DMSO-D6) δ ppm1.74 (m, 4H), 2.29 (s, 3H), 2.64 (m, 4H), 3.69 (s, 2H), 5.86 (s, 2H), 6.80 (d, J=7.8 Hz, 1H), 7.16 (t, J=7.6 Hz, 1H), 7.25 (d, J=6.0 Hz, 1H), 7.31 (s, 1H), 7.42 (d, J=8.5 Hz, 2H), 7.61 (d, J=8.5 Hz, 2H), 7.98 (s, 1H), 8.00 (s, 1H), 8.65 (s, 1H), 8.85 (s, 1H); MS ESI(+)) m/e 466 (M+H)+. 30 Example 552 N-{4-[4-amino-7-(3-amino-3-methylbut-l-vnvl) thieno[3,2-c]pyridin-3-yl]phenyl|-N'-[3- niethylphenyl)urea 35 . Example 552A tert-butyl lJ-dimethvlprop-2-vnylcarbamate The desired product was prepared by substituting l,l-dimethyl-prop-2-ynylamine for propargylamine in Example 516A. 1H NMR (300 MHz, DMSO-D6) δ ppm1.39 (s, 9H), 1.42 -233- WO 2005/010009 PCT/US2004/024003 (s, 6H), 3.02 (si 1H), 6.94 (s, 1H),; Example 552B tert-butvl3-[4-amino-3-(4-aminophenyl)tfo 5 ynylcarbamate The desired product was prepared by substituting Example 77B and Example 552A for Example 144A and 3-butyn-l-ol, respectively, in Example 144B. MS ESI(+)) m/e 423 (M+H)+. 10 Example 552C tert-but7l3-{4-amino-3-[4-({[(3-memylphenyl)arnmo1carbonyl]airimo)phenyl]tm clpyridin-7-ylH,l-dimethylprop-2-ynylcarbamate The desired product was prepared by substituting Example 552B for Example 1C in Example ID. 15 Example 552D N-(4-[4-amino-7-(3-ammo-3-methylbut-l-ynyl)thieno[3,2-c]pyridm-3-yl]phenyl)-N1-(3- methylphenyl)urea The desired product was prepared by substituting Example 552C for Example 76B in 20 Example 76C. !H NMR (300 MHz, DMSO-D,) δ ppm1.70 (s, 6H), 2.29 (s, 3H), 5.06 (m, J=81.04 Hz, 2H), 6.47 (s, 2H), 6.80 (d, J=7.46 Hz, 1H), 7.17 (t, J-7.63 Hz, 1H), 7.26 (m, 1H), 7.33 (s, 1H), 7.39 (d, J=8.48 Hz, 2H), 7.64 (d, J=8.S2 Hz, 2H), 7.70 (s, 2H), 8.85 (s, 1H), 9.08 (s31H); MS ESI(+)) m/e 456 (M+H)+. 25 Example 553 N-{4-[4-ammo-7-(3-ariimo-3-meth fluoro-5-methylphenyl)urea Example 553A 30 tert-butyl 3-{4-amino-3-[4-({[(2-£luoro-5- memylphenyl)ammolcarbonyl)aiiu o)phenyl]tM ynylcarbamate The desired product was prepared by substituting Example 552B and l-fluoro-2-isocyanato-4-methylbenzene for Example ICand l-isocyanato-3-methylbenzene, 35 respectively, in Example ID. Example 553B N-(4-[4-amino-7-(3-amino-3-methylbut-l-ynyl)thieno[3,27c]pyridin-3-yl]phenvl]-N'--(2- -234- WO 2005/010009 PCT/US2004/024003 fluoro-5-mefcylphenvl)urea The desired product was prepared by substituting Example 553A for Example 76B in Example 76C. 1H NMR (300 MHz, DMSO-D6) 6 ppm 1.70 (s, 6H), 2.28 (s, 3H), 6.47 (s, 2H), 6.81 (m, 2H), 7.13 (m, 2H), 7.40 (m, 2H), 7.64 (m, 3H), 7.98 (dd, J=7.63,1.86 Hz, 1H), 5 8.06 (m, 1H), 8.60 (d, J=2.37 Hz, 1H), 934 (s, 1H); MS ESI(+)) m/e 474 (M+H)+. Example 554 N-{4-[4-amko-7 3-ammo-3-methylbttt-l-ynyl)t eno[3,2-c]pyridin-3-yl]phenyl)-N'-(3- chlorophenypurea 10 Example 554A . tert-butyl 3- (4-amino-3-[4-({[(3-clilorophenyl)amino1carbonvl| amino)phenyl-lthieno[3,2-c]pyridin-7-yl) -1,1 -dimethylprop-2-ynylcarbamate The desired product was prepared by substituting Example 552B and 3-chloro-15 isocyanato-4-methylbenzene for Example IC and l-isocyanato-3-methylbenzene, respectively, in Example ID. Example 554B tert-butyl 3-(4-ainmo-3-[4-({[(3-chlorophenvl)an olcarbonyl}ammo)phenyl]thieno[3,2- 20 clpyridin-7-yl) -1,1 -dimethylprop-2-ynylcarbamate The desired product was prepared by substituting Example 554A for Example /or> m Example 76C. 1H NMR (300 MHz, DMSO-D6) δ ppm1.70 (s, 6H), 6.45 (s, 2H), 7.04 (m, 1H), 7.31 (d, J=5.09 Hz, 2H), 7.40 (d, J=8.81 Hz, 2H), 7.65 (m, 2H), 7.69 (s, 1H), 7.75 (m, 1H), 8.07 (s, 1H), 8.64 (s, 2H), 9.26 (s, 1H), 9.2S (s, 1H); MS ESI(+)) m/e 476 (M+H)+. 25 Example 555 N-{4-[4-ammo-7-(3-ammo-3-methylbut-l-ynyl)thieno[3,2-c]pyridm-3-yl]phenyl}-N,-[2 fluoro-5 -(trifiuoromethyl)phenyl]urea 30 Example 555A tert-butyl 3-(4-aimno-3-{4-[((r2-fluoro-5-(trifluoromemylphenyl]ammo)carbonyl)amm dimethylprop-2-vnylcarbamate The desired product was prepared by substituting Example 552B and l-fluoro-2-35 isocyanato-4-(triflu6romethyl)benzene for Example IC and l-isocyanato-3-methylbenzene, respectively, in Example ID. Example 555B -235- WO 2005/010009 PCT/US2004/024003 N-{4-[4-animo-7-(3-ammo-3-methylbut-l- fluoro-S-ftrifluoromethyl)phenyl]urea The desired product was prepared by substituting Example 555A for Example 76B in Example 76C. 1H NMR (300 MHz, DMSO-D6) S.ppm 1.70 (s, 6H), 6.39 (s, 2H), 7.43 (d, J=8.48 Hz, 2H), 7.52 (m, IH), 7.65 (d, J=8.82 Hz, 2H), 7.69 (s, 1H)5 8.07 (s, IH), 8.62 (m, 4H), 9.02 (d, J=2.71 Hz, IH), 9.46 (s, IH); MS ESI(+)) m/e 528 (M+H)*. Example 556 N-{4-[4-amino-7-(3-ammo-3-methylbut-l-ynyl)m (trifluoromethyl)phenyl]urea Example 556A tert-butyl 3-(4-amino-3-{4-[(([3-(trifluoromefoyl)phenyl]ammo}carponyl)amm dimethylprop-2-ynylcarbamate The desired product was prepared by substituting Example 552B and l-isocyanato-3- (trifluoromethyl)benzene for Example IC and l-isocyanato-3-methylbenzene, respectively, in Example ID. _ ■ Example 55 6B N-{4-[4-ammo-7-(3-arnmo-3-memylbut-l-ynyl)fe (trifluoromethyl)phenyl] urea The desired product was prepared by substituting Example 556A for Example 76B in Example 76C. 1H NMR (300 MHz, DMSO-De) 8 ppm 1.70 (s, 6H), 6.44 (s, 2H), 7.33 (d, J=7.80 Hz, IH), 7.41 (d, J=8.48 Hz, 2H), 7.53 (t, J=7.97 Hz, IH), 7.65 (m, 4H), 8.07 (m, >=3.05 Hz, 2H), S.64 (s, 2H), 9.34 (s, IH), 9.43 (s, IH); MS ESI(+)) m/e 510 (M+H)+. Example 557 N-(4-(4-airimo-7-[3-(4-methylpiperazm N'"(3-methylphenyl)urea Example 557 A 1 -methyl-4-prop-2-ynylpiperazine The desired product was prepared by substituting N-methyl-piperazine for pyrrolidine in Example 506A. JH NMR (300 MHz, DMSO-Dg) 8 ppm 2.14 (s, 3H), 2.30 (m, 4H), 2.43 (m, 4H), 3.12 (t, J=2.54 Hz, IH), 3.23 (d, J=2.37 Hz, 2H). Example 557B -236- WO 2005/010009 PCT/US2004/0 24003 3-(4-aminopheDvlV7-[3-(4-mefaylpiperaziM The desired product was prepared by substituting Example 77B and Example 557A for Example 144A and 3-butyn-l-ol, respectively, in Example 144B. MS (ESI(+)) m/e 378 (M+H)+. 5 Example 557C N-(4-{4-amino-7-[3-(4-methylpiperazin-l N'-(3-methylphenyl)urea The desired product was prepared by substituting Example 557B for Example 1C in 10 Example ID. 1H NMR (300 MHz, DMSO-DJ δ ppm2.17 (s, 3H), 2.29 (s, 3H), 2.38 (m, 4H), 2.60 (m, 4H), 3.61 (s, 2H), 5.76 (s, 2H), 6.80 (d, J=7.12 Hz, 1H), 7.17 (t, J=7.63 Hz, 1H), 7.25 (m, 1H), 7.31 (s, 1H), 7.37 (d, J=8.4S Hz, 2H), 7.51 (s, 1H), 7.60 (d, J=8.48 Hz, 2H), 7.97 (s, 1H), 8.66 (s, 1H), 8.86 (s, 1H); MS ES1(+)) m/e 511 (M+H)+. 15 Example 55S N-(4-{4-amino-7-[3-(4-memylpiperazm-l-yl)prop-l-ynyl]thieno[3,2-c]pyridm-3-yU N'-(3 -chlorophenyDurea The desired product was prepared by substituting Example 557B and 3-chloro-l-isocyanatobenzene for Example 1C and l-isocyanato-3-methylbenzne, respectively, in 20 Example ID. 1H NMR (300 MHz, DMSO-D6) δ ppm2.17 (s, 3H), 2.37 (m, J=2.03 Hz, 4H), 2.59 (m, 4H), 3.61 (s, 2H), 5.76 (s, 2H), 7.03 (m, 1H), 7.32 (m, 2H), 7.39 (d, JMS.48 Hz, 2H), 7.52 (sb 1H), 7.61 (d, J=8.48 Hz, 2H)5 7.73 (s, 1H), 7.97 (ss 1H), 8.97 (m, 2H); MS ESI(+)) m/e53l(M+H)+.' 25 Example 559 3-(4-arninophenyl)-7-[4-(emylsulfonyl)phen The desired product was prepared by substituting Example 77B and 4-ethanesulfonyl-phenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. (300 30 MHz, DMSO-D,-) δ ppm1.17 (t, J=7.3 Hz, 3 H) 3.36 (q, J=7.5 Hz, 2 H) 5.39 (s, 2 H) 5.75 (br s, 2 H) 6.69 (d, J-8.5 Hz, 2 H) 7.12 (d, J=8.1 Hz, 2 H) 7.38 (s, 1 H) 7.99 (m, 5 H); MS ESI(+) m/e410(M+H)+. Example 560 35 3-(4-ammophenyl)-7-[3-(memylsulfonyl)pheny The desired product was prepared by substituting Example 77B and 3-methanesulfonyl-phenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. 1H NMR (300 MHz, DMSO-D6) δ ppm3.30 (s, 3H) 5.38 (m, 2 H) 5.73 (br m,. -237- WO 2005/010009 PCT/US2004/024003 2 H) 6.69 (d, J=8.5 Hz, 2 H) 7.12 (d, J=8.5 Hz, 2 H) 7.38 (s, 1 H) 7.80 (t, J-7.S Hz, 1 H) 7.93 (m, 1 H) 7.96 (m, 1 H) 8.00 (s, 1 H) 8.03 (m, 1 H) 8.05 (m, J=2.0 Hz, 1 H) 8.19 (t, J=1.7 Hz, 1 H); MS ESI(+) m/e 396 (M+H)+. 5 Example 561 3-(4-ammophenyl)-7-[3-(ethylsulfonyl)phenyl] thieno[3,2-c]pyridk-4-arnine The desired product was prepared by substituting Example 77B and 3-ethanesulfonyl-phenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. 1H NMR (300 MHz, DMSO-D,) 8 ppm 1.16 (t, J=7.3 Hz, 3 H) 3.39 (q, J=7.4 Hz, 2 H) 5.39 (s, 2 10 H) 5.74 (br m, 2 H) 6.69 (d, J=8.4S Hz, 2 H) 7.11 (d, J=8.5 Hz, 2 H) 7.38 (s, 1 H) 7.81 (t, J=7.8 Hz, 1 H) 7.90 (m, 1 H) 7.99 (s, 1 H) 8.04 (m, 1 H) 8.14 (m, 1 H); MS ESI(+) m/e 410 (M+H)+. Example 562 15 3-(4-aminophenyl)-7-[4-(memylsulfonyl)phenyl]thieno[3,2-c]pyridm amine The desired.product was prepared by substituting Example 77B and 4-methanesulfonyl-phenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. 1H NMR (300 MHz, DMSO-DJ 6 ppm 3.31 (s, 3 J£) 5.39 (s, 2 H) 5.75 (br s, 2 H) 6.69 (d, J-S.5 Hz, 2 H) 7.12 (d, J=8.5 Hz, 2 H) 7.38 (s, 1 H) 7.95 (d, J=8.5 Hz, 2 H) 7.99 20 (s, 1 H) 8.05 (d, J=8.5 Hz, 2 H); MS ESI(+) m/e 396 (M+H)+. Example 563 3-[4-arm o-3-(4-aminophenyl)thieno[3,2-c]pyridin-7-yl]phenol The desixed product was prepared by substituting Example 77B and 25 3-hydroxyphenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example . 10A. ]H NMR (300 MHz, DMSO-D6) 6 ppm 5.36 (s,' 2 H) 5.56 (br s, 2 H) 6.68 (d, J=8.5 Hz, 2 H) 6.78 (m, 1 H) 7.07 (m, 4 H) 7.29 (m, 2 H) 7.82 (s, 1 H) 9.58 (s, 1 H); MS ESI(+) m/e 334(M+H)+. 30 Example 564 3-[4-(memylariimo)phenyl] thieno[3,2-c]pyrid1n-4-amine The desired product was prepared by substituting methyl-[4-(4,4,5,5-tetramethyl-[l,3,2]oUoxaborolan-2-yl)-phenyl]-amine for 4-phenoxyphenylboronic acid in example 10A. 1H NMR (300 MHz, DMSO-D6) δ ppm2.73 (d, J=4.8 Hz, 3 H) 5.47 (br s, 2 H) 5.83-6.09 35 (m,l H) 6.65 (d, J=8.5 Hz, 2 H) 7.16 (d, J=8.5 Hz, 2 H) 7.21 (d, J=5.4 Hz, 1 H) 7.28 (s, 1 H) 7.79 (d, J=5,S Hz, 1 H); MS ESI(+) m/e 256 (M+H)+. Example 56!) -238- WO 2005/010009 PCT/US2004/024003 N-(4-{4-ammo-743tpiperidm-l-ylprop-l methylpherryl)urea The desired product was prepared using the general reductive amination procedure described in example 177, reacting example 464 with piperidine. 1H NMR (300 MHz, 5 DMSO-D6) δ ppm1.49 (br m, 6 H) 2.29 (s, 3 H) 2.44 (br m, 4 H) 3.17 (br m, 2 H) 5.56 (br s, 2 H) 6.22 (m, 1 H) 6.66 (d, J-15.6 Hz, 1 H) 6.81 (d, J=7.1 Hz, 1 H) 7.17 (t, J=7.8 Hz, 1 H) 7.25 (m, 1 H) 7.32 (s, 1 H) 7.37 (d, J=S.8 Hz, 2 H) 7.50 (s, 1 H) 7.60 (d, J=8.S Hz, 2 H) 7.94 (s, 1 H) S.67 (s, 1 H) 8.87 (s, 1 H); MS ESI(+) m/e 498 (M+H)+. 10 Example 566 N-(4-{4-arnino-7-[3-(dimemylammo)prop-l-en rnethylphenyl)urea The desired product was prepared using the general reductive animation described in 15 example 177, reacting example 464 with dimethylamine. 1H NMR (300 MHz, DMSO-D6) 5 ppm2.29 (s,9H)3.22 (d, J=6.4Hz,2H) 5.58(brs,2H) 6.22 (dt, J=16.1,6.8Hz, 1 H)6.70 (d, J=16.3 Hz, 1 H) 6.80 (d, J=7.5 Hz, 1 H) 7.17 (t, J=7.6 Hz, 1 H) 7.26 (d, J=8.1 Hz, 1 H) 7.31 (s, 1 H) 7.37 (d, J=S.8 Hz, 2 H) 7.52 (s, 1 H) 7.60 (d, J=8.5 Hz, 2 H) 7.95 (s, 1 H) 8.71 (s, 1 H) 8.92 (s, 1 H); MS ESI(+) m/e 458 (M+H)+. Example 567 N-(4-{4-ammo-7-[3-(4-memylpiperazm-l-yl)prop4-enyl]thieno[3,2-c]pyridin-3-yl} phenyl)- N'-(3-methylphenyl)urea 25 The desired product was prepared using the general reductive amination described in example 177, reacting example 464 with 1-methyl-piperazine. lH NMR (300 MHz, DMSO-. D6) 8 ppm 2.17 (s, 3 H) 2.29 (s, 3 H) 2.31-2.48 (brm, 8 H) 3.17 (d, J=5.8 Hz, 2 H) 5.56 (br s, 2 H) 6.21 (dt, J-16.3, 6.4 Hz, 1 H) 6.66 (d, JN15.9 Hz, 1 H) 6.81 (d, J=7.1 Hz, .1 H) 7.17 (t, J=7.6 Hz, 1 H) 7.25 (d, J=8.8 Hz, 1 H) 7.32 (s, 1 H) 7.37 (d, J=8.5 Hz, 2 H) 7.50 (s, 1 H) 7.60 30 (d, J=8.5 Hz, 2 H) 7.94 (s, 1. H) 8.67 (s, 1 H) 8.87 (s, 1 H); MS ESI(+) m/e 513 (M+H)+. Example 568 N-(4-{4-ammo-7-[3-(3-oxopiperazin-l-yl)prop-l-enyl]mieno[3,2-c]pyridin-3-yl}phenyl)-N'- (3-methylphenyl)urea 35 The desired product was prepared using the general reductive amination described in example 177, reacting example 464 with piperazin-2-one. lH NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3 H) 2.64 (t, J=5.3 Hz, 2 H) 3.00 (s, 2 H) 3.14-3.23 (m, 2 H) 3.26 (d, J-6.8 Hz, 2 H) 5.58 (s, 2 H) 621 (dt, J=16.0, 6.6 Hz, 1 H) 6.71 (d, J=15.9 Hz, 1 H) 6.81 (d, J=7.5 Hz, 1 -239- WO 2005/010009 PCT/US2004/024003 H) 7.17 ft J=7.8Hz, 1 H)7.25 (d, J=8.1;Hzj 1 H) 7:32(s, 1 H)7.37 (d, J=8.5 Hz,2H) 7.51/ (s, 1H) 7.60 (d, J=8.5 Hz, 2 H) 7.74 (s, 1H) 7.96 (s, 1H) 8.66 (s, 1 H) 8.87 (s, 1 H); MS ESI(+)m/e513(M+H)+. 5 Example 569 N-(4-{4-ammo-7-[4-(me%lsulfonyl)phenyl]thieno[3,2-c]pyridin-3-yl}pheayl)-N,-(3- methylphenyl)urea The desired product was prepared by substituting Example 144A and 4-methanesulfonyl-phenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in 10 Example 10A. 1H NMR (400 MHz, DMSO-D6) δ ppm2.29 (s, 3 H) 3.29 (s, 3 H) 5.69 (s, 2 H) 6.81 (d, J=7.4 Hz, 1 H) 7.17 (t, J=7.8 Hz, 1 H) 7.26 (d, J=S.6 Hz, 1 H) 7.32 (s, 1 H) 7.41 (d, J=8.6 Hz, 2 H) 7.52 (s, 1 H) 7.62 (d, J=S.6 Hz, 2 H) 7.97 (d, J=8.6 Hz, 2 H) 8.02 (s, 1 H) 8.06. (d, J=8.6 Hz, 2 H) 8.66 (s, 1 H) 8.87 (s, 1 H); MS ESI(-) m/e 527 (M-H)-. 15 Example 570 N-(4-{4-amino-7-[4-(ethylsulfonyl)phenyl]thieno[3,2-c]pyridm-3-yl}phenyl)-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 144A and 4-ethanesulfonyl-phenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in 20 Example 10A. 1H NMR (300 MHz, DMSO-D6) δ ppm1.17 ft J=7.3 Hz, 3 H) 2.29 (s; 3 H) 3.37 (q, J=7.4 Hz, 2 H) 5.71 (br s, 2 H) 6.81 (d, J=7.1 Hz, 1 H) 7.17 ft J=7.8 Hz, 1 H) 7.26 (d, J=S.l Hz, 1 H) 7.32 (s, 1 H) 7.41 (d, J=8.5 Hz, 2 H) 7.53 (s, 1 H) 7.62 (d, J=8.5 Hz, 2 H) 7.99 (m,5 H) 8.67 (s, 1 H) 8.88 (s, 1 H); MS ESI(-) m/e 541 (M-H)-. 25 Example 571 N-{4-[4-amino-7-(3-methylphenyl)thieno[3,2-c]pyridin-3-yl]phenyl}-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 144A and 3-methylphenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example 30 10A. !H NMR (300 MHz, DMSO-Dg) δ ppm2.29 (s, 3 H) 2.40 (s, 3 H) 5.52 (br s, 2 H) 6.81 (d, J=7.5 Hz, 1 H) 7.21 (m, 4 H) 7.32 (s,. 1 H) 7.43 (m, 5 H) 7.61 (d, J=8.8 Hz, 2 H) 7.89 (s, 1 H) 8.66 (s, 1 H) 8.86 (s, 1 H); MS ESI(+) m/e 465 (M+H)+. Example 572 35 ■ N-{4-[4-ammo-7-(4-me1±ylphenyl)ttt methylphenyl)urea The desired product was prepared by substituting Example 144A and 4-methylphenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example -240- WO 2005/010009 PCT/US2004/024003 10A. 1HNMR (300MHz, DMSO-D6) 5 ppm2:29 (s,13 H) 2;38 (s, 3 H) 5.50 (br s, 2 H) 6.81 (d, J=7.5 Hz, 1 H) 7.17 (m, 1 H) 7.26 (d, J=8.5 Hz, 1 H) 7.33 (m, 3 H) 7.40 (d, J=8.5 Hz, 2 H) 7.47 (s, 1 H) 7.55 (d, J=S.l Hz, 2 H) 7.61 (d, J-8.5 Hz, 2 H) 7.87 (s, 1 H) 8.66 (s, 1 H) 8.86 (s, 1 H); MS ESI(+) m/e 465 (M+H)+. Example 573 N-(4-{4-animo-7-[(E)-2-phenylvmyl]tHeno[3,2-c]pyridin-3-yl}phenyl)-N'-(3- • methylphenyl)urea The desired product was prepared by substituting Example 144A and (E)-2-phenylvinylboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. 1H NMR (300 MHz, DMSO-D6) 6 ppm 2.29 (s, 3 H) 5.68 (br s, 2 H) 6.81 (d, J=7.5 Hz, 1 H) 7.30 (m, 9 H) 7.57 (s, 1 H) 7.63 (m, 5 H) 8.15 (s, 1 H) S.67 (s, 1 H) 8.87 (s, 1 H); MS ESI(+) m/e 477 (M+H)+. Example 574 N-(4-{4-ainmo-7-[4-(methyltm )phenyl]traeno[3,2-c]pyridin-3-yl}phenyl)-N'-(3- metrrylphenyl)urea The desired product was prepared by substituting Example 144A and 4-(methylthio)phenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. 1H NMR (300 MHz, DMSO-D6) 6 ppm 2.29 (s, 3 H) 2.54 (s, 3 H) 5.53 (br s, 2 H) 6.81 (d, J=7.5 Hz, 1 H) 7.17 (t, J-7.5 Hz, 1 H) 7.26 (d, J=8.1 Hz, 1 H) 7.32 (s, 1 H) 7.40 (m, 4 H) 7.48 (s, 1 H) 7.61 (m, 4 H) 7.89 (s, 1 H) 8.66 (s, 1 H) 8.86 (s, 1 H); MS ESI(+) m/e 497 (M+H)+. Example 575 N-'{4-[4-amino-7-(3-hydroxyphenyl)du>no[3,2-c]pyridin-3-yl]phenyl}-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 144A and 3-hydroxyphenylboromc acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. 1H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3 H) 5.51 (br s, 2 H) 6.81 (d, J=7.5 Hz, 2 H) 7.07 (m, 2 H) 7.17 (t, J=7.8 Hz, 1 H) 7.29 (m, 3 H) 7.40 (d, J-8.5 Hz, 2 H) 7.47 (s, 1 H) 7.61 (d, J=8.5 Hz, 2 H) 7.86 (s, 1 H) 8.67 (s, 1 H) 8.S6 (s, 1 H) 9.60 (s, 1 H); MS ESI(+) m/e 467 (M+H)+. Example 576 N-(4-{4-ammo-7-[3Tidm-3-yl]phenyl}-N'-(3- methylphenyl)urea The desired product was prepared by substituting Example 144A and • 3,4-dimethoxyphenylboromc acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. 1H NMR (300 MHz, DMSO-D,) δ ppm2.29 (s, 3 H) 3.82 (s, 3 H) 3.83 (s, 3 25 H) 5.48 (br s, 2 H) 6.81 (d, J=7.1 Hz, 1 H) 7.11 (m, 1 H) 7.20 (m, 4 H) 7.32 (s, 1 H) 7.39 (d, J=8.5 Hz, 2 H) 7.47 (s, 1 H) 7.61 (d, J=8.8 Hz, 2 H) 7.90 (s, 1 H) 8.66 (s, 1 H) 8.86 (s, 1 H); MSESI(+)m/e511(M+H)+. Example 579 30 4-{4-ammo-3-[4-({[(3-memylphenyl)amino]carbonyl}animo)phenyl] thieno[3,2-c]pyridin-7- yl}-N-methylbenzamide The desired product was prepared by substituting Example 144A and 4-[(methylamino)carbonyl]phenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. lH NMR (300 MHz, DMSO-D6) δ ppm2.29 (s,- 3 H) 2.82 (d, J=4.4 Hz, 35 3 H) 5.61 (br s, 2 H) 6.81 (d, J=7.1 Hz, 1 H) 7.17 (t, J=7.6 Hz, 1 H) 7.26 (d, J=8.5 Hz, 1 H) 7.32 (s, 1 H) 7.40 (d, J-8.8 Hz, 2 H) 7.50 (s, 1 H) 7.62 (d, J=8.8 Hz, 2 H) 7.76 (d, J=8.5 Hz, 2 H) 7.96 (m, J=6.4 Hz, 3 H) 8.50 (q, J=4.5 Hz, 1 H) 8.67 (s, 1 H) 8.87 (s, 1 H); MS ESI(+) m/e 508 (M+H)+. -242- WO 2005/010009 PCT/US2004/024003 Example 580 N_{4-R4_atnmo-7-(l-benzothien-2-yl)thieno[3,2-c]pyridin-3-yl]plienyl}-N,-(3- methylphenyl)urea 5 The desired product was prepared by substituting Example 144A and 2-benzothiopheneboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. lH NMR (300 MHz, DMSO-D6) 8 ppm 2.29_(s, 3 H) 5.77 (br s, 2 H) 6.81 (d, J=7.5 Hz, 1 H) 7.17 ft J=7.8 Hz, 1 H) 7.26 (d5 J=8.5 Hz, 1 H) 7.32 (s, 1 H) 7.40 (m, 4H) 7.60 (s, 1 H) 7.63 (d, J=8.5 Hz, 2 H) 7.80 (s, 1 H) 7.92 (m, 1 H) 8.02 (d, J=7.5 Hz, 1 H) 8.22 (s, 1 H) 8.67 10 (s, 1 H) 8.88 (s, 1 H); MS ESI(+) m/e 507 (M+H)+. Example 581 N-{4-[7-(4-acetylphenyl)-4-aminothieno[3,2-c]pyridin-3-yl]phenyl}-N'-(3- methylphenyl)urea 15 The desired product was prepared by substituting Example 144A and 4-acetylphenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. lH NMR (300 MHz, DMSO-D6) 8 ppm 2.29 (s, 3 H) 2.64 (s, 3 H) 5.67 (br s, 2 H) 6.81 (d, J=7.1 Hz, 1 H) 7.17 ft J-7.6 Hz, 1 H) 7.26 (d, J=8.1 Hzvl H) 7.32 (s, 1 H) 7.41 (d, J=8.5 Hz, 2 H) 7.52 (s, 1 H) 7.62 (d, J=8.5 Hz, 2 H) 7.85 (d, J=8.1 Hz, 2 H) 8.01 (s, 1 H) 8.10 (d, 20 J=S.l Hz, 2 H) 8.67 (s, 1 H) 8.87 (s, 1 H); MS ESI(+) m/e 493 (M+H)+. Example 582 N-{4-[7-(3-acetylphenyl)-4-aminothieno[3)2-c]pyridin-3-yl]phenyl}-N,-(3- methylphenyl)urea 25 The desired product was prepared by substituting Example 144A and 3-acetylphenylboronic acid for Example IB and 4-phehoxyphenylboromc acid in Example 10A. 1H NMR (300 MHz, D'MSO-D6) δ ppm2.29 (s, 3 H) 2.66 (s, 3 H) 5.62 (br s, 2 H) 6.81 (d, J=7.5 Hz, 1 H) 7.17 ft J=7.6 Hz, 1 H) 7.26 (d, J=8.5 Hz, 1 H) 7.32 (s, 1 H) 7.41 (d, J=8.5 Hz, 2 H) 7.50 (s, 1 H) 7.62 (d, J=8.5 Hz, 2 H) 7.69 ft J=7.8 Hz, 1 H) 7.97 (m, 3 H) 8.24 (m, 1 30 H) 8.67 (s, 1 H) 8.87 (s, 1 H); MS ESI(+) m/e 493 (M+H)+. Example 583 N-{4-[4-ammo-7-(3-cyanophenyl)thieno[3 -c]pyridin-3-yl]phenyl}-N'-(3- methylphenyl)urea 35 The desired product was prepared by substituting Example 144A and 3-cyanophenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. 1H NMR (300 MHz, DMSO-D6) 8 ppm 2.29 (s, 3 H) 5.67 (br s, 2 H) 6.81 (d, J=7.5 Hz, 1 H) 7.17 ft J=7.8 Hz, 1 H) 7.26 (d, J=8.5 Hz, 1 H) 7.32 (s, 1 H) 7.40 (d, J=8.5 Hz, 2 H) 7.51 -243- WO 2005/010009 PCT/US2004/024003 (s, 1 H) 7.62(d, J=8.5 Hz, 2 H) 7.74 (t, J=7.8 Hz, 1 H) 7.88 (m, 1 H) 7.99 (s, 1 H) 8.05 (m, 1-H) 8.12 (m, 1 H) 8.67 (s, 1 H) 8.87 (s, 1 H); MS ESI(+) m/e 476 (M+H)+. Example 584 5 4-{4-ammo-3-[4-({[(3-methylphenyl)ammo]carbonyl}amino)phenyl]thieno[3J2-c]pyridin-7- yljbenzamide -: - The desired product was prepared by substituting Example 144A and 4-aminocarbonylphenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. 1H NMR (300 MHz, DMSO-D6) 8 ppm 2.29 (s, 3 H) 5.62 (br s, 2 H) 6.81 (d, 10 J=7.5 Hz, 1 H) 7.17 (t, J=7.8 Hz, 1 H) 7.26 (d, J=S.8 Hz, 1 H) 7.32 (s, 1 H) 7.40 (d, J=8.5 Hz, 2 H) 7.50 (s, 1 H) 7.62 (d, J=8.5 Hz, 2 H) 7.76 (d, J=8.5 Hz, 2 H) 8.00 (m, 5 H) 8.67 (s, 1 H) 8.88 (s, 1 H); MS ESI(+) m/e 494 (M+H)+. Example 585 15 3-{4-ammo-3-R4 {[(3-memylphenyl)ammo]carbonyl}ammo)phenyl]thieno[3,2-c]pyridin-7- yl}benzamide The desired product was prepared by substituting Example 144A and 3-aminocarbonylphenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. 1HNMR (300 MHz, DMSO-D6) 8 ppm 2.29 (s, 3 H) 5.59 (br s, 2 H) 6.81 (d, 20 J=7.5 Hz, 1 H) 7.17 (t, J=7.6 Hz, 1 H) 7.26 (d, J=8.5 Hz, 1 H) 7.32 (s, 1 H) 7.41 (d, J=8.5 Hz, 2 H) 7.49 (s, 1 H) 7.60 (m, 3 H) 7.88 (m, 2 H) 7.97 (s, 1 H) 8.07 (br s, 2 H) 8.17 (m, 1 H) 8.68 (s, 1 H) 8.88 (s, 1 H); MS ESI(+) m/e 494 (M+H)+. Example 586 25 N-{4-[4-ammo-7-(3-niryl)tin no[3,2 ]pyTidm-3-yl]phenyl}-N'-(3-mem The desired product was prepared by substituting Example 144A and 3-furylboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. 1H NMR (300 MHz, DMSO-Dfi) 6 ppm 2.29 (s, 3 H) 5.53 (br s, 2 H) 6.81 (d, J=7.5 Hz, 1 H) 7.05 (m, 1 H) 7.17 (t, J=7.6 Hz, 1 H) 7.26 (d, J=8.S Hz, 1 H) 7.32 (s, 1 H) 7.39 (d, J=8.5 Hz, 2 H) 7.53 (s, 1 30 H) 7.61 (d, J=8.5 Hz, 2 H) 7.84 (t, J=1.70 Hz, 1 H) 8.10 (s, 1 H) 8.12 (m, 1 H) 8.66 (s, 1 H) 8.87'(s, 1 H); MS ESI(+)m/e 441 (M+H)+. - Example 587 N-{4-[4-ammo-7-(3,4,5-trimetho\7ph 35 methylphenyl)urea The desired product was prepared by substituting Example 144A and 3,4,5-trimethoxy-phenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. 1HNMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3 H) 3.73 (s, 3 H) 3.86 (s, 6 -2-[4- WO 2005/010009 PCT/US2004/024003 H) 5.53 (br s, 2 H) 6.81 (d, 1=7.8 Hz,-1 H) 6.96 (s, 2 H) 7.17 (t, J=7.6 Hz, 1 H) 7.26(d, J=8.5 Hz, 1 H) 7.32 (s, 1 H) 7.39 (d, J=8.5 Hz, 2 H) 7.49 (s, 1 H) 7.62 (d, J=8.5 Hz, 2 H) 7.98 (s, 1 H) 8.66 (s, 1 H) 8.87 (s, 1 H); MS ESI(+) m/e 541 (M+H)+. 5 Example 588 tert-butyl 3-{4-amino-3-[4-({[(3-rn€thylphenyl)amino]carbonyl} amino)phenyl]thieno[3,2- c]pyridin-7-yl} benzoate The desired product was prepared by substituting Example 144A and 3-tert-butoxycarbonylphenylboronic acid for Example IB and 4-phenoxyphenylboronic acid 10 in Example 10A. 1H NMR (300 MHz, DMSO-D6) δ ppm1.58 (s, 9 H) 2.29 (s, 3 H) 5.61 {br s, 2 H) 6.81 (d, J=7.1 Hz, 1 H) 7.17 (t, J=7.8 Hz, 1 H) 7.26 (m, 1 H) 7.32 (s, 1 H) 7.41 (d, J=8.5 Hz, 2 H) 7.50 (s, 1 H) 7.62 (d, J=8.5 Hz, 2 H) 7.67 (d, 1 H) 7.85-8.02 (m, 3 H) 8.21 (s, 1 H) 8.66 (s, 1 H) 8.87 (s, 1 H); MS ESI(+) m/e 551 (M+H)+. 15 Example 589 memyl4-{4-ammo-3-[4-({[(3-methylphenyl)arnmo]carbonyl}amino)phenyl]tlneno[3J2- c]pyridin-7-yl}benzoate The desired product was prepared by substituting Example 144A and 4-methoxycarbonylphenylboronic acid for Example IB and 4-phenoxyphenylboronic acid in 20 Example 10A. lHNMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3 H) 3.90 (s, 3 H) 5.67 (br s, 2 H) 6.81 (d, J=7.5 Hz, 1 H) 7.17 (t, J=7.6 Hz, 1 H) 7.26 (d, J=8.5 Hz, 1 H) 7.32 (s, 1 H) 7.40 (d, J=8,8 Hz, 2 H) 7.51 (s, 1 H) 7.62 (d, J-S.5 Hz, 2'H) 7.85 (d, J=8.5 Hz, 2 H) 8.01 (s, 1 H) 8.10 (d, J=8.5 Hz, 2 H) 8.66 (s, 1 H) 8.87 (s, 1 H); MS ESI(+) m/e 509 (M+H)+. 25 Example 590 4-{4-arrmio-3-[4-( {[(3-me&ylphenyl)ammo] yl}benzoic acid The desired product was prepared by substituting example 589 for example 601 in example 602. lH NMR (300 MHz, DMSO-D6) 8 ppm 2.29 (s, 3 H) 6.80 (br s, 2H) 6.81 (d, 30 J=7.5 Hz,l H) 7.17 (t, J=7.8 Hz, 1 H) 7.27 (d, J=S.l Hz, 1 H) 7.33 (s, 1 H) 7.46 (d, J=8.8 Hz, 2 H) 7.67 (d, J=8.5 Hz, 2 H) 7.79-7.92 (m, 3 H) 8.06 (s, 1 H) 8.13 (d, J=8.5 Hz, 2 H) 8.79 (s, 1 H) 9.04 (s, 1 H) 13.20 (br s, 1H); MS ESI(+) m/e 495 (M+H)+. Example 591 35 3-{4-ammo-3-[4-({[(3-memylphenyl)ammo]carbonyl}ammo)phenyl]thieno[3,2-c]pyridm yl}benzoic acid The desired product was prepared as the trifluoroaceate salt by substituting example 588 for 11A in example 1 IB. 1H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3 H) 6.81 (d, -245- WO 2005/010009 PCT/US2004/024003 J=7.1 Hz, 1 H) 7.03 (br s, 2 H) 7.18 (t, J=7.6 Hz, 1 H) 7.27 (m, 1 H) 7.33 (s, 1 H) 7.47 (d, J=8.5 Hz, 2 H) 7.68 (d, J=8.5 Hz, 2 H) 7.75 (t, >7.8 Hz, 1 H) 7.89 (s, 1 H) 7.98 (d, J=7.8 Hz, 1 H) 8.04-8.15 (m, 2 H) 8.26 (s, 1 H) 8.82 (s, 1 H) 9.08 (s, 1 H); MS ESI(+) m/e 495 (M+H)+ 5 Example 592 N-(4- {4-animo-7-[4-(methylsulfonyl)phenyl] thieno[3,2-c]pyridin-3-yl}phenyl)-N'--(3- chlorophenyl)urea The desired product was prepared by substituting example 562 and 3-chIoro-l-isocyanatobenzene for 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in 10 example 122. 'H MMR (300 MHz, DMSO-D6) δ ppm3.30 (s, 3 H) 5.70 (br s, 2 H) 6.93-7.10 (m, 1 H) 7.28-7.34 (m, 2 H) 7.42 (d, J=S.5 Hz, 2 H) 7.53 (s, 1 H) 7.63 (d, J=8.5 Hz, 2 H) 7.73 (m, 1 H) 7.97 (d, J=8.S Hz, 2 H) 8.02 (s, 1 H) 8.06 (d, J=8.5 Hz, 2 H) 8.98 (d, J=2.4 Hz, 2 H); . . .MSESI(+)m/e549(M+H)+. 15" Example 593 N-(4-{4-amino-7-[4-(memylsulfonyl)phenyl]trn no[3,2-c]pyridm-3-yl}phenyl)-N'-(2-fluoro- 5-methylphenyl)urea The desired product was prepared by substituting example 562 and l-fluoro-2-isocyanato-4-methylbenzene for 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene 20 in example 122. !H NMR (300 MHz, DMSODfi) 8 ppm 2.29 (s, 3 H) 3.30 (s, 3 H) 5.70 (br s, 2 H) 6.72-6.94 (m, J=2.4 Hz, 1 H) 7.12 (dd, J=l 1.2, 8.5 Hz, 1 H) 7.42 (d, J=8.5 Hz, 2 H) 7.54 (s, 1 H) 7.62 (d, J-S.8 Hz, 2 H) 7.97 (d, J=8.8 Hz, 2 H) 8.00-8.04 (m, 2 H) 8.06 (d, J=8.8 Hz, 2 H) 8.56 (d, J=2.0 Hz, 1 H) 9.27 (s, 1 H); MS ESI(+) m/e 549 (M+H)+. 25 Example 594 N-(4-{4-an o-3-[4-({[(3-cldorophenyl)aiimio]c 7-yl}phenyl)acetamide The desired product was prepared by substituting example 454 and 3-chloro-l-isocyanatobenzene for 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in 30 example 122. *HNMR (300 MHz/DMSO-D,) δ ppm2.08 (s, 3 H) 5.50 (br s, 2 H) 6.99-7.08 (m, 1 H) 7.26-7.33 (m, 2 H) 7.41 (d, J=8.5 Hz, 2 H) 7.48 (s, 1 H) 7.54-7.67 (m, 4 H) 7.68-7.76 (m, 3 H) 7.87 (s, 1 H) 8.97 (s, 2 H) 10.07 (s, 1 H); MS ESI(+) m/e 528 (M+H)+. Example 595 35 N-(4-{4-armno-3-[4-({[(2-fluoro-5-memylphenyl)ammo]carbonyl}ammo)phenyl]tru no[3,2- c]pyridin-7-yl}phenyl)acetamide The desired product was prepared by substituting example 454 and l-fluoro-2-isocyanato-4-methylbenzene for 12 IB and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene -246- WO 2005/010009 PCT/US2004/024003 in example 122. lH NMR (300 MHz, DMSO-DJ 8 ppm 2.08 (s, 3 H) 2.28 (s, 3 H) 5.49 (br s, 2 H) 6.73-6.92 (m, 1 H) 7.12 (dd, W 1.4, 8.3 Hz, 1 H) 7.41 (d, J=8.5 Hz, 2 H) 7.48 (s, 1 H) 7.54-7.65 (m, J=8.0, 7.9 Hz, 4 H) 7.72 (d, J=8.8 Hz, 2 H) 7.87 (s, 1 H) 8.00 (dd, J-8.1,1.7 Hz, 1 H) 8.55 (d, J-2.4 Hz, 1 H) 9.26 (s, 1 H) 10.06 (s, 1 H); MS ESI(+) m/e 526 (M+H)+. Example 596 N-[4-(4-amino-3-{4-[({[3- (trifluoromemyl)phenyl]ammo}caLRbonyl)amino]phenyl}thieno[3,2-c]pyridin-7- 10 yl)phenyl]acetamide The desired product was prepared by substituting example 454 and l-isocyanato-3-trifluoromethylbenzene for 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzenein example 122. JH NMR (300 MHz, DMSO-DJ 8 ppm 2.08 (s, 3 H) 5.49 (br s, 2 H) 7.33 (d, J=7.5 Hz, 1 H) 7.41 (d, J=8.8 Hz, 2 H) 7:48 (s, 1 H) 7.53 (t, J=S.O Hz, 1 H) 7.57-7.67 (m, 5 15 H) 7.72 (d, J-8.8 Hz, 2 H) 7.87 (s, 1 H) 8.04 (s, 1 H) 9.01 (s, 1 H) 9.13 (s, 1 H) 10.06 (s, 1 H); MS ESI(+) m/e 562 (M+H)+. Example 597 3-(4-aimnophenyl)-7-(l,3-bei3zodioxol-5-yl)thieno[3,2-c]pyridm-4-anime 20 The desired product was prepared by Example 77B and benzo[l,3]dioxol-5-yl boronic acid for Example IB and 4-phenoxyphenylboronic acid, in Example 10A. 1H NMR (300 MHz, DMSO-Dg) 8 ppm 5.37 (br s, 2 H) 5.54 (br s, 2 H) 6.09 (s, 2 H) 6.68 (d, J*8.5 Hz, 2 H) 7.00-7.15 (m, 4 H) 7.18 (d, >1.7 Hz, 1 H) 7.32 (s, 1 H) 7.80 (s, 1 H)jMS ESI(+)) m/e 362 (M+H)+. 25 Example 598 N-{4-[4-ammo-7-(l,3-benzomoxol-5-yl)thieno[3,2-c]pyri methylphenyl)urea The desired product was prepared by substituting example 597 and l-fluoro-2-30 isocyanato-4-rhethylbenzene for 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-D6) 8 ppm 2.28 (s, 3 H) 5.49 (br s, 2 H) 6.10 (s, 2 H) 6.69-6.92 (m, 1 H) 7.03-7.16 (m, 3 H) 7.19 (d, J=1.7 Hz, 1 H) 7.41 (d, J=8.5 Hz, 2 H) 7.47 (s, 1 H) 7.61 (d, J-8.5 Hz, 2 H) 7.85 (s, 1 H) 8.00 (dd, J=7.8, 2.0 Hz, 1 H) 8.55 (d, J=2.7 Hz, 1 H) 9.27 (s, 1 H); MS ESI(+) m/e 513 (M+H)+. 35 Example 599 N-/4-[4-ammo-7-a.3-ber odioxol-5-yl)thieno[3,2-c]pyridin-3-yl]phenyl}-N,-[3- (trifluoromethyl)pheny 1] urea -247- The desired product was prepared'by substituting example 597' and l-isocyanato-3' trifluoromethylbenzene for 12 IB and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-D6) 5ppm 5.49 (s, 2 H) 6.10 (s, 2 H) 7.06 (d, >S.l Hz, 1 H) 7.09-7.16 (m, 1 H) 7.19 (d, J=1.7Hz, 1 H) 7.33 (d, J-7.S Hz, 1 H) 7.41 (d, 5 J=S.8 Hz, 2 H) 7.47 (s, 1 H) 7.53 ft J=8.0 Hz, 1 H) 7.58-7.67 (m, 3 H) 7.85 (s, 1 H) 8.04 (s, 1 H) 9.01 (s, 1 H) 9.13 (s, 1 H); MS ESI(+) rn/e 549 (M+H)+. Example 600 N-{4-[4-amino-7-(l,3-benzodioxol-5-yl)thieno[3,2-c]pyridin-3-yl]phenyl}-N'-(3- 10 chlorophenyl)urea The desired product was prepared by substituting example 597 and 3-chloro-l-isocyanatobenzene for 121B and l-fluoro-2-isocyanato-4-(trifiuoromethyl)benzene in example 122. !H NMR (300 MHz, DMSO-D6) δ ppm5.48 (br s, 2 H) 6.10 (s, 2 H) 7.00-7.09 (m, 2 H) 7.10-7.16 (m, 1 H) 7.19 (d, J=1.7 Hz, 1 H) 7.27-7.34 (m, 2 H) 7.40 (d, .NS.5 Hz, 2 15 H) 7.47 (s, 1 H) 7.61 (d, J=8.S Hz, 2 H) 7.69-7.77 (m, 1 H) 7.S4 (s, 1 H) 8.96 (s, 2 H); MS ESI(+)m/e515(M+H)+. Example 601 memyl4-amino-3-[4-({[(3-memylphenyl)arnmo]carbonyl}amino)phenylJthieno[3,2- 20 c]pyridine-7-carboxylate Example 601A memyl4-amino-3-(4-aminophenyl)thieno[3,2-c]pyridine-7-carboxylate A solution of example 77B (3g, 8.17 mmol) in MeOH (90 mL) and Et3N (3.4 mL) 25 was treated withl0mol% PdCl2(dppf).CHaCl2) (668 mg, 0.82 mmol) then heated at 120 °C under 300psi CO fro 16 hours. The reaction mixture was cooled, concentrated, and the residue purified via silica gel chromatography eluting with 5 to 7% MeOH in CH2C12. The product isolated was further purified by suspending in 5% MeOH in CH2C12 filtering, and washing the solids with CH2C12 to give 1.32 g of the title compound. MS (ESI (+) m/e 300 30 (M+H)+. Example 60 IB methyl 4-arnmoO-[4-({[(3-mefoylpte c]pyridine-7-carboxylate 35 The desired product was prepared by substituting example 597 and l-isocyanato-3- methylbenzene for 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-D 6 ppm 2.29 (s, 3 H) 3.89 (s, 3 H) 6.81 (d, J-7.5 Hz, 1 H) 7.17 ft J=7.6 Hz, 1 H) 7.25 (d, J=8.1 Hz, 1 H) 7.32 (s, 1 H) 7.38 (d, >8.5 Hz, 2 H) 7.54 -248- WO 2005/010009 PCIYUS2004/024003 (s, 1 H) 7.61 (d, J=8.8 Hz, 2 H) 8.54 (s, 1 H) 8.66 (s, 1 H) 8.86 (s, 1 H); MS ESI(+) m/e 433 (M+H)+. Example 602 5 4-ammo-3-[4-({[(3-memylphenyl)ammo]carbo carboxylic acid A suspension of example 601 (2.35g, 5.44 mmol) in THF (20 mL) and MeOH (10 mL) was treated with 2M aqueous LiOH (13.6 mL, 27.2 mmol) and heated at 70 °C for 1 hour. The mixture was filtered and the solids were washed with water, diethyl ether, and 10 dried to give 1.4g of the title compound. 1H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3 H) 6.22 (br s, 2 H) 6.80 (d, J=7.5 Hz, 1 H) 7.17 (t, J=7.8 Hz, 1 H) 7.26 (d, J=8.5 Hz, 1 H) 7.32 (br s, 1 H) 7.38 (d, J=8.5 Hz, 2 H) 7.54 (s, 1 H) 7.61 (d, J=8.5 Hz, 2 H) 8.51 (s, 1 H) 8.69 (s, 1 H) 8.90 (s, 1 H) 12.90 (br s, 1H); MS ESI(+) m/e 419 (M+H)+. 15 Example 603 4-ammo-N-memyl-3-[4-({[(3-metiiylphenyl)anmio]carbonyl}amino)phenyl]thieno[3,2- c]pyridine-7-carboxamide The desired product was prepared by substituting example 602 and methylamine hydrochloride for example 11B and 2-piperazinone in example 11C. 1H NMR (300 MHz, 20 DMSO-D6) δ ppm2.29 (s, 3 H) 2.82 (d, J=4.4 Hz, 3 H) 5.89 (br s, 2 H) 6.80 (d, J=7.5 Hz, 1 H) 7.17 (t, JM7.8 Hz, 1 H) 7.25 (d, J=8.5 Hz, 1 H) 7.32 (s, 1 H) 7.36 (d, J=8.5 Hz, 2 H) 7.47 (s, 1 H) 7.59 (d, J=8.S Hz, 2 H) S.42 (m, 1 H) 8.48 (s, 1 H) 8.66 (s, 1 H) 8.85 (s, 1 H); MS ESI(+) m/e 432 (M+H)+. 25 Example 604 4-ammo-NJN-dimemyl-3-[4-({[(3-memylphenyl)an c]pyridine-7-carboxamide The desired product was prepared by substituting example 602 and dimethylamine . hydrochloride for example 1 IB and 2-piperazinone in example 11C. 1H NMR (300 MHz, 30 DMSO-D6) 8 ppm 2.29 (s, 3 H) 3.07 (s, 6 H) 5.80 (br s, 2 H) 6.81 (d, J=7.5 Hz, 1 H) 7.17 (t, J=*7.6 Hz, 1 H) 7.26 (d, JK7.8 Hz, 1 H) 732 (s, 1 H) 7.38 (d, J=8.5 Hz, 2 H) 7.49 (s, 1 H) 7.60 (d, J=8.5 Hz, 2 H) S.03 (s, 1 H) 8.66 (s, 1 H) 8.86 (s, 1 H); MS ESI(+) m/e 446 (M+H)+. Example 605 35 N-(4-{4-ammo-7-[(4-memylpiperazm-l-yl)carbonyl] thieno[3,2-c]pyridm methylphenyl)urea The desired product was prepared by substituting example 602 and 1-methylpiperazine for example 1 IB and 2-piperazinone in example 11C. 1H NMR (300 -249- WO 2005/010009 PCT/US2004/024003 MHz,DMSO-DJ 5ppm 2.21 (s, 3 H) 2.29 (s, 3 H) 2.36 (m, 4H) 3.58 (m,-4H>5-82 (brs, 2 H) 6.81 (d, J=7.1Hz, 1 H) 7.17 (t, J=7.6 Hz, 1 H) 7.25 (d, J=8.5 Hz, 1 H) 7.31 (s, 1 H) 7.37 (d, J=8.5 Hz, 2 H) 7.49 (s, 1 H) 7.60 (d, J=8.5 Hz, 2 H) 7.95 (s, 1 H) 8.66 (s, 1 H).8.S6 (s, 1 H); MS ESI(+) m/e 501 (M+H)+ 5 Example 606 4-amino-3-[4-({[(3-memylphenyl)amino]carbonyl}ammo)phenyl]-N-(pyridin-3- ylmemyl)thieno[352-c]pyridme-7-caiboxamide The desired product was prepared by substituting example 602 and pyridin-3-10 ylmethylamine for example 1 IB and 2-piperazinone in example 1 IC. 1H NMR (500 MHz, DMSO-Dfi) 6 ppm 2.29 (s, 3 H) 4.54 (d, J=5.8 Hz, 2 H) 5.97 (br s, 2 H) 6.81 (d, J=7.6 Hz, 1 H) 7.17 (t, J=7.8 Hz, 1 H) 7.26 (d, J=8.2 Hz, 1 H) 7.32 (s, 1 H) 7.34-7.41 (m, 3 H) 7.48 (s, 1 .. H) 7.60 (d, J=8.5 Hz, 2 H) 7.76 (d, J=7.9 Hz, 1 H) 8.38-8.54 (m, 1 H) 8.59 (s, 2 H) 8.67 (s, 1 H) 8.87 (s, 1 H) 9.08 (t, J=5.8 Hz, 1 H); MS ESI(+) m/e 509 (M+H)+. 15 Example 607 4-ammo-3-[4-({[(3;memylphenyl)ammo]carbonyl}ammo)phenyl]thieno[3,2-c]p3nidine-7- carboxamide The desired product was prepared by substituting example 602 and ammonium 20 hydroxide for example 1 IB and 2-piperazinone in example 1 IC. 1H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3 H) 5.91 (br s, 2 H) 6.80 (d, J=7.1 Hz, 1 H) 7.17 (t, J=7.6 Hz, 1 H) 7.24 (m, 1 H) 7.31 (s, 1 H) 7.36 (d, J=S.5 Hz, 2 H) 7.45 (s, 1 H) 7.59 (d, J-8.5 Hz, 2 H) 7.93 (br s, 2 H) 8.53 (s, 1 H) 8.65 (s, 1 H) 8.85 (s, 1 H); MS ESI(+) m/e 418 (M+H)+. 25 Example 608 N-[3-(4-aminothieno[3,2-c]pyridin-3-yl)phenyl]-N'-phenylurea Example 608A 3-(3-anmaophenyl)tlneno[3,2-c]pyrio -amine 30 The desired product was prepared by substituting 3-(4,4J5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)aniline for 4-phenoxyphenylboronic acid in Example 10A. MS ESI(+) m/e 241 (M+H)+. Example 608B N-iJ- 4-ammothieno[3,2-c]pyridin-3-yl)phenyl]-N'-phenylurea 35 The desired product was prepared by substituting example 608A and' 1-isocyanatobenzene for example 12 IB and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-D5) δ ppm5.47 (br s, 2 H) 6.97 (t, J=7.3 Hz, 1 H) 7.05 (d, J=7.1 Hz, 1 H) 7.21-7.32 (m, 4 H) 7.38-7.55 (m, 4 H) -250- WO 2005/010009 PCT/US2004/024003 7.59-7.65 (m, 1 H) 7.84 (d, J=5.8 Hz, 1 H) 8.72 (s, 1 H) 8.86 (s, 1 H); MS ESI(+) m/e 361 (M+H)+. Example 609 5 N43-(4-aminothieno[3,2-c]pyridin-3-yl)phenyl]-N,-(3-methylphenyl)urea -'- The desired product was prepared by substituting example 608A and l-isocyanato-3-methylbenzene for 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122, 1H NMR (300 MHz, DMSO-D6) δ ppm2.27 (s, 3 H) 5.47 (s, 2 H) 6.79 (d, J=7.1 Hz, 1 H) 7.05 (d, J=7.5 Hz, 1 H) 7.11-7.18 (m, 1 H) 7.21 (d, J=7.8 Hz, 1 H) 7.27 (d, J=5.8 Hz, 1 H) 10 7.31 (s, 2 H) 7.42 (t, J=7.8 Hz, 1 H) 7.4S (s, 1 H) 7.63 (s, 1 H) 7.S4 (d, J=5.S Hz, 1 H) 8.64 (s, 1 H) 8.84 (s, 1 H); MS ESI(+) m/e 375 (M+H)+. Example 610 iN-L - -armnomieno[3,2-c]pyridin:3-yl)phenyl]-N'-(4-methylphenyl)urea 15 The desired product was prepared by substituting example 17A and l-isocyanato-4- methylbenzene for 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example . 122. 1H NMR (300 MHz, DMSO-Dg) δ ppm2.25 (s, 3 H) 5.42 (br s, 2 H) 7.10 (d, J=8.1 Hz, 2 H) 7.25 (d, J=5.S Hz, 1 H) 7.36 (dd, J-S.5,2.4 Hz, 4 H) 7.4I.(s, 1 H) 7.59 (d, J=8.5 Hz, 2 H) 7.82 (d, J=5.4 Hz, 1 H) 8.62 (s, 1 H) 8.82 (s, 1 H); MS ESI(+) m/e 375 (M+H)+. 20 Example 611 N-[4-(4-aminothieno[3,2-c]pyridin-3-yl)phenyl]-N'-(2-methylphenyl)urea The desired product was prepared by substituting example 17A and l-isocyanato-2-methylbenzene for 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 25 122. 1H NMR (300 MHz, DMSO-D6) 8 ppm 2.26 (s, 3 H) 5.42 (br s, 2 H) 6.96 (t, J=7.5 Hz, 1 H) 7.12-7.22 (m, 2 H) 7.25 (d," J=5.4 Hz, 1 H) 7.37 (d, J=8.5 Hz, 2 H) 7.42 (s, 1 H) 7.61 (d, J=8.5 Hz, 2 H) 7.80-7.87 (m, 2 H) 7.99 (s, 1 H) 9.21 (s, 1 H); MS ESI(+) m/e 375 (M+H)+. Example 612 30 N-[4-(4-ammothieno[3,2-c]pyridin-3-yl)phenyl]-N-methyl-N'-(3-methylphenyl)urea Example 612A 3-[4-(methylamino)phenyl]thieno[3,2-c]pyridm -amine The desired product was prepared by substituting substituting methyl-[4-(4,4,5,5-35 tetramethyl-[l,3J2]dioxaborolan-2-yl)-phenyl]-amine for 4-phenoxyphenylboronic acid in Example 10A. MS ESI(+) m/e 256 (M+H)+. Example 612B N-[4-(4-arnmothieno[3,2-c]pyridin-3-yl)phenyl]-N-memyl-N,-(3-memylphenyl)urea -251- WO 2005/010009 PCIYUS2004/024003 '' The desired product was prepared by substituting example 612A and l-isocyanato-3-methylbenzene for 12 IB and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-D6) 6 ppm 2.25 (s, 3 H) 3.32 (s, 3 H) 5.61 (br s, 2 H) 6.78 (d, J=7.5 Hz, 1 H) 7.12 (t, J=7.8 Hz, 1 H) 7.20-7.34.(m, 3 H) 7.35-7.59 (m, 5 H) 7.84 (d, 5 J=5.8 Hz, 1 H) 8.28 (s, 1 H); MS ESI(+) m/e 389 (M+H)+ Example 613 N-[4-(4-ammothieno[3J2-c]pyridin-3-yl)phenyl]benzamide The desired product was prepared by substituting benzoyl chloride for acetyl chloride 10 in example 17B. 1H NMR (300 MHz, DMSO-DJ δ ppm5.42 (br s, 2 H) 7.27 (d, J=5.8 Hz, 1 ' H) 7.41-7.49 (m, 3 H) 7.51-7.66 (m, 3 H) 7.83 (d, >5.8 Hz, 1 H) 7.90-8.02 (m, 4 H) 10.43 (s, 1 H); MS ESI(+) m/e 346 (M+H)+. Examples 614-634 were prepared coupling the appropriate aryl boronic acid with example 15 77B using the procedure of example 10A. The products were purified by preparative HPLC on a Waters Symmetry C8 column (25 mm x 100 mm, 7 um particle size) using a gradient of 10% to 100% acetonitrile:0.1% aqueous TFA over 8 min (10 min run time) at a flow rate of 40 ml/min to give the desired product as the trifluoroacetic acid salt 20 .Example K, *4 MS (ESI) (M+HT 614 H OMe H H 348 615 H H OMe H 348 616 Jf H H . *i 336 617 H Jf' H H 336 618 CI H H H 352 619 H CI H H 352 62U a H CI H 352 621 H ■ CN H H 343 -252- WO 2005/010009 PCT/US2004/024003 622 i COMe H H 360 623 H C[3 H H 386 624 H H CF, H 386 625 H OCJt-3 • H H 402 626 H H PhO H 410 627 H H OC[3. H - 402 628 H Me H Me 346 629 H JitU H H 362 630 MeO H H MeO 378 631 H MeO MeO H 378 .632 H MeO MeO MeO 408 633 H CI CI H 386 634 H CI H CI 386 Example 635 N-{3-[4-amino-3-(4-ammophenyl)te 5 The desired product was prepared by substituting example 77B and N-prop-2-ynyl- isonicotinamide for example 144A and 3-butyn-l-ol in example 144B. 1H NMR (300 MHz, DMSO-D,) δ ppm4.44 (d, J-5.76 Hz, 2 H) 5.37 (s, 2 H) 5.82 (s, 2 H) 6.66 (d, J=8.48 Hz, 2 H) 7.08 (d, J=S.4S Hz, 2 H) 7.36 (s, 1 H) 7.81 (d, J=6.10 Hz, 2 H) 7.94 (s, 1 H) S.75 (d, J=6.10 Hz, 2 H) 9.40 (t, J=5.59 Hz, 1 H); MS (ESI(+)) m/e 400 (M+H)+. 10 Example 636 N-(3-{4-anmio-3-[4-({[(3-memylphenyl)ainmo]carto 7-yl} prop-2-ynyl)isonicotinamide The desired product was prepared by substituting example 635 and l-isocyanato-3-15 methylbenzene for example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. 1HNMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3 H) 4.45 (d, J=5.42 Hz, 2 H) 5.79 (s, 2 H) 6.80 (d, J=7.46 Hz, 1 H) 7.16 (t, J-7.80 Hz, 1 H) 7.22-7.27 (m, 1 H) 7.31 (s, 1 H) 7.37 (d, J=8.S1 Hz, 2 H) 7.51 (s, 1 H) 7.60 (d, J=S.81 Hz, 2 H) 7.81 (d, J=6.10 Hz, 2 H) 7.98 (s, 1 H) 8.66 (s, 1 H) 8.75 (d, J=6.10 Hz, 2 H) 8.86 (s, 1 H) 9.41 (t, J=5.59 Hz, 1 H); MS 20 (ESI(+)) m/e 533 (M+H)+. Example 637 N-(3-{4-ammo-3-[4-({[(3-crdorophenyl)arru 7-yl}prop-2-ynyl)isonicotinamide -253- WO 20Q5/010009 PCT/US2004/02400 The desired product was prepared by 'substituting example 635 and LRchloro-3-isocyanatobenzene for example 12 IB and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. 1HNMR (300 MHz, DMSO-D6) δ ppm4.45 (d, J=5.76 Hz, 2 H) 5.78 (s, 2 H) 7.03 (d, J=6.44 Hz, 1 H) 7.27-7.32 (m, 2 H) 7.38 (d, J=8.48 Hz, 2 H) 7.51 (s, 1 H) 7.60 (d, J=8.48 Hz, 2 H) 7.73 (s, 1 H) 7.81 (d, J=6.10 Hz, 2 H) 7.98 (s, 1 H) 8.75 (d, J=5.76 Hz, 2 H) 8.96 (s, 2 H) 9.41 (t, J=5.42 Hz, 1 H); MS (ESI(+)) m/e 553 (M+H)+. Example 638 N-[3-(4-amino-3-{4-[({[2-fluoro-5-(trifluorometoyl)phenyl]amino}caibonyl)am ynyljisonicotinamide The desired product was prepared by substituting example 635 and I-fluoro-2-isocyanato-4-(trifluoromethyl)benzene for example 12IB and l-fluoro-2-isocyanato-4-(triiluoromethyl)benzene in example 122. !H NMR (300 MHz, DMSO-D6) δ ppm4.46 (d, J=5.43 Hz, 2 H) 5.78 (s, 2 H) 7.41 (d, J=8.48 Hz, 3 H) 7.47-7.55 (m, 2 H) 7.62 (d, J=8.4S Hz, 2 H) 7.82 (d, J=5.76 Hz, 2 H) 7.99 (s, 1 H) 8.63 (d, J=7.46 Hz, 1 H) 8.76 (d, J=6.10 Hz, 2 H) 8.97 (d, J=2.71 Hz, 1 H) 9.37 (s, 1 H) 9.41 (t, J=5.59 Hz, 1 H); MS (ESI(+)) m/e 605 (M+H)+. Example 639 N-(3-{4-amino-3-[4-({[(2-fluoro-5-meto c]pyridin-7-yl}prop-2-ynyl)isonicotinamide The desired product was prepared by substituting example 635 and l-fluoro-2-isocyanato-4-methylbenzene for example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-D6) 6 ppm 2.28 (s, 3 H) 4.45 (d, J=5.43 Hz, 2 H) 5.78 (s, 2 H) 6.78-6.85 (m, 1 H) 7.05-7.16 (m, 1 H) 7.39 (d, J=8.48 Hz, 2 H) 7.52 (s, 1 H) 7.60 (d, J=8.48 Hz, 2 H) 7.82 (d, J=6.10 Hz, 2 H) 7.96-8.02 (m, 2 H) 8.55 (d, J=2.37 Hz, 1 H) 8.76 (d, J=5.76 Hz, 2 H) 9.26 (s, 1 H) 9.41 (t, J-5.26 Hz, 1 H); MS (ESI(+)) m/e 551 (M+H)+. Example 640 -254- WO 2005/010009 PCT/US2004/024003 N-[3-(4-amino-3-{4-[({[3-(trifluorome1byl)phenyl]aiin o}carbonyl)arm o]p ynyl]isonicotinamide The desired product was prepared by substituting example 635 and l-isocyanato-3-5 (trifluoromethyl)benzene for example 121B and l-fluoro-2-isocyanato-4- (trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-D6) δ ppm4.46 (d, J=5.43 Hz, 2 H) 5.79 (s, 2 H) 7.33 (d, J=7.46 Hz, 1 H) 7.39 (d, J=S.4S Hz, 2 H) 7.49-7.57 (m, 2 H) 7.62 (d, J=8.82 Hz, 3 H) 7.82 (d, J=6.10 Hz, 2 H) 7.9S (s, 1 H) 8.04 (s, 1 H) S.76 (d, J=6.10 Hz, 2 H) 9.03 (s, 1 H) 9.15 (s, 1 H) 9.41 (t, J-5.43 Hz, 1 H); MS (ESI(+)) m/e 587 10 (M+H)+. Example 641 N-{3-[4-aim o-3-(4-aminophenyl)tru>no[3,2-c]pyridin-7-yl]prop-2- ynyljmethanesulforiamide 15 The desired product was prepared by substituting example 77B and N-prop-2- ynylmethanesulfonamide for example 144A and 3-butyn-l-ol in example 144B. 1H NMR (300 MHz, DMSO-D6) δ ppm3.06 (s, 3 H) 4.15 (d, J=6.10 Hz, 2 H) 5.38 (s', 2 H) 5.86 (s, 2 H) 6.67 (d, J=8.48 Hz, 2 H) 7.08 (d, J=S.14Hz, 2 H) 7.38 (s, 1 H) 7.69 (t, J=6.10 Hz, 1 H) 7.96 (s, 1 H); MS (ESI(+)) m/e 373 (M+H)+. 20 Example 642 N-(3-{4-ammo-3-[4-({[(3-memylphenyl)amino]carbonyl}arnino)phenyl]thieno[3)2-c]pyridm 7-yl}prop-2-ynyl)methanesulfonamide The desired product was prepared by substituting example 641 and l-isocyanato-3-25 methylbenzene for example 121B and l-fluoro-2-isocyanato-4-(trifluoromemyl)benzene in example 122. 1H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3 H) 3.07 (s, 3 H) 4.17 (d, J=5.43 Hz, 2 H) 5.83 (s, 2 H) 6.81 (d, J=6.44 Hz, 1 H) 7.17 (t, J=7.63 Hz, 1 H) 7.22-7.29 (m, 1 H) 7.32 (s, 1 H) 7.38 (d, J=8.48 Hz, 2 H) 7.53 (s, 1 H) 7.60 (d, J=8.14 Hz, 2 H) 7.70 (t, J=5.76 Hz, 1 H) S.00 (s, 1 H) 8.66 (s, 1 H) 8.86 (s, 1 H);); MS (ESI(+)) m/e 506 (M+H)+. 30 Example 643 ■ N-(3-{4-arnmo-3-[4-({[(2-fluoro-5-memylphenyl)arnmo]carbonyl}amino)phenyl]tM c]pyridin-7-yl}prop-2-ynyl)methanesulfonamide The desired product was prepared by substituting example 641 and l-fluoro-2-35 isocyanato-4-methylbenzene for example 121B and l-fluoro-2-isocyanato-4- (trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-Dg) δ ppm2.28 (s, 3 H) 3.07 (s, 3 H) 4.17 (d, J=6.10Hz, 2 H) 5.82 (s, 2 H) 6.76-6.87 (m, 1 H) 7.04-7.16 (m, 1 H) -255- WO 2005/010009 PCT/US2004/024003 7.39 (d, J=8.48 Hz, 2 H) 7.53 (s, 1 H) 7.61 (d, J=8.48 Hz, 2 H) 7.70 (t, J=5.93 Hz, 1 H) 8.00 (s, 2 H) 8.55 (s, 1 H) 9.26 (s, 1 H); MS (ESI(+)) m/e 524 (M+H)+. Example 644 5 N-(3-{4-ammo-3-[4-({[(3-cHorophenyl)arnmo]ca 7-yl}prop-2-ynyl)methanesulfonamide The desired product was prepared by substituting example 641 and l-chloro-3-isocyanatobenzene for example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. lH NMR (300 MHz, DMSO-D6) 6 ppm 3.07 (s, 3 H) 4.17 (d, J=6.10 Hz, 2 10 H) 5.S2 (s, 2 H) 7.01-7.07 (m, 1 H) 7.29-7.33 (m, 2 H) 7.39 (d, J=8.48 Hz, 2 H) 7.53 (s, 1 H) 7.61 (d, J=8.82 Hz, 2 H) 7.67-7.71 (m, 1 H) 7.73 (t, J=2.03 Hz, 1 H) 8.00 (s, 1 H) 8.97 (s, 2 H); MS (ESI(+)) m/e 526 (M+H)+. Example 645 15 N-[3-(4-amino-3-{4-[({[3- (Mfluoromemyl)phenyl]ammo}caxbonyl)airimo]phenyl}thieno[3,2-c]pyridm-7-yl) ynyljmethanesulfonamide The desired product was prepared by substituting example 641 and l-isocyanato-3-(trifluoromethyl)benzene for example 12 IB and l-fluoro-2-isocyanato-4-20 (trifluoromethyl)benzene in example 122. lH NMR (300 MHz, DMSO-D6) δ ppm3.07 (s, 3 H) 4.17 (d, J-6.10 Hz, 2 H) 5.82 (s, 2 H) 7.33 (d, J=7.S0 Hz, 1 H) 7.40 (d, J=8.48 Hz, 2 H) 7.49-7.57 (m, 2 H) 7.59 (s, 1 H) 7.63 (d, J-8.48 Hz, 2 H) 7.70 (t, J=5.93 Hz, 1 H) 8.00 (s, 1 H) S.04 (s, 1 H) 9.01 (s, 1 H) 9.13 (s, 1 H); MS (ESI(+)) m/e 560 (M+H)+. 25 Example 646 N-[3-(4-amino-3-{4-[({[2-iluoro-5-(trirluoromemyl)phenyl]ammo}carbonyl)ammo]phenyl}thieno[3,2-c]pyridin-7-yl)prop-2- ynyljmethanesulfonamide The desired product was prepared by substituting example 641 for example 121B in ■ 30 example 122. 1H NMR (300 MHz, DMSO-D6) δ ppm3.07 (s, 3 H) 4.17 (d, J=6.10 Hz, 2 H) 5.82 (s, 2 H) 7.41 (d, J=8.48 Hz, 3 H) 7.50 (d, J=10.85 Hz, 1 H) 7.54 (s, 1 H) 7.62 (d, J=8.48 Hz, 2 H) 7.70 (t, J=5.93 Hz, 1 H) 8.01 (s, 1 H) 8.63 (d, J-7.12 Hz, 1 H) 8.97 (d, J=2.71 Hz, 1 H) 9.38 (s, 1 H); MS (ESI(+)) m/e 578 (M+H)+. 35 Example 647 N-R4 4-ammo-7-pyrirm -5-yl thieno[3,2-c methylphenyl)urea -256- WO 2005/010009 PCT/US2004/024003 The desired product was prepared by substituting example 136A and l-fluoro-2-isocyanato-4-methyl-benzene for example 12 IB and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-D6) δ ppm2.29 (s, 3 H) 5.74 (s, 2 H) 6.78-6.86 (m, 1 H) 7.10 (d, J-8.14.Hz, 1 H) 7.14 (d, J=8.14 Hz, 1 H) 7.42 (d, 5 J=8.81 Hz, 2 H) 7.55 (s, 1 H) 7.63 (d, J=8.48 Hz, 2 H) 8.00 (dd, J=7.S0, 2.03 Hz, 1 H) 8.04 (s, 1 H) S.56 (d, J=2.71 Hz, 1 H) 9.14 (s, 1 H) 9.23 (s, 1 H) 9.28 (s, 1 H); MS (ES1(+)) m/e 471(M+H)+. Example 648 10 N-[4-(4-ammo-7-pyrirnidin-5-ylthieno[3,2-c]pyri The desired product was prepared by substituting example 136A and l-fluoro-3-isocyanatobenzene for example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-DJ 8 ppm 5.74 (s, 2 H) 6.75-6.85 (m, 1 H) 7.15 (d, J-9.16 Hz, 1H) 7.26-7.37 (m, 1 H) 7.42 (d, J=8.48.Hz, 2 H) 7.48-7.56 (m, 2 H) 7.63 (d, 15 J-8.48 Hz, 2 H) 8.04 (s, 1 H) 8.99 (d, J=6.44 Hz, 2 H) 9.14 (s, 2 H) 9.23 (s, 1 H); MS (ESI(+))m/e457(M+H)+. Example 649 N-[4-(4-ammo-7-pyriiru m-5-ylthieno[3,2-c]p 20 methylphenyl)urea The desired product was prepared by substituting example 136A and l-fluoro-4-isocyanato-2-methyl-benzene for example 121B and l-£luoro-2-isocyanato-4- (trifluoromethyl)benzene in example 122. "H NMR (300 MHz, DMSO-D6) δ ppm2.18 (s, 3 H) 5.74 (s, 2 H) 7.02-7.10 (m, 1 H) 7.18 (t, J=S.65 Hz, 1 H) 7.41 (d, J=8.4S Hz, 3 H) 7.54 (s, 25 1 H) 7.62 (d, J=8.48 Hz, 2 H) 8.04 (s,'l H) 8.86 (s, 1 H) 8.93 (s, 1 H) 9.14 (s, 2 H) 9.23 (s, 1 H); MS (ESI(+)) m/e 470 (M+H)+. Example 650 . N-[4-(4-arrn o-7-tmen-3-ylthieno[3,2-c]pyridm-3 30 The desired product was prepared by substituting example 126 and l-chloro-3- isocyanatobenzene for example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-DJ δ ppm5.53 (s, 2 H) 7.00-7.07 (m, 1 H) 7.28-7.34 (m, 2 H) 7.41 (d, J=8.48 Hz, 2 H) 7.52 (s, 1 H) 7.57 (d, J=6.10 Hz, 1 H) 7.62 (d, >8.48 Hz, 2 H) 7.73 (t, J=3.73 Hz, 2 H) 7 81 (d, J=3.73 Hz, 1 H) 8.09 (s, 1 H) 8.97 (s, 2 H); 35 MS (ESI(+)j m/e 478 (M+H)+. Example 651 -257- WO 2005/010009 PCT/US2004/024003 N-[4-(4-amino-7-thien-3-yltHieno[3J2-c]pyridin-3-yl)phenyl]-N'-[2-fluoro-5- (trifluoromethyl)phenyl]urea The desired product was prepared by substituting example 126 for example 121B in example 122. 1H NMR (300 MHz, DMSO-D6) 6 ppm 5.53 (s, 2 H) 7.43 (d, JM8.48 Hz, 3 H) 5 7.48-7.54 (m, 2 H) 7.57 (d, J=3.39 Hz, -; H) 7.63 (d, J=8.48 Hz, 2 H) 7.74 (dd, J=5.09,2.71 Hz, 1 H) 7.81 (d, J=4.07 Hz, 1 H) 8.09 (s, 1 H) 8.64 (d, J=5.43 Hz, 1 H) S.98 (s, 1 H) 9.38 (s, 1 H); MS (ESI(+)) m/e 529 (M+H)+. Example 652 10 N-[4-(4-arnmo-7-mien-3-yl thieno[3,2-c]pyridin-3-yl)phenyl]-N'-[3- (trifluoromethyl)phenyl]urea The desired product was prepared by substituting example 126 and l-isocyanato-3-(trifluoromethyl)benzene for example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-D6) 8 ppm 5.53 (s, 2 15 H) 7.33 (d, J=7.46 Hz, 1 H) 7.42 (d, J=8.48 Hz, 2 H) 7.52 (s, 2 H) 7.55-7.61 (m, 2 H) 7.61-7.67 (m, 2 H) 7.73 (dd, J=5.09, 3.05 Hz, 1 Hi 7.81 (dd, J=2.71, 1.36 Hz, 1 H) 8.04 (s, 1 H) 8.09 (s, 1 H) 9.01 (s, 1 H) 9.13 (s, 1 H); MS (ESI(+)) m/e 511 (M+H)+. Example 653 20 N-[4-(4-anu o-7-th n-3-yltIu>no[3,2-c]pyri The desired product was prepared by substituting example 126 and l-fluoro-3-' isocyanatobenzene for example 121B and l-fluoro-2-isocyanato-4-(trifluor6methyl)benzene in example 122. 1H NMR (300 MHz, DMSO-D6) 6 ppm 5.53 (s, 2 H) 6.74-6.85 (m, 1 H) 7.15 (d, J=8.14 Hz, 1 H) 7.27-7.38 (m, 1 H) 7.41 (d, J=8.48 Hz, 2 H) 7.47-7.55 (m, 2 H) 7.57 25 (d, J=3.73 Hz, 1 H) 7.62 (d, J=8.48 Hz, 2 H) 7.73 (dd, J=5.09,2.71 Hz, 1 H) 7.78-7.84 (m, 1 H) 8.09 (s, 1 H) 8.96 (s, 1 H) 8.99 (s, 1 H); MS (ESI(+)) m/e 461 (M+H)+- Example 654 N-[4-(4-animo-7-tiu n-3-ylthieno[3,2-c]pyrim -3-yl)phenyl]-N,-(2-fluoro-5- 30 methylphenyl)urea The desired product was prepared by substituting example 126 and l-fluoro-2-isocyanato-4-methylbenzene for example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. lH NMR (300 MHz, DMSO-D6) 6 ppm 2.28 (s, 3 H) 5.53 (s, 2 H) 6.77-6.86 (m, 1 H) 7.12 (dd, >11.36, 8.31 Hz, 1 H) 7.41 (d, J-8.48 Hz, 2 H) 35 7.52 (s, 1 H) 7.57 (dd, J=4.92,1.19 Hz, 1 H) 7.62 (d, J=8.48 Hz, 2 H) 7.69-7.76 (m, 1 H) 7.78-7.84 (m, 1 H) 7.92-8.07 (m, 1 H) 8.09 (s, 1 H) 8.55 (d, J=2.71 Hz, 1 H) 9.27 (s, 1 H); MS (ESI(+)) m/e 475 (M+H)+. -258- WO 2005/010009 PCT/US2004/024003 Example 655 3-(4-ammophenyl)-7-[3-(diisopropylaimno)pro Example 655A 5 N,N-diisopropyl-N-prop-2-ynylamine The desired product was prepared by substituting diisopropylamine for pyrrolidine in example 5 06A. Example 655B 10 3-(4-ammophenyl)-7-[3-(diisopropylarmno)prop-l-ynyl]tm o[3J2-c]pyridm-4-amme The desired product was prepared by substituting example 77B and example 655A for example 144A and 3-butyn-l-ol in example 144B. !H NMR (300 MHz, DMSO-D6).δ ppm1.11 (d, J=6.44 Hz, 12 H) 3.14-3.29 (m, 2 H) 3.68 (s, 2 H) 5.37 (s, 2 H) 5.75 (s, 2 H) 6.67 (d, J=S.48 Hz, 2 H) 7.08 (d, J=8.48 Hz, 2 H) 735 (s, 1 H) 7.S8 (s, 1 H); MS (ESI(+)) m/e 379 15 (M+H)+. Example 656-N-(4-{4-aimjio-7-[3-(diisopropylammo)prop-l-ynyl]thieno[3,2-c]pyridm-3-yl}phenyl)-N,-(3- methylphenyl)urea 20 The desired product was prepared by substituting example 655B and l-isocyanato-3- methylbenzene for example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. lH NMR (300 MHz, DMSO-Dg) 6 ppm 1.12 (d, J=6.44 Hz, 12 H) 2.29 (s, 3 H) 3.18-3.30 (m, 2 H) 3.69 (s, 2 H) 5.72 (s, 2 H) 6.80 (d, J=7.46 Hz, 1 H) 7.17 (t, J=7.80 Hz, 1 H) 7.22-7.29 (m, 1 H) 7.31 (s, 1-H) 7.37 (d, J=S.48 Hz, 2 H) 7.50 (s, 1 H) 7.60 (d, J=8.82 Hz, 25 2 H) 7.92 (s, 1 H) 8.66 (s, 1 H) 8.86 (s, 1 H); MS (ESI(+)) m/e 512 (M+H)+. Example 657 N-(4- {4-amino-7-[3-(diisopropylamino)prop-1 -ynyl]thieno[3,2-c]pyridin-3-yl} phenyl)-N,-(3 - fluorophenyl)urea 30 The desired product was prepared by substituting example 655B and l-fluoro-3- isocyanatobenzene for example 121B and l-fluoro-2-isocyanato-4-(trifiuoromethyl)benzene in example 122. 1HNMR (300 MHz, DMSO-D δ ppm1.12 (d, J=6.44 Hz, 12 H) 3.17-3.28 (m, 2 H) 3.69 (s, 2 H) 5.72 (s, 2 H) 6.76-6.84 (m, 1 H) 7.14 (d, J=9.15 Hz, 1 H) 7.27-7.34 (m, 1 H) 7.38 (d, J=8.48 Hz, 2 H) 7.47-7.55 (m, 2 H) 7.60 (d, J=8.48 Hz, 2 H) 7.91 (s, 1 H) 8.95 35 (s, 1 H) 8.98 (s, 1 H); MS (ESI(+)) m/e 516 (M+H)+ Example 658 -259- WO 2005/010009 PCT/US2004/024003 N-(4-{4-ammo-7-[3-(dusopropylamm (trifluoromethyl)phenyl]urea The desired product was prepared by substituting example 655B and l-isocyanato-3-(trifluoromethyl)benzene for example 121B and l-fluoro-2-isocyanato-4-5 (trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-D6) δ ppm1.12 (d, J=6.44 Hz, 12 H) 3.18-3.28 (m, 2 H) 3.69 (s, 2 H) 5.72 (s, 2 H) 7.33 (ds J=7.46 Hz, 1 H) 7.39 (d, J=8.48 Hz, 2 H) 7.51 (s, 1 H) 7.54 (d, J=7.46 Hz, 1 H) 7.59 (s, 1 H) 7.62 (d, J=S.48 Hz, 2 H) 7.92 (s, 1 H) 8.03 (s, 1 H) 9.01 (s, 1 H) 9.12 (s, 1 H); MS (ESI(+)) m/e 566 (M+H)+. 10 Example 659 N-(4-{4-ammo-7-[3-(dUisopropylamino)prop-l-ynyl] thieno[3,2-c]pyridin-3-yl}pbenyl)-N'-[2- fluoro-5-(trifluorometbyl)phenyl]urea The desired product was prepared by substituting example 655B for example 121B in example 122. ]HNMR (300MHz, DMSO-DJ 8 ppm 1.12 (d, J=6.78 Hz, 12 H) 3.17-3.28 15 (m, 2 H) 3.70 (s, 2 H) 5.72 (s, 2 H) 7.37-7.44 (m, 3 H) 7.46-7.56 (m, 2 H) 7.62 (d, J=8.48 Hz, - 2 H) 7.92 (s, 1 H) 8.64 (dd, J=7.12, 2.03 Hz, 1 H) 8.97 (d, J=2.71 Hz, 1 H) 9.38 (s, 1 H);_MS (ESI(+))m/e5S4(M+H)+. Example 660 20 N-(4-{4-ammo-7-[3-(dusopropylammo chlorophenyl)urea The desired product was prepared by substituting example 655B and l-chloro-3-isocyanatobenzene for example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-D6) δ ppm1.12 (d, J=6.78 Hz, 12 H) 3.17-3.29 25 (m, 2 H) 3.70 (s, 2 H) 5.72 (s, 2 H) 7.00-7.07 (m, 1 H) 7.28-7.33 (m, 2 H) 7.38 (d, J=8.4S Hz, 2 H) 7.50 (s, I H) 7.61 (d, J=8.48 Hz, 2 H) 7.68-7.75 (m, 1 H) 7.92 (s, 1 H) 8.97 (d, J=1.70 Hz, 2 H); MS (ESI(+)) m/e 532 (M+H)+. Example 661 30 N-(4-{4-animo-7-[3-(du opropylammo)prop-l-ynyl]mieno[3 -c]pyridm-3-yl}ph fluoro-5-methylphenyl)urea The desired product was prepared by substituting example 655B and l-fluoro-2-isocyanato-4-methylbenzene for example 121B and l-ftuoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. lHNMR (300 MHz, DMSO-Dg) δ ppm1.12 (d, 35 J=6.44 Hz, 12 H) 2.28.(s, 3 H) 3.16-3.29 (m, 2 H) 3.69 (s, 2 H) 5.72 (s, 2 H) 6.82 (dd, J=7.29, 6.61 Hz, 1 H) 7.12 (dd, J=11.53, 8.48 Hz, 1 H) 7.38 (d, J=8.48 Hz, 2 H) 7.50 (s, 1 H) 7.60 (d, J=S.48 Hz, 2 H) 7.92 (s, 1IX) 7.99 (d, J=8.14 Hz, 1 H) 8.54 (d, J=2.37 Hz, 1 H) 9.26 (s, 1 H); MS (ESI(+)) m/e 530 (M+H)+. -260- WO 2005/010009 PCT/US2004/024003 Example 662 3 4-ammophenyl)-7-(3-iluyl)thieno[3J2-c]pyridm-4-ainine The desired product was prepared by substituting Example 77B and 3-fiirylboronic 5 acid for Example IB and 4-phenoxyphenylboronic acid in Example 10A. 1H NMR £300 MHz, DMSO-D6) 6 ppm 5.37 (s, 2 H) 5.58 (s, 2 H) 6.68 (d, J=8.4S Hz, 2 H) 7.01-7.04 (m, 1 H) 7.10 (d, J=8.4S Hz, 2 H) 7.38 (s, 1 H) 7.79-7.85 (m, 1 H) 8.06 (s, 1 H) 8.08-8.11 (m, 1 H); MS (ESI(+)) m/e 308 (M+H)+. 10 Example 663 N-{4-[4-amrac-7-(3-fiuyl) thieno[3 The desired product was prepared by substituting example 662 and l-chloro-3-isocyanatobenzene for example 12IB and l-fluoro-2-isocyanato-4-(trifluoromethyl)berizene in example 122. 1H NMR (300 MHz, DMSO-D6j δ ppm5.52 & 2 H) 7.01-7.06 (m, 2 H) 15 7.28-7.33 (m, 2 H) 7.41 (d, J=8.48 Hz, 2 H) 7.53 (s, 1 H) 7.62 (d, J=8.48 Hz, 2 H) 7.73 (t, J=2.03 Hz, 1 H) 7.84 (t, J=l .70 Hz, 1 H) 8.10 (s, 1 H) 8.11-8.14 (m, 1 H) 8.96 (s, 2 H); MS (ESI(+)) m/e 460 (M+H)+. Example 664 20 N-{4-[4-ammo-7-(3-furyl)thieno[3,2 The desired product was prepared by substituting example 662 and l-fluoro-3-isocyanatobenzene for example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-D6) δ ppm5.53 (s, 2 H) 6.73-6.86 (m, 1 H) 7.05 (s, 1 H) 7.15 (d, J=8.48 Hz, 1 H) 7.25-7.38 (m, 1 H) 7.41 (d, J=S.14 Hz, 2 H) 7.48-7.56 25 (m, 2 H) 7.62 (d, J=8.48 Hz, 2H) 7.84 (s, 1 H) 8.07-8.17 (m, 2 H) 8.97 (d, J-8.S2 Hz, 2H); MS (ESI(+)) m/e 445 (M+H)+. Example 665 N-{4-[4-ammo-7-(3-fiuyl)thieno[3J2-c]pyridm-3-yl]phenyl}-N,-[3- 30 ' (trifluoromethyl)phenyl]urea The aesrred product was prepared by substituting example 662 and l-isocyanato-3-(trifluoromethyl)benzene for example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-D6) δ ppm5.53 (s, 2 H) 6.94-7.11 (m, 1 H) 7.33 (d, J=7.46.Hz, 1 H) 7.41 (d, J=S.4S Hz, 2 H) 7.49-7.57 (m, 2 H) 35 7.59 (s, 1 H) 7.63 (d, J=8.81 Hz, 2 H) 7.84 (t, J=1.70 Hz, 1 H) 8.04 (s, 1 H) 8.10 (s, 1 H) 8.12 (s, 1 H) 9.01 (s, 1 H) 9.12 (s, 1 H); MS (ESI(+)) m/e 495 (M+H)+ Example 666 -261- WO 2005/010009 PCT/US2004/024003 N-{4-[4-amino-7-(3-foryl)tfce methylphenyl)urea The desired product was prepared by substituting example 662 and l-fluoro-2-isocyanato-4-methylbenzene for example 121B and l-fluoro-2-isocyanato-4-5 (trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-Dg) δ ppm2.28 (s, 3 H) 5.52 (s, 2 H) 6.75-6.87 (m, 1 H) 7.05 (s, 1 H) 7.12 (dd, J-11.36, 8.31 Hz, 1 H) 7.41 (d, J=8.14 Hz, 2 H) 7.53 (s, 1 H) 7.61 (d, J=8.48 Hz, 2 H) 7.84 (s, 1 H) 8.00 (d, J=6.10 Hz, 1 H) 8.07-8.16 (m, 2 H) 8.54 (s, 1 H) 9.26 (s, 1 H); MS (ESI(+)) m/e 459 (M+H)+. 10 Example 667 N-{4-[4-ammo-7-(3-ruiyl)tHeno[3,2-c]pyridin-3-yl]phenyl}-N'-(2-fIuorophenyl)urea The desired product was prepared by substituting example 662 and l-fluoro-2-isocyanatobenzene for example 121B and l-fluoro-2-isocyanato-4-(trifluoromethyl)benzene in example 122. 1H NMR (300 MHz, DMSO-D6) δ ppm5.52 (s, 2 H) 7.00-7.07 (m, 2 H) 15 7.16 (t, J=7.80 Hz, 1 H) 7.26 (dd, J=11.70,7.97 Hz, 1 H) 7.41 (d, J=8.48 Hz, 2 H) 7.53 (sf 1 H) 7.62 (d, J=8.S1 Hz, 2 H) 7.84 (t, J=1.70Hz, 1 H) 8.08-8.14 (m, 2 H) 8.18 (t, J=8.31 Hz, 1 H) 8.62 (d, JM2.37 Hz, 1 H) 9.28 (s, 1 H); MS (ESI(+)) m/e 445 (M+H)+. Example 668 20 N-{4-[4-ariiino-7-(3-fluoropyridm-4-yl)te (trifluoromethyl)phenyl]urea Example 668A 3-(4-ammophenyl)-7-(3-fluorop}Tidm-4-yl) thieno[3,2-c]pyridm-4-amine 25 The desired product was prepared by substituting 3-fluoro-4-pyridineboronic acid and example 77B for Example IB and 4-phenoxyphenylborbnic acid in example 10A, Example 668B N-{4-[4-arm o-7-(3-fluoropyri6Un-4-yl)to 30 (trifluoromethyl)phenyl]urea The desired product was prepared by-substituting example 668A for example 121B in example 122. 1H NMR (300 MHz, DMSO-Dfi) δ ppm5.79 (s, 2 H) 7.38-7.42 (m, 1 H) 7.45 (d, J=8.48 Hz, 2 H) 7.51 (d, J=10.85 Hz, 1 H) 7.54-7.56 (m, 1 H) 7.64 (d, J=8.48 Hz, 2 H) 7.74 (dd, J-6.61,4.92 Hz, 1 H) 7.98 (d, J=1.70 Hz, 1 H) 8.57 (d, J=5.43 Hz, 1 H) 8.64 (dd, 35 J=7.12, 2.03 Hz, 1 H) 8.74 (d, J=2.03 Hz, 1 H) 8.98 (d, J=3.05 Hz, 1 H) 9.39 (s, 1 HJ MS . (ESI(4-))m/e542(M+H)+. Example 669 -262-